<SEC-DOCUMENT>0001193125-25-198747.txt : 20250909
<SEC-HEADER>0001193125-25-198747.hdr.sgml : 20250909
<ACCEPTANCE-DATETIME>20250909060959
ACCESSION NUMBER:		0001193125-25-198747
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250908
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250909
DATE AS OF CHANGE:		20250909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tourmaline Bio, Inc.
		CENTRAL INDEX KEY:			0001827506
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40384
		FILM NUMBER:		251301599

	BUSINESS ADDRESS:	
		STREET 1:		27 WEST 24TH STREET
		STREET 2:		SUITE 702
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		646-481-9832

	MAIL ADDRESS:	
		STREET 1:		27 WEST 24TH STREET
		STREET 2:		SUITE 702
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Talaris Therapeutics, Inc.
		DATE OF NAME CHANGE:	20201007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d80074d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:trml="http://www.tourmalinebio.com/20250908" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-402">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-09-08_to_2025-09-08">0001827506</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="trml-20250908.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-09-08_to_2025-09-08"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001827506</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-09-08</xbrli:startDate> <xbrli:endDate>2025-09-08</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-413">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-09-08_to_2025-09-08" format="ixt:datemonthdayyearen" id="ixv-414">September 8, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-415">TOURMALINE BIO, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-09-08_to_2025-09-08" format="ixt-sec:stateprovnameen" id="ixv-416">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-417">001-40384</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-418">83-2377352</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-71">27 West 24<sup style="font-size:75%; vertical-align:top">th</sup> Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-419">Suite 702</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-420">New York</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-421">NY</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-422">10010</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-423">(646)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-424">481-9832</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-09-08_to_2025-09-08" format="ixt-sec:boolballotbox" id="ixv-425">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-09-08_to_2025-09-08" format="ixt-sec:boolballotbox" id="ixv-426">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-09-08_to_2025-09-08" format="ixt-sec:boolballotbox" id="ixv-427">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-09-08_to_2025-09-08" format="ixt-sec:boolballotbox" id="ixv-428">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-429">Common stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-430">TRML</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-09-08_to_2025-09-08" format="ixt-sec:exchnameen" id="ixv-431">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-09-08_to_2025-09-08" format="ixt-sec:boolballotbox" id="ixv-432">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2025-09-08_to_2025-09-08" format="ixt-sec:boolballotbox" id="ixv-433">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2025, Tourmaline Bio, Inc., a Delaware corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221; or &#8220;<span style="font-weight:bold"><span style="font-style:italic">Tourmaline</span></span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Merger Agreement</span></span>&#8221;) with Novartis AG, a company limited by shares (<span style="font-style:italic">Aktiengesellschaft</span>) incorporated under the laws of Switzerland (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Parent</span></span>&#8221; or &#8220;<span style="font-weight:bold"><span style="font-style:italic">Novartis</span></span>&#8221;), and Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Purchaser</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, Purchaser will commence a cash tender offer (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Offer</span></span>&#8221;) no later than September&#160;29, 2025. The Offer will consist of an offer to purchase all of the outstanding shares of common stock of the Company, par value $0.0001 per share (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Shares</span></span>&#8221;), at a price of $48.00 per Share, in cash, without interest, and subject to any withholding of taxes required by applicable legal requirements (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Offer Price</span></span>&#8221;). Following the date and time of the irrevocable acceptance for payment by Purchaser of the Shares that have been validly tendered and not validly withdrawn pursuant to and subject to the conditions of the Offer (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Offer Acceptance Time</span></span>&#8221;) and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Parent, Purchaser and the Company will, pursuant to Section&#160;251(h) of the General Corporation Law of the State of Delaware (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">DGCL</span></span>&#8221;) without a vote of the Company stockholders, effect a merger of Purchaser with and into the Company (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Merger</span></span>&#8221; and, together with the Offer and the other transactions contemplated by the Merger Agreement, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Transactions</span></span>&#8221;), with the Company continuing as the surviving corporation of the Merger and an indirect wholly owned subsidiary of Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligation of Purchaser to accept for payment, and pay for, Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to satisfaction or waiver, to the extent permitted under applicable legal requirements, of certain conditions set forth in the Merger Agreement, including (i)&#160;there being validly tendered and not validly withdrawn Shares that, considered together with all other Shares (if any) beneficially owned by Parent or any of its wholly owned subsidiaries, represent a majority of Shares outstanding at the time of the expiration of the Offer (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Minimum Condition</span></span>&#8221;) and (ii)&#160;any waiting period (and any extension thereof) applicable to the Offer, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (&#8220;<span style="font-weight:bold"><span style="font-style:italic">HSR</span></span>&#8221;), including any voluntary agreements not to consummate the Offer or the Merger for any period of time, shall have expired or been terminated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Merger (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Effective Time</span></span>&#8221;), each Share then outstanding (other than Shares (a)&#160;held by the Company or in the Company&#8217;s treasury (other than, in each case, Shares that are held in a fiduciary or agency capacity and are beneficially owned by third parties), Parent, Purchaser, any other direct or indirect wholly owned subsidiary of Parent, or by stockholders of the Company who have properly exercised and perfected their statutory rights of appraisal under Delaware law, or (b)&#160;irrevocably accepted for payment in the Offer) will be converted into the right to receive the Offer Price (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Merger Consideration</span></span>&#8221;), without interest and subject to any applicable withholding of taxes required by applicable legal requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Company&#8217;s stock options (collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Options</span></span>&#8221;) outstanding as of immediately prior to the Effective Time will accelerate and become fully vested and exercisable immediately prior to, and contingent upon, the Effective Time. As of the Effective Time, each vested Option (after giving effect to such acceleration), will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i)&#160;the total number of Shares subject to such Option immediately prior to the Effective Time, <span style="font-style:italic">multiplied by</span> (ii)&#160;the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration will be cancelled for no consideration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of restricted stock of the Company outstanding as of immediately prior to the Effective Time, will accelerate and become fully vested immediately prior to, and contingent upon, the Effective Time and will be treated as a Share pursuant to the terms of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each restricted stock unit award (collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">RSUs</span></span>&#8221;) outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i)&#160;the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, <span style="font-style:italic">multiplied by</span> (ii)&#160;the Merger Consideration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement includes representations, warranties and covenants of the parties customary for a transaction of this nature. From the date of the Merger Agreement until the earlier of the Effective Time and the termination of the Merger Agreement, the Company has agreed, subject to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain exceptions, to conduct its operations in the ordinary course consistent in all material respects with past practice and has agreed to certain other interim operating covenants, as set forth more fully in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has also agreed to customary <span style="white-space:nowrap">non-solicitation</span> restrictions on its ability to solicit or engage in discussions or negotiations with third parties regarding alternative acquisition proposals. Notwithstanding these restrictions, the Company may under certain circumstances provide, pursuant to an acceptable confidentiality agreement, information to and engage in or otherwise participate in discussions or negotiations with third parties with respect to a <span style="font-style:italic">bona fide</span> alternative acquisition proposal which did not result from a breach of the <span style="white-space:nowrap">non-solicitation</span> restrictions that the board of directors of the Company has determined in good faith, after consultation with its financial advisor and outside legal counsel, constitutes or would reasonably be expected to lead to a superior acquisition proposal, as set forth more fully in the Merger Agreement. The Merger Agreement also requires that the Company&#8217;s board of directors recommend that the stockholders of the Company accept the Offer and tender their Shares pursuant to the Offer (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company Board Recommendation</span></span>&#8221;) and not, among other things, (i)(A) withdraw or qualify, amend or modify in a manner adverse to Parent or Purchaser the Company Board Recommendation; (B)&#160;publicly approve, recommend or declare advisable, any alternative acquisition proposal; (C)&#160;fail to include the Company Board Recommendation in the Schedule <span style="white-space:nowrap">14D-9</span> when disseminated to the Company&#8217;s stockholders; (D)&#160;fail to recommend against acceptance of competing tender or exchange offers commenced by a third party within ten business days of such commencement; (E)&#160;fail to reaffirm the Company Board Recommendation within ten business days after Parent&#8217;s written request following the public announcement of any alternative acquisition proposal; (F)&#160;take any action or exempt any person or any action taken by any person from any takeover law; or (G)&#160;publicly propose to do any of the foregoing, (any such action in (A)&#8212;(G), a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company Adverse Change Recommendation</span></span>&#8221;) or (ii)&#160;approve, recommend or declare advisable, or allow the Company to enter into or execute any alternative agreement for the acquisition of the Company. Notwithstanding these restrictions, the board of directors of the Company is permitted, subject to the terms and conditions set forth in the Merger Agreement, to make a Company Adverse Change Recommendation (or terminate the Merger Agreement to enter into a definitive agreement with respect to a superior acquisition proposal) to accept a superior acquisition proposal or in response to a Change in Circumstance (as defined in the Merger Agreement), subject in each case to certain conditions and matching rights in favor of Parent and payment of the termination fee described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement includes customary termination rights for the parties, including that, subject to certain limitations, the Company or Parent may terminate the Merger Agreement prior to the Effective Time if: (i)&#160;a governmental body has entered, enforced, enacted or issued a final and <span style="white-space:nowrap">non-appealable</span> legal restraint after the date of the Merger Agreement having the effect of permanently restraining, enjoining or otherwise prohibiting the acceptance for payment of Shares pursuant to the Offer or the Merger or making the consummation of the Offer or the Merger illegal, (ii)&#160;the Effective Time has not occurred on or prior to 11:59 p.m. Eastern Time on the twelve month anniversary of the date of the Merger Agreement (subject to two automatic extensions to the fifteen month anniversary of the date of the Merger Agreement and the eighteen month anniversary of the date of the Merger Agreement if the only outstanding conditions to closing (other than the Minimum Condition and other conditions tested at Closing) at the original termination date relate to antitrust or foreign direct investment laws) (such date, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Outside Date</span></span>&#8221;) or (iii)&#160;the Offer expires in accordance with its terms without the acceptance for payment of Shares tendered in the Offer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may terminate the Merger Agreement in certain additional limited circumstances, including to allow the Company to enter into an agreement providing for an alternative acquisition transaction that constitutes a superior proposal under the Merger Agreement, subject to certain conditions. Parent may terminate the Merger Agreement in certain additional limited circumstances, including if there is a Company Adverse Change Recommendation or if the board of directors of the Company or the Company intentionally and materially breaches its <span style="white-space:nowrap">&#8220;non-solicitation&#8221;</span> restrictions or &#8220;company board recommendation&#8221; obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon termination of the Merger Agreement under certain specified circumstances, the Company will be required to pay Parent a termination fee (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company Termination Fee</span></span>&#8221;) of $47,950,000. Specifically, the Company Termination Fee is payable if: (i)&#160;the Merger Agreement is terminated in certain circumstances; (ii)&#160;prior to such termination (but after the date of the Merger Agreement) a <span style="font-style:italic">bona fide</span> proposal for an alternative acquisition transaction has been made to the Company or publicly disclosed or otherwise made known to the Company&#8217;s board of directors or its stockholders and in each case, not publicly withdrawn and (iii)&#160;within twelve months after such termination, the Company subsequently consummates an alternative acquisition transaction or enters into a definitive agreement providing for an alternative acquisition transaction, whether or not related to the alternative </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquisition transaction commenced prior to the Transactions. The Company Termination Fee will also be payable if the Merger Agreement is terminated: (a)&#160;by Parent following a Company Adverse Change Recommendation or (b)&#160;by the Company in order to enter into an agreement providing for an alternative acquisition transaction that constitutes a Superior Proposal (as defined in the Merger Agreement). The Merger Agreement also provides that Parent will be required to pay a regulatory termination fee of $68,500,000 to the Company under certain specified circumstances, including if the Merger Agreement is terminated by either Parent or the Company because the Offer Acceptance Time has not occurred by the Outside Date, and as of termination, the conditions to the Offer related to obtaining any required consents, approvals or the expiration or termination of applicable waiting periods or the absence of any law or order that prohibits consummation of the Offer or the Merger or that has the effect of making the Offer or Merger illegal is arising under any antitrust or foreign direct investment law has not be satisfied, and all other conditions to the Offer (other than those conditions that by their nature are to be satisfied at the Offer Acceptance Time) have been satisfied or waived. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Merger Agreement and the Transactions does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which is filed as Exhibit 2.1 hereto and which is incorporated herein by reference. The Merger Agreement has been filed to provide information to investors regarding its terms. The Merger Agreement is not intended to provide any other factual information about the Company, Parent or Purchaser, their respective businesses, or the actual conduct of their respective businesses during the period prior to the consummation of the Offer, the Merger or the Transactions or otherwise. The Merger Agreement and this summary should not be relied upon as disclosure about the Company or Parent. None of the Company&#8217;s stockholders or any other third parties should rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or conditions of the Company, Parent, Purchaser or any of their respective subsidiaries or affiliates. The Merger Agreement contains representations and warranties that are the product of negotiations among the parties thereto and that the parties made to, and solely for the benefit of, each other as of specified dates. The assertions embodied in those representations and warranties are subject to qualifications and limitations agreed to by the respective parties and are also qualified in important part by confidential disclosure schedules delivered by the Company to Parent and Purchaser in connection with the Merger Agreement. The representations and warranties may have been made for the purpose of allocating contractual risk among the parties to the Merger Agreement and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to stockholders or investors. Accordingly, investors should consider the information in the Merger Agreement in conjunction with the entirety of the factual disclosure about the Company in the Company&#8217;s public reports filed with the Securities and Exchange Commission (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">SEC</span></span>&#8221;). Information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company&#8217;s public disclosures if such updates are not required by law. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;9, 2025, the Company issued a press release announcing the execution of the Merger Agreement as described above. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained in this Item 7.01 of this report, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 7.01 of Form <span style="white-space:nowrap">8-K</span> and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the SEC made by the Company regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:5%"/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d80074dex21.htm">Agreement and Plan of Merger, dated as of September&#160;8, 2025, by and among Tourmaline Bio, Inc., Novartis AG and Torino Merger Sub Inc.</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:5%"/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:92%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d80074dex991.htm">Press Release of Tourmaline Bio, Inc., dated September&#160;9, 2025.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">104</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Date File (embedded within the Inline XBRL document).</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Schedules omitted pursuant to Item 601(b)(2) of Regulation <span style="white-space:nowrap">S-K.</span> The Company agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Tourmaline and Novartis, including statements relating to the ability to complete and the timing of completion of the Transactions contemplated by the Merger Agreement, including the anticipated occurrence, manner and timing of the proposed Offer, the parties&#8217; ability to satisfy the conditions to the consummation of the Offer and the other conditions to the consummation of the Merger set forth in the Merger Agreement, the possibility of any termination of the Merger Agreement, and the prospective benefits of the proposed Transactions, and other statements that are not historical facts. The forward-looking statements contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. These statements may contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;opportunity,&#8221; &#8220;potential&#8221; or other similar words and expressions indicating future results. Risks that may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the timing of the Offer; uncertainties as to how many of Tourmaline&#8217;s stockholders will tender their stock in the Offer; the possibility that competing offers or acquisition proposals will be made; the possibility that various closing conditions for the Transactions may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the Transactions (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; the possibility that the Transactions do not close; risks related to the parties&#8217; ability to realize the anticipated benefits of the proposed Transactions, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period and that Tourmaline and Novartis will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; the effects of the Transactions on relationships with employees, suppliers, manufacturers, other business partners or governmental entities; negative effects of this announcement or the consummation of the proposed Transactions on the market price of Tourmaline&#8217;s common stock and/or Tourmaline&#8217;s operating results; significant transaction costs; unknown or inestimable liabilities; the risk of litigation and/or regulatory actions related to the proposed Transactions; Novartis&#8217;s ability to fund the proposed Transactions; the time-consuming and uncertain regulatory approval process; the uncertainties inherent in the costly and time-consuming therapeutic product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the parties&#8217; business operations and financial results; the sufficiency of the parties&#8217; cash flows and capital resources; the parties&#8217; ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; and other risks and uncertainties affecting Tourmaline, including those described from time to time under the caption &#8220;Risk Factors&#8221; and elsewhere in Tourmaline&#8217;s filings and reports with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), including Tourmaline&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2024 and Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarterly period ended June&#160;30, 2025, as well as the Tender Offer Statement on Schedule TO and related tender offer documents to be filed by Novartis and the Purchaser, and the Solicitation/Recommendation Statement on Schedule <span style="white-space:nowrap">14D-9</span> to be filed by Tourmaline. Any forward-looking statements are made based on the current beliefs and judgments of Tourmaline&#8217;s and Novartis&#8217;s management, and the reader is cautioned not to rely on any forward-looking statements made by Tourmaline or Novartis. Except as required by law, Tourmaline and Novartis do not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Important Information about the Tender Offer and Where to Find It </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Offer for Tourmaline outstanding common stock referred to in this Current Report on Form <span style="white-space:nowrap">8-K</span> has not yet commenced. The description contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell any shares of common stock of Tourmaline or any other securities, nor is it a substitute for the tender offer materials that Novartis and the Purchaser will file with the SEC. The solicitation and offer to purchase Tourmaline&#8217;s common stock will only be made pursuant to an offer to purchase and related tender offer materials. At the time the Offer is commenced, Novartis and the Purchaser will file a tender offer statement on Schedule TO and thereafter Tourmaline will file a solicitation/recommendation statement on Schedule <span style="white-space:nowrap">14D-9</span> with the SEC with respect to the Offer. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE <span style="white-space:nowrap">14D-9,</span> AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER. ANY HOLDERS OF TOURMALINE SHARES ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offer to purchase, the letter of transmittal, the solicitation/recommendation statement and related offer documents will be made available for free at the SEC&#8217;s website at www.sec.gov. Copies of those offer documents and all other documents filed by Novartis, the Purchaser and Tourmaline will be made available at no charge by directing a request to the information agent for the Offer, which will be named in the Schedule TO to be filed with the SEC. Copies of the solicitation/recommendation statement on Schedule <span style="white-space:nowrap">14D-9</span> to be filed with the SEC by Tourmaline will be available free of charge on Tourmaline&#8217;s investor relations website at https://ir.tourmalinebio.com/. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">In addition, Tourmaline files annual, quarterly and current reports and other information with the SEC, which are also made available free of charge on the Company&#8217;s investor relations website at https://ir.tourmalinebio.com/ and at the SEC&#8217;s website at www.sec.gov. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Tourmaline Bio, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: September&#160;9, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ryan Robinson</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Ryan Robinson</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>d80074dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTION VERSION </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF
MERGER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and among: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OVARTIS</SMALL> AG, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a company limited by shares (<I>Aktiengesellschaft</I>) incorporated under the laws of Switzerland; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ORINO</SMALL> M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> I<SMALL>NC</SMALL>., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>OURMALINE</SMALL> B<SMALL>IO</SMALL>, I<SMALL>NC</SMALL>., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of September 8, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;1.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>THE OFFER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>1.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>The Offer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>1.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Company Actions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;2.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>MERGER TRANSACTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Merger</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Effect of the Merger</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Closing; Effective Time</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Certificate of Incorporation and Bylaws</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Directors and Officers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Conversion of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Surrender of Certificates; Stock Transfer Books</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Dissenters&#8217; Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Treatment of Company Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Company ESPP</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>No Dividends or Distributions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.12</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Further Action</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.13</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Merger Without a Vote of Stockholders</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Due Organization and Good Standing</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Certificate of Incorporation and Bylaws</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Authority; Binding Nature of Agreement; Anti-Takeover Laws</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Capitalization, Etc.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Merger Approval</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>SEC Filings; Financial Statements</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Rule <FONT STYLE="white-space:nowrap">14d-10</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Absence of Changes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Title to Assets</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.12</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Real Property</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.13</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Intellectual Property</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.14</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Data Protection</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.15</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Contracts</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.16</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Compliance with Legal Requirements; Regulatory Matters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.17</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Trade Control Laws; Anti-Corruption Laws</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.18</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Governmental Authorizations; Compliance with Legal Requirements</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.19</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Tax Matters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.20</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Employee Matters; Benefit Plans</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.21</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Environmental Matters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.22</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Insurance</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.23</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Legal Proceedings; Orders</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.24</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Brokers and Finders</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.25</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Fairness Opinion</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.26</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>National Security</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.27</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Related Party Transactions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.28</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>No Other Representations or Warranties; Acknowledgment by the Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;4.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Due Organization</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Purchaser</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Authority; Binding Nature of Agreement</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Disclosure</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Absence of Litigation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Sufficiency of Funds</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Ownership of Company Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Brokers and Finders</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Stockholder and Management Arrangements</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>No Other Representations or Warranties; Acknowledgement by Parent and Purchaser</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE&nbsp;5.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COVENANTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Access and Investigation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Operation of the Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>No Solicitation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Company Board Recommendation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Filings, Consents and Approvals</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Employee Benefits</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Indemnification of Officers and Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Securityholder Litigation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Public Announcement</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Takeover Laws; Advice of Changes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Section&nbsp;16 Matters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.12</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Rule <FONT STYLE="white-space:nowrap">14d-10</FONT> Matters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.13</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Stock Exchange Delisting; Deregistration</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.14</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Purchaser Stockholder Consent</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.15</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Termination of Certain Agreements</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.16</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Communications and Interactions with Governmental Bodies and Regulatory Authorities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 6.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONDITIONS PRECEDENT TO THE MERGER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>No Restraints</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Consummation of Offer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 7.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TERMINATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Termination</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Manner and Notice of Termination; Effect of Termination</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Expenses; Termination Fee</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ARTICLE 8.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>MISCELLANEOUS PROVISIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>No Survival of Representations, Warranties, Covenants and Agreements</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Amendment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Waiver</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Entire Agreement; Counterparts</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies; Waiver of Jury Trial</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Assignability</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>No Third Party Beneficiaries</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Notices</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Severability</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Obligation of Parent&#8217;s Subsidiaries</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Transfer Taxes</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.12</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Company Disclosure Letter References</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.13</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Construction</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Exhibits</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Definitions</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit B</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Certificate of Incorporation of Surviving Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit C</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Bylaws of Surviving Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Annexes</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annex I</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Conditions to the Offer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>AND</SMALL> </B><B>P<SMALL>LAN</SMALL> <SMALL>OF</SMALL>
M<SMALL>ERGER</SMALL></B><SMALL></SMALL> is made and entered into as of September 8, 2025, by and among <B>N<SMALL>OVARTIS</SMALL> AG</B>, a company limited by shares (<I>Aktiengesellschaft</I>) incorporated under the laws of Switzerland
(&#8220;<B><I>Parent</I></B>&#8221;); <B>T<SMALL>ORINO</SMALL> M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> I<SMALL>NC</SMALL>.</B>, a Delaware corporation and an indirect wholly owned Subsidiary of Parent (&#8220;<B><I>Purchaser</I></B>&#8221;); and
<B>T<SMALL>OURMALINE</SMALL> B<SMALL>IO</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;). Certain capitalized terms used in this Agreement are defined in <U>Exhibit A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B> On the terms and subject to the conditions of this Agreement, Parent has agreed to cause Purchaser to commence a cash tender offer
(as it may be amended from time to time as permitted under this Agreement, the &#8220;<B><I>Offer</I></B>&#8221;) to acquire all of the outstanding shares of Company Common Stock (the &#8220;<B><I>Shares</I></B>&#8221;) other than Excluded Shares
for an amount in cash equal to $48.00 per Share, without interest, and subject to any withholding of Taxes required by applicable Legal Requirements in accordance with <U>Section</U><U></U><U>&nbsp;2.7(g</U>)(such amount or any higher amount per
Share paid pursuant to the Offer, the &#8220;<B><I>Offer Price</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B> Following the consummation of the Offer,
Purchaser will be merged with and into the Company (the &#8220;<B><I>Merger</I></B>&#8221;), with the Company continuing as the surviving corporation in the Merger (the &#8220;<B><I>Surviving Corporation</I></B>&#8221;), on the terms and subject to
the conditions set forth in this Agreement, whereby, except as expressly provided in <U>Section</U><U></U><U>&nbsp;2.6</U>, (i)&nbsp;each issued and outstanding Share (other than any Excluded Shares) as of the Effective Time shall be converted into
the right to receive the Offer Price, and (ii)&nbsp;the Company shall become an indirect wholly owned Subsidiary of Parent as a result of the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B> The board of directors of the Company (the &#8220;<B><I>Company Board</I></B>&#8221;) has unanimously adopted resolutions
(i)&nbsp;determining that this Agreement and the consummation of the Transactions are advisable, fair to and in the best interest of, the Company and its stockholders, (ii)&nbsp;determining that the Merger shall be governed and effected in
accordance with Section&nbsp;251(h) of the DGCL, (iii)&nbsp;authorizing and approving the execution, delivery and performance by the Company of this Agreement and the consummation of the Transactions and (iv)&nbsp;resolving to recommend that the
holders of Shares accept the Offer and tender their Shares to Purchaser pursuant to the Offer (the recommendation of the Company Board, the &#8220;<B><I>Company Board Recommendation</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D. </B>The board of directors of each of Parent and Purchaser has unanimously adopted resolutions (i)&nbsp;determining that this Agreement
and the consummation of the Transactions are advisable and (ii)&nbsp;authorizing and approving the execution, delivery and performance by each of Parent and Purchaser of this Agreement and the consummation of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E.</B> Each of Parent, Purchaser and the Company acknowledges and agrees that the Company Board has determined that the Merger shall be
effected pursuant to Section&nbsp;251(h) of the DGCL and shall, subject to satisfaction of the conditions set forth in this Agreement, be consummated as soon as practicable following the consummation (as defined in Section&nbsp;251(h) of the DGCL)
of the Offer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F.</B> Each of Parent, Purchaser and the Company desires to make certain representations,
warranties, covenants and agreements specified herein in connection with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties to this Agreement, intending to be legally bound, agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1. THE OFFER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> <B>The Offer</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Commencement of the Offer</B>. Provided that this Agreement shall not have been terminated in accordance with <U>Article 7</U>
and the Company shall have timely provided to Parent and Purchaser all information required to be provided by it pursuant to <U>Section</U><U></U><U>&nbsp;1.1(e)</U>, as promptly as practicable after the date of this Agreement but in no event later
than fifteen (15)&nbsp;Business Days following the date of this Agreement, Purchaser shall (and Parent shall cause Purchaser to) commence (within the meaning of Rule <FONT STYLE="white-space:nowrap">14d-2</FONT> under the Exchange Act) the Offer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Terms and Conditions of the Offer</B>. Subject to the satisfaction or (to the extent permitted hereunder) waiver of the
conditions set forth in <U>Annex</U><U></U><U>&nbsp;I</U> (collectively, the &#8220;<B><I>Offer Conditions</I></B>&#8221;), as soon as practicable after the Expiration Date, Purchaser shall (and Parent shall cause Purchaser to) consummate the Offer
in accordance with its terms and promptly accept for payment and promptly thereafter pay for all Shares validly tendered and not properly withdrawn pursuant to the Offer. The Offer shall be made by means of an offer to purchase (the
&#8220;<B><I>Offer to Purchase</I></B>&#8221;) that contains the terms set forth in this Agreement, including the Offer Conditions. Purchaser expressly reserves the right to (i)&nbsp;increase the Offer Price, (ii)&nbsp;waive, in whole or in part,
any Offer Condition and (iii)&nbsp;make any other changes to the terms and conditions of the Offer not inconsistent with the terms of this Agreement; <I>provided, however,</I> that unless otherwise provided by this Agreement, without the prior
written consent of the Company, Purchaser shall not (and Parent shall cause Purchaser not to)(A)&nbsp;decrease the Offer Price, (B)&nbsp;change the form of consideration payable in the Offer, (C)&nbsp;decrease the maximum number of Shares sought to
be purchased in the Offer, (D)&nbsp;impose conditions or requirements to the Offer in addition to the Offer Conditions, (E)&nbsp;amend or modify any of the Offer Conditions or any other terms or conditions of this Agreement in a manner that is
adverse to the holders of Shares or that would, individually or in the aggregate, reasonably be expected to prevent or materially delay the consummation of the Offer or prevent, materially delay or materially impair the ability of Parent or
Purchaser to consummate the Offer, the Merger or the other Transactions, (F)&nbsp;change or waive the Minimum Condition, (G)&nbsp;terminate the Offer or accelerate, extend or otherwise change the Expiration Date in a manner other than as required or
permitted by this Agreement or (H)&nbsp;provide any &#8220;subsequent offering period&#8221; (or any extension thereof) within the meaning of Rule <FONT STYLE="white-space:nowrap">14d-11</FONT> promulgated under the Exchange Act. Parent and
Purchaser shall, and each of Parent and Purchaser shall ensure that all of their respective controlled Affiliates shall, tender any Shares held by them (if any) into the Offer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Expiration and Extension of the Offer</B>. The Offer shall initially be
scheduled to expire at one minute following 11:59 p.m., Eastern Time, on the twentieth (20<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day following (and including the day of) the Offer Commencement Date, determined as set forth
in Rule <FONT STYLE="white-space:nowrap">14d-1(g)(3)</FONT> and Rule <FONT STYLE="white-space:nowrap">14e-1(a)</FONT> under the Exchange Act, unless otherwise agreed to in writing by Parent and the Company (such date or such subsequent date to which
the expiration of the Offer is extended in accordance with the terms of this Agreement, including this <U>Section</U><U></U><U>&nbsp;1.1(c)</U>, the &#8220;<B><I>Expiration Date</I></B>&#8221;). Subject to the Parties&#8217; respective termination
rights under <U>Article 7</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If, as of any then-scheduled Expiration Date, any Offer Condition, other than the Minimum
Condition, is not satisfied or, to the extent waivable in accordance with the terms hereof, has not been waived by Purchaser or Parent, Purchaser may, in its discretion (and without the consent of the Company or any other Person), and at the request
of the Company, Purchaser shall, extend the Offer on one or more occasions for an additional period of up to ten (10)&nbsp;Business Days each per extension, to permit such Offer Condition to be satisfied; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Purchaser shall extend the Offer from time to time for the minimum period required by any Legal Requirement, any interpretation
or position of the SEC, the staff thereof or Nasdaq applicable to the Offer; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> if, as of the then-scheduled Expiration
Date, all of the Offer Conditions have been satisfied or, to the extent waivable in accordance with the terms hereof, waived, except that the Minimum Condition has not been satisfied, Purchaser may, in its discretion (and without the consent of the
Company or any other Person) and at the request of the Company, Purchaser shall, extend the Offer on one or more occasions for an additional period specified by the Company of up to ten (10)&nbsp;Business Days per extension, to permit the Minimum
Condition to be satisfied; <I>provided</I>, <I>however</I>, that in no event shall Purchaser be required to extend the Offer pursuant to this clause (iii)&nbsp;for more than three (3)&nbsp;additional such extensions;
<I>provided</I>,<I></I><I>&nbsp;however</I>, that in no event shall Purchaser (x)&nbsp;be required to extend the Offer beyond the earliest to occur of the valid termination of this Agreement in compliance with <U>Article 7</U> and the Outside Date
or (y)&nbsp;be permitted to extend the Offer beyond the Outside Date without the prior written consent of the Company. For the avoidance of doubt, nothing in the foregoing clauses (i), (ii)&nbsp;or (iii)&nbsp;of this
<U>Section</U><U></U><U>&nbsp;1.1(c)</U> shall be deemed to impair, limit or otherwise restrict in any manner the right of the Parties to terminate this Agreement pursuant to and in accordance with the terms of <U>Article 7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Termination of Offer</B>. In the event that this Agreement is terminated pursuant to the terms of this Agreement, Purchaser
shall (and Parent shall cause Purchaser to) promptly (and, in any event, within one Business Day of such termination), irrevocably and unconditionally terminate the Offer and shall not acquire any Shares pursuant to the Offer. If the Offer is
terminated or withdrawn by Purchaser, Purchaser shall promptly return, and shall cause any depository acting on behalf of Purchaser to return, in accordance with applicable Legal Requirements, all tendered Shares to the registered holders thereof.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Offer Documents</B>. On the Offer Commencement Date, Parent and Purchaser
shall (i)&nbsp;file with the SEC a tender offer statement on Schedule TO with respect to the Offer (together with all amendments, supplements and exhibits thereto, the &#8220;<B><I>Schedule TO</I></B>&#8221;) that will contain or incorporate by
reference the Offer to Purchase and form of the related letter of transmittal and (ii)&nbsp;cause the Offer to Purchase and related documents to be disseminated to holders of Shares. Parent and Purchaser agree that they shall cause the Schedule TO
and all amendments, supplements and exhibits thereto (which together constitute the &#8220;<B><I>Offer Documents</I></B>&#8221;) filed by either Parent or Purchaser with the SEC to comply in all material respects with the Exchange Act and the rules
and regulations thereunder and other applicable Legal Requirements. Each of Parent, Purchaser and the Company agrees to promptly correct any information provided by it for use in the Offer Documents if and to the extent that such information shall
have become false or misleading in any material respect, or to correct any material omissions therefrom, and Parent further agrees to take all steps necessary to cause the Offer Documents as so corrected to be filed with the SEC and to be
disseminated to holders of Shares, in each case, as and to the extent required by applicable Legal Requirements (including the Exchange Act). The Company shall promptly furnish or otherwise make available to Parent and Purchaser or Parent&#8217;s
legal counsel all information concerning the Company and the Company&#8217;s stockholders that may be required or reasonably requested in connection with any action contemplated by this <U>Section</U><U></U><U>&nbsp;1.1(e)</U>. Unless the Company
Board has effected a Company Adverse Change Recommendation, Parent and Purchaser shall provide the Company and its counsel a reasonable opportunity to review and comment on the Offer Documents prior to the filing thereof with the SEC. Parent and
Purchaser agree to provide the Company and its counsel with any comments Parent, Purchaser or their counsel may receive from the SEC or its staff with respect to the Offer Documents promptly after receipt of such comments. Unless the Company Board
has effected a Company Adverse Change Recommendation, Parent and Purchaser shall provide the Company and its counsel a reasonable opportunity to participate in the formulation of any response to any such comments of the SEC or its staff and a
reasonable opportunity to participate in any discussions with the SEC or its staff concerning such comments, and Parent and Purchaser shall give reasonable and good faith consideration to any such comments made by the Company or its counsel. Parent
and Purchaser shall respond promptly to any comments of the SEC or its staff with respect to the Offer Documents or the Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>
<B>Adjustments to Offer Price</B>. If, between the date of this Agreement and the Offer Acceptance Time, the outstanding Shares are changed into a different number or class of shares by reason of any stock split, division or subdivision of shares,
stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction, then the Offer Price shall be equitably adjusted to reflect such change and provide the holders of each Share the same
economic effect as contemplated by this Agreement prior to such event; <I>provided</I>, that nothing in this <U>Section</U><U></U><U>&nbsp;1.1(f)</U> shall be construed to permit the Company to take any action that is prohibited by the terms of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Payment; Funds</B>. On the terms and subject to the conditions set forth in this Agreement and the Offer,
including the satisfaction or, to the extent permitted hereunder, waiver of all Offer Conditions, Purchaser shall (and Parent shall cause Purchaser to), at or as promptly as practicable following the Expiration Date (as it may be extended in
accordance with <U>Section</U><U></U><U>&nbsp;1.1(c)</U>), but in any event within one (1)&nbsp;Business Day thereof, irrevocably accept for payment (the time of such acceptance, the &#8220;<B><I>Offer Acceptance Time</I></B>&#8221;), and, at or as
promptly as practicable following the Offer Acceptance Time, but in any event within three (3)&nbsp;Business Days thereof, pay for, all Shares that are validly tendered and not withdrawn pursuant to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Offer. Without limiting the generality of <U>Section</U><U></U><U>&nbsp;8.10</U>, Parent shall cause to be provided to Purchaser all of the funds necessary to purchase any Shares that Purchaser
becomes obligated to purchase pursuant to the Offer, and shall cause Purchaser to perform, on a timely basis, all of Purchaser&#8217;s obligations under this Agreement. The Company shall register the transfer of any Shares irrevocably accepted for
payment effective immediately after the Offer Acceptance Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Tender Offer Reports</B>. Between the commencement of the
Offer and the Expiration Date, Purchaser shall (and Parent shall cause Purchaser to) use commercially reasonable efforts to keep the Company informed on a reasonably current basis regarding the status of the Offer and the number of Shares validly
tendered (and not validly withdrawn) pursuant to the Offer (including using commercially reasonable efforts to provide the Company with tender offer reports received from the depository and/or Paying Agent on at least a weekly basis; <I>provided</I>
that during the five (5)&nbsp;Business Days prior to the Expiration Date, Purchaser shall use commercially reasonable efforts to promptly provide daily tender offer reports each Business Day) and shall use commercially reasonable efforts to give
notice to the Company promptly following the expiration of the Offer, indicating whether, as of such date and time, sufficient Shares have been validly tendered (and not validly withdrawn) to satisfy the Minimum Condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> <B>Company Actions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT></B>. On the Offer Commencement Date and substantially concurrently with
the filing by Parent and Purchaser of the Schedule TO, the Company shall file with the SEC in a manner that complies with Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> under the Exchange Act a Tender Offer Solicitation/Recommendation Statement
on Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> (together with any amendments, supplements and exhibits thereto, the &#8220;<B><I>Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT></I></B>&#8221;) that (i)&nbsp;shall reflect the terms
set forth in this Agreement, (ii) unless the Company Board has made a Company Adverse Change Recommendation in accordance with <U>Section</U><U></U><U>&nbsp;5.4(b)</U>, shall reflect the Company Board Recommendation and (iii)&nbsp;shall include a
notice of appraisal rights and other information in accordance with Section<U></U>&nbsp;262(d)(2) of the DGCL. The Company agrees that it shall cause the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> to comply in all material respects with
the Exchange Act and other applicable Legal Requirements. Unless requested otherwise by the Company, Parent shall cause the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> to be disseminated to the holders of Shares together with the Offer
Documents. Each of Parent, Purchaser and the Company agrees to respond promptly to any comments of the SEC or its staff and to promptly correct any information provided by it for use in the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> if
and to the extent that such information shall have become false or misleading in any material respect, and to correct any material omissions therefrom, and the Company further agrees to use all reasonable efforts to cause the Schedule <FONT
STYLE="white-space:nowrap">14D-9</FONT> as so corrected to be promptly filed with the SEC and disseminated to holders of Shares, in each case as and to the extent required by applicable federal securities laws. Parent and Purchaser shall promptly
furnish or otherwise make available to the Company or its legal counsel all information concerning Parent and Purchaser and their stockholders that may be required or reasonably requested in connection with any action contemplated by this
<U>Section</U><U></U><U>&nbsp;1.2(a)</U> so as to enable the Company to comply with its obligations hereunder. Unless the Company Board has made a Company Adverse Change Recommendation in accordance with <U>Section</U><U></U><U>&nbsp;5.4(b)</U>, the
Company shall (A)&nbsp;provide Parent and its counsel reasonable opportunity to review and comment on the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> prior to the filing thereof with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the SEC, (B)&nbsp;provide Parent and its counsel with any comments the Company or its counsel may receive from the SEC or its staff with respect to the Schedule
<FONT STYLE="white-space:nowrap">14D-9</FONT> promptly after receipt of such comments and (C)&nbsp;provide Parent and its counsel a reasonable opportunity to participate in the formulation of any response to any such comments of the SEC or its staff
and a reasonable opportunity to participate in any discussions with the SEC or its staff concerning such comments, and the Company shall give reasonable and good faith consideration to any such comments made by Parent or its counsel. The Company
shall respond promptly to any comments from the SEC or its staff with respect to the Schedule <FONT STYLE="white-space:nowrap">14D-9.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Stockholder Lists</B>. The Company shall, promptly furnish, or cause to be promptly furnished, to Parent a list of its
stockholders, mailing labels and any available listing or computer file containing the names and addresses of all record holders of Shares and lists of securities positions of Shares held in stock depositories, in each case accurate and complete as
of the most recent practicable date, and shall provide to Parent such additional information (including updated lists of stockholders, mailing labels and lists of securities positions) and such other assistance as Parent may reasonably request from
time to time in connection with the commencement of the Offer. Parent and Purchaser and their agents shall hold in confidence the information contained in any such labels, lists and files, shall use such information only in connection with the Offer
and the Merger and, if this Agreement shall be terminated, shall promptly deliver, and shall use their reasonable best efforts to cause their agents to deliver, to the Company (or destroy) all copies and any extracts or summaries from such
information then in their possession or control and, if requested by the Company, promptly confirm to the Company in writing that all such material has been returned or destroyed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2. MERGER TRANSACTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Merger</B>. Upon the terms and subject to the conditions set forth in this Agreement and in accordance with Section&nbsp;251(h)
of the DGCL, at the Effective Time, the Parties shall consummate the Merger, whereby Purchaser shall be merged with and into the Company, and the separate existence of Purchaser shall cease. The Company will continue as the Surviving Corporation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>Effect of the Merger</B>. The Merger shall have the effects set forth in this Agreement and in the applicable provisions of
the DGCL. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, all of the property, rights, privileges, powers and franchises of the Company and Purchaser shall vest in the Surviving Corporation, and all
debts, liabilities and duties of the Company and Purchaser shall become the debts, liabilities and duties of the Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Closing</B><B>; Effective Time</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Unless this Agreement shall have been terminated pursuant to <U>Article 7</U>, and unless otherwise mutually agreed in writing
between the Company, Parent and Purchaser, the consummation of the Merger (the &#8220;<B><I>Closing</I></B>&#8221;) shall take place remotely as promptly as reasonably practicable after (but in no case later than the second (2<SUP
STYLE="font-size:75%; vertical-align:top">nd</SUP>) Business Day following) the Offer Acceptance Time, following the satisfaction or waiver of the last to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
satisfied or waived of the conditions set forth in <U>Article 6</U> (other than any such conditions that by their nature are to be satisfied by actions taken at the Closing, but subject to the
satisfaction or waiver (to the extent permitted hereunder) of such conditions), unless another date, time or place is agreed to in writing by the Parties. The date on which the Closing actually occurs is referred to in this Agreement as the
&#8220;<B><I>Closing Date</I></B><B><I>.</I></B>&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Subject to the provisions of this Agreement, as soon as practicable on
the Closing Date, the Company and Purchaser shall file or cause to be filed a certificate of merger with the Secretary of State of the State of Delaware with respect to the Merger, in such form as required by, and executed and acknowledged in
accordance with the DGCL. The Merger shall become effective upon the date and time of the filing of such certificate of merger with the Secretary of State of the State of Delaware or such later date and time as is agreed upon in writing by the
Parties hereto and specified in the certificate of merger (such date and time, the &#8220;<B><I>Effective Time</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B>Certificate of Incorporation</B><B> and Bylaws</B>. At the Effective Time: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> the certificate of incorporation of the Surviving Corporation shall be amended and restated as of the Effective Time to read in its
entirety as set forth on <U>Exhibit</U><U></U><U>&nbsp;B</U><B> </B>attached hereto and, as so amended and restated, shall be the certificate of incorporation of the Surviving Corporation until thereafter amended as provided by the DGCL and such
certificate of incorporation; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> the bylaws of the Surviving Corporation shall be amended and restated as of the Effective
Time to read in their entirety as set forth on <U>Exhibit C</U> attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5</B> <B>Directors and Officers</B>. The initial
directors of the Surviving Corporation shall be the directors of Purchaser as of immediately prior to the Effective Time, each to hold office in accordance with the certificate of incorporation and bylaws of the Surviving Corporation until their
respective successors are duly elected or appointed and qualified. The initial officers of the Surviving Corporation shall be the officers of Purchaser as of immediately prior to the Effective Time, each to hold office in accordance with the
certificate of incorporation and bylaws of the Surviving Corporation until their respective successors are duly appointed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6</B>
<B>Conversion of Shares</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> At the Effective Time, by virtue of the Merger and without any further action on the part of
Parent, Purchaser, the Company or any stockholder of the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any Shares then held by the Company or held in the
Company&#8217;s treasury (other than, in each case, Shares that are held in a fiduciary or agency capacity and are beneficially owned by third parties) shall automatically be canceled and retired and shall cease to exist, and no consideration shall
be delivered in exchange therefor; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> any Shares then held by Parent, Purchaser or any other direct or indirect
wholly owned Subsidiary of Parent shall automatically be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> any Shares irrevocably accepted for payment in the Offer shall no longer be outstanding and shall be canceled and shall cease to
exist, and no additional consideration shall be delivered in exchange therefor; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> except as provided in
<U>Section</U><U></U><U>&nbsp;2.6(a)(i)</U>, <U>Section</U><U></U><U>&nbsp;2.6(a)(ii)</U> and <U>Section</U><U></U><U>&nbsp;2.6(a)(iii)</U> and subject to <U>Section</U><U></U><U>&nbsp;2.6(b)</U>, each Share then outstanding immediately prior to the
Effective Time (other than any Dissenting Shares, which shall have only the rights set forth in <U>Section</U><U></U><U>&nbsp;2.8</U>) shall be canceled and cease to exist and be converted into the right to receive the Offer Price (such per share
amount, the &#8220;<B><I>Merger Consideration</I></B>&#8221;), without interest thereon and subject to any withholding of Taxes required by applicable Legal Requirements in accordance with <U>Section</U><U></U><U>&nbsp;2.7(g)</U>; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> each share of the common stock, par value of $0.001 per share, of Purchaser then outstanding immediately prior to the Effective
Time shall be converted into one validly issued, fully paid, and <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of common stock of the Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If, between the date of this Agreement and the Effective Time, the outstanding Shares are changed into a different number or class
of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction, then the Merger Consideration shall be
equitably adjusted to reflect such change and provide the holders of Shares and holders of Company Options and RSUs with the same economic effect as contemplated by this Agreement prior to such event; <I>provided</I>, that nothing in this
<U>Section</U><U></U><U>&nbsp;2.6(b)</U> shall be construed to permit the Company to take any action that is prohibited by the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7</B> <B>Surrender of </B><B>Certificates</B><B>; Stock Transfer Books</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Prior to the Offer Acceptance Time, Parent shall designate a reputable U.S. bank or trust company reasonably acceptable to the
Company to act as depositary agent for the Company Stockholders entitled to receive the Offer Price pursuant to <U>Section</U><U></U><U>&nbsp;1.1(b)</U> and to act as the paying agent for the Company Stockholders entitled to receive Merger
Consideration pursuant to <U>Section</U><U></U><U>&nbsp;2.6</U> (the &#8220;<B><I>Paying Agent</I></B>&#8221;). Parent shall pay, or cause to be paid, all fees and expenses of the Paying Agent. The agreement entered into prior to Closing pursuant to
which Parent shall appoint the Paying Agent (the &#8220;<B><I>Paying Agent Agreement</I></B>&#8221;) shall be in form and substance reasonably acceptable to the Company. At or promptly following the Effective Time, Parent shall deposit, or shall
cause to be deposited, with the Paying Agent cash in immediately available funds in U.S. dollars an amount sufficient to make payment of the aggregate Offer Price payable pursuant to <U>Section</U><U></U><U>&nbsp;1.1(b)</U> and the aggregate Merger
Consideration (such deposit, the &#8220;<B><I>Payment Fund</I></B>&#8221;). The Payment Fund shall not be used for any purpose other than to pay the aggregate Offer Price in the Offer and the aggregate Merger Consideration in the Merger as provided
herein. Earnings from such investments shall be the sole and exclusive property of Parent, and no part of such earnings shall accrue to the benefit of the Company Stockholders, or holders of Company Options or RSUs in each case, as of immediately
prior to the Effective Time. The Payment Fund shall be invested by the Paying Agent as directed by Parent, in its sole discretion; <I>provided</I>, that such investments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be in obligations of or guaranteed by the United States of America in commercial paper obligations rated <FONT STYLE="white-space:nowrap">A-1</FONT> or
<FONT STYLE="white-space:nowrap">P-1</FONT> or better by Moody&#8217;s Investors Service, Inc. or Standard&nbsp;&amp; Poor&#8217;s Corporation, respectively, in certificates of deposit, bank repurchase agreements or banker&#8217;s acceptances of
commercial banks with capital exceeding $1&nbsp;billion, or in money market funds having a rating in the highest investment category granted by a recognized credit rating agency at the time of acquisition or a combination of the foregoing and, in
any such case, no such instrument shall have a maturity exceeding three months; <I>provided</I>, <I>further</I>, that no gain or loss on the Payment Fund shall affect the amounts payable hereunder. In the event the Payment Fund shall be insufficient
to pay the Offer Price in accordance with <U>Section</U><U></U><U>&nbsp;1.1(b)</U> and the aggregate Merger Consideration in accordance with <U>Section</U><U></U><U>&nbsp;2.9(d)</U>, Parent shall promptly deposit, or cause to be deposited,
additional funds with the Paying Agent in an amount that is equal to the shortfall that is required to make such payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
Promptly after the Effective Time (but in no event later than two (2)&nbsp;Business Days thereafter), Parent shall cause the Paying Agent to mail or otherwise provide to each Person who was, at the Effective Time, a holder of record of Shares (other
than Excluded Shares) that are (i)&nbsp;represented by certificates evidencing such Shares (the &#8220;<B><I>Certificates</I></B>&#8221;) or (ii)&nbsp;Book-Entry Shares that are not held, directly or indirectly, through the Depository Trust Company
(&#8220;<B><I>DTC</I></B>&#8221;), in the case of each of clauses (i)&nbsp;and (ii), notice advising such Person of the occurrence of the Effective Time, which notice shall include (A)&nbsp;appropriate transmittal materials, including a letter of
transmittal (which shall be in reasonable and customary form), specifying that delivery shall be effected, and risk of loss and title to the Certificates or such Book-Entry Shares shall pass only upon proper delivery of the Certificates (or
effective affidavits of loss in lieu thereof) or the surrender of such Book-Entry Shares to the Paying Agent (which shall be deemed to have been effected upon the delivery of a customary &#8220;agent&#8217;s message&#8221; with respect to such
Book-Entry Shares or such other reasonable evidence, if any, of such surrender as the Paying Agent may reasonably request pursuant to the terms of the conditions of the Paying Agent Agreement), as applicable and (B)&nbsp;instructions for use in
effecting the surrender of the Certificates (or effective affidavits of loss in lieu thereof) or such Book-Entry Shares to the Paying Agent in exchange for the Merger Consideration that such holder is entitled to receive as part of the Merger
pursuant to <U>Section</U><U></U><U>&nbsp;2.6</U>. No interest shall accrue or be paid on the Merger Consideration payable upon the surrender of any Certificates or Book-Entry Shares for the benefit of the holder thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> With respect to Book-Entry Shares held, directly or indirectly, through DTC, Parent and the Company shall cooperate to establish
procedures with the Paying Agent, DTC, DTC&#8217;s nominees and such other necessary or desirable third-party intermediaries to ensure that the Paying Agent will transmit to DTC or its nominees as promptly as practicable after the Effective Time,
upon surrender of Shares held of record by DTC or its nominees in accordance with DTC&#8217;s customary surrender procedures and such other procedures as agreed by Parent, the Company, the Paying Agent, DTC, DTC&#8217;s nominees and such other
necessary or desirable third-party intermediaries, the Merger Consideration to which the beneficial owners thereof are entitled to receive as a result of the Merger pursuant to <U>Section</U><U></U><U>&nbsp;2.6</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Upon surrender to the Paying Agent of the Shares that (i)&nbsp;are represented by
Certificates, by physical surrender of such Certificates (or effective affidavits of loss in lieu thereof), together with duly completed and executed appropriate transmittal materials required by the Paying Agent, (ii)&nbsp;are Book-Entry Shares not
held through DTC, by book-receipt of an &#8220;agent&#8217;s message&#8221; by the Paying Agent in connection with the surrender of such Book-Entry Shares (or such other reasonable evidence, if any, of such surrender as the Paying Agent may be
reasonably request pursuant to the terms and conditions of the Paying Agent Agreement) and (iii)&nbsp;are Book-Entry Shares held, directly or indirectly, through DTC, in accordance with DTC&#8217;s customary surrender procedures and such other
procedures as agreed by the Company, Parent, the Paying Agent, DTC, DTC&#8217;s nominees and such other necessary and desirable third-party intermediaries pursuant to <U>Section</U><U></U><U>&nbsp;2.7(c)</U>, the holder of such Certificates or
Book-Entry Shares shall be entitled to receive in exchange therefor, and Parent shall cause the Paying Agent to pay and deliver, out of the Payment Fund, as promptly as practicable to such holders, an amount in cash in immediately available funds
equal to the Merger Consideration for each Share formerly evidenced by such Certificates or Book-Entry Shares and such Certificates and Book-Entry Shares shall then be canceled. No interest shall accrue or be paid on the Merger Consideration payable
upon the surrender of any Certificates or Book-Entry Shares for the benefit of the holder thereof. If the payment of any Merger Consideration is to be made to a Person other than the Person in whose name the surrendered Certificates formerly
evidencing the Shares is registered on the stock transfer books of the Company, it shall be a condition of payment that the Certificate so surrendered shall be endorsed properly or otherwise be in proper form for transfer and that the Person
requesting such payment shall have paid all transfer and other similar Taxes required by reason of the payment of the Merger Consideration to a Person other than the registered holder of the Certificate surrendered, or shall have established to the
reasonable satisfaction of the Surviving Corporation that such Taxes either have been paid or are not applicable. Payment of the applicable Merger Consideration with respect to Book-Entry Shares shall only be made to the Person in whose name such
Book-Entry Shares are registered. Until surrendered as contemplated by this <U>Section</U><U></U><U>&nbsp;2.7</U>, each Certificate and Book-Entry Share shall be deemed, after the Effective Time, to represent only the right to receive the applicable
Merger Consideration as contemplated by <U>Section</U><U></U><U>&nbsp;2.6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> At any time following twelve (12)&nbsp;months
after the Effective Time, the Surviving Corporation shall be entitled to require the Paying Agent to deliver to it any funds which had been made available to the Paying Agent and not disbursed to holders of Certificates or Book-Entry Shares
(including, all interest and other income received by the Paying Agent in respect of all funds made available to it), and, thereafter, such holders shall be entitled to look to the Surviving Corporation (subject to abandoned property, escheat and
other similar Legal Requirements) only as general creditors thereof with respect to the Merger Consideration that may be payable upon due surrender of the Certificates or Book-Entry Shares held by them, without any interest thereon. None of Parent,
Purchaser, the Surviving Corporation or the Paying Agent shall be liable to any holder of Certificates or Book-Entry Shares for the Merger Consideration delivered in respect of such share to a public official pursuant to any abandoned property,
escheat or other similar Legal Requirements. Any amounts remaining unclaimed by such holders at such time at which such amounts would otherwise escheat to or become property of any Governmental Body shall become, to the extent permitted by
applicable Legal Requirements, the property of the Surviving Corporation or its designee, free and clear of all claims or interest of any Person previously entitled thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> At the Effective Time, the stock transfer books of the Company with respect to
the Shares shall be closed and thereafter there shall be no further registration of transfers of Shares on the records of the Company. From and after the Effective Time, the holders of the Shares outstanding immediately prior to the Effective Time
shall cease to have any rights with respect to such Shares except as otherwise provided herein or by applicable Legal Requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> Each of the Surviving Corporation, Parent, Purchaser and their respective Affiliates and agents shall be entitled to deduct and
withhold (or cause the Paying Agent or any other applicable withholding agent to deduct and withhold) from any consideration payable pursuant to this Agreement (including the Offer and the Merger) to any holder of Shares, Company Options or RSUs or
any other consideration otherwise payable pursuant to this Agreement such Taxes or other amounts as it is required by any applicable Legal Requirements to deduct and withhold. Each such payor shall remit such amounts so deducted and withheld to the
appropriate Governmental Body. If any deduction or withholding obligation may be avoided or reduced by a payee providing information or documentation to the applicable payor, such payor shall use commercially reasonable efforts to provide the payee
the opportunity to provide applicable Tax forms, such as an IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> or an appropriate IRS Form <FONT STYLE="white-space:nowrap">W-8,</FONT> as applicable to avoid or reduce such deduction or withholding
to the extent permitted by applicable Legal Requirements. To the extent that any amounts are so deducted or withheld and are remitted to the appropriate Governmental Body, such amounts shall be treated for all purposes under this Agreement as having
been paid to the Person to whom such amounts would otherwise have been paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> If any Certificate shall have been lost, stolen
or destroyed, upon the making of an affidavit of that fact by the Person claiming such Certificate to be lost, stolen or destroyed and, if required by the Surviving Corporation, the posting by such Person of a bond, in such reasonable amount as
Parent may direct, as indemnity against any claim that may be made against it with respect to such Certificate (which shall not exceed the Merger Consideration payable with respect to such Certificate), the Paying Agent will pay (less any amounts
entitled to be deducted or withheld pursuant to <U>Section</U><U></U><U>&nbsp;2.7(g)</U>, in exchange for such lost, stolen or destroyed Certificate, the applicable Merger Consideration to be paid in respect of the Shares formerly represented by
such Certificate, as contemplated by this <U>Article 2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.8</B> <B>Dissenters</B><B>&#8217;</B><B> Rights</B>. Notwithstanding
anything to the contrary in this Agreement, any Shares outstanding immediately prior to the Effective Time that are held by holders and beneficial owners who (a)&nbsp;have not voted in favor of the Merger or consented to it in writing, (b)&nbsp;are
entitled to demand appraisal rights and have properly demanded appraisal rights with respect to such Shares pursuant to, and have complied in all respects with, all provisions of Section&nbsp;262 of the DGCL concerning the rights of holders or
beneficial owners to demand appraisal of such Shares in connection with the Merger and (c)&nbsp;as of the Effective Time have not failed to perfect nor have waived, effectively withdrawn or otherwise lost their rights to such appraisal and payment
under the DGCL (such Shares, the &#8220;<B><I>Dissenting Shares</I></B>&#8221;), shall not be converted into or represent the right to receive the Merger Consideration as of the Effective Time, but shall, by virtue of the Merger, be automatically
cancelled and no longer outstanding, shall cease to exist </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and shall be entitled to only such consideration as shall be determined pursuant to Section&nbsp;262 of the DGCL; <I>provided</I>,<I> </I>that, if any such holder or beneficial owner shall have
failed to perfect or shall have waived, effectively withdrawn or otherwise lost such holder&#8217;s right to appraisal and payment under the DGCL, or a court of competent jurisdiction has determined that such holders or beneficial owners are not
entitled to the relief provided by Section&nbsp;262 of the DGCL, then the right of such holder or beneficial owner to receive those rights under Section&nbsp;262 and to be paid the fair value of such Dissenting Shares shall cease and such
holder&#8217;s or beneficial owner&#8217;s Shares shall thereupon be deemed to have been converted as of the Effective Time into the right to receive the Merger Consideration (less any amounts entitled to be deducted or withheld pursuant to
<U>Section</U><U></U><U>&nbsp;2.7(g)</U>, and such Shares shall not be deemed to be Dissenting Shares. The Company shall provide Parent prompt written notice of any written demands received by the Company for appraisal of any Shares, any written
withdrawal of any such demand and any other demand, notice or instrument delivered to the Company prior to the Effective Time pursuant to the DGCL or other applicable Legal Requirements that relates to such demand, and Parent will have the
opportunity and right to participate in and, and after the Effective Time direct, all negotiations and Legal Proceedings with respect to such demands. The Company shall provide each of the holders of Shares as of the record date for the purpose of
receiving the notice required by Section&nbsp;262(d) of the DGCL with the notice contemplated thereby as part of the Schedule <FONT STYLE="white-space:nowrap">14D-9.</FONT> Prior to the Effective Time, the Company shall not, except with the prior
written consent of Parent, voluntarily make any payment or deliver any consideration with respect to, or settle or compromise, any demands for appraisal or payment, in respect of Dissenting Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.9</B> <B>Treatment of Company Stock Awards</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Each Company Option that is outstanding as of immediately prior to the Effective Time shall accelerate and become fully vested and
exercisable effective immediately prior to, and contingent upon, the Effective Time. As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Company, each vested
Company Option (after giving effect to the acceleration treatment set forth in the preceding sentence) that is then outstanding and unexercised as of immediately before the Effective Time shall be cancelled and converted into the right to receive an
amount in cash, without interest, equal to the product of (i)&nbsp;the total number of Shares subject to such Company Option immediately prior to the Effective Time, <I>multiplied by</I> (ii)&nbsp;the excess of&nbsp;the Merger Consideration
over&nbsp;the exercise price payable per Share under such Company Option (the &#8220;<B><I>Option Consideration</I></B>&#8221;). Each Company Option with a per share exercise price that is equal to or greater than the Merger Consideration shall be
cancelled at the Effective Time without the payment of consideration therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Each Company Restricted Share outstanding as of
immediately prior to the Effective Time shall become fully vested effective as of immediately prior to, and contingent upon the occurrence of, the Effective Time and shall, by virtue of the Merger and without any further action on the part of the
holders thereof, Parent, Purchaser or the Company, and net of any applicable withholding Taxes required to be deducted and withheld by applicable Tax Legal Requirements and pursuant to the individual award agreement pursuant to which the Company
Restricted Share was granted, be treated as a Share for all purposes under the terms of this Agreement (including, for the avoidance of doubt, <U>Section</U><U></U><U>&nbsp;2.6</U> and <U>Section</U><U></U><U>&nbsp;2.7</U>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Each restricted stock unit award granted pursuant to any of the Company Equity
Plans or otherwise (each, an &#8220;<B><I>RSU</I></B>&#8221; and together, the &#8220;<B><I>RSUs</I></B>&#8221;) that is outstanding as of immediately prior to the Effective Time, whether vested or unvested, shall, by virtue of the Merger and
without any further action on the part of the holders thereof, Parent, Purchaser or the Company, be cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i)&nbsp;the total number of Shares
issuable in settlement to such RSU immediately prior to the Effective Time without regard to vesting, <I>multiplied by</I> (ii)&nbsp;the Merger Consideration (the &#8220;<B><I>RSU Consideration</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> As soon as reasonably practicable after the Effective Time (but no later than the second payroll date after the Effective Time),
Parent shall, or shall cause the Surviving Corporation (or, at Parent&#8217;s election, a third party payroll provider of national reputation) to, pay through the Surviving Corporation&#8217;s (or such third party payroll provider&#8217;s) payroll
the aggregate Option Consideration and RSU Consideration payable with respect to Company Options and RSUs held by current or former employees of the Company (net of any withholding Taxes required to be deducted and withheld by applicable Legal
Requirements in accordance with <U>Section</U><U></U><U>&nbsp;2.7</U>(<U>g)</U>; <I>provided, however</I>, that to the extent the holder of a Company Option or RSU is not, and was not at any time during the vesting period of the Company Option or
RSU, an employee of the Company for employment tax purposes, the Option Consideration or RSU Consideration payable pursuant to this <U>Section</U><U></U><U>&nbsp;2.9</U> with respect to such Company Option or RSU shall be deposited in the Payment
Fund and paid by the Paying Agent in the manner described in <U>Section</U><U></U><U>&nbsp;2.7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Prior to the Closing, the
Company Board or any committee thereof shall (i)&nbsp;adopt such resolutions and take such other actions as are necessary to give effect to the transactions contemplated by this <U>Section</U><U></U><U>&nbsp;2.9</U>, (ii) ensure that after the
Effective Time no holder of Company Stock Awards shall have any right thereunder to acquire any securities of the Company, the Surviving Corporation or Parent, or to receive any payment or benefit with respect to any Company Stock Award, except as
provided in this <U>Section</U><U></U><U>&nbsp;2.9</U>, and (iii)&nbsp;ensure that after the Effective Time no further Company Stock Awards or other rights with respect to Shares shall be granted or outstanding under the Company Equity Plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.10</B> <B>Company ESPP</B>. As soon as reasonably practicable following the date hereof, the Company shall take all actions with respect
to the Company&#8217;s 2023 Employee Stock Purchase Plan (the &#8220;<B><I>Company ESPP</I></B>&#8221;) that are necessary to provide that: (a)&nbsp;following the date hereof, no Person may become a participant in the Company ESPP and no offering
period shall commence under the Company ESPP and (b)&nbsp;subject to the consummation of the Merger, the Company ESPP shall terminate effective immediately prior to the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.11</B> <B>No Dividends or Distributions</B>. No dividends or other distributions with respect to the capital stock of the Surviving
Corporation with a record date on or after the Effective Time will be paid to the holder of any Shares that are represented by Certificates or Book-Entry Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.12</B> <B>Further Action</B>. If, at any time after the Effective Time, any further
action is reasonably determined by Parent to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to all rights and property of Purchaser and the
Company, the officers and directors of the Surviving Corporation and Parent shall be fully authorized (in the name of Purchaser, in the name of the Company and otherwise) to take such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.13</B> <B>Merger Without a Vote of Stockholders</B>. The Merger will be governed by and effected under Section&nbsp;251(h) of the DGCL.
The parties hereto shall take all necessary and appropriate action to cause the Merger to become effective as soon as practicable following the consummation of the Offer, without a vote of the holders of the Shares in accordance with
Section&nbsp;251(h) of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except (a)&nbsp;as disclosed in the reports, statements and other documents filed by the Company with the SEC or furnished by the Company to
the SEC, in each case, pursuant to the Exchange Act on or after January&nbsp;1, 2024 and at least two (2)&nbsp;Business Days prior to the date of this Agreement (other than any disclosures contained or referenced therein under the captions
&#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; and any other disclosures contained or referenced therein, in each case to the extent such disclosures are predictive, cautionary or forward-looking in
nature) (it being acknowledged and agreed that this clause (a)&nbsp;shall not apply to the representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;3.1</U> (Due Organization and Good Standing), <U>Section</U><U></U><U>&nbsp;3.2</U>
(Certificate of Incorporation and Bylaws), <U>Section</U><U></U><U>&nbsp;3.3</U> (Authority; Binding Nature of Agreement; Anti-Takeover Laws), <U>Section</U><U></U><U>&nbsp;3.4</U> (Capitalization, Etc.), <U>Section</U><U></U><U>&nbsp;3.5</U>
(Merger Approval), <U>Section</U><U></U><U>&nbsp;3.6</U> <FONT STYLE="white-space:nowrap">(Non-contravention;</FONT> Consents), <U>Section</U><U></U><U>&nbsp;3.8</U> <FONT STYLE="white-space:nowrap">(14d-10</FONT> Matters) and
<U>Section</U><U></U><U>&nbsp;3.24</U> (Brokers and Finders)) or (b)&nbsp;subject to the terms of <U>Section</U><U></U><U>&nbsp;8.13</U>, as set forth in the Company Disclosure Letter, the Company hereby represents and warrants to Parent and
Purchaser as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>Due Organization and Good Standing</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has
all necessary power and authority: (i)&nbsp;to conduct its business in the manner in which its business is currently being conducted; and (ii)&nbsp;to own, lease and use its assets in the manner in which its assets are currently owned, leased and
used. The Company is qualified or licensed to do business, and is in good standing, in each jurisdiction where the nature of its business requires such qualification or licensing, except where the failure to be so qualified, licensed or in good
standing does not have, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company does not own any capital stock of, or any other equity interest of, or any equity interest of any nature in, any other
Entity. The Company has not agreed and is not obligated to make and is not bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>Certificate of Incorporation</B><B> and Bylaws</B>. The Company has delivered
or made available to Parent or Parent&#8217;s Representatives accurate and complete copies of the certificate of incorporation and bylaws of the Company, including all amendments thereto, as in full force and effect, and the Company is not in
violation of its certificate of incorporation and bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Authority; Binding Nature of </B><B>Agreement</B><B>;
Anti-Takeover Laws</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company has the corporate power and authority to enter into and deliver and to perform its
obligations under this Agreement and, subject to the satisfaction of the Minimum Condition, to consummate the Transactions. The Company Board (at a meeting duly called and held) has unanimously adopted resolutions (i)&nbsp;determining that this
Agreement and the consummation of the Transactions are advisable, fair to and in the best interest of, the Company and its stockholders, (ii)&nbsp;determining that the Merger shall be governed and effected in accordance with Section&nbsp;251(h) of
the DGCL, (iii)&nbsp;authorizing and approving the execution, delivery and performance by the Company of this Agreement and the consummation of the Transactions and (iv)&nbsp;resolving to recommend that the holders of Shares accept the Offer and
tender their Shares to Purchaser pursuant to the Offer, and to include the Company Board Recommendation in the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> when filed with the SEC and disseminated to the Company&#8217;s stockholders, which
resolutions, subject to <U>Section</U><U></U><U>&nbsp;5.4</U>, have not been subsequently withdrawn or modified in a manner adverse to Parent. This Agreement has been duly executed and delivered by the Company, and assuming due authorization,
execution and delivery by Parent and Purchaser, this Agreement constitutes the legal, valid and binding obligations of the Company and is enforceable against the Company in accordance with its terms, subject to the Bankruptcy and Equity Exceptions.
Except for the filing of the Certificate of Merger with the Secretary of State of the State of Delaware, no additional corporate proceedings or actions on the part of the Company are necessary to authorize the execution and delivery by the Company
of this Agreement, the performance by the Company of its covenants and obligations hereunder or the consummation of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Assuming the accuracy of the representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4.8</U>, the Company Board
has taken all actions so that the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL and any other Takeover Laws shall be inapplicable to: (i)&nbsp;the execution, delivery and performance of this Agreement and
(ii)&nbsp;the consummation of the Offer, the Merger and the other Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>Capitalization, Etc</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The authorized capital stock of the Company consists of: (i)&nbsp;140,000,000 shares of Company Voting Common Stock, of which
25,756,021 shares (including 74,836 Company Restricted Shares) have been issued or are outstanding as of the close of business on the Reference Date; (ii) 10,000,000 shares of Company <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock,
none of which have been issued or are outstanding as of the close of business on the Reference Date; and (iii)&nbsp;10,000,000 shares of Company Undesignated Preferred Stock, none of which are issued or outstanding as of the close of business on the
Reference Date. All of the outstanding Shares have been, and all such Shares that may be issued prior to the Effective Time will be when issued, duly authorized and validly issued, and are and will be fully paid and nonassessable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> (i)&nbsp;None of the outstanding Shares is entitled or subject to any preemptive
right, right of repurchase or forfeiture (other than the Company Restricted Shares), right of participation, right of maintenance or any similar right, (ii)&nbsp;none of the outstanding Shares is subject to any right of first refusal in favor of the
Company, (iii)&nbsp;there are no outstanding bonds, debentures, notes or other Indebtedness of the Company having a right to vote on any matters on which the Company Stockholders have a right to vote and (iv)&nbsp;there is no Company Contract
relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or from granting any option or similar right with respect to), any Shares. The Company is not under any obligation,
nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding Shares. The Company Common Stock constitutes the only outstanding class of securities of the Company registered
under the Securities Act or the Exchange Act. All outstanding securities of the Company have been offered and issued in compliance in all material respects with all applicable securities Legal Requirements, including the Securities Act and
&#8220;blue sky&#8221; Legal Requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> As of the close of business on the Reference Date: (i)&nbsp;3,808,540 Shares are
subject to issuance pursuant to Company Options granted and outstanding under the Company Equity Plans, (ii)&nbsp;10,387 Shares are subject to or otherwise deliverable in connection with outstanding RSUs under Company Equity Plans,
(iii)&nbsp;1,602,913 Shares are reserved for future issuance under the Company&#8217;s 2023 Equity Incentive Plan, (iv)&nbsp;662,920 Shares are reserved for future issuance under the Company ESPP as approved by the Company and (v) 74,836 Company
Restricted Shares are outstanding. The Company has delivered or made available to Parent or Parent&#8217;s Representatives copies of all Company Equity Plans covering the Company Options and RSUs outstanding as of the date of this Agreement and the
forms of all award agreements evidencing such Company Stock Awards, and no Company Stock Award materially deviates from such forms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Except as otherwise set forth in this <U>Section</U><U></U><U>&nbsp;3.4</U>, as of the close of business on the Reference Date,
there are no: (i)&nbsp;outstanding shares of capital stock, or other equity interest in the Company; (ii)&nbsp;outstanding subscriptions, options, calls, warrants, rights or other agreements (whether or not currently exercisable) to acquire any
shares of capital stock, restricted stock units, stock-based performance units or any other rights that are linked to (including any &#8220;phantom&#8221; stock, &#8220;phantom&#8221; stock rights, stock appreciation rights, stock-based units or any
other similar interests), or the value of which is in any way based on or derived from the value of any shares of capital stock or other securities of the Company; (iii)&nbsp;outstanding securities, instruments, bonds, debentures, notes or
obligations that are or may become convertible into or exchangeable for any shares of the capital stock or other securities of the Company ((i), (ii) and (iii), collectively, &#8220;<B><I>Company Securities</I></B>&#8221;); (iv) other obligations by
the Company to make any payments based on the price or value of the Shares or (v)&nbsp;stockholder rights plans (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contracts under which the Company is or may become obligated to
sell or otherwise issue any shares of its capital stock or any other securities. From the Reference Date to the execution of this Agreement, there have been no issuances by the Company of any Company Securities, except for the issuance of Shares
pursuant to the exercise of Company Options or the settlement of RSUs outstanding as of the Reference Date in accordance with their terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The Company has delivered or made available to Parent or Parent&#8217;s
Representatives accurate and complete copies of all Company Equity Plans covering the Company Options, Company Restricted Shares and RSUs outstanding as of the date of this Agreement and the forms of all award agreements evidencing such Company
Stock Awards, and no Company Stock Award agreement materially deviates from such forms. <U>Section</U><U></U><U>&nbsp;3.4(e)</U> of the Company Disclosure Letter sets forth, as of the close of business on the Reference Date, an accurate and complete
list of each outstanding Company Option, Company Restricted Share and RSU and, to the extent applicable, (i) the name (or employee identification number) of the holder thereof, (ii) the number of Shares subject to such Company Stock Award, (iii) the
exercise price per Share, (iv) the Company Stock Award Grant Date, (v)&nbsp;the vesting commencement date, (vi)&nbsp;the vesting schedule, including any performance conditions (and the terms of any acceleration thereof) and the extent to which the
Company Stock Award is vested and unvested as of the Reference Date, (vii)&nbsp;the Tax status of such Company Option under Section&nbsp;422 of the Code (or any applicable foreign Tax law providing favorable Tax treatment), (viii) the expiration
date of each Company Stock Award, (ix)&nbsp;the Company Equity Plan under which such Company Stock Award was granted, and (x)&nbsp;the country and/or state of residence of such Company Stock Award holder. All grants of Company Options, Company
Restricted Shares, and RSUs were validly issued no later than the date on which the grant of such Company Stock Award was by its terms to be effective (the &#8220;<B><I>Company Stock Award Grant Date</I></B>&#8221;) and properly approved by the
Company Board (or a committee thereof) in accordance with all applicable Legal Requirements and the terms of the applicable Company Equity Plan and the exercise price per Share of each Company Option was not less than the fair market value of a
Share on the applicable Company Stock Award Grant Date. Other than as set forth in <U>Section</U><U></U><U>&nbsp;3.4(e)</U> of the Company Disclosure Letter, as of the Reference Date, there is no issued, reserved for issuance, outstanding or
authorized stock option, restricted stock unit award, performance stock unit award, restricted stock award, stock appreciation, phantom stock, profit participation or similar rights or equity or equity-based awards with respect to the Company. Each
Company Stock Award was granted pursuant to a Company Equity Plan and is in compliance with all requirements set forth in such Company Equity Plan. Each Company Stock Award is either exempt or in compliance with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> None of the Company Associates have an outstanding offer letter, employment agreement or other Contract or Employee Plan as of the
date hereof that contemplates a grant of, or right to purchase or receive: (i)&nbsp;Company Options, RSUs, Company Restricted Shares or other equity awards with respect to Shares or (ii)&nbsp;other securities of the Company that, in each case, have
not been issued or granted as of the close of business on the Reference Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B>Merger Approval</B>. Following the Offer
Acceptance Time, assuming satisfaction of the Minimum Condition and the accuracy of the representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4.8</U>, no vote of the holders of any class or series of the Company&#8217;s capital
stock will be required in order to adopt this Agreement and the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6</B>
<B><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</B>. Assuming compliance with the applicable provisions of the Exchange Act, the DGCL, the HSR Act and any other applicable filing, notification or approval in any jurisdiction
required by Antitrust and FDI Laws and set forth on <U>Section</U><U></U><U>&nbsp;5.5(b)</U> of the Company Disclosure Letter and the rules and regulations of Nasdaq, the execution and delivery of this Agreement by the Company and the consummation
by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company of the Transactions will not: (a)&nbsp;conflict with or&nbsp;cause a violation of any of the provisions of the Certificate of Incorporation or bylaws (or similar organizational documents)
of the Company; (b)&nbsp;conflict with or cause a violation by the Company of any Legal Requirements or order applicable to the Company, or to which the Company is subject; (c)(i) conflict with, result in breach of, or constitute a default (or give
rise to any right of purchase, termination, cancellation, modification, acceleration or any other obligation or any event that, with the giving of notice, would constitute a default or give rise to any such right), under, any Material Contract,
(ii)&nbsp;require any Consent or notice under any Material Contract or (iii)&nbsp;cause the loss of any benefit to which the Company is entitled under any Material Contract or (d)&nbsp;result in any Encumbrance (other than a Permitted Encumbrance)
on any of the property or assets of the Company, except in the case of clauses&nbsp;(b), (c) and (d), for such violations, conflicts, breaches, defaults, loss of rights or benefits or failure to provide any Consents or notices as would not
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Except as may be required by the Exchange Act (including the filing with the SEC of the Schedule <FONT STYLE="white-space:nowrap">14D-9),</FONT> the DGCL,
the HSR Act and any other applicable filing, notification or approval in any jurisdiction required by Antitrust and FDI Laws and set forth on <U>Section</U><U></U><U>&nbsp;5.5(b)</U> of the Company Disclosure Letter and the rules and regulations of
Nasdaq, the Company is not required to give notice to, make any filing with or obtain any Consent from any Governmental Body at or prior to the Closing in connection with the execution and delivery of this Agreement or the consummation by the
Company of the Merger, except those notifications, filings or Consents that the failure to so give, make, obtain or receive would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.7</B> <B>SEC Filings; Financial Statements</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Since October&nbsp;19, 2023, the Company has filed or furnished all material reports, schedules, forms, statements and other
documents (including exhibits and all other information incorporated therein) required to be filed or furnished by the Company with the SEC (the &#8220;<B><I>Company SEC Documents</I></B>&#8221;). As of their respective dates, the Company SEC
Documents complied as to form in all material respects with the applicable requirements of the Securities Act, the Exchange Act or the Sarbanes-Oxley Act, as the case may be, and the rules and regulations of the SEC promulgated thereunder applicable
to such Company SEC Documents and, except to the extent that information contained in such Company SEC Document has been revised, amended, modified or superseded (prior to the date of this Agreement) by a later filed Company SEC Document, none of
the Company SEC Documents when filed or furnished contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. Since October&nbsp;19, 2023, no executive officer of the Company has failed in any respect to make the certifications required of him or her under Sections 302 or 906 of the Sarbanes-Oxley Act with respect
to any Company SEC Document. There are no outstanding loans or other extension of credit made by the Company to any executive officer (as defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> promulgated under the Exchange Act) or director of
the Company. There are no amendments or modifications to the Company SEC Documents that are required to be filed with (or furnished to) the SEC, but that have not yet been filed with (or furnished to) the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The audited and unaudited financial statements (including any related notes and
schedules) contained or incorporated by reference in the Company SEC Documents (except to the extent that information contained in such Company SEC Document has been revised, amended, modified or superseded (prior to the date of this Agreement) by a
later filed Company SEC Document): (i)&nbsp;complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii)&nbsp;were prepared in accordance with United States generally accepted accounting
principles (&#8220;<B><I>GAAP</I></B>&#8221;) applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements or as permitted by
<FONT STYLE="white-space:nowrap">Regulation&nbsp;S-X,</FONT> or, in the case of unaudited financial statements, as permitted by <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,</FONT> <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> or any
successor form under the Exchange Act); and (iii)&nbsp;fairly present, in all material respects, the financial position of the Company as of the respective dates thereof and the stockholders&#8217; equity, results of operations and cash flows of the
Company for the periods covered thereby (subject, in the case of the unaudited financial statements, to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments that are not, individually or in the aggregate, material). No
financial statements of any Person are required by GAAP to be included in the financial statements of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Company
maintains, and at all times since October&nbsp;19, 2023 has maintained, a system of internal controls over financial reporting (as defined in <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(f)</FONT> and
<FONT STYLE="white-space:nowrap">15d-15(f)</FONT> under the Exchange Act) which is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with GAAP. The Company&#8217;s management has completed an assessment of the effectiveness of the Company&#8217;s system of internal control over financial reporting in compliance with the requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act for the fiscal year ended December&nbsp;31, 2024, and, except as set forth in the Company SEC Reports filed prior to the date of this Agreement, that assessment concluded that those controls were effective.&nbsp;Except as set
forth in the Company SEC Documents filed prior to the date of this Agreement, since October&nbsp;19, 2023, neither the Company nor the Company&#8217;s independent registered accountant has identified or been made aware of: (A)&nbsp;any significant
deficiency or material weakness in the design or operation of internal control over financial reporting utilized by the Company; (B)&nbsp;any illegal act or fraud, whether or not material, that involves the management or other employees of the
Company; or (C)&nbsp;any claim or allegation regarding any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The Company maintains, and at all times since
October&nbsp;19, 2023 has maintained, disclosure controls and procedures required by <FONT STYLE="white-space:nowrap">Rule&nbsp;13a-15(e)</FONT> or <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> under the Exchange Act that are designed to provide
reasonable assurance that all information (both financial and nonfinancial) required to be disclosed in the Company&#8217;s reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the rules and forms of the SEC and that all such information is accumulated and communicated to the Company&#8217;s management as appropriate to allow timely decisions regarding required disclosure and to enable each of the
principal executive officer of the Company and the principal financial officer of the Company to make the certifications required under the Exchange Act with respect to such reports. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The Company is not a party to and has no obligation or other commitment to become
a party to any securitization transaction, off-balance sheet partnership or any similar Contract (including any Contract relating to any transaction or relationship between the Company, on the one hand, and any unconsolidated Affiliate, including
any structured finance, special purpose or limited purpose Entity, on the other hand, or any &#8220;off-balance sheet arrangements&#8221; (as defined in Item&nbsp;303(a) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> under the
Exchange Act)) where the result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, the Company in the Company&#8217;s published financial statements or other Company
SEC Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received
from the SEC with respect to the Company SEC Documents. To the knowledge of the Company, none of the Company SEC Documents is the subject of ongoing SEC review and there are no inquiries or investigations by the SEC or any internal investigations
pending or threatened, in each case regarding any accounting practices of the Company. The Company has made available to Parent copies of all material correspondence from October&nbsp;19, 2023 through the date hereof between the SEC and the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> Each document required to be filed by the Company with the SEC in connection with the Offer (the &#8220;<B><I>Company
Disclosure Documents</I></B>&#8221;) (including the Schedule <FONT STYLE="white-space:nowrap">14D-9),</FONT> and any amendments or supplements thereto, when filed, distributed or disseminated, as applicable, will comply as to form in all material
respects with the applicable requirements of the Exchange Act. The Company Disclosure Documents, at the time of the filing of such Company Disclosure Documents or any supplement or amendment thereto with the SEC and at the time such Company
Disclosure Documents or any supplements or amendments thereto are first distributed or disseminated to the Company&#8217;s stockholders, will not contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> The
information with respect to the Company that the Company furnishes to Parent or Purchaser in writing specifically for use in the Schedule TO and the Offer Documents, at the time of the filing of the Schedule TO, at the time of any amendment of or
supplement thereto, at the time of any publication, distribution or dissemination of the Offer Documents and at the time of the commencement of the Offer or at the Offer Acceptance Time will not contain any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> The Company makes no representation or warranty with respect to statements made or incorporated by reference in any Company
Disclosure Documents based on information supplied by or on behalf of Parent or Purchaser for inclusion or incorporation by reference in the Company Disclosure Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> The Company is, and since October&nbsp;19, 2023 has been, in compliance in all material respects with all applicable listing and
corporate governance requirements of Nasdaq, and is, and since October&nbsp;19, 2023 has been, in compliance in all material respects with all applicable rules, regulations and requirements of the Sarbanes-Oxley Act of 2002 and the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.8</B> <B>Rule <FONT STYLE="white-space:nowrap">14d-10</FONT></B>. The Compensation
Committee of the Company Board has, on or prior to the date hereof, (a)&nbsp;duly and unanimously adopted resolutions approving as an &#8220;employment compensation, severance or other employee benefit arrangement&#8221; within the meaning of Rule <FONT
STYLE="white-space:nowrap">14d-10(d)(1)</FONT> under the Exchange Act each agreement, plan, program, arrangement or understanding entered into or established by the Company or any of its Affiliates on or before the date hereof with or on behalf of
any of its officers, directors or employees and (b)&nbsp;has taken all other actions reasonably necessary to satisfy the requirements of the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> safe harbor under Rule
<FONT STYLE="white-space:nowrap">14d-10(d)</FONT> under the Exchange Act with respect to the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.9</B> <B>Absence of
Changes</B>. (a)&nbsp;Since December&nbsp;31, 2024, (i) except for the transactions contemplated by this Agreement and discussions and negotiations related thereto and to other strategic transactions and alternatives considered by the Company, the
Company has operated in all material respects in the ordinary course of business and (ii)&nbsp;there has not occurred a Material Adverse Effect and (b)&nbsp;since the date of the Balance Sheet, no actions have been taken by the Company that, if
taken or proposed to be taken after the date of this Agreement would have been prohibited by <U>Sections 5.2(b)(i)</U>, <U>(ii)</U>, <U>(vi)</U>, <U>(vii)</U>, <U>(viii)</U>, <U>(ix)</U>, <U>(x)</U>, <U>(xiii)</U>, <U>(xv)</U>, <U>(xviii)</U>,
<U>(xix)</U>, <U>(xxiii)</U>, <U>(xxiv)</U>, <U>(xxv)</U> and, solely as it relates to the foregoing, <U>(xxix)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.10</B>
<B>Liabilities</B>. The Company does not have any Liabilities, except for: (a)&nbsp;Liabilities accrued or reserved against on the Company&#8217;s Balance Sheet; (b)&nbsp;Liabilities or obligations incurred pursuant to the terms of this Agreement;
(c)&nbsp;Liabilities for performance of obligations of the Company under Company Contracts that have been made available to Parent (other than resulting from any breach or failure by the Company to perform thereunder) in effect as of the date hereof
or entered into from and after the date hereof to the extent permitted to be entered into; (d)&nbsp;Liabilities incurred since the date of the Balance Sheet in the ordinary course of business or in connection with the Transactions; and
(e)&nbsp;liabilities that have not had or would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.11</B> <B>Title to Assets</B>. The Company has good and valid title to all material tangible assets owned by it as of the date of this
Agreement, including all material tangible assets (other than capitalized or operating leases) reflected on the Company&#8217;s unaudited balance sheet in the most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (the
&#8220;<B><I>Balance Sheet</I></B>&#8221;) filed prior to the date hereof by the Company with the SEC (but excluding intellectual property which is covered by <U>Section</U><U></U><U>&nbsp;3.13</U>), except for assets (including inventory) sold or
otherwise disposed of in the ordinary course of business since the date of such Balance Sheet and except where such failure to have good and valid title would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.12</B> <B>Real Property</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company does not own, nor has it ever owned, any real property or any interest therein. The Company is not a party to any
agreement or option to purchase any real property or any interest therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <U>Section</U><U></U><U>&nbsp;3.12(b)</U> of the Company Disclosure Letter sets
all forth real property that is leased, subleased, used or otherwise occupied by the Company from another Person (the &#8220;<B><I>Leased Real Property</I></B>&#8221;). The Company holds a valid and existing leasehold interest in each Leased Real
Property, and such leasehold interest in each Leased Real Property is free and clear of all Encumbrances other than Permitted Encumbrances. As of the date of this Agreement, the Company has not received any written notice regarding any termination
event or material violation or breach or default under any Company Lease that has not since been cured and, to the knowledge of the Company no such termination event or uncured material violation, breach or default exists under any such Company
Lease. The Company has not exercised or given any notice of exercise of, nor has any landlord exercised or given any notice of, any right of first offer or right of first refusal contained in any Company Lease. The Company is in peaceful and
undisturbed possession of the Leased Real Property and there are no restrictions that preclude or restrict the ability of the Company to use the Leased Real Property for the purposes for which it is currently being used. The Company has not
subleased or otherwise granted to any Person the right to use, enjoy or occupy any portion of the Leased Real Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.13</B>
<B>Intellectual Property</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <U>Section</U><U></U><U>&nbsp;3.13(a)</U> of the Company Disclosure Letter identifies each item
of Registered IP in (i)&nbsp;the Company Owned IP (the &#8220;<B><I>Registered Company Owned IP</I></B>&#8221;) or (ii)&nbsp;the Company Licensed IP, in each case, together with the name of the current record owner(s) and if different, the legal
owner and beneficial owner (and if any other Person has an ownership interest in such item of Registered IP, the nature of such ownership interest), the applicable jurisdictions, the issuance, application or registration numbers and the date of
issuance, application or registration of the item. All Registered IP in the Company Owned IP or the Company Licensed IP that has been issued or that has completed registration is subsisting and, to the knowledge of the Company, valid and enforceable
(other than pending applications included in the Registered IP). No interference, opposition, reissue, reexamination, <I>inter partes</I> review, post-grant review, deviation proceeding, cancellation proceeding, arbitration, mediation, Governmental
Body proceeding, or other contested proceedings (other than patent or trademark prosecution activities being conducted before a Governmental Body in the ordinary course of business) is pending or, to the knowledge of the Company, threatened, in
which the scope, validity, enforceability, or ownership of any Registered Company Owned IP or Registered IP in the Company Licensed IP is being or has been contested or challenged. The Company has made available to Parent, for each item of
Registered Company Owned IP and Registered IP in the Company Licensed IP, a listing of all registration, maintenance, renewal, and other relevant fees, filings, and actions due or required, or that will come due or be required prior to the Closing
Date or the date one hundred twenty (120)&nbsp;days thereafter that the Company has knowledge of, in connection with perfecting the Company&#8217;s rights in or maintaining, in full force and effect, the Registered IP in the Company Owned IP and
Company Licensed IP. All such fees, filings, and actions due or required prior to the Closing or within thirty (30)&nbsp;days thereafter have been timely paid, filed, or taken, or will be timely paid, filed, or taken (except for fees, filings, and
actions that will come due between the date of this Agreement and the Closing Date or within thirty (30)&nbsp;days thereafter in connection with the Company Licensed IP for which the Company does not control filing, prosecution, and maintenance
under the terms of the applicable license Contract). The entity identified as the applicant upon initial filing of each patent or patent application in the Registered Company Owned IP that contains a priority claim to an earlier patent application
held the entire right to claim such priority to such earlier patent application at the time of such initial filing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company (i)&nbsp;is the sole and exclusive owner of all right, title and
interest in and to all Company Owned IP and all Intellectual Property Rights incorporated or embodied in each Company Product Candidate, free and clear of all Encumbrances other than Permitted Encumbrances, (ii)&nbsp;holds valid and enforceable
rights under all Company Licensed IP, free and clear of all Encumbrances other than Permitted Encumbrances, and (iii)&nbsp;owns or has sufficient, valid and enforceable license rights in, and after the Closing the Surviving Corporation will continue
to own or have sufficient valid and enforceable license rights in, all Intellectual Property Rights used by the Company in, or necessary for the conduct of, the Company&#8217;s business as currently conducted and as currently contemplated to be
conducted. Each Company Associate and other Person involved in the creation or development of any material Company Owned IP (or, to the knowledge of the Company, material Company Licensed IP) (each, an &#8220;<B><I>IP Developer</I></B>&#8221;) has
(in the case of third party licensors, to the knowledge of the Company) signed a valid and enforceable written agreement containing (A)&nbsp;a present assignment of Intellectual Property Rights to the Company (or such third party licensor in the
case of Company Licensed IP) and (B)&nbsp;customary confidentiality provisions. To the knowledge of the Company, no IP Developer has breached any such agreement. To the knowledge of the Company, no IP Developer has any claim, right (whether or not
currently exercisable) or interest (or has alleged that they have any such claim, right, or interest) to or in any (1)&nbsp;Intellectual Property Rights used by, or necessary for the operation of the business of the Company (or for the further
research, development, or commercialization of any Company Product Candidate) or (2)&nbsp;Company Owned IP (or, to the knowledge of the Company, Company Licensed IP). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No funding, facilities or personnel of any Governmental Body or any university, college, research institute or educational
institution has been used or is being used to create, in whole or in part, any Company Owned IP, or, to the knowledge of the Company, Company Licensed IP, or any other Intellectual Property Rights which would otherwise constitute Company Owned IP or
Company Licensed IP. No such Governmental Body, university, college, research institute or educational institution has, or has asserted, (i)&nbsp;ownership of or other rights in Intellectual Property Rights that are, or would otherwise constitute,
Company Owned IP or Company Licensed IP, (ii)&nbsp;licenses, pricing rights, or access rights to material Company Owned IP or Company Licensed IP, <FONT STYLE="white-space:nowrap">(iii)&nbsp;march-in</FONT> rights or rights to share in revenue
associated with material Company Owned IP or Company Licensed IP, or (iv)&nbsp;rights to direct manufacturing or require U.S. manufacturing of products embodying material Company Owned IP or Company Licensed IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <U>Section</U><U></U><U>&nbsp;3.13(d)</U> of the Company Disclosure Letter sets forth each agreement pursuant to which the Company:
(i)&nbsp;is granted a license, covenant not to sue, assert, or enforce, or other right or immunity under or to any material Intellectual Property Right that covers, is incorporated into, or is currently used in the development, testing, manufacture,
production, distribution, delivery or support of, any Company Product Candidate (each, an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;<B><I>In</I></B><B><I><FONT STYLE="white-space:nowrap">-bound</FONT> License</I></B>&#8221;) or (ii)&nbsp;grants to any third party a license, covenant not to sue, assert, or enforce, or
other right or immunity under or to any material Company Owned IP or Company Licensed IP (each, an &#8220;<B><I>Out</I></B><B><I><FONT STYLE="white-space:nowrap">-bound</FONT> License</I></B>&#8221;); <I>provided</I>, that <FONT
STYLE="white-space:nowrap">(x)&nbsp;In-bound</FONT> Licenses shall not include (and <U>Section</U><U></U><U>&nbsp;3.13(d)</U> of the Company Disclosure Letter may exclude) any (1)&nbsp;materials transfer agreements, (2)&nbsp;clinical trial
agreements, (3)&nbsp;nondisclosure agreements, (4)&nbsp;Contracts under which a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license is granted to Company that is incidental to its receipt of services or deliverables, and
(5)&nbsp;commercially available <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">software-as-a-service</FONT></FONT></FONT> offerings agreements, commercially available
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software license agreements, or license agreements commonly referred to as &#8220;open source,&#8221; &#8220;public,&#8221; or &#8220;freeware&#8221;
software licenses, in each case which is made generally available, in each case under (1)-(5), which are entered into in the ordinary course of business and in the case of clauses (1)&nbsp;and (2) above, do not involve the grant of any license,
covenant, or other right or immunity under or to any Intellectual Property Rights or technologies that are material to the Company or any Company Product Candidate, and <FONT STYLE="white-space:nowrap">(y)&nbsp;Out-bound</FONT> Licenses shall not
include (and <U>Section</U><U></U><U>&nbsp;3.13(d)</U> of the Company Disclosure Letter may exclude) any (1)&nbsp;materials transfer agreements, (2)&nbsp;clinical trial agreements, (3)&nbsp;nondisclosure agreements, and (4)&nbsp;Contracts under
which <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">out-bound</FONT> licenses are granted from the Company that are incidental to its receipt of services or deliverables, in each case under (1)-(4), which
are entered into in the ordinary course of business and, in each case, which do not grant any exclusive license or other exclusive right to or under any Company Owned IP or Company Licensed IP, and do not involve any right to make, have made, sell,
offer to sell, distribute, or commercialize any technology, product, or service ((x) and (y)&nbsp;collectively, &#8220;<B><I>Standard Contracts</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Except as would not, individually or in the aggregate, have or reasonably be expected to be material to the Company, the execution,
delivery, or performance of this Agreement and the consummation of the Transactions will not result in any Person acquiring, having, or receiving any ownership, <FONT STYLE="white-space:nowrap">co-ownership,</FONT> license, covenant not to sue,
assert, or enforce, or other right or immunity under or to any Company Owned IP, Company Licensed IP, Company Product Candidate, or Intellectual Property Rights of Parent or any of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> To the knowledge of the Company, the conduct of the business of the Company does not, and none of the Company Product Candidates
(or the development, manufacture, sale, offer for sale, distribution, use, or importation thereof) does, infringe, misappropriate, violate, or make unlawful use of any Intellectual Property Right owned by any other Person, and the Company has never
infringed, misappropriated or otherwise violated or made unlawful use of (directly, contributorily, by inducement or otherwise) any Intellectual Property Right owned by any other Person, in each case in any material way or in a manner that would
create a material liability for the Company. To the knowledge of the Company, no Person has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise violating, any Company Owned IP or any Company Licensed IP,
except for infringements, misappropriations, or violations that would not, individually or in the aggregate, be or reasonably be expected to be material to the Company. There is no Legal Proceeding (i)&nbsp;pending (or, to the knowledge of the
Company, threatened) against the Company alleging that the operation of the business of the Company, any Company Owned IP, or any Company Product Candidate (or the development, manufacture, sale, offer for sale, distribution, use, or importation
thereof) infringes or constitutes the misappropriation or other violation of any Intellectual Property Rights of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
another Person (or has done any of the foregoing in the past); or (ii)&nbsp;pending (or threatened in writing) by the Company that another Person has infringed, misappropriated or otherwise
violated any of the Company Owned IP or any Company Licensed IP. The Company has not received any written notice or other written communication (A)&nbsp;alleging or implying that the Company, any Company Product Candidate (or the development,
manufacture, sale, offer for sale, distribution, use, or importation thereof), or the operation of the business of the Company infringes or constitutes the misappropriation or other violation of any Intellectual Property Right of another Person (or
has done any of the foregoing in the past), (B) suggesting or offering that the Company obtain a license to any Intellectual Property Right of another Person, or (C)&nbsp;requesting or demanding defense of, or indemnification with respect to, any
infringement or misappropriation claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> Except as would not, individually or in the aggregate, be or reasonably be expected to
be material to the Company, the Company has taken reasonable security and other measures to protect the secrecy, confidentiality, and value of, and to protect against unauthorized disclosure of, its trade secrets and other material confidential
information, and, to the knowledge of the Company, no such trade secrets or other confidential information have been disclosed by the Company to any Person other than to Company Associates and other Persons, in each case, that are bound by
reasonable, written, valid and binding confidentiality agreements (or equivalent obligations) protecting such trade secrets or other confidential information. To the knowledge of the Company, there has been no material violation, infringement, or
unauthorized access or disclosure of the foregoing trade secrets or confidential information or breach of any of the foregoing agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> None of the Company Owned IP or, to the knowledge of the Company, Company Licensed IP, is subject to any pending or outstanding
injunction, directive, order, judgment, or other disposition of a dispute that adversely and materially restricts the use of any such Company Owned IP or Company Licensed IP, other than patent or trademark prosecution activities being conducted
before a Governmental Body in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.14</B> <B>Data Protection</B>.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Since the Lookback Date, the Company (i)&nbsp;is, and has been, in material compliance with applicable Data Security Requirements,
(ii)&nbsp;has not experienced any Security Incidents that required notification under applicable Data Security Requirements to any Person and (iii)&nbsp;has not received, or, to the knowledge of the Company, otherwise been subject to, any written
notices, complaints, notices, audits, proceedings, investigations or claims conducted or asserted by any other Person (including any Governmental Body) regarding the Company&#8217;s unauthorized or unlawful Processing of Personal Information or
violation of applicable Data Security Requirements. The Company has at all times taken all steps reasonably necessary, including implementing and monitoring appropriate physical, administrative, and technical safeguards and monitoring its compliance
with adequate measures with respect to technical and physical security, to ensure that all Personal Information in its possession or control is protected against loss and against unauthorized access, use, modification or disclosure in accordance
with Data Security Requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> To the knowledge of the Company, the execution, delivery, or performance of this
Agreement by the Company and the consummation of this Agreement will not violate applicable Data Security Requirements in any material respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect: (i)&nbsp;the
computer systems, including the software, firmware, hardware, networks, interfaces, platforms and related systems, owned, leased, or licensed by the Company (collectively, the &#8220;<B><I>Company Systems</I></B>&#8221;) operate and perform in all
material respects as required by the Company in connection with the conduct of its business as presently conducted and as presently contemplated to be conducted, (ii)&nbsp;since the Lookback Date, there have been no failures, breakdowns, continued
substandard performance or other adverse events affecting any such Company Systems that have caused or, to the knowledge of the Company, could reasonably be expected to result in the substantial disruption or interruption in or to the use of such
Company Systems or the conduct of the business of the Company as presently conducted and as presently contemplated to be conducted, and (iii)&nbsp;since the Lookback Date, there have not been any incidents of unauthorized access or other security
breaches of the Company Systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.15</B> <B>Contracts</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <U>Section</U><U></U><U>&nbsp;3.15(a)</U> of the Company Disclosure Letter identifies each Company Contract that constitutes a
Material Contract as of the date of this Agreement. For purposes of this Agreement, other than any Company Contract that is a nondisclosure agreement entered into (x)&nbsp;in the ordinary course of business and not otherwise containing any of the
terms described in clauses (i)&nbsp;through (xi) of this <U>Section</U><U></U><U>&nbsp;3.15(a)</U>, (y)&nbsp;in connection with discussions, negotiations and transactions related to this Agreement, or (z)&nbsp;that is an Employee Plan, each of the
following Company Contracts, whether or not set forth in the Company Disclosure Letter, shall be deemed to constitute a &#8220;<B><I>Material Contract</I></B>&#8221;: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any Company Contract (A)&nbsp;containing any exclusivity obligations or otherwise limiting the freedom or right of the Company (or
after the Offer Acceptance Time, Parent or its Affiliates) to research, develop, sell, distribute or manufacture any products or services for any other Person (or after the Offer Acceptance Time, Parent or its Affiliates), (B) otherwise limiting in
any respect the freedom or right of the Company, to engage in any line of business or to compete with any other Person in any location or line of business, (C)&nbsp;containing any &#8220;most favored nations&#8221; terms and conditions (including
with respect to pricing) granted by the Company, (D)&nbsp;provide for the purchase or supply of a minimum quantity of goods or services, or provide for the purchase or supply of all or substantially all of a certain type of good or service used by
the Company from a single vendor and its Affiliates or (E)&nbsp;provide for a guarantee by the Company of availability of supply or services; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> any Company Contract (other than Company Leases, offer letter and employment agreements) that requires (or is reasonably expected
to require)&nbsp;by its terms the payment or delivery of cash or other consideration by or to the Company in an amount having an expected value in excess of $1,000,000 in any fiscal year ending on or after December&nbsp;31, 2025; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> any Company Contract that is an offer letter or employment agreement that
requires by its terms the payment or delivery of cash or other consideration by or to the Company in an amount having an expected value in excess of $250,000 in any fiscal year ending on or after December&nbsp;31, 2025; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> any Company Contract that constitutes a manufacturing, supply, distribution or marketing agreement or with a contract research
organization that provides for minimum payment obligations by the Company of at least $1,000,000 in any fiscal year ending on or after December&nbsp;31, 2025; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> any Company Contract or series of Company Contracts (A)&nbsp;relating to Indebtedness, individually or in the aggregate, in excess
of $100,000 (whether incurred, assumed, guaranteed or secured by any asset) of the Company, (B)&nbsp;relating to any loan, extension of credit or capital contribution by the Company or other investment in any Person (other than investments in
marketable securities in the ordinary course of business) or (C)&nbsp;granting any Encumbrance (other than Permitted Encumbrances) over any assets of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> any Company Contract that provides for or governs the formation, creation, operation, management or control of a joint venture,
partnership, or limited liability corporation, in each case, for the sharing of profits and losses; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> any Company Contract
that prohibits the payment of dividends or distributions in respect of the capital stock of the Company, the pledging of the capital stock or other equity interests of the Company or prohibits the issuance of any guaranty by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> any Company Contract (A)&nbsp;with any record or, to the knowledge of the Company, beneficial owner as of the date hereof of
five percent or more of the voting securities of the Company or (B)&nbsp;of the type that would be required to be disclosed under Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act or filed as a
&#8220;material contract&#8221; pursuant to Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> any Company Contract (A)&nbsp;that provides for the acquisition or disposition by the Company of assets for consideration in
excess of $500,000 or (B)&nbsp;pursuant to which the Company has acquired or will acquire any ownership interest in any other Person for consideration in excess of $500,000, in each case of clause (A)&nbsp;and (B), with material obligations
remaining to be performed or material Liabilities continuing after the date of this Agreement, but excluding any <FONT STYLE="white-space:nowrap">non-exclusive</FONT> software licenses granted to customers, resellers and original equipment
manufacturers in the ordinary course of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> any Company Contract with any Governmental Body with (A)&nbsp;continuing
material obligations of the Company or (B)&nbsp;that contains rights to funding for research and development activities involving the creation of Intellectual Property Rights; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xi)</B> any Company Contract that is (A)&nbsp;a collective bargaining agreement; (B)&nbsp;with any labor organization or (C)&nbsp;with a
third-party professional employer organization; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xii)</B> any Company Contract that is an
<FONT STYLE="white-space:nowrap">In-bound</FONT> License or an <FONT STYLE="white-space:nowrap">Out-bound</FONT> License; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xiii)</B>
any Company Contract for the joint development of products, technology or other Intellectual Property Rights; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xiv)</B> any Company
Contract that grants any rights of first refusal, rights of first option or similar rights or options to purchase or otherwise acquire any interest in any of the properties or assets or business owned by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xv)</B> any Company Contract pursuant to which the Company has unfulfilled obligations or interests involving (A)&nbsp;earnout, milestone
or other similar contingent payments, including upon the achievement of developmental, regulatory or commercial milestones or (B)&nbsp;payment of royalties or other amounts calculated based upon any revenues or income of the Company or any Company
Product Candidate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xvi)</B> any Company Contract requiring the Company to use commercially reasonable (or similar) efforts to
conduct certain activities or achieve specific milestones, with respect to, or otherwise related to, the research, development or commercialization of any Company Product Candidate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xvii)</B> any Company Contract that provides for indemnification (or reimbursement or advancement of legal fees or expenses) of any
current or former officer, director or employee of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xviii)</B> any Company Lease; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xix)</B> any Company Contract that evidences financial or commodity hedging or similar trading activities, including any interest rate
swaps, financial derivatives master agreements or confirmations, or futures account opening agreements and/or brokerage statements or similar Contract; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> any Company Contract that obligates the Company to make any expenditure, including a capital commitment, loan or capital
expenditure, in an aggregate amount in excess of $1,000,000 after the date of this Agreement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xxi)</B> any Company Contract or
series of Company Contracts that involves the settlement of any past, pending or threatened Legal Proceeding that (A)&nbsp;requires the Company to pay, individually or in the aggregate, in excess of $500,000 where such amount remains unpaid as of
the date of this Agreement or (B)&nbsp;will impose, or imposed, any continuing <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations on the Company, including any monitoring or reporting obligations to any other Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company has made available to Parent or Parent&#8217;s Representatives an
unredacted, correct and complete copy of each Material Contract (and all amendments or supplements thereto and waivers thereunder) or has publicly made available an unredacted, correct and complete copy of such Material Contract in the Electronic
Data Gathering, Analysis and Retrieval (EDGAR) database of the SEC. Neither the Company nor, to the knowledge of the Company, any other party thereto is in material breach of or material default under any Material Contract and, neither the Company,
nor, to the knowledge of the Company, any other party thereto has taken or failed to take any action that with or without notice, lapse of time or both would constitute a material breach of or material default under any Material Contract. Each
Material Contract is enforceable by the Company in accordance with its terms, subject to (i)&nbsp;laws of general application relating to bankruptcy, insolvency and the relief of debtors and (ii)&nbsp;rules of law governing specific performance,
injunctive relief and other equitable remedies (clauses&nbsp;(i) and (ii), the &#8220;<B><I>Bankruptcy and Equity Exceptions</I></B>&#8221;). Since the Lookback Date, the Company has not received any notice regarding any material violation or
material breach or material default under any Material Contract that has not since been cured, and to the knowledge of the Company, there are no circumstances that could reasonably be expected to give rise to such material violation, material breach
or material default. Since June&nbsp;1, 2025 and through the date hereof, none of the Company or any of its Representatives acting on behalf of the Company has granted any waiver, amendment or release of or under, or knowingly and intentionally
failed to enforce, any confidentiality, standstill or similar agreement (or any confidentiality, standstill or similar provision of any other Contract) relating to, arising from, or in connection with, any consideration or evaluation of any
Acquisition Proposal or any proposal that would reasonably be expected to lead to an Acquisition Proposal from any Person or group of Persons. Since the Lookback Date, the Company has not waived any rights under any Material Contract, except for
such waivers that have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Company has never received or otherwise been a party to a Government Contract, nor does it have any outstanding Government
Bids. The Company is not subject to the Government Contract Legal Requirements or rules, including those found within 2 C.F.R. Part 200 and agency supplements, the Federal Acquisition Regulation (&#8220;<B><I>FAR</I></B>&#8221;) and agency
supplements, and the Bayh-Dole Act, 35 U.S.C. &#167; 201 <I>et seq.</I>,&amp; 37 C.F.R. part 401. The Company and its directors, officers, and employees are not presently, and have never been, debarred, suspended, or otherwise rendered ineligible
for award of a Government Contract. The Company neither has contracted with, nor is in the process of contracting with, any &#8220;biotechnology company of concern&#8221; as defined under the &#8220;Biosecure&#8221; proposed legislation of 2024 or
2025 (Senate Amendment (SA) 3236, FY2026 National Defense Authorization Act (NDAA)), including WuXi Biologics, WuXi Apptech, BGI, MGI, Complete Genomics, and their respective Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.16</B> <B>Compliance with Legal Requirements; Regulatory Matters</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company, its Representatives and, to the knowledge of the Company and to the extent relating to any Company Product Candidate,
its distributors, resellers, third party contract manufacturers, clinical research organizations, consultants, clinical investigators, agents or other third parties acting on its or their behalf (&#8220;<B><I>Third Parties</I></B>&#8221;), are, and
since the Lookback Date, have been, in compliance with all Legal Requirements applicable to the Company or any Company Product Candidate, or by which any property, business, product or other asset of the Company is bound or affected, including all
applicable Healthcare Laws except where the failure to be in compliance would not and would not reasonably be expected to be, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individually or in the aggregate, material to the Company. Since the Lookback Date, the Company has not (and to the knowledge of the Company and to the extent relating to any Company Product
Candidate, none of its Third Parties have) been given written notice of, or charged with, or, to the knowledge of the Company, been alleged of any noncompliance or violation of, or Liability with respect to, any Healthcare Law (including any pending
or threatened noncompliance or violation, or claim, suit, proceeding, hearing, enforcement, audit, investigation or arbitration from any Governmental Body) except, in each case, for any such violation that has not had and would not reasonably be
expected to be, individually or in the aggregate, material to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company, its Representatives and, to the
knowledge of the Company, its Third Parties, (i)&nbsp;have not made any false, misleading, or untrue statement of material fact, or failed to disclose a material fact required to be disclosed, to any Regulatory Authority, nor committed any act, made
any statement, or failed to make any statement that would reasonably be likely to provide a basis for the U.S. Food and Drug Administration or any successor agency thereto (the &#8220;<B><I>FDA</I></B>&#8221;) to invoke its policy with respect to
&#8220;Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities&#8221; (the &#8220;<B><I>FDA Application Integrity Policy</I></B>&#8221;) or for any other Regulatory Authority to invoke any similar policy, and (ii)&nbsp;are not the
subject of any threatened or pending investigation by the FDA under the FDA Application Integrity Policy or by any other Regulatory Authority under a similar policy. The preclinical studies and clinical trials sponsored or conducted by or on behalf
of the Representatives of the Company have been, and if still pending are, conducted in all material respect in compliance with applicable Legal Requirements, including Healthcare Laws. Since the Lookback Date, the Company and its employees,
officers, and directors have not been, and, to the knowledge of the Company, no Third Parties, or other party acting on behalf of, or providing products or services to, the Company has been, (i)&nbsp;debarred (under the provisions of the Generic
Drug Enforcement Act of 1992, 21 U.S.C. &#167;335a(a) or (b)&nbsp;or any similar Legal Requirements), (ii) excluded or suspended from participation in United States federal healthcare programs (under the provisions of 42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7</FONT> or any similar Legal Requirements) including persons identified on the HHS/OIG List of Excluded Individuals/Entities, (iii)&nbsp;convicted of a crime for which a Person can be so (or would reasonably be
expected to be) debarred, suspended or excluded, (iv)&nbsp;threatened in writing to be so debarred or excluded, (v)&nbsp;declared ineligible for the awards of contracts by any U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state,
provincial or other agency; (vi)&nbsp;disqualified as a clinical investigator by the FDA or other Governmental Body or Regulatory Authority; or (vii)&nbsp;convicted of any offense related to any U.S. and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> federal, state, provincial or other healthcare program. Since the Lookback Date, the Company, its Representatives and, to the knowledge of the Company, their Third Parties has not (A)&nbsp;been
subject to a Governmental Body shutdown or import or export prohibition received from a Governmental Body written notice of inspectional observations, or received from the FDA any Form FDA 483, warning letter or untitled letter, or written requests
or requirements to make any material change to any Company Product Candidate or any of the Company&#8217;s processes or procedures that if not complied with, would reasonably be expected to be material to the Company, or (B)&nbsp;to the knowledge of
the Company, been the subject of any Legal Proceeding commenced by or on behalf of a Governmental Body, including the FDA, the DEA, the DOJ, the United States Department of Health and Human Services Office of the Inspector General
(&#8220;<B><I>OIG</I></B>&#8221;), any institutional review board or ethics committee or any similar foreign Governmental Body. Since the Lookback Date, the Company, its Representatives and, to the knowledge of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company and to the extent related to any Company Product Candidate, their Third Parties have not become, continued to be a party to, or been required to enter into any corporate integrity
agreement, monitoring agreement, consent decree, settlement order, or other similar written agreement, in each case, with or imposed by any Governmental Body, including the FDA, the DEA, the DOJ, the OIG, or any similar foreign Governmental Body.
Except as would not, individually or in the aggregate, be expected to be material to the Company, since the Lookback Date, all reports, documents, claims, permits, submissions, filings, permits, applications, and notices required to be filed with,
maintained in connection with, or furnished to a Governmental Body by the Company pursuant to Healthcare Laws have been so filed, maintained, or furnished, and all such reports, documents, claims, permits, submissions, filings, permits,
applications, and notices were true and complete on the date filed (or were corrected in or supplemented by a subsequent filing) and the Company holds such Governmental Authorizations required by the FDA or any other Regulatory Authority under
applicable Healthcare Laws for the conduct of their respective businesses as currently conducted (&#8220;<B><I>Regulatory Permits</I></B>&#8221;) and all such Regulatory Permits are in full force and effect. The Company is not authorized to bill,
nor has the Company directly claimed or received reimbursement from, any Governmental Program or from any other Third-Party Payor Program for services reimbursable under such programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> All development and manufacture of the Company Product Candidates, including any components thereof and any clinical supplies used
in any clinical trials, by or on behalf of the Company has been conducted in compliance in all material respects with the applicable specifications and requirements of Good Manufacturing Practices and Healthcare Laws. All development, testing,
labeling, distribution, storage, packaging, import, export, advertising, sale, promotion, and manufacture of the Company Product Candidate, including any components thereof and any clinical supplies used in any clinical trials, by or on behalf of
the Company are being conducted, and at all times since the Lookback Date, has been conducted in compliance with the terms of all Regulatory Permits and applicable Healthcare Laws, including any requirements under such applicable Regulatory Permits
or Healthcare Laws relating to the protection of human subjects or governing the privacy of patient medical records and other personal information and data, except where the failure to so comply, whether individually or in the aggregate, would not
reasonably be expected to be material to the Company. No clinical trial conducted or proposed to be conducted by or, on behalf of, the Company has been terminated or suspended by any Governmental Body. Neither the Company, nor, to the knowledge of
the Company any Third Party has received any written notifications or other communications from any Governmental Body, institutional review board, ethics committee or safety monitoring committee raising any material issues with respect to any
ongoing clinical or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or trials, threatening the initiation of any action to place a clinical hold order on any such studies or trials, or otherwise requiring the delay, termination,
suspension or material modification of such studies or trials in each case, solely with respect to a Company Product Candidate. All preclinical studies conducted by or on behalf of the Company (i)&nbsp;have been and are being conducted, as
applicable, in compliance with all requirements of the Animal Welfare Act, the United States Department of Agriculture&#8217;s implementing regulations, and the Guide for the Care and Use of Laboratory Animals, if applicable, and with all
requirements of 21 C.F.R. Part 58, (ii) which constitute in vivo activities have been approved by an external ethical review or animal welfare body, to the extent required by Healthcare Laws, and have been conducted
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with purpose bred animals (i.e., not wild caught), and (iii)&nbsp;have employed the procedures and controls required under Good Laboratory Practices, if applicable. The Company have instituted
and maintain policies and procedures reasonably designed to ensure the integrity of data generated in manufacturing all Company Product Candidates and to encourage employees to report any compliance issues related thereto, and the Company has made
available to Parent copies or written summaries of any such reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> None of the Company, any of its officers or employees,
or, to the knowledge of the Company and to the extent relating to any Company Product Candidate, any of its representatives, agents or third party contract manufacturers or contract research organizations (in each case, acting in the capacity of a
representative or agent of the Company) has engaged in any conduct that is not compliant in any material respect with applicable Healthcare Laws relating to the integrity of data generated or used in any clinical trials or other studies related to
the development, use, handling, safety, efficacy, reliability or manufacturing of Company Product Candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The Company has
made available to Parent true, correct and complete copies of: (i)&nbsp;all Regulatory Permits from the FDA or any other Regulatory Authority and all material Regulatory Permits from any other applicable Governmental Body held by the Company related
to Pacibekitug, (ii)&nbsp;all material written submissions made to, and material written regulatory communications with, the FDA, other Regulatory Authority or any other applicable Governmental Body related to Pacibekitug after the date on which the
Company designated Pacibekitug as a clinical candidate (the &#8220;<B><I>CC Date</I></B>&#8221;) that are in the Company&#8217;s possession or control (&#8220;control&#8221;, for purposes of this <U>Section</U><U></U><U>&nbsp;3.16(e)</U> and
<U>Section</U><U></U><U>&nbsp;5.16</U>, shall mean the legal, contractual or other right to access, including access to the information and materials of Collaboration Partners) as of the date of this Agreement and (iii)&nbsp;all reports, results,
data and information obtained, developed or prepared after the CC Date in the Company&#8217;s possession or control as of the date of this Agreement relating to the safety or efficacy of Pacibekitug, including all final reports prepared under 21
C.F.R. 58.185, all information collected pursuant to 21 C.F.R. Part 58 and all adverse event (as such term is defined or described in 21 C.F.R. 312.32) and other safety information (collectively, &#8220;<B><I>Healthcare Submissions</I></B>&#8221;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> The Company and its Subsidiaries have filed all material Healthcare Submissions as required under Healthcare Laws and all such
Healthcare Submissions were complete and accurate and in compliance with applicable Healthcare Laws when filed (or were corrected or completed in a subsequent filing). As of the date hereof, no deficiencies have been asserted by any applicable
Governmental Body to the Company with respect to any Healthcare Submission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.17</B> <B>Trade Control Laws; </B><B>Anti-Corruption
Laws</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Neither the Company, nor any of its officers, directors or employees, nor, to the knowledge the Company, any agent
or other third party representative acting on behalf of the Company: (i)&nbsp;is currently, or has been since January&nbsp;1, 2020: (A)&nbsp;a Sanctioned Person, (B)&nbsp;organized, resident or located in a Sanctioned Country, (C)&nbsp;engaging in
any dealings or transactions with any Sanctioned Person or in any Sanctioned Country, to the extent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such activities violate applicable Sanctions Laws or <FONT STYLE="white-space:nowrap">Export-Import</FONT> Laws or (D)&nbsp;in violation of or targeted under any applicable Sanctions Laws, <FONT
STYLE="white-space:nowrap">Export-Import</FONT> Laws, or the <FONT STYLE="white-space:nowrap">anti-boycott</FONT> Legal Requirements administered by the U.S. Department of Commerce and the IRS and Office of Foreign Assets Control (collectively with
Sanction Laws and Export-Import Laws, &#8220;<B><I>Trade Control Laws</I></B>&#8221;); or (ii)&nbsp;since January&nbsp;1, 2020, has on behalf of or in connection with the Company, directly or indirectly, (A)&nbsp;made or accepted any unlawful
payment or given, offered, promised, or authorized or agreed to give, any money or thing of value, directly or indirectly, to any Government Official or other Person in violation of any applicable Anti-Corruption Laws or (B)&nbsp;used any corporate
funds for unlawful contributions, gifts, entertainment or other unlawful expenses or renumerations relating to foreign or domestic political activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Since the Lookback Date, the Company has not directly or indirectly engaged in, facilitated, or permitted any bulk transfer of
sensitive personal data or human genomic data to any Person that is (i)&nbsp;located in, organized under the laws of, or owned or controlled by a person or entity in a country of concern as defined under 15 C.F.R. Part 7, or (ii)&nbsp;subject to the
jurisdiction of a &#8220;country of concern&#8221; as designated under Executive Order 14117 and related regulations issued by the U.S. Department of Justice, including the rule published at 88 Fed. Reg. 10690 (Feb. 16, 2024). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Since January&nbsp;1, 2020, the Company has not, in connection with or relating to the business of the Company, received any
written or, to the knowledge of the Company, oral, notice, inquiry, or any internal or external allegation, made any voluntary or involuntary disclosure to a Governmental Body, or conducted any internal investigation or audit concerning any actual
or potential violation or wrongdoing related to Trade Control Laws or <FONT STYLE="white-space:nowrap">Anti-Corruption</FONT> Laws and nothing relating to the foregoing is pending or, to the knowledge of the Company, threatened, against the Company
or any of the Company&#8217;s officers, directors or employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The Company has (i)&nbsp;adopted, maintained, complied with
and taken appropriate steps to enforce customary &#8220;know-your-customer&#8221; programs and anti-money laundering programs, as applicable, and (ii)&nbsp;maintains and complies with policies and procedures that are reasonably tailored to the
Company&#8217;s size, complexity, operations, business lines, geographic footprint, and business model&nbsp;and which are reasonably designed to ensure compliance with applicable Trade Control Laws and Anti-Corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.18</B> <B>Governmental Authorizations</B><B>; Compliance with Legal Requirements</B><B></B><B></B>. The Company holds, and since the
Lookback Date, has held, all Governmental Authorizations necessary for the Company to conduct its business in the manner in which its business is currently being conducted, except where failure to hold such Governmental Authorizations has not been
and would not reasonably be expected to be, individually or in the aggregate, material to the Company. The Governmental Authorizations held by the Company are valid and in full force and effect, except where the failure to be in full force and
effect has not been and would not reasonably be expected to be, individually or in the aggregate, material to the Company. The Company is in compliance with the terms and requirements of such Governmental Authorizations, except where failure to be
so in compliance has not been and would not reasonably be expected to be, individually or in the aggregate, material to the Company. The Company is, and has been since the Lookback Date, in compliance with all applicable Legal Requirements, except
for instances of noncompliance that have not been, and would not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonably be expected to be, individually or in the aggregate, material to the Company. Since the Lookback Date, (a)&nbsp;the Company has not received any written notice or any other
communications from any Governmental Body that alleges any violation or noncompliance (or reflects that the Company is under investigation or the subject of an inquiry by any such Governmental Body for such alleged noncompliance)&nbsp;with any
applicable Legal Requirement and (b)&nbsp;the Company has not entered into any agreement or settlement with any Governmental Body with respect to any alleged noncompliance with, or violation of, any applicable Legal Requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.19</B> <B>Tax Matters</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Except as would not have or reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect,
(i)&nbsp;each of the Tax Returns required to be filed by the Company with any Governmental Body have been filed on or before the applicable due date (taking into account any extensions of such due date), and all such Tax Returns are accurate,
complete and correct in all material respects, and&nbsp;(ii) the Company has paid, or caused to be paid, all Taxes imposed on or required to be paid by or with respect to the Company, whether or not shown as due on any such Tax Returns, including
any Taxes required to be withheld, collected or deposited by or with respect to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Except as would not have or
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, the Company has complied with all applicable Legal Requirements relating to the payment, collection, withholding and remittance of Taxes (including
information reporting requirements) with respect to payments made to any employee, creditor, independent contractor, stockholder or other third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No deficiency for any material Tax has been asserted or assessed by a Governmental Body in writing against the Company which
deficiency has not been paid, settled, resolved or withdrawn, and no current audit, examination, investigation, inquiry or other proceeding in respect of any material Taxes or material Tax Returns of the Company has been proposed or threatened in
writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The Company has not received written notice of any claim made by a Governmental Body in a jurisdiction where the
Company does not file a Tax Return that the Company is subject to taxation by that jurisdiction. The Company has not extended (which extension remains outstanding), and there are no outstanding requests, agreements, consents or waivers to extend,
the statutory period of limitations applicable to the assessment of any material Taxes or material Tax deficiencies against the Company, other than pursuant to extensions of time to file Tax Returns obtained in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The Company is not a party to, and is not bound by, any (i)&nbsp;material Tax sharing, allocation or indemnification agreement or
arrangement that would have a continuing effect after the Closing Date (other than such agreements or arrangements made in the ordinary course of business, the principal purpose of which is not Tax), (ii) closing agreement within the meaning of
Section&nbsp;7121 of the Code (or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Legal Requirements), which agreement will be binding on the Company after the Closing Date or (iii) private letter ruling of
the IRS or comparable ruling of any Governmental Body requested by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> There are no Encumbrances for Taxes upon the assets of the Company, other than
Permitted Encumbrances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> The Company (i)&nbsp;has not been a member of an affiliated group (within the meaning of
Section&nbsp;1504(a) of the Code) filing a consolidated U.S. federal income Tax Return or any similar group for state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax purposes (in each case, other than a group the common parent of
which was the Company) and (ii)&nbsp;does not have any liability for the Taxes of another Person under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any similar provision of state, local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Legal Requirements), by reason of having been a member of an affiliated, consolidated, combined, unitary, group relief or similar Tax group, as a transferee or successor or otherwise by operation of Legal
Requirements (in each case, other than liability for the Taxes of a former Subsidiary as a member of such group including the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> Within the past two (2)&nbsp;years, the Company has not been either a &#8220;distributing corporation&#8221; or a &#8220;controlled
corporation&#8221; in a distribution of stock intended to qualify for <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment under Section&nbsp;355 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> The Company has not been a party to, entered into or participated in a transaction that constitutes a &#8220;listed
transaction&#8221; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2)</FONT> (or any similar provision of state or local Legal Requirements). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> The Company will not be required to include any material item of income in, or exclude any material item of deduction from, taxable
income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i)&nbsp;change in method of accounting for a taxable period ending on or prior to the Closing Date, (ii)&nbsp;intercompany transactions or any
excess loss account described in Treasury Regulations under Section&nbsp;1502 of the Code (or any corresponding or similar provision of state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Legal Requirements) with respect to a
transaction occurring prior to the Closing, (iii)&nbsp;installment sale or open transaction disposition made prior to the Closing, (iv)&nbsp;an election under Section&nbsp;965 of the Code, or (v)&nbsp;prepaid amount received prior to the Closing
outside the ordinary course of business consistent with past practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> The Company does not have, and has never had, a
permanent establishment (as defined under applicable Legal Requirements or in an applicable income Tax treaty, if any) in any country other than the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> To the knowledge of the Company, there is no material abandoned or unclaimed property or escheat obligations with respect to
property or other assets held or owned by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> The Company has not been a &#8220;United States real property holding
company&#8221; within the meaning of Section&nbsp;897(c) of the Code during the applicable period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.20</B> <B>Employee Matters; Benefit Plans</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company is not and has never been a party to or subject to any collective bargaining agreement or other Contract with, and is
not and has never had a duty to bargain with, a labor organization or works council representing any of its employees. There is not any union organizing campaign, strike, material slowdown, work stoppage, lockout, picketing or labor dispute, and, to
the knowledge of the Company, there has not been since the Lookback Date. The Company is in material compliance with all applicable Legal Requirements related to employment and employment practices, including any pertaining to payment of wages and
hours of work, leaves of absence, plant closing notifications, employment statutes or regulations, workplace health and safety, equal employment opportunity, pay equity and pay transparency, reasonable accommodations, engagement of independent
contractors (including the appropriate classification of the same), retaliation, or discrimination matters, including charges of unfair labor practices or harassment, and there is no material Legal Proceeding pending or, to the knowledge of the
Company, threatened relating to such applicable Legal Requirements. Since the Lookback Date, the Company has not experienced any material labor disputes, or any strikes, work stoppages, slowdowns, lockouts or union organization attempts. The Company
is not engaging, and has not engaged, in any unfair labor practice, nor is there any unfair labor practice charge or complaint or other Legal Proceeding presently pending or threatened in writing against the Company. All individuals who perform
services for the Company and who have been classified as other than employees have been properly classified as such. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Since the
Lookback Date, (i)&nbsp;no Governmental Body has, to the knowledge of the Company, threatened or initiated any complaints, charges, lawsuits, grievances, claims, arbitrations, administrative proceedings or other proceeding(s) or investigation(s)
with respect to the Company arising out of, in connection with, or otherwise relating to any Legal Requirements related to employment and employment practices and (ii)&nbsp;no Governmental Body has issued or, to the knowledge of the Company,
threatened to issue any significant citation, order, judgment, fine, penalty, charge, or decree against the Company with respect to any Legal Requirements related to employment and employment practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Since the Lookback Date, the Company has not implemented any &#8220;plant closing,&#8221; &#8220;mass layoff,&#8221;
&#8220;relocation,&#8221; or other action that did or would reasonably be expected to require notification under the Worker Adjustment Notification and Retraining Act or similar foreign, federal, or state law requiring advance notice to employees of
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Since the Lookback Date, no formal (or to the knowledge of the Company, informal) allegation, complaint, charge,
or claim of harassment on the basis of gender, sex or race, sexual assault, sexual misconduct, gender discrimination, racial or ethnic discrimination has been made against any Person who is or was an officer, director, manager or supervisory-level
employee of the Company (a &#8220;<B><I>Misconduct Allegation</I></B>&#8221;), and the Company has not entered into any settlement agreement, tolling agreement, <FONT STYLE="white-space:nowrap">non-disparagement</FONT> agreement, confidentiality
agreement or <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement, or any similar contract with respect to any Misconduct Allegation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The Company has made available a complete and accurate list of each individual
who is employed by the Company as of the date hereof, listed by their name and title, including their salaries, wage rates, commissions, bonus targets, overtime entitlement and accrual, location of employment, status as full-time or part-time,
exempt or <FONT STYLE="white-space:nowrap">non-exempt</FONT> status under the Fair Labor Standards Act (as applicable), employing entity and hire date, annual vacation entitlement in days (if applicable) and accrued and unused vacation days (if
applicable), and any other paid <FONT STYLE="white-space:nowrap">time-off</FONT> entitlement in days and accrued and unused days of such paid <FONT STYLE="white-space:nowrap">time-off</FONT> (if applicable). The Company has also made available a
list of each individual currently on a leave of absence and their expected date of return to work, if known. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>
<U>Section</U><U></U><U>&nbsp;3.20(f)</U> of the Company Disclosure Letter sets forth a list of the material Employee Plans (other than (i)&nbsp;individual grants of Company Options, as long as the form stock option award agreements evidencing such
Company Options are in a form previously made available to Parent, (ii)&nbsp;offer letters or employment contracts that may be terminated by the Company without notice and which do not contain any severance, change in control, retention bonus, or
vesting acceleration or other similar compensation or benefits, as long as such offer letter or employment contract is in a form previously made available to Parent, and (iii)&nbsp;individual consultant contracts or arrangements that may be
terminated by the Company with no more than sixty (60)&nbsp;days&#8217; notice without penalty). The Company has made available to Parent, with respect to each material Employee Plan, accurate and complete copies of the following, as relevant:
(A)&nbsp;all material plan documents and all material amendments thereto, and all related trust or other funding documents; (B)&nbsp;any currently effective determination letter or opinion letter received from the IRS; (C)&nbsp;the most recent
annual actuarial report, asset statement, financial statement, and the most recent Form&nbsp;5500, including all schedules and attachments thereto; (D)&nbsp;the most recent summary plan descriptions and any material modifications thereto;
(E)&nbsp;the most recent nondiscrimination tests required to be performed under the Code and (F)&nbsp;all material, <FONT STYLE="white-space:nowrap">non-routine</FONT> correspondence with a Governmental Body received in the last three (3)&nbsp;years
with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> Neither the Company nor any of its ERISA Affiliates has during the past six&nbsp;(6) years maintained,
contributed to, or been required to contribute to or has had any actual or contingent liability under a plan that (i)&nbsp;is or was subject to Title&nbsp;IV of ERISA or Section&nbsp;412 of the Code, including any &#8220;single employer&#8221;
defined benefit plan or any &#8220;multiemployer plan&#8221; each as defined in Section&nbsp;4001 of ERISA, (ii)&nbsp;is or was a &#8220;multiple employer plan&#8221; as defined in ERISA or the Code, (iii)&nbsp;is or was a &#8220;funded welfare
plan&#8221; as defined in Section&nbsp;419 of the Code, (iv)&nbsp;is or was a &#8220;voluntary employees&#8217; beneficiary association&#8221; as defined in Section&nbsp;501(c)(9) of the Code, or (v)&nbsp;is or was a &#8220;multiple employer welfare
arrangement&#8221; as defined in Section&nbsp;3(40)(A) of ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> Each of the Employee Plans that is intended to be qualified
under Section&nbsp;401(a) of the Code has obtained a favorable determination letter (or opinion letter, if applicable) as to its qualified status under the Code, and, to the knowledge of the Company, there are no facts or circumstances that could
reasonably be expected to result in the revocation of such determination or opinion. To the knowledge of the Company, each of the Employee Plans is now and has been established, maintained, funded and operated in compliance in all material respects
with its terms and all applicable Legal Requirements, including ERISA and the Code. There are no claims (other than claims for benefits in the ordinary course) pending or, to the knowledge of the Company, threatened, with respect to any Employee
Plan or the assets thereof. All contributions, payments and premiums with respect to each Employee Plan that are required to be made by the Company with respect to periods ending on or prior to the Closing Date have been, or will be, timely made or
accrued before the Closing Date in accordance with the terms of the applicable Employee Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> The Company has not engaged in any
<FONT STYLE="white-space:nowrap">non-exempt</FONT> &#8220;prohibited transaction&#8221; (as defined in Section&nbsp;4975 of the Code or Section&nbsp;406 of ERISA), and no conditions exist, in each case which could reasonably be expected to subject
the Company, the Employee Plans or their related trusts to any Tax or penalty imposed under Section&nbsp;4975 of the Code or Section&nbsp;502 of ERISA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> Except to the extent required under Section&nbsp;601 et seq. of ERISA or Section&nbsp;4980B of the Code (or any other similar state
or local Legal Requirement) and at the full premium expense of the participant or beneficiary, neither the Company nor any Employee Plan could have any obligation to provide post-employment welfare benefits to or make any payment to, or with respect
to, any present or former employee, officer or director of the Company pursuant to any retiree medical benefit plan or other retiree welfare plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> Each Employee Plan that is a <FONT STYLE="white-space:nowrap">&#8220;non-qualified</FONT> deferred compensation plan&#8221; within
the meaning of Section&nbsp;409A of the Code complies in all material respects with Section&nbsp;409A of the Code. No Employee Plan or Contract provides for the <FONT STYLE="white-space:nowrap">gross-up,</FONT> reimbursement or indemnification of
any Taxes imposed by Section&nbsp;409A or Section&nbsp;4999 of the Code or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> The consummation of the Transactions
(including in combination with other events or circumstances) will not (i)&nbsp;accelerate the time of payment, vesting or funding of, or increase the amount of, compensation or benefits due to any such Company Associate, (ii)&nbsp;directly or
indirectly cause the Company to transfer or set aside any assets to fund any benefits under any Employee Plan (iii)&nbsp;entitle any current or former employee or individual service provider of the Company to any payment or benefit or any
forgiveness of indebtedness, or (iv)&nbsp;result in the payment or provision of any amount that would, individually or in combination with any other payment, be subject to tax under Section&nbsp;4999 of the Code or not be deductible by reason of
Section&nbsp;280G of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> No Employee Plan or Contract provides compensation or benefits to any current or former
employee or individual service provider of the Company who resides or performs services primarily outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.21</B> <B>Environmental Matters</B>. Except as would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect, (i)&nbsp;the Company is, and since the Lookback Date has been, in compliance with all applicable Environmental Laws, which compliance includes obtaining, maintaining or complying with all Governmental Authorizations required under
Environmental Laws for the ownership and operation of its business as currently owned and operated; (ii)&nbsp;there is no investigation or Legal Proceeding relating to or arising under any Environmental Law that is (A)&nbsp;pending or, to the
knowledge of the Company, threatened against the Company or (B)&nbsp;to the knowledge of the Company, pending or threatened against any Leased Real Property; (iii)&nbsp;since the Lookback Date or previously as to matters that have not been fully
resolved, the Company has not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received any written notice, report or other information of or entered into any legally-binding agreement or Order involving violations, Liabilities or requirements on the part of the Company
relating to or arising under Environmental Laws; (iv)&nbsp;the Company has not caused the Release of Hazardous Materials, at, under or under any Leased Real Property or any real property formerly owned, operated or leased by the Company;
(v)&nbsp;the Company has not arranged, by contract, agreement or otherwise, for the transportation, disposal or treatment of Hazardous Materials at any location; (vi)&nbsp;to the knowledge of the Company, (A)&nbsp;no Person has been exposed to any
Hazardous Materials at a property or facility of the Company, and (B)&nbsp;there are have been no Hazardous Materials present or Released on, at, under or from an property or facility, including the Leased Real Property; and (vii)&nbsp;the Company
has not assumed, undertaken or otherwise become subject to any Liability of another Person relating to Environmental Laws other than any indemnities in Material Contracts or Company Leases. The Company has made available to Parent copies of all
environmental assessments, reports, audits, Governmental Authorization, and all material documents in its possession or under its control that relate to the Company&#8217;s compliance with Environmental Laws, or the environmental condition of the
Leased Real Property or any other real property that Company has owned, operated, or leased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.22</B> <B>Insurance</B>. The Company
has made available to Parent a true, correct and complete copy of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets and operations of the Company. The Company maintains
insurance coverage in such amounts and covering such risks as are in accordance in all material respects with normal industry practice for companies of similar size and stage of development as the Company. Except as would not reasonably be expected
to be material to the Company, all such insurance policies are in full force and effect as of the date hereof, no notice of cancellation or modification has been received as of the date hereof, and there is no existing default or event which, with
the giving of notice or lapse of time or both, would constitute a default by any insured thereunder. As of the date of this Agreement, (i)&nbsp;to the knowledge of the Company, no insurer under any insurance policy has been declared insolvent or
placed in receivership, conservatorship or liquidation and (ii)&nbsp;there is no material claim pending under any of the Company&#8217;s insurance policies as to which coverage has been questioned, denied or disputed by the underwriters of such
policies, in each case, except as would not be, or would not reasonably be expected to be, individually or in the aggregate, material to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.23</B> <B>Legal Proceedings; Orders</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> There is no Legal Proceeding pending and served (or, to the knowledge of the Company, pending and not served or threatened) against
the Company or to the knowledge of the Company, against any present or former officer, director or employee of the Company in such individual&#8217;s capacity as such, other than any Legal Proceedings that would not reasonably be expected
(i)&nbsp;to be material to the operation of the Company (including the development, commercialization or other exploitation of any Company Product Candidate) or (ii)&nbsp;to prevent or materially impair the ability of the Company to consummate the
Transactions prior to the Outside Date or perform its obligations under this Agreement;<I>&nbsp;provided</I>, that to the extent this representation and warranty pertains to Legal Proceedings that relate to any Transaction Litigation, such
representation and warranty is made only as of the date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> There is no Order to which the Company is subject that would reasonably be
expected (i)&nbsp;to be material to the operation of the Company (including the development, commercialization or other exploitation of any Company Product Candidate) or (ii)&nbsp;to prevent or materially impair the ability of the Company to
consummate the Transactions prior to the Outside Date or perform its obligations under this Agreement; <I>provided</I>, that to the extent this representation and warranty pertains to an Order that relates to the execution, delivery, performance or
consummation of this Agreement or any of the transactions contemplated by this Agreement, such representation and warranty is made only as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> To the knowledge of the Company, no investigation or review by any Governmental Body with respect to the Company is pending or, to
the Company&#8217;s knowledge, is being threatened, other than any investigations or reviews that would not reasonably be expected (i)&nbsp;to be material to the operation of the Company (including the development, commercialization or other
exploitation of any Company Product Candidate) or (ii)&nbsp;prevent or materially impair the ability of the Company to consummate the Transactions prior to the Outside Date or perform its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.24</B> <B>Brokers and Finders</B>. Except for Leerink Partners LLC or its Affiliate, no broker, finder, investment banker, financial
advisor or other Person is entitled to any brokerage, finder&#8217;s or other similar fee or commission, or the reimbursement of expenses in connection therewith, in connection with the Transactions based upon arrangements made by or on behalf of
the Company or any of its Affiliates. The Company has made available to Parent a true, correct and complete copy of the engagement letter with Leerink Partners LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.25</B> <B>Fairness</B><B> Opinion</B><B></B><B></B>. The Company Board has received the oral opinion (to be subsequently confirmed by
delivery of a written opinion) of Leerink Partners LLC, as financial advisor to the Company, on or prior to the date of this Agreement, that, as of the date of such opinion, and based upon and subject to the various assumptions made, and the
qualifications and limitations upon the review undertaken by Leerink Partners LLC in preparing such opinion, the Offer Price or Merger Consideration to be paid to the holders of Company Common Stock (other than holders of Shares described in
Sections 2.6 (a)(i) and (ii)&nbsp;and holders of Dissenting Shares) pursuant to the terms of this Agreement is fair, from a financial point of view, to such holders. An executed copy of such opinion will be made available to Parent solely for
informational purposes after receipt thereof by the Company. It is agreed and understood that such opinion is for the benefit of the Company Board (in its capacity as such) and may not be relied upon by Parent or Purchaser or any of their respective
directors, officers or employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.26</B> <B>National Security</B><B></B><B></B>. The Company does not (a)&nbsp;produce, design,
test, manufacture, fabricate or develop one or more critical technologies, as defined at 31 C.F.R. &#167; 800.215, (b) perform the functions set forth in column 2 of Appendix A to 31 C.F.R. part 800 with respect to covered investment critical
infrastructure, as defined at 31 C.F.R. &#167; 800.212 or (c)&nbsp;maintain or collect, directly or indirectly, U.S. citizens&#8217; sensitive personal data, as defined at 31 C.F.R. &#167; 800.241. The Company is not a covered foreign person within
the meaning of 31 C.F.R. &#167; 850.209. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.27</B> <B>Related Party Transactions</B>. No&nbsp;current director, officer or
controlled Affiliate of the Company, (a)&nbsp;has outstanding any Indebtedness to the Company or (b)&nbsp;is otherwise a party to, or directly or indirectly benefits from, any Contract, arrangement or understanding with the Company (other than an
Employee Plan) of a type that would be required to be disclosed under Item 404 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K&nbsp;under</FONT> the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.28</B> <B>No</B><B> Other Representations or Warranties; Acknowledgment by the Company</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Except for the representations and warranties expressly set forth in this <U>Article 3</U> and in the certificate to be delivered
by the Company pursuant to clause (d)&nbsp;of <U>Annex I</U>, none of the Company, any of its Affiliates or any other Person on behalf of any of them is making or has made any express or implied representation or warranties of any kind or nature
whatsoever, including with respect to the Company or its business or with respect to any other information made available to Parent, Purchaser or their Representatives in connection with the Transactions, including the accuracy or completeness
thereof and the Company hereby expressly disclaims any such other representations and warranties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company acknowledges and
agrees that, except for the representations and warranties made by Parent and Purchaser in <U>Article 4</U>, none of Parent, Purchaser or any of their Affiliates nor any other Person is making or has made any representations or warranties, expressed
or implied, at law or in equity, with respect to or on behalf of Parent, Purchaser or any of their Subsidiaries, their respective businesses, operations, assets, liabilities, financial condition, results of operations, future operating or financial
results, estimates, projections, forecasts, plans or prospects (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, plans or prospects) or the accuracy or completeness of any information regarding
Parent, Purchaser or any of their Subsidiaries or any other matter made available to the Company or its Representatives in expectation of, or in connection with, this Agreement or the Transactions. The Company is not relying upon, and specifically
disclaims that it is relying upon, or has relied upon any such other representations or warranties that may have been made by any Person and acknowledges and agrees that Parent, Purchaser and their Affiliates have specifically disclaimed and do
hereby specifically disclaim any representations and warranties other than those set forth in <U>Article 4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4.
REPRESENTATIONS AND WARRANTIES OF PARENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND PURCHASER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parent and Purchaser represent and warrant to the Company as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Due Organization</B>. Each of Parent and Purchaser is a corporation duly organized, validly existing and in good standing under
the laws of its jurisdiction of organization and has all necessary power and authority: (a)&nbsp;to conduct its business in the manner in which its business is currently being conducted and (b)&nbsp;to own and use its assets in the manner in which
its assets are currently owned and used, except where any such failure does not, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>Purchaser</B>. Purchaser was formed solely for the purpose of engaging in the
Transactions and activities incidental thereto and has not engaged in any business activities or conducted any operations other than in connection with the Transactions and those incidental to its formation and its entry into this Agreement and
performance hereunder. A Subsidiary of Parent is the record and beneficial owner of all of the outstanding capital stock of Purchaser and Purchaser does not have any other outstanding securities or instruments exercisable for, or otherwise
convertible or exchangeable into, capital stock or any other security of Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Authority; Binding Nature of
</B><B>Agreement</B>. Parent and Purchaser have all requisite corporate power and authority to execute and deliver and perform their obligations under this Agreement and to consummate the Transactions. The execution, delivery and performance by
Parent and Purchaser of this Agreement and the consummation by Parent and Purchaser of the Transactions, subject to the adoption of this Agreement by Parent, as the sole shareholder of Purchaser (which adoption shall occur immediately after the
execution and delivery of this Agreement), have been duly authorized by all necessary action on the part of Parent and Purchaser and their respective boards of directors, and no other corporate proceedings on the part of Parent and Purchaser are
necessary to authorize the execution, delivery and performance of this Agreement or to consummate the Transactions (subject, in case of the Merger, to the recordation of appropriate merger documents as required by the DGCL). This Agreement
constitutes the legal, valid and binding obligation of Parent and Purchaser, and assuming due authorization, execution and delivery by the Company, is or will be, as applicable, enforceable against them in accordance with its terms, subject to the
Bankruptcy and Equity Exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</B>. Assuming
compliance with the applicable provisions of the Exchange Act, the DGCL, the HSR Act, if applicable, and any other applicable filing, notification or approval in any jurisdiction required by Antitrust and FDI Laws in those jurisdictions identified
in <U>Section</U><U></U><U>&nbsp;5.5(b)</U> of the Company Disclosure Letter, the execution and delivery of this Agreement by Parent and Purchaser, and the consummation of the Transactions, will not: (a)&nbsp;conflict with or cause a violation of
any of the provisions of the certificate of incorporation or bylaws or other organizational documents of Parent or Purchaser; (b)&nbsp;conflict with or cause a violation by Parent or Purchaser of any Legal Requirements or Order applicable to Parent
or Purchaser, or to which they are subject; or (c)&nbsp;conflict with, result in a breach of, or constitute a default on the part of Parent or Purchaser under any Contract, except, in the case of clauses&nbsp;(b) and (c), for such conflicts,
violations, breaches or defaults as would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. Except as may be required by the Exchange Act (including the filing with the SEC of the Offer
Documents), Takeover Laws, the DGCL, the HSR Act and any other applicable filing, notification or approval in any jurisdiction required by Antitrust and FDI Laws in those jurisdictions identified in <U>Section</U><U></U><U>&nbsp;5.5(b)</U> of the
Company Disclosure Letter, neither Parent nor Purchaser, nor any of Parent&#8217;s other Affiliates, is required to give notice to, make any filing with or obtain any Consent from any Governmental Body at or prior to the Closing in connection with
the execution and delivery of this Agreement or the consummation by Parent or Purchaser of the Offer, the Merger or the other Transactions, other than such filings, notifications, approvals, notices or Consents that, if not obtained, made or given,
would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. No vote of Parent&#8217;s stockholders is necessary to approve this Agreement or any of the Transactions that has not already been obtained
as of the date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5</B> <B>Disclosure</B>. None of the Offer Documents will, at the time such document is
filed with the SEC, at any time such document is amended or supplemented or at the time such document is first published, sent or given to the Company&#8217;s stockholders, contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; <I>provided</I>,<I> however</I>, that neither Parent nor Purchaser makes any
representation or warranty with respect to statements made or incorporated by reference in any Offer Documents based on information supplied by or on behalf of the Company for inclusion or incorporation by reference therein. None of the information
with respect to Parent or Purchaser supplied or to be supplied by or on behalf of Parent or Purchaser or any of their Subsidiaries specifically for inclusion or incorporation by reference in the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT>
will, at the time such document is filed with the SEC, at any time such document is amended or supplemented or at the time such document is first published, sent or given to the Company&#8217;s stockholders, contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6</B> <B>Absence of Litigation</B>. As of the date hereof, there is no Legal Proceeding pending and served or, to the knowledge of Parent
or Purchaser, pending and not served or threatened against Parent or Purchaser, except as would not and would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse Effect. To the knowledge of Parent or
Purchaser neither Parent nor Purchaser is subject to any continuing investigation by, any Governmental Body, or any Order of any Governmental Body, except as would not and would not reasonably be expected to, individually or in the aggregate, have a
Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.7</B> <B>Sufficiency of </B><B>Funds</B><B></B><B></B>. Parent has, and at all times from and after
the date hereof through the Closing will have, available to it, and Purchaser will have as of the Closing, sufficient funds to permit Parent or Purchaser to consummate the Transactions, including the payment of all amounts payable hereunder in cash,
and to comply with their obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.8</B> <B>Ownership of Company Common Stock</B>. As of the date hereof,
neither Parent nor any of Parent&#8217;s controlled Affiliates owns, beneficially or otherwise, any shares of the Company&#8217;s capital stock or any securities, contracts or obligations convertible into or exercisable or exchangeable for shares of
the Company&#8217;s capital stock (other than shares beneficially owned through passive investments, pension or employee benefit plans or trusts for Parent&#8217;s or its Affiliates&#8217; employees, or limited partnership funds, mutual funds or
similar entities that Parent has invested in, in all cases that Parent and its Affiliates do not directly or indirectly control the management or policies thereof). Neither Parent nor Purchaser is, or has been at any time during the period
commencing three (3)&nbsp;years prior to the date hereof,&nbsp;an &#8220;interested stockholder&#8221; of the Company under Section&nbsp;203(c) of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.9</B> <B>Brokers and </B><B>Finders</B>. No broker, investment banker, financial advisor, finder, agent or other Person is entitled to
any broker&#8217;s, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission in connection with the Transactions based upon arrangements made by or on behalf of Parent or any of its Subsidiaries except for Persons, if any, whose
fees and expenses shall be paid by Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.10</B> <B>Stockholder and Management Arrangements</B>. As of the date hereof, neither
Parent or Purchaser nor any of their respective Affiliates is a party to any Contract, or has authorized, made or entered into, or committed or agreed to enter into, any formal or informal arrangements or other understandings (whether or not
binding) with any stockholder, director, officer, employee or other Affiliate of the Company (a)&nbsp;relating to (i)&nbsp;this Agreement, the Offer or the Merger; (ii)&nbsp;the Company or (iii)&nbsp;the Surviving Corporation, businesses or
operations (including as to continuing employment) from and after the Effective Time; or (b)&nbsp;pursuant to which (i)&nbsp;any holder of shares of Company Common Stock would be entitled to receive consideration of a different amount or nature than
the Per Share Price in respect of such holder&#8217;s shares of Company Common Stock; (ii)&nbsp;any holder of shares of Company Common Stock has agreed to tender its Company Common Stock or vote against any Superior Proposal; or (iii)&nbsp;such
stockholder, director, officer, employee or other Affiliate of the Company agreed to provide, directly or indirectly, equity investment to Parent, Purchaser or the Company to finance any portion of the Offer or the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.11</B> <B>No Other Representations or Warranties; Acknowledgement by Parent and Purchaser</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Except for the representations and warranties expressly set forth in this <U>Article 4</U>, none of Parent, Purchaser or any of
their Affiliates nor any other Person on behalf of any of them is making or has made any express or implied representation or warranties of any kind or nature whatsoever, including with respect to Parent, Purchaser or their respective businesses or
with respect to any other information made available to the Company or its Representatives in connection with the Transactions, including the accuracy or completeness thereof and Parent and Purchaser hereby expressly disclaim any such other
representations and warranties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Parent and Purchaser acknowledge and agree that, except for the representations and warranties
made by the Company in this Agreement (as qualified by the Company Disclosure Letter) and in the certificate to be delivered by the Company pursuant to clause (d)&nbsp;of <U>Annex I</U>, none of the Company or any of their Affiliates nor any other
Person is making or has made any representations or warranties, expressed or implied, at law or in equity, with respect to or on behalf of the Company, its businesses, operations, assets, liabilities, financial condition, results of operations,
future operating or financial results, estimates, projections, forecasts, plans or prospects (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, plans or prospects) or the accuracy or completeness of
any information regarding the Company or any other matter made available to Parent, Purchaser or their Representatives in expectation of, or in connection with, this Agreement or the Transactions. Neither Parent nor Purchaser is relying upon and
specifically disclaim that they are relying upon or have relied upon any such other representations or warranties that may have been made by any Person and acknowledges and agrees that the Company and its Affiliates have specifically disclaimed and
do hereby specifically disclaim any such representations and warranties other than those set forth in <U>Article 3</U> or in the certificate to be delivered by the Company pursuant to clause (d)&nbsp;of <U>Annex I</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Parent and Purchaser have conducted their own independent investigation of the
Company and the Transactions and have had an opportunity to discuss and ask questions regarding the Company&#8217;s businesses with the management of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5. COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Access and Investigation</B>. During the period from the date of this Agreement until the earlier of the Effective Time and the
termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> (the &#8220;<B><I>Pre</I></B><B><I><FONT STYLE="white-space:nowrap">-Closing</FONT> Period</I></B>&#8221;), upon reasonable advance notice to the Company, the Company
shall, and shall cause the Representatives of the Company to provide Parent and Parent&#8217;s Representatives with reasonable access to the Company and its Representatives, properties, offices, books and records, Contracts, commitments and
personnel (other than any of the foregoing to the extent solely related to the negotiation and execution of this Agreement or any sale process preceding the execution and delivery of this Agreement, or, except as expressly provided in this
<U>Section</U><U></U><U>&nbsp;5.1</U> or <U>Section</U><U></U><U>&nbsp;5.4</U>, to any Acquisition Proposal), in each case as Parent reasonably requests for purposes of furthering the consummation of the Transactions or reasonable integration
planning; <I>provided, however,</I> that any such access shall be conducted at Parent&#8217;s sole cost and expense, at a reasonable time during the Company&#8217;s normal business hours, under the supervision of appropriate personnel of the Company
and in such a manner as not to unreasonably interfere with the normal operation of the business of the Company, and shall be subject to the Company&#8217;s reasonable security measures and insurance requirements and shall not include invasive
testing without the Company&#8217;s prior written consent (which shall not be unreasonably withheld, conditioned or delayed). Nothing herein shall require the Company to disclose any information, that in the reasonable judgement (after consultation
with its outside legal counsel) would reasonably be expected to (i)&nbsp;jeopardize any <FONT STYLE="white-space:nowrap">attorney-client</FONT> or other legal privilege (<I>provided</I>, that the Company shall use its commercially reasonable efforts
to allow the disclosure of such document or information (or as much of it as possible) in a manner that does not result in a loss of attorney-client or other legal privilege); <I>provided, further</I>, that information may be redacted to remove
references to valuation of the Company or the identity of alternative potential acquirers, (ii)&nbsp;contravene any applicable Legal Requirement, fiduciary duty or binding agreement entered into prior to the date of this Agreement (including any
confidentiality agreement to which the Company or its Affiliates is a party); <I>provided, further,</I> that the Company shall use good faith, commercially reasonable efforts to disclose such information to Parent and Parent&#8217;s Representatives
in a manner that does not contravene any Legal Requirement, fiduciary duty or agreement, including, if reasonably necessary, by requiring Parent to execute a joint defense agreement in customary form, or by limiting disclosure to outside counsel for
Parent, (iii)&nbsp;result in the disclosure of any valuations of the Company prepared in connection with the Transactions or any other strategic alternative or (iv)&nbsp;result in the disclosure or use of such document or information in any Legal
Proceeding among the Parties. With respect to the information disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;5.1</U>, Parent shall comply with, and shall instruct Parent&#8217;s Representatives to comply with, all of its obligations under
the Confidentiality Letter Agreement, dated August&nbsp;19, 2025, between the Company and Parent (as amended from time to time, the &#8220;<B><I>Confidentiality Agreement</I></B>&#8221;) and the Addendum to the Confidentiality Agreement, dated
August&nbsp;19, 2025, between the Company and Parent (as amended from time to time, the &#8220;<B><I>Addendum</I></B>&#8221;). All requests for information made pursuant to this <U>Section</U><U></U><U>&nbsp;5.1</U> shall be directed to the
executive officer or other Person designated by the Company from time to time. Notwithstanding anything in this <U>Section</U><U></U><U>&nbsp;5.1</U> to the contrary, nothing in this <U>Section</U><U></U><U>&nbsp;5.1</U> shall be construed to
require the Company or any of its Representatives to prepare or produce any financial statements, projections, reports, analyses, appraisals or opinions that are not prepared in the ordinary course of business and otherwise readily available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B>Operation of the Company</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, except (i)&nbsp;as expressly required or otherwise expressly
contemplated under this Agreement, (ii)&nbsp;as required by applicable Legal Requirements, (iii)&nbsp;with the written consent of Parent, which consent shall not be unreasonably withheld, conditioned or delayed or (iv)&nbsp;as set forth in
<U>Section</U><U></U><U>&nbsp;5.2(a)</U> of the Company Disclosure Letter, the Company shall (A)&nbsp;conduct its operations according to its ordinary course of business in all material respects consistent with past practice; (B)&nbsp;use its
commercially reasonable efforts to maintain its existence in good standing pursuant to applicable Legal Requirements; and (C)&nbsp;use its commercially reasonable efforts to (1)&nbsp;preserve intact its material assets, properties, Contracts or
other material legally binding understandings, licenses, permits and business organizations, (2)&nbsp;keep available the services of its present employees (other than any terminations for cause or voluntary resignations); and (3)&nbsp;preserve the
current relationships with Governmental Bodies and with material customers, vendors, distributors, manufacturers, consultants, researchers, partners, lessors, licensors, licensees, creditors, contractors and other Persons with which the Company
material business relations; <I>provided</I>, that any failure to take any action prohibited by <U>Section</U><U></U><U>&nbsp;5.2(b)</U> as a result of Parent&#8217;s unreasonable withholding, conditioning or delaying consent shall not be deemed a
breach of this <U>Section</U><U></U><U>&nbsp;5.2(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Period, except (w)&nbsp;as required or otherwise expressly contemplated under this Agreement, (x)&nbsp;as required by applicable Legal Requirements, (y)&nbsp;with the written consent of Parent, which consent shall not be unreasonably withheld,
conditioned or delayed or (z)&nbsp;as set forth in the Company Disclosure Letter, the Company shall not: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> (A)&nbsp;establish a
record date for, declare, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock (including the Company Common Stock) or (B)&nbsp;repurchase, redeem or otherwise reacquire any of its shares of
capital stock (including any Company Common Stock), or any rights, warrants or options to acquire any shares of its capital stock, other than: (1)&nbsp;repurchases or reacquisitions of Shares outstanding as of the date hereof pursuant to the
Company&#8217;s right (under written commitments in effect as of the date hereof) to purchase or reacquire Shares held by a Company Associate only upon termination of such associate&#8217;s employment or engagement by the Company;
(2)&nbsp;repurchases of Company Stock Awards (or shares of capital stock issued upon the exercise or vesting thereof) outstanding on the date hereof (in cancellation thereof) pursuant to the terms of any such Company Stock Award (in effect as of the
date hereof) between the Company and a Company Associate or member of the Company Board only upon termination of such Person&#8217;s employment or engagement by the Company; or (3)&nbsp;in connection with withholding to satisfy the exercise price or
Tax obligations with respect to Company Stock Awards; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> split, combine, subdivide or reclassify any shares of its capital stock
(including the Company Common Stock) or other equity interests; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> sell, issue, grant, deliver, pledge, transfer, encumber or
authorize the issuance, sale, delivery, pledge, transfer, encumbrance or grant by the Company (other than pursuant to agreements in effect as of the date of this Agreement) of (A)&nbsp;any capital stock, equity interest or other security of the
Company, (B)&nbsp;any option, call, warrant, restricted securities or right to acquire any capital stock, equity interest or other security of the Company or (C)&nbsp;any instrument convertible into or exchangeable for any capital stock, equity
interest or other security of the Company (except that the Company may (1)&nbsp;issue Shares as required to be issued upon the settlement of RSUs outstanding on the date of this Agreement, upon the exercise of Company Options outstanding on the date
of this Agreement, or the vesting of Company Stock Awards outstanding as of the date of this Agreement, (2)&nbsp;sell shares upon exercise of Company Options if necessary to effectuate an optionee direction upon exercise or sales to satisfy the
exercise price or Tax obligations with respect to Company Stock Awards and (3)&nbsp;authorize purchases of shares under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> except as required by the terms of any Employee Plan in effect on the date hereof and made available to Parent, or as otherwise
permitted under <U>Section</U><U></U><U>&nbsp;5.2(b)(i)</U> or <U>Section</U><U></U><U>&nbsp;5.2(b)(iii)</U>, establish, adopt, terminate or amend any Employee Plan (or any plan, program, arrangement, practice or agreement that would be an Employee
Plan if it were in existence on the date hereof), or amend or waive any of its rights under, or accelerate the vesting under, any provision of any of the Employee Plans (or any plan, program, arrangement, practice or agreement that would be an
Employee Plan if it were in existence on the date hereof) (except that the Company: (A)&nbsp;may amend any Employee Plans to the extent required by applicable Legal Requirements; and (B)&nbsp;may replace, renew or extend a broadly applicable
Employee Plan in the ordinary course of business that does not materially increase the cost of such Employee Plan or benefits provided under such Employee Plan based on the cost on the date of this Agreement); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> (A)&nbsp;enter into any change-of-control agreement with any executive officer, director, employee or independent contractor,
(B)&nbsp;enter into any employment or severance agreement with any executive officer or director, or (C)&nbsp;hire, promote, or terminate (other than for cause) the employment or service of any employee or other individual service provider with an
annual base salary or annualized rate of compensation in excess of $300,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> amend or permit the adoption of any amendment
to its Certificate of Incorporation or bylaws or other charter or organizational documents; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> change any financial accounting
methods, principles or practices used by it, except as required by GAAP or applicable Legal Requirements; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> acquire any
business or Person (including by merger, consolidation, acquisition of stock or assets or license); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> make any loans, advances or capital contributions to, or investments in, any
other Person (including any loans or other extension of credit made by the Company to any executive officer (as defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> promulgated under the Exchange Act) or director of the Company), except for
(A)&nbsp;advances for employee expenses in the ordinary course of business or (B)&nbsp;the extension of trade credit in the ordinary course of business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> form any Subsidiary or enter into any joint venture, partnership, limited liability corporation or similar arrangement, in each
case, for the sharing of profits and losses; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xi)</B> make or authorize any capital expenditure except (A)&nbsp;in connection with
the repair or replacement of facilities, properties or assets destroyed or damaged due to casualty or accident (whether or not covered by insurance) that do not exceed, individually or in the aggregate, $250,000 or (B)&nbsp;capital expenditures not
addressed by the foregoing clause (A)&nbsp;that do not exceed, individually or in the aggregate, $250,000 in the aggregate during any fiscal year; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xii)</B> sell, license, sublicense, place any Encumbrance on, lease, transfer or otherwise dispose of, divest or <FONT
STYLE="white-space:nowrap">spin-off,</FONT> abandon, waive, covenant not to assert, relinquish or permit to lapse, transfer or assign any right or other asset or property, or portion of its properties or assets, for consideration, or having a value,
that is individually or in the aggregate, in excess of $250,000, except (A)&nbsp;selling inventory and entering into <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license agreements in the ordinary course of business, or
(B)&nbsp;dispositions of obsolete, surplus or worn out tangible assets that are no longer useful in, and are not material to, the conduct of the business of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xiii)</B> enter into any new line of business outside pharmaceuticals; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xiv)</B> acquire any ownership or leasehold interest in any real property; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xv)</B> with respect to Intellectual Property Rights, acquire, sell, lease, license, sublicense, place any Encumbrance on, transfer or
otherwise dispose of, divest or <FONT STYLE="white-space:nowrap">spin-off,</FONT> abandon, waive, covenant not to assert, relinquish or permit to lapse (other than any patent expiring at the end of its statutory term and not capable of being
extended), transfer, or assign any material Intellectual Property Rights, including such Intellectual Property Rights pertaining to any Company Product Candidate, except pursuant to <FONT STYLE="white-space:nowrap">(A)&nbsp;non-exclusive</FONT>
licenses or sublicenses made in the ordinary course of business that are incidental to performance under the relevant agreement and granted to a Person solely with limited rights to perform services for the Company or (B)&nbsp;subject to
<U>Section</U><U></U><U>&nbsp;5.2(b)(xvii)</U> decisions made regarding the prosecution and maintenance of Intellectual Property Rights that is obsolete or otherwise no longer useful in the conduct of the business of the Company, excluding decisions
to abandon or permit to lapse patents, patent applications, trademarks, or trademark applications related to any Company Product Candidate or any claim in any patent or patent application within Company Owned IP or Company Licensed IP where such
abandonment or lapse of such claim would materially degrade the scope of protection related to any Company Product Candidate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xvi)</B> voluntarily relinquish or abandon, or fail to use commercially reasonable efforts to take any action necessary to maintain and
not permit to lapse, any material Company Owned IP or Company Licensed IP or rights of the Company therein; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xvii)</B> make any submissions or filings, or submit any other material correspondence,
to the U.S. Patent and Trademark Office or any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> equivalent related to any patent or trademark (including any application therefor) included in the Company Owned IP or Company Licensed IP without
providing Parent a reasonable opportunity to review and comment on such submissions, filings or other correspondence and considering in good faith any reasonable comments from Parent that are received in a timely fashion; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xviii)</B> (A) incur any Indebtedness or (B)&nbsp;assume, guarantee, endorse or otherwise become liable or responsible (whether directly,
contingently or otherwise) for the Liabilities of any other Person, in each case after the date of this Agreement in excess of $250,000, individual or in the aggregate, at any one time outstanding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xix)</B> (A) make, change or revoke any Tax election outside the ordinary course of business, (B)&nbsp;adopt or change any material
method of Tax accounting or any annual Tax accounting period in each case outside of the ordinary course of business, (C)&nbsp;enter into any &#8220;closing agreement&#8221; as described in Section&nbsp;7121 of the Code (or any comparable or similar
provisions of applicable Legal Requirements), settle or compromise any liability in each case with respect to material Taxes, (D)&nbsp;file any amended income or other material Tax Return, (E)&nbsp;affirmatively surrender any right to claim a
material Tax credit or refund, or (F)&nbsp;consent to any extension or waiver of the limitations period applicable to any claim or assessment with respect of material Taxes other than such extensions obtained in the ordinary course of business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> (A) enter into any Contract that would constitute a Material Contract if it had been in effect on the date of this Agreement or
(B)&nbsp;amend or modify in any material respect, or voluntarily waive or release any material rights under, any Material Contract (other than expirations at the end of the term of such Contract); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xxi)</B> commence any Legal Proceeding, except with respect to: (A)&nbsp;routine matters in the ordinary course of business; (B)&nbsp;in
such cases where the Company reasonably determines in good faith that the failure to commence suit would result in a material impairment of a valuable aspect of the Company&#8217;s businesses (<I>provided</I>, that the Company consults with Parent
and considers the views and comments of Parent with respect to such Legal Proceedings prior to commencement thereof); or (C)&nbsp;in connection with a breach of this Agreement or any other agreements between or among the Company, Parent or
Purchaser; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xxii)</B> settle, release, waive or compromise any Legal Proceeding or other claim (or threatened Legal Proceeding or
other claim), other than (A)&nbsp;any Legal Proceeding relating to a breach of this Agreement or any other agreements between or among the Company, Parent or Purchaser, (B)&nbsp;a settlement that results solely in a monetary obligation involving
only the payment of monies by the Company of not more than $250,000 individually or $500,000 in the aggregate, (C)&nbsp;that&nbsp;does not involve the admission of wrongdoing by, does not impose any restrictions or changes on the business or
operations of, and does not involve any injunctive or equitable or other nonmonetary relief (other than immaterial <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief incidental thereto)&nbsp;against, the Company, (D)&nbsp;that does not
provide for the grant to any third party of a license, cross license or other grant of rights to any material Intellectual Property Rights, and (E)&nbsp;that provides for a complete release of the claims in dispute giving rise to such settlement,
release, waiver or compromise; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xxiii)</B> enter into any collective bargaining agreement or other agreement with any
labor organization; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xxiv)</B> adopt a plan or agreement of complete or partial liquidation or dissolution, consolidation,
restructuring, recapitalization or other reorganization of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xxv)</B> adopt or implement any stockholder rights plan or
similar arrangement or enter into any agreement with respect to the voting or registration of any Company Securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xxvi)</B> fail
to maintain in full force and effect the existing insurance policies of the Company or to renew or replace such insurance policies with comparable insurance policies; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xxvii)</B> fail to file, report, complete or otherwise make any required Healthcare Submission or maintain any material Governmental
Authorization; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xxviii)</B> enter into any Contract that by its terms would bind or purport to bind Parent or its Affiliates in a
manner adverse to Parent or any of its Affiliates in any non <I>de minimis</I> respect; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(xxix)</B> authorize any of, or agree or
commit to take, any of the actions described in this <U>Section</U><U></U><U>&nbsp;5.2(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, nothing contained herein
shall give to Parent or Purchaser, directly or indirectly, the right to control or direct the operations of the Company prior to the Effective Time. Prior to the Effective Time, each of Parent and the Company shall exercise, consistent with the
terms and conditions hereof, complete control and supervision of its respective Subsidiaries&#8217; respective operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
Subject to applicable Legal Requirements and without limiting the foregoing in <U>Section</U><U></U><U>&nbsp;5.2(a)</U> and <U>Section</U><U></U><U>&nbsp;5.2(b)</U>, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, the Company:
(i)&nbsp;shall reasonably promptly inform Parent in writing of any correspondence or other written communications from any third party related to the settlement or disposition of any pending or threatened Legal Proceeding relating to the Company
Owned IP or Company Licensed IP (each such Legal Proceeding initiated by a third party, an &#8220;<B><I>Applicable Proceeding</I></B>&#8221;) and shall reasonably promptly provide Parent with copies of any such correspondence or other
communications; (ii)&nbsp;shall reasonably promptly provide Parent with copies of any correspondence or other written communications by or on behalf of the Company or any of its Representatives to any third party related to the settlement or
disposition of any Applicable Proceeding and shall provide Parent with a reasonable opportunity to review and comment thereon, prior to sending such correspondence or other communication; and (iii)&nbsp;shall notify Parent in writing prior to
engaging in any settlement or disposition of any Applicable Proceeding and shall consider in good faith Parent&#8217;s timely input with respect thereto; <I>provided, however</I>, that nothing herein shall require the Company to provide or disclose
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any information that, in the reasonable judgement of the Company (after consultation with its legal counsel) would jeopardize any attorney-client or other legal privilege (provided, that the
Company shall use good faith, commercially reasonable efforts to disclose such information in a manner that does not jeopardize any attorney-client or other legal privilege, including, if reasonably necessary, by executing a joint defense agreement
with Parent in customary form, or by limiting disclosure to outside counsel for Parent (or as much of it as possible)); <I>provided, further</I>, that this <U>Section</U><U></U><U>&nbsp;5.2(c)</U> shall not apply to any Legal Proceeding subject to
<U>Section</U><U></U><U>&nbsp;2.8</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B>No Solicitation</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Acceptable Confidentiality Agreement</B><B>.</B><B> </B>For the purposes of this Agreement, &#8220;<B><I>Acceptable
Confidentiality Agreement</I></B>&#8221; shall mean a confidentiality agreement that is entered into after the date of this Agreement and contains confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> and other provisions that are not
less favorable in the aggregate to the Company than those contained in the Confidentiality Agreement; <I>provided</I>, that any such confidentiality agreement (i)&nbsp;need not contain any standstill or similar provision and (ii)&nbsp;shall not
include any provision calling for any exclusive right to negotiate with such party or having the effect of prohibiting the Company or Parent, as applicable, from satisfying any of its obligations under this <U>Section</U><U></U><U>&nbsp;5.3</U>. The
Company shall provide Parent with a copy of each Acceptable Confidentiality Agreement entered into from and after the date of this Agreement substantially concurrently with its execution thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><FONT STYLE="white-space:nowrap">Non-Solicit</FONT></B><B>.</B><B> </B>Except as permitted by this
<U>Section</U><U></U><U>&nbsp;5.3</U>, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, the Company shall not, and shall cause its directors and officers and use its reasonable best efforts to cause its other Representatives
not to, directly or indirectly, (i)&nbsp;continue any solicitation, knowing facilitation or knowing encouragement or negotiations with any Persons that may be ongoing with respect to an Acquisition Proposal, (ii)&nbsp;solicit, initiate or knowingly
facilitate or knowingly encourage any Acquisition Proposal or any inquiries regarding, or the making of any proposal or offer that constitutes, or that could reasonably be expected to lead to, an Acquisition Proposal, (iii)&nbsp;engage in, continue
or otherwise participate in any discussions or negotiations regarding, or furnish to any other Person any information or data relating to the Company or afford to any Person (other than Parent, its Affiliates or its Representatives) access to the
business, properties, assets, books, records or other <FONT STYLE="white-space:nowrap">non-public</FONT> information, or to any personnel, of the Company, in any such case, in connection with, or for the purpose of, soliciting, initiating or
knowingly facilitating or encouraging, an Acquisition Proposal or any inquiry, proposal or offer that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal, (iv)&nbsp;enter into any letter of intent, acquisition agreement,
merger agreement, agreement in principle or similar agreement with respect to an Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition Proposal (each, a &#8220;<B><I>Company Acquisition
Agreement</I></B>&#8221;), (v) approve any transaction under, or any third party becoming an &#8220;interested stockholder&#8221; under, Section&nbsp;203 of the DGCL, (vi)&nbsp;subject to the last sentence of
<U>Section</U><U></U><U>&nbsp;5.3(c)</U>, grant any waiver, amendment or release of or under, or fail to enforce, any confidentiality, standstill or similar agreement (or any confidentiality, standstill or similar provision of any other Contract)
relating to any Acquisition Proposal or any proposal that would reasonably be expected to lead to an Acquisition Proposal from any Person or group of Persons or (vii)&nbsp;approve, authorize, agree or publicly announce any intention to do any of the
foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Immediately after the execution of this Agreement, the Company shall, and shall cause its directors and officers to, and shall use its reasonable best efforts to cause its other Representatives
to, immediately cease any solicitation and any and all existing discussions or negotiations with any Person conducted heretofore with respect to any Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an
Acquisition Proposal. After the execution of this Agreement, the Company shall and shall cause its directors and officers to, and the Company shall direct and use its reasonable best efforts to cause its other Representatives to: (x)&nbsp;as
promptly as reasonably practicable (and in any event within twenty-four (24)&nbsp;hours) terminate access by any third party (other than Parent, its Affiliates and its other Representatives) to any physical or electronic data room or similar
information sharing platform relating to any potential Acquisition Proposal or any proposal or offer that would reasonably be expected to lead to an Acquisition Proposal and (y)&nbsp;as promptly as reasonably practicable (and in any event within two
(2)&nbsp;Business Days) request the prompt return or destruction of any <FONT STYLE="white-space:nowrap">non-public</FONT> information previously furnished or made available to such Persons and their Representatives through such platform or in
connection with a potential Acquisition Proposal (or prior discussions in respect of a potential Acquisition Proposal). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Acquisition Proposal</B><B>.</B><B> </B>If at any time during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, the Company or any of its Representatives receives a <I>bona fide</I> unsolicited written Acquisition Proposal or any
proposal that would reasonably be expected to lead to an Acquisition Proposal from any Person or group of Persons which did not result from or arise out of any breach of this <U>Section</U><U></U><U>&nbsp;5.3</U> or
<U>Section</U><U></U><U>&nbsp;5.4</U>, (i)&nbsp;the Company and its Representatives may contact and engage in discussions with such Person or group of Persons solely to the extent necessary to clarify the terms and conditions of such Acquisition
Proposal or proposal, request that any oral Acquisition Proposal or proposal be provided in written form and inform such Person or group of Persons of the terms of this <U>Section</U><U></U><U>&nbsp;5.3</U> and (ii)&nbsp;if the Company Board
determines in good faith, after consultation with its financial advisor and outside legal counsel that such Acquisition Proposal (or proposal that would reasonably be expected to lead to an Acquisition Proposal) constitutes or would reasonably be
expected to lead to a Superior Proposal and that the failure to take such action described in clause (A)&nbsp;or (B) below would be inconsistent with its fiduciary duties under applicable Legal Requirements, then the Company and its Representatives
may (A)&nbsp;enter into an Acceptable Confidentiality Agreement and subject to entry into such Acceptable Confidentiality Agreement furnish pursuant thereto information (including <FONT STYLE="white-space:nowrap">non-public</FONT> information) with
respect to the Company to the Person or group of Persons who has made such Acquisition Proposal and their respective Representatives and financing sources; <I>provided</I>,<I> </I>that the Company shall substantially concurrently provide to Parent
any copies of any information or data concerning the Company, or access to the Company&#8217;s properties, books and records or personnel, that is provided to any Person given such access which was not previously provided to Parent or its
Representatives and (B)&nbsp;engage in or otherwise participate in discussions or negotiations with the Person or group of Persons making such Acquisition Proposal and their respective Representatives and financing sources, including soliciting the
submission of a revised Acquisition Proposal. Prior to the Company first taking any of the actions described in clauses (A)&nbsp;or (B) of the immediately preceding sentence with respect to an Acquisition Proposal, the Company shall provide written
notice to Parent of the determination of the Company Board made pursuant to the immediately preceding sentence. During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, the Company will not be required to enforce, and will be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permitted to waive, any provision of any standstill or confidentiality agreement that prohibits or purports to prohibit an Acquisition Proposal being made to the Company if, in each case,
(x)&nbsp;the Person making the Acquisition Proposal has not been solicited in breach of this <U>Section</U><U></U><U>&nbsp;5.3</U> and (y)&nbsp;the Company Board determines in good faith, after consultation with its outside legal counsel, that the
failure to take such action would be inconsistent with the fiduciary duties of the Company Board under applicable Legal Requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Notice of Acquisition Proposal</B><B>.</B><B> </B>The Company shall promptly (and in any event within twenty four
(24)&nbsp;hours) (i)&nbsp;notify Parent if any <I>bona fide</I> Acquisition Proposals or any proposals, inquiries or offers that would reasonably be expected to lead to an Acquisition Proposal are received by the Company or any of its
Representatives during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, together with the identity of the Person or group of Persons making such inquiries, proposals, indications of interest or offers, (ii)&nbsp;provide to Parent a
copy of any written Acquisition Proposal or written materials comprising such inquiry, proposal or offer received by the Company or any of its Representatives and a summary of the material terms and conditions of any oral Acquisition Proposal or any
such inquiry, proposal or offer, (iii)&nbsp;keep Parent reasonably informed on a reasonably prompt basis with respect to any material developments, discussions or negotiations regarding any Acquisition Proposal, or inquiry, proposal or offer that
would reasonably be expected to lead to an Acquisition Proposal, and the material terms and conditions thereof (including any change in price or form of consideration or other material amendment thereto), and (iv)&nbsp;upon the reasonable written
request of Parent, reasonably inform Parent of the status of such Acquisition Proposal or such inquiry, proposal or offer that would reasonably be expected to lead to an Acquisition Proposal. Without limiting the generality of the foregoing, the
Company will, promptly upon receipt or delivery thereof, provide Parent (and its outside counsel) with copies of all drafts and final versions (and any comments thereon) of definitive or other agreements (including schedules and exhibits thereto),
relating to such Acquisition Proposal exchanged between the Company or any Representative of the Company, on the one hand, and the Person or group of Persons making such Acquisition Proposal and their Representatives, on the other hand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Permitted Disclosures</B><B>.</B><B> </B>Nothing in this <U>Section</U><U></U><U>&nbsp;5.3</U> or elsewhere in this Agreement
shall prohibit the Company or the Company Board from (nor shall any of the following constitute a Company Adverse Change Recommendation) (i)&nbsp;taking and disclosing to the Company Stockholders a position contemplated by <FONT
STYLE="white-space:nowrap">Rule&nbsp;14e-2(a),</FONT> <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-9</FONT> or Item&nbsp;1012(a) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;M-A</FONT> promulgated under the Exchange Act, (ii)&nbsp;making
any disclosure to the Company Stockholders that is required by applicable Legal Requirements, (iii)&nbsp;making any &#8220;stop, look and listen&#8221; communication pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-9(f)</FONT> promulgated
under the Exchange Act, (iv)&nbsp;informing any Person of the existence of the provisions contained in this <U>Section</U><U></U><U>&nbsp;5.3</U>, (v) complying with its disclosure obligations under applicable Legal Requirements with regard to an
Acquisition Proposal, including making any disclosure to the Company Stockholders (including regarding the business, financial condition or results of operations of the Company) that the Company Board has determined to make in good faith after
consultation with outside legal counsel that failure to make such disclosure would be inconsistent with its fiduciary duties under applicable Legal Requirements or other Legal Requirements, it being understood that any such statement or disclosure
made by the Company Board must be subject to the terms and conditions of this Agreement or (vi)&nbsp;making a factually accurate public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statement that describes the Company&#8217;s receipt of an Acquisition Proposal, the identity of the Person making such Acquisition Proposal, the material terms of such Acquisition Proposal and
the operation of this Agreement with respect thereto; <I>provided</I>, in the case of each of clauses (i)&nbsp;through (vi), that any such disclosure by the Company shall state that the Company Board Recommendation continues to be in effect unless,
prior to the time of such public disclosure, a Company Adverse Change Recommendation has been made in compliance with <U>Section</U><U></U><U>&nbsp;5.4</U>, and that the Company and the Company Board may not in any event effect a Company Adverse
Change Recommendation or take any action prohibited by <U>Section</U><U></U><U>&nbsp;5.4(a)(ii)</U> except as otherwise permitted pursuant to <U>Section</U><U></U><U>&nbsp;5.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Representatives</B><B>.</B><B> </B>Any action taken or not taken by any Representative of the Company, at the direction or on
behalf of the Company or any of its officers or directors that violates this&nbsp;<U>Section&nbsp;5.3</U> or&nbsp;<U>Section 5.4</U>&nbsp;shall be deemed a violation of such applicable Section by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B> <B>Company Board Recommendation</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>No Company Adverse Change Recommendation</B><B>.</B><B> </B>During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Period, neither the Company Board nor any committee thereof shall (i)(A)&nbsp;withdraw or qualify, amend or modify in a manner adverse to Parent or Purchaser, the Company Board Recommendation; (B)&nbsp;publicly approve, recommend or declare
advisable, any Acquisition Proposal; (C)&nbsp;fail to include the Company Board Recommendation in the Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> when disseminated to Company Stockholders; (D)&nbsp;if any Acquisition Proposal is
structured as a tender offer or exchange offer for the outstanding Shares and is commenced pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2</FONT> under the Exchange Act (other than by Parent or an Affiliate of Parent) fail to recommend
against acceptance by the Company Stockholders of such tender offer or exchange offer, within ten (10)&nbsp;Business Days of the commencement of such tender or exchange offer; (E)&nbsp;fail to reaffirm the Company Board Recommendation within ten
(10)&nbsp;Business Days after receipt of a written request of Parent following the public announcement of any Acquisition Proposal; (F)&nbsp;take any action to exempt any Person (other than Parent or its Subsidiaries) or any action taken by any
Person (other than Parent and its Subsidiaries) from any Takeover Law&nbsp;or (G)&nbsp;publicly propose to do any of the foregoing (any action described in this clause&nbsp;(i) being referred to as a &#8220;<B><I>Company Adverse Change
Recommendation</I></B>&#8221;) or (ii)&nbsp;approve, recommend or declare advisable, or propose to approve, recommend or declare advisable or allow the Company to execute or enter into any Company Acquisition Agreement (other than an Acceptable
Confidentiality Agreement in accordance with <U>Section</U><U></U><U>&nbsp;5.3</U>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Permitted Company Adverse Change
Recommendation</B><B>.</B><B> </B>Notwithstanding anything to the contrary contained in <U>Section</U><U></U><U>&nbsp;5.4(a)</U> or elsewhere in this Agreement, at any time prior to the Offer Acceptance Time: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> in the event that (x)&nbsp;the Company or any of its Representatives receives a <I>bona fide</I> written Acquisition Proposal from
any Person that did not result from a breach of <U>Section</U><U></U><U>&nbsp;5.3</U>) that has not been withdrawn and (y)&nbsp;the Company Board determines in good faith, after consultation with its financial advisor and outside legal counsel, that
such Acquisition Proposal is a Superior Proposal, the Company Board may (A)&nbsp;make a Company Adverse Change Recommendation and/or (B)&nbsp;authorize the Company to terminate this Agreement in accordance with
<U>Section</U><U></U><U>&nbsp;7.1(h)</U> to enter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
into a Company Acquisition Agreement with respect to such Superior Proposal, in the case of each of clauses (A)&nbsp;and (B) if and only if: (1)&nbsp;the Company Board determines in good faith,
after consultation with the Company&#8217;s outside legal counsel, that the failure to do so in the manner contemplated by this <U>Section</U><U></U><U>&nbsp;5.4(b)</U> would be inconsistent with the fiduciary duties of the Company Board under
applicable Legal Requirements; (2)&nbsp;the Company shall have given Parent prior written notice of its intention to make a Company Adverse Change Recommendation and/or terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(h)</U> at
least four (4)&nbsp;Business Days prior to making any such Company Adverse Change Recommendation or effecting such termination (a &#8220;<B><I>Determination Notice</I></B>&#8221;) (which notice, or the public disclosure thereof, shall not constitute
a Company Adverse Change Recommendation); (3)(I)&nbsp;the Company shall have provided to Parent a copy of the applicable written Acquisition Proposal in accordance with <U>Section</U><U></U><U>&nbsp;5.3(d)</U> and (II)&nbsp;the Company shall have
afforded Parent four (4)&nbsp;Business Days (the &#8220;<B><I>Match Period</I></B>&#8221;) after delivery of the Determination Notice to propose revisions to the terms of this Agreement or make another proposal so that such Acquisition Proposal
would cease to constitute a Superior Proposal, and, to the extent Parent desires to negotiate, shall have (and shall have caused its Representatives to have) negotiated in good faith with Parent with respect to such proposed revisions or other
proposal, if any; and (4)&nbsp;after considering the terms of this Agreement and any written proposals (which continue to remain able to be accepted by the Company) made by Parent, if any, prior to 11:59 p.m. Eastern Time on the last day of the
Match Period were to be given effect whether pursuant to this <U>Section</U><U></U><U>&nbsp;5.3(b)(i)</U> or <U>Section</U><U></U><U>&nbsp;5.3(b)(ii)</U>, the Company Board shall have determined in good faith after consultation with its financial
advisors and outside legal counsel that such Acquisition Proposal continues to constitute a Superior Proposal and the failure to make the Company Adverse Change Recommendation and/or terminate this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;7.1(h)</U> would be inconsistent with the fiduciary duties of the Company Board under applicable Legal Requirements. For the avoidance of doubt, issuance of any &#8220;stop, look and listen&#8221; communication by or on
behalf of the Company pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-9(f)</FONT> under the Exchange Act shall not be considered a Company Adverse Change Recommendation and shall not require the giving of a Determination Notice or
compliance with the procedures set forth in this <U>Section</U><U></U><U>&nbsp;5.4</U>. The provisions of clauses <U>Section</U><U></U><U>&nbsp;5.4(b)(i)(2)</U>, <U>Section</U><U></U><U>&nbsp;5.4(b)(i)(3)</U> and
<U>Section</U><U></U><U>&nbsp;5.4(b)(i)(4)</U> shall also apply to any material amendment to any Acquisition Proposal (including any change to its financial terms such as any change to the amount or form of consideration payable) and require a new
Determination Notice, except that the Match Period shall be deemed to be the greater of (x)&nbsp;three (3) Business Days and (y)&nbsp;the remaining period in the then-existing Match Period; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> other than in connection with an Acquisition Proposal, the Company Board may only make a Company Adverse Change Recommendation in
response to a Change in Circumstance, if and only if: (A)&nbsp;the Company Board determines in good faith, after consultation with the Company&#8217;s outside legal counsel, that the failure to do so in the manner contemplated by this
<U>Section</U><U></U><U>&nbsp;5.4(b)</U> would be inconsistent with the fiduciary duties of the Company Board under applicable Legal Requirements; (B)&nbsp;the Company shall have given Parent a Determination Notice at least four (4)&nbsp;Business
Days prior to making any such Company Adverse Change Recommendation (which notice describes the Change in Circumstance in reasonable detail) (which notice, or the public disclosure thereof, shall not constitute a Company Adverse Change
Recommendation); and (C)(1)&nbsp;the Company shall have afforded Parent the Match Period after delivery of the Determination Notice to propose revisions to the terms of this Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or make another proposal so that such Change in Circumstance would no longer necessitate a Company Adverse Change Recommendation, and, to the extent Parent desires to negotiate, shall have
negotiated in good faith with Parent with respect to such proposed revisions or other proposal, if any, and (2)&nbsp;after considering the terms of this Agreement and any binding written proposals made by Parent, if any, prior to 11:59 p.m. Eastern
Time on the last day of the Match Period if they were to be given effect, the Company Board shall have determined, in good faith after consultation with its financial advisor and outside legal counsel, that the failure to make the Company Adverse
Change Recommendation in response to such Change in Circumstance would be inconsistent with the fiduciary duties of the Company Board under applicable Legal Requirements. For the avoidance of doubt, the provisions of clauses
<U>Section</U><U></U><U>&nbsp;5.4(b)(ii)(B)</U> and <U>Section</U><U></U><U>&nbsp;5.4(b)(ii)(C)</U> shall also apply to any material change to the facts and circumstances relating to such Change in Circumstance and require a new Determination
Notice, except that the Match Period shall be deemed to be the greater of (x)&nbsp;three (3) Business Days and (y)&nbsp;the remaining period in the then-existing Match Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B> <B>Filings, Consents and Approvals</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Reasonable Best Efforts</B><B>.</B><B> </B>Subject to the terms and conditions set forth in this Agreement, including the
limitations set forth in <U>Section</U><U></U><U>&nbsp;5.5(d)</U>, each of the Parties shall use, and shall cause their respective Affiliates to use, their respective reasonable best efforts to take, or cause to be taken, all actions, to file, or
cause to be filed, all documents and to do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper or advisable to satisfy the conditions to the Closing and consummate and make effective the
Transactions as soon as reasonably practicable and in any event prior to the Outside Date, including: (i)&nbsp;obtaining all necessary actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals and, expirations or
terminations of waiting periods from Governmental Bodies and making all necessary registrations and filings and taking all steps as may be necessary to obtain any such consent, decision, declaration, approval, clearance or waiver, or expiration or
termination of a waiting period by or from, or to avoid an action or proceeding by, any Governmental Body, (ii)&nbsp;obtaining all other necessary Consents from third parties, (iii)&nbsp;executing and delivering any additional instruments necessary
or reasonably advisable to consummate the Transactions and (iv)&nbsp;defending or contesting in good faith any Legal Proceeding brought by a third party that would prevent, materially impair or materially delay the consummation of the Transactions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Filing</B><B>.</B><B> </B>Subject to the terms and conditions of this Agreement, each of the Parties hereto shall (and
shall cause their respective Affiliates, if applicable, to) (i)&nbsp;as promptly as reasonably practicable, but in no event later than twenty (20)&nbsp;Business Days after the date hereof (or such later date as may be agreed in writing between
antitrust counsel for each Party), make an appropriate initial submission of all Notification and Report forms as required by the HSR Act with respect to the Transactions and (ii)&nbsp;as soon as reasonably practicable, make all other filings,
notifications or other consents as may be required to be made or obtained under foreign Antitrust and FDI Laws; <I>provided, however</I>, the jurisdictions identified in <U>Section</U><U></U><U>&nbsp;5.5(b)</U> of the Company Disclosure Letter, if
any, are the only jurisdictions where filing, notification, expiration of a waiting period or consent or approval is a condition to Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Cooperation</B><B>.</B><B> </B>Without limiting the generality of anything
contained in this <U>Section</U><U></U><U>&nbsp;5.5</U>, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, each Party hereto shall use its reasonable best efforts to, with respect to the Transactions, (i)&nbsp;cooperate in all
respects and consult with each other in connection with any filing or submission in connection with any investigation or other inquiry by a Governmental Body or third party before a Governmental Body, including allowing the other Party to have a
reasonable opportunity to review in advance and comment on drafts of filings and submissions, (ii)&nbsp;give the other Parties prompt notice of the making or commencement of any request, inquiry, investigation or Legal Proceeding brought by a
Governmental Body or brought by a third party before any Governmental Body, (iii)&nbsp;promptly and regularly keep the other Parties informed as to the status of any such request, inquiry, investigation, action or Legal Proceeding,
(iv)&nbsp;promptly inform the other Parties of any communication to or from the FTC, DOJ or any other Governmental Body in connection with any such request, inquiry, investigation, action or Legal Proceeding, (v)&nbsp;promptly furnish to the other
Party copies of documents, communications or materials provided to or received from any Governmental Body and material details of any oral communications in connection with any such request, inquiry, investigation, action or Legal Proceeding,
(vi)&nbsp;consult in advance and cooperate with the other Parties and consider in good faith the views of the other Parties in connection with any substantive communication, analysis, appearance, presentation, memorandum, brief, argument, opinion or
proposal to be made or submitted in connection with any such request, inquiry, investigation, action or Legal Proceeding and (vii)&nbsp;except as may be prohibited by any Governmental Body or by any Legal Requirement, in connection with any such
request, inquiry, investigation or Legal Proceeding in respect of the Transactions, each Party shall provide advance notice of and permit authorized Representatives of the other Party to be present at each meeting or conference (including telephone
or video) relating to such request, inquiry, investigation or Legal Proceeding and to have access to and be consulted in advance in connection with any argument, opinion or proposal to be made or submitted to any Governmental Body in connection with
such request, inquiry, investigation or Legal Proceeding; <I>provided</I>, that documents and information provided to the other Party pursuant to this paragraph (A)&nbsp;may be redacted (1)&nbsp;to remove references to valuation of the Company or
the identity of alternative potential acquirers, (2)&nbsp;to comply with contractual arrangements or (3)&nbsp;to preserve legal privilege and/or (B)&nbsp;may, to the extent deemed reasonably necessary, be designated as &#8220;outside counsel
only,&#8221; in which case such documents and information shall be provided only to outside counsel and consultants retained by such counsel. Each Party, unless otherwise agreed to in writing, shall use their respective reasonable best efforts to
respond as promptly as reasonably practicable to requests for information, documentation, other material or testimony that may be reasonably requested by any Governmental Body, including by responding at the earliest reasonably practicable date to
any request for additional information, documents or other materials received by any Party or any of their respective Subsidiaries from any Governmental Body in connection with the Transactions. Parent shall pay all filing fees under the HSR Act and
other Antitrust and FDI Laws; <I>provided</I>, that Parent and the Company shall each bear its own costs for the preparation of any such filings. Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;5.5</U>, Parent shall,
in consultation with the Company, determine strategy, lead all proceedings and coordinate all activities with respect to seeking any actions or Consents of any Governmental Body as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated hereby, and Company shall take such actions as reasonably requested by Parent in connection with obtaining such Consents; <I>provided</I>, notwithstanding anything to the contrary
contained in this <U>Section</U><U></U><U>&nbsp;5.5</U> or elsewhere in this Agreement, none of Parent, the Company or any of their respective Affiliates shall be required to propose, execute, carry out or agree or submit to any condition,
limitation or remedy that is not conditioned on the consummation of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Regulatory Obligations</B><B>.</B><B>
</B>In furtherance and not in limitation of this <U>Section</U><U></U><U>&nbsp;5.5</U>, Parent agrees to use its reasonable best efforts to promptly take, and cause its Affiliates to take, any and all actions necessary to cause the prompt expiration
or termination of any applicable waiting period, obtain any consent, permit, authorization, waiver or clearance under the HSR Act or other Antitrust and FDI Laws, resolve objections, if any, of the FTC, DOJ, or any other Governmental Bodies with
respect to the Transactions under the HSR Act or other Antitrust and FDI Laws, avoid the commencement of a Legal Proceeding by the FTC, the DOJ or other Governmental Bodies, and avoid the entry of, effect the dissolution of, or to eliminate, any
Order in any suit or proceeding which would otherwise have the effect of preventing the Closing or delaying the Offer Acceptance Time beyond the Expiration Date, and to otherwise promptly take all actions to resolve any objections and take all
actions requested or required by any Governmental Body under applicable Antitrust and FDI Laws. Notwithstanding anything to the contrary contained in this Agreement, Parent and Purchaser and their respective Affiliates shall not be obligated to (and
without Parent&#8217;s prior written consent, Company and its Affiliates shall not) take any of the following actions: selling, divesting (including through a license or a reversion of licensed or assigned rights), holding separate, transferring or
disposing of any assets, operations, rights, product lines or businesses, or interests therein, of itself, its Subsidiaries, or its Affiliates (or consent to any of the foregoing actions) (any such action, a &#8220;<B><I>Burdensome
Condition</I></B>&#8221;). The Parties shall oppose and defend through litigation or another Legal Proceeding on the merits any claim asserted in court or another venue by any Person, including any Governmental Body, under Antitrust and FDI Laws in
order to avoid entry of, or to promptly have vacated or terminated, any Order that could restrain, delay, or prevent the Closing; <I>provided </I>that such litigation in no way limits the obligation of Parent and Purchaser to promptly take all
actions and steps to eliminate each and every impediment identified herein. The Company shall not settle or compromise or offer to settle or compromise any request, inquiry, investigation, action or other Legal Proceeding by or before any
Governmental Body with respect to the Transactions without the prior written consent of Parent and, at the written request of Parent, Company shall take (or agree to take) any of the actions described in the definition of Burdensome Condition;
<I>provided</I>, notwithstanding anything to the contrary contained in this <U>Section</U><U></U><U>&nbsp;5.5</U> or elsewhere in this Agreement, the Company shall not be required to propose, execute, carry out or agree or submit to any condition,
limitation or remedy that is not conditioned on the consummation of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>No Acquisitions</B><B>.</B><B> </B>Prior to
Closing, each of Parent and Purchaser shall not, and Parent shall cause its Affiliates not to, directly or indirectly, acquire or agree to acquire, or publicly announce the intent to acquire, all or substantially all of the assets, business or any
Person, whether by merger, consolidation, exclusive license, purchasing all or substantially all of the assets of or equity in any Person, if the entering into of an agreement relating to or the consummation of such acquisition, merger,
consolidation or purchase or other transaction (i)&nbsp;would result in Parent or any of its Affiliates owning, directly or indirectly, any product or product candidate that is an <FONT STYLE="white-space:nowrap">IL-6</FONT> inhibitor or an <FONT
STYLE="white-space:nowrap">IL-6R</FONT> inhibitor and (ii)&nbsp;would reasonably be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expected to (A)&nbsp;impose any delay in the expiration or termination of any applicable waiting period or impose any delay beyond the Outside Date in the obtaining of, or increase the risk of
not obtaining, any authorization, consent, clearance, approval or Order of a Governmental Body necessary to consummate the Offer, the Merger and the other Transactions, including any approvals and expiration of waiting periods pursuant to the HSR
Act or any other applicable Legal Requirements, (B)&nbsp;increase the risk of any Governmental Body entering, or increase the risk of not being able to remove or successfully challenge, any Order that would delay beyond the Outside Date, restrain,
prevent, enjoin or otherwise prohibit consummation of the Offer, the Merger and the other Transactions or (C)&nbsp;otherwise delay or impede the consummation of the Offer, the Merger and the other Transactions beyond the Outside Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6</B> <B>Employee Benefits</B><B></B><B></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> For a period of at least one (1)&nbsp;year following the Effective Time, Parent shall provide, or cause to be provided, to each
employee of the Company who is employed by the Company as of immediately prior to the Effective Time and who continues to be employed by the Surviving Corporation (or any Subsidiary or Affiliate thereof) during such period following the Effective
Time (each, a &#8220;<B><I>Continuing Employee</I></B>&#8221;): (i)&nbsp;at least the same base salary (or base wages, as the case may be), target annual cash incentive compensation opportunities (excluding, in each case, any change in control,
transaction, retention and other similar <FONT STYLE="white-space:nowrap">one-time</FONT> or <FONT STYLE="white-space:nowrap">non-recurring</FONT> payments and any equity or equity-based compensation) and vacation provided to such Continuing
Employee immediately prior to the execution of this Agreement, (ii)&nbsp;severance pay and benefits no less favorable in the aggregate than the severance pay and benefits provided under the Employee Plans set forth on
<U>Section</U><U></U><U>&nbsp;3.20(f)</U> of the Company Disclosure Letter or any other agreement as in effect on the date of this Agreement, and (iii)&nbsp;retirement and health and welfare benefits that are substantially comparable in the
aggregate to those provided to such Continuing Employee as of the Effective Time, or, at Parent&#8217;s election, the retirement, health and welfare benefits provided to similarly situated employees of Parent or its Affiliates; except to the extent
more favorable compensation and benefits may be required by applicable Legal Requirements. For the avoidance of doubt, in no event shall clauses (i)&nbsp;through (iii) of this <U>Section</U><U></U><U>&nbsp;5.6(a)</U> take into account any change in
control, transaction, retention or similar compensation, or benefits, equity or equity-based compensation or other similar compensation or benefits, or defined benefit pension, deferred compensation, retiree health or welfare, or similar
compensation or benefits. Parent acknowledges that, upon the occurrence of the Effective Time, a &#8220;Change in Control&#8221; (or &#8220;Change of Control&#8221; or similar defined term, as the case may be) of the Company shall have occurred for
purposes of each of the Employee Plans in which such definition occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Without limiting the foregoing: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Parent shall use commercially reasonable efforts to ensure that each Continuing Employee shall be given service credit for all
purposes other than with respect to equity and equity-based compensation and transaction-based compensation, including for eligibility to participate, accrual of benefits, vesting, and accrual of vacation or paid time off under Parent or the
Surviving Corporation&#8217;s employee benefit plans, policies and arrangements (&#8220;<B><I>Parent Plans</I></B>&#8221;) with respect to his or her length of service with the Company (and its predecessors) prior to the Closing Date to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extent that (A)&nbsp;such service was recognized prior to the Effective Time under a comparable Employee Plan and (B)&nbsp;such service is recognized for purposes of the applicable Parent Plan;
<I>provided</I>, that in each case the foregoing shall not apply to (1)&nbsp;the extent that its application would result in the duplication of benefits or to benefit accrual under any pension plan or (2)&nbsp;any benefit plan that is a frozen plan
or that provides benefits to a grandfathered population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Under any Parent Plan that provides group health benefits in which
any Continuing Employee is eligible to participate after the Effective Time, Parent shall use commercially reasonable efforts to (A)&nbsp;waive all limitations as to <FONT STYLE="white-space:nowrap">pre-existing</FONT> conditions, exclusions and
waiting periods or required physical examinations under the Parent Plan with respect to participation and coverage requirements applicable to the Continuing Employees, to the extent that such conditions, exclusions, waiting periods or physical
examinations would not apply under a similar Employee Plan in which such Continuing Employees participated prior to the Effective Time and (B)&nbsp;ensure that such Parent Plan shall, for purposes of eligibility, vesting, deductibles, <FONT
STYLE="white-space:nowrap">co-payments</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> maximums and allowances (including paid time off), credit Continuing Employees for all service and all
deductibles, <FONT STYLE="white-space:nowrap">co-payments</FONT> and other amounts incurred for such Continuing Employees or their covered dependents prior to the Effective Time with the Company to the same extent that such service and amounts paid
was recognized prior to the Effective Time under the corresponding health or welfare benefit plan of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If, at least
twenty (20)&nbsp;Business Days prior to the Effective Time, Parent provides written notice to the Company directing the Company to terminate each Employee Plan intended to be qualified under Section&nbsp;401(a) of the Code (the &#8220;<B><I>Company
401(k) Plan</I></B>&#8221;), the Company shall terminate (or terminate its participation in) the Company 401(k) Plan effective as of the day immediately preceding the day on which the Effective Time occurs (the
&#8220;<B><I>401(k)</I></B><B><I></I></B><B><I>&nbsp;Termination Date</I></B>&#8221;). If the Company 401(k) Plan is terminated pursuant to this <U>Section</U><U></U><U>&nbsp;5.6(c)</U>, then as soon as practicable following the 401(k) Termination
Date, Parent shall, to the maximum extent permitted under any retirement plan of Parent or any of its Affiliates that is intended to be qualified under Section&nbsp;401(a) of the Code (the &#8220;<B><I>Parent 401(k) Plan</I></B>&#8221;), permit all
Continuing Employees who were eligible to participate in the Company 401(k) Plan immediately prior to the 401(k) Termination Date to participate in the Parent 401(k) Plan and shall permit each such Continuing Employee to elect to transfer their
account balance when distributed from the terminated Company 401(k) Plan, including any outstanding participant loans, to the Parent 401(k) Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> If annual bonuses with respect to the Company&#8217;s 2025 fiscal year have not been paid prior to the Closing Date, Parent shall
pay (or&nbsp;cause to be paid) such annual bonuses in an amount equal to each Continuing Employee&#8217;s annual target bonus for 2025 under the applicable bonus arrangements of the Company in effect as of the date hereof, and any such bonuses shall
be paid on the payment date consistent with the Company&#8217;s past practice to each Continuing Employee who remains employed on such date, except as otherwise provided in <U>Section</U><U></U><U>&nbsp;5.6(d)</U> of the Company Disclosure Letter
(the &#8220;<B><I>2025 Bonus Payment</I></B>&#8221;). The Company, Parent and Purchaser shall take all actions reasonably necessary to provide for and give effect to the treatment contemplated by this <U>Section</U><U></U><U>&nbsp;5.6(d)</U>,
including obtaining all reasonably necessary approvals and consents and delivering evidence reasonably satisfactory to the other Parties that all reasonably necessary determinations by the board of directors of the Company, Parent, or Purchaser (as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable) or an applicable committee thereof have been made. If the Closing Date does not occur prior to the payment of annual bonuses in respect of the Company&#8217;s 2025 fiscal year, the
Company may pay to each employee who is employed at the Company on such date a 2025 Bonus Payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The provisions of this
<U>Section</U><U></U><U>&nbsp;5.6</U> are solely for the benefit of the Parties, and no provision of this <U>Section</U><U></U><U>&nbsp;5.6</U> is intended to, or shall, constitute the establishment or adoption of or an amendment to any Employee
Plan, Parent Plan or other employee benefit plan for purposes of ERISA or otherwise and no current or former employee or any other individual associated therewith shall be regarded for any purpose as a third party beneficiary of this Agreement or
have the right to enforce the provisions hereof. Nothing in this <U>Section</U><U></U><U>&nbsp;5.6</U> or elsewhere in this Agreement shall (i)&nbsp;be construed to create a right in any Person to employment with Parent, the Surviving Corporation or
any of their respective Affiliates or (ii)&nbsp;limit the right of Parent or its Affiliates (including, following the Effective Time, the Surviving Corporation) to amend, terminate or otherwise modify any Employee Plan, Parent Plan or other employee
benefit plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7</B> <B>Indemnification of Officers and Directors</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Parties agree that, to the fullest extent permitted by applicable Legal Requirements, all rights to indemnification,
advancement of expenses and exculpation by the Company existing in favor of those Persons who are directors, officers and employees of the Company as of the date of this Agreement or have been directors, officers or employees of the Company in the
past (such individuals, the &#8220;<B><I>Indemnified Persons</I></B>&#8221;) for their acts and omissions occurring prior to the Effective Time (whether asserted or claimed prior to, at or after the Effective Time), as provided in the certificate of
incorporation and bylaws of the Company (as in effect as of the date of this Agreement) or as provided in any indemnification agreements between the Company and said Indemnified Persons set forth on <U>Section</U><U></U><U>&nbsp;5.7(a)</U> of the
Company Disclosure Letter (the &#8220;<B><I>Indemnification Agreements</I></B>&#8221;), shall survive the Closing and to the fullest extent permitted under applicable Legal Requirements shall not be amended, repealed or otherwise modified in any
manner that would adversely affect the rights thereunder of such Indemnified Persons, and shall be observed by Parent, the Surviving Corporation to the fullest extent available under applicable Legal Requirements for a period of six years from the
Effective Time, and any claim made pursuant to such rights within such six year period shall continue to be subject to this <U>Section</U><U></U><U>&nbsp;5.7(a)</U> and the rights provided under this <U>Section</U><U></U><U>&nbsp;5.7(a)</U> until
disposition of such claim (even if after such <FONT STYLE="white-space:nowrap">six-year</FONT> period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> From the Effective
Time until the sixth anniversary of the date on which the Effective Time occurs, Parent shall cause the Surviving Corporation (together with its successors and assigns, the &#8220;<B><I>Indemnifying Parties</I></B>&#8221;), to the fullest extent
provided in the certificate of incorporation and bylaws of the Company as of the date hereof or as provided in any Indemnification Agreement, to indemnify and hold harmless each Indemnified Person in his or her capacity as an officer or director of
the Company against all losses, claims, damages, liabilities, fees, expenses (including reasonable and documented attorneys&#8217; fees), judgments, amounts paid in settlement or fines incurred by such Indemnified Person in connection with any
pending or threatened Legal Proceeding based on or arising out of, in whole or in part, the fact that such Indemnified Person is or was (or any acts or omissions by such Indemnified Person in his or her capacity as) a director or officer of the
Company prior to the Effective Time and pertaining to any and all matters </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pending, existing or occurring prior to the Effective Time, whether asserted or claimed prior to, at or after the Effective Time (but only to the extent, in each case, such action or omission, or
alleged action or omission, occurred prior to the Effective Time), including any such matter arising under any claim with respect to the Transactions. Without limiting the foregoing, from the Effective Time until the sixth anniversary of the date on
which the Effective Time occurs, the Indemnifying Parties shall also, to the fullest extent provided in the certificate of incorporation and bylaws of the Company as of the date hereof or provided in any Indemnification Agreement, advance reasonable
and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including reasonable and documented attorneys&#8217; fees) incurred by the Indemnified Persons in connection with
matters for which such Indemnified Persons are eligible to be indemnified pursuant to this <U>Section</U><U></U><U>&nbsp;5.7(b)</U> promptly after receipt by Parent of a written request for such advance, subject to the execution by such Indemnified
Persons of appropriate undertakings in favor of the Indemnifying Parties to repay such advanced costs and expenses if it is ultimately determined in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent
jurisdiction that such Indemnified Person is not entitled to be indemnified under this <U>Section</U><U></U><U>&nbsp;5.7(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> From the Effective Time until the sixth anniversary of the Effective Time, the Surviving Corporation shall, and Parent shall cause
the Surviving Corporation to, maintain in effect the existing policy of directors&#8217; and officers&#8217; liability insurance maintained by the Company as of the date of this Agreement (an accurate and complete copy of which has been made
available to Parent or Parent&#8217;s Representatives prior to the date of this Agreement) (the &#8220;<B><I>Existing D&amp;O Policies</I></B>&#8221;) for the benefit of the Indemnified Persons who are currently covered by the Existing D&amp;O
Policy or become covered by the Existing D&amp;O Policy prior to the Effective Time with respect to their acts and omissions occurring prior to the Effective Time in their capacities as directors and officers of the Company (as applicable), on terms
with respect to coverage, deductibles and amounts no less favorable than the Existing D&amp;O Policy; <U>provided</U> that, in the event the Existing D&amp;O Policies are maintained by Parent, neither Parent nor the Surviving Corporation shall be
required to pay an aggregate premium for such insurance policies in excess of the Maximum Amount (as defined below) and, in the event a &#8220;tail&#8221; insurance policy is obtained by Parent, neither Parent nor the Surviving Corporation shall be
required to pay an aggregate amount for such &#8220;tail&#8221; insurance policy in excess of the Maximum Amount. At the Company&#8217;s election prior to the Effective Time, the Company may (through a nationally recognized insurance broker)
purchase a six year &#8220;tail&#8221; policy for the existing policy effective as of the Effective Time and, if such &#8220;tail policy&#8221; has been obtained, it shall be deemed to satisfy all obligations to obtain or maintain insurance pursuant
to this <U>Section</U><U></U><U>&nbsp;5.7(c)</U>; <I>provided, however,</I> that in no event shall the Company expend (and the Surviving Corporation shall not be required to expend) an amount in excess of 300% of the annual premium currently payable
by the Company as of the date of this Agreement with respect to the Existing D&amp;O Policy (the &#8220;<B><I>Maximum Amount</I></B>&#8221;), it being understood that if the annual premiums payable for such insurance coverage exceeds the Maximum
Amount, Parent shall be obligated to cause the Surviving Corporation to obtain a policy with the greatest coverage available for a cost equal to such amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> In the event Parent, the Surviving Corporation or any of their respective
successors or assigns (i)&nbsp;consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or Entity of such consolidation or merger or (ii)&nbsp;transfers or conveys all or substantially all of its
properties and assets to any Person, then, and in each such case, Parent shall ensure that the successors and assigns of Parent or the Surviving Corporation, as the case may be, or at Parent&#8217;s option, Parent, shall assume the obligations set
forth in this <U>Section</U><U></U><U>&nbsp;5.7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The provisions of this <U>Section</U><U></U><U>&nbsp;5.7</U> shall
survive the acceptance of Shares for payment pursuant to the Offer and the consummation of the Merger and are (i)&nbsp;intended to be for the benefit of, and shall be enforceable by, each of the Indemnified Persons and their successors, assigns and
heirs and (ii)&nbsp;in addition to, and not in substitution for, any other rights to indemnification or contribution that any such Person may have by contract or otherwise. Unless required by applicable Legal Requirement, this
<U>Section</U><U></U><U>&nbsp;5.7</U> may not be amended, altered or repealed after the Offer Acceptance Time in such a manner as to adversely affect the rights of any Indemnified Person or any of their successors, assigns or heirs without the prior
written consent of the affected Indemnified Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8</B> <B>Securityholder Litigation</B>. Prior to the Effective Time, the Company
will provide Parent with prompt (and in any event within two (2)&nbsp;Business Days) notice of all Transaction Litigation (including by providing copies of all pleadings with respect thereto) and keep Parent informed on a reasonably prompt basis
with respect to such Transaction Litigation, including as to the proposed strategy and other significant decisions with respect to such Legal Proceedings. The Company will (a)&nbsp;give Parent the opportunity to participate in (but not control) the
defense, settlement or prosecution of any Transaction Litigation; and (b)&nbsp;consult with Parent with respect to the defense, settlement and prosecution of any Transaction Litigation. The Company may not compromise or settle, or agree to
compromise or settle, any Transaction Litigation, or file any supplemental disclosures to moot or otherwise address the claims in any Legal Proceeding, unless Parent has consented thereto in writing (which consent will not be unreasonably withheld,
conditioned or delayed). For purposes of this <U>Section</U><U></U><U>&nbsp;5.8</U>, &#8220;participate&#8221; shall mean that (i)&nbsp;Parent shall be kept apprised of proposed strategy and other significant decisions with respect to the
Transaction Litigation by the Company receiving notice of Transaction Litigation (to the extent that the attorney-client privilege between the Company and its counsel is not undermined or otherwise affected) and (ii)&nbsp;Parent may offer comments
or suggestions with respect to such Transaction Litigation but will not be afforded any decision-making power or other authority over such Transaction Litigation except for the settlement or compromise consent set forth above and as otherwise
expressly provided in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9</B> <B>Public Announcement</B>. Parent and Purchaser, on the one hand, and the Company, on
the other, shall not, and shall cause their respective Affiliates and Representatives not to, issue any press release or make any public statement or announcement with respect to the Offer, the Merger, this Agreement or any of the other Transactions
without the prior written consent of the other party (which shall not be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing: (a)&nbsp;each Party may, without such consultation or consent, make any statement to (including
to media, analysts, Company Stockholders, investors or those attending industry conferences) and make disclosures in Company SEC Documents, in each case, so long as such statements are consistent with previous press releases, public disclosures or
public statements and do not contain any information that has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not previously been announced or made public; (b)&nbsp;a Party may, without the prior consent of the other Party, issue any such press release or make any such public announcement or statement as
may be required by any Legal Requirement, in which case, to the extent permitted by applicable Legal Requirement and practicable under the circumstances, the party proposing to issue such press release or make such public announcement or statement
shall consult in good faith with the other party before issuing any such press release or making such public announcement or statement; (c)&nbsp;the Company need not consult with Parent in connection with any press release, public statement or
filing to be issued or made pursuant to <U>Section</U><U></U><U>&nbsp;5.3(d)</U> or that relates to any Acquisition Proposal or Company Adverse Change Recommendation and any related matters and (d)&nbsp;no consultation or consent of the other Party
shall be required with respect to any good faith and material dispute between the Parties related to this Agreement or the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.10</B> <B>Takeover Laws; Advice of Changes</B>. If any Takeover Law may become, or may purport to be, applicable to the Transactions,
each of Parent and the Company and the members of their respective boards of directors (or respective committees thereof) shall use their respective reasonable best efforts to grant such approvals and take such actions as are necessary so that the
Transactions may be consummated as promptly as practicable on the terms and conditions contemplated hereby and otherwise act to lawfully eliminate the effect of any Takeover Law on any of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.11</B> <B>Section 16 Matters</B>. The Company, and the Company Board (or committee thereof), shall, to the extent necessary, take
appropriate action, prior to or as of the Offer Acceptance Time, to approve, for purposes of Section&nbsp;16(b) of the Exchange Act, the disposition and cancellation or deemed disposition and cancellation of Shares and Company Stock Awards in the
Transactions by applicable individuals and to cause such dispositions or cancellations to be exempt under <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.12</B> <B>Rule <FONT STYLE="white-space:nowrap">14d-10</FONT> Matters</B>. Prior to the Offer Acceptance Time and to the extent permitted
by applicable Legal Requirements, the Compensation Committee of the Company Board shall (a)&nbsp;adopt resolutions approving as an &#8220;employment compensation, severance or other employee benefit arrangement&#8221; within the meaning of Rule <FONT
STYLE="white-space:nowrap">14d-10(d)(1)</FONT> under the Exchange Act, each agreement, arrangement or understanding entered into or established by the Company or any of its Affiliates with or on behalf of any of the officers, directors or employees
of the Company that are effective after the date of this Agreement pursuant to which compensation is paid to such officer, director or employee and (b)&nbsp;will take all other action reasonably necessary to satisfy the requirements of the <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> safe harbor set forth in Rule <FONT STYLE="white-space:nowrap">14d-10(d)</FONT> under the Exchange Act with respect to the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.13</B> <B>Stock Exchange Delisting; Deregistration</B>. Prior to the Effective Time, the Company shall cooperate with Parent and use its
reasonable best efforts to take, or cause to be taken, all actions and do, or cause to be done, all things reasonably necessary, proper or advisable on its part pursuant to applicable Legal Requirements and the rules and regulations of Nasdaq to
cause (a)&nbsp;the delisting of the Company Common Stock from Nasdaq as promptly as practicable after the Effective Time; and (b)&nbsp;the deregistration of the Company Common Stock pursuant to the Exchange Act as promptly as practicable after such
delisting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.14</B> <B>Purchaser Stockholder Consent</B>. Immediately following the execution of
this Agreement, Parent shall execute and deliver, in accordance with Section&nbsp;228 of the DGCL and in its capacity as the sole stockholder of Purchaser, a written consent approving the adoption of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.15</B> <B>Termination of Certain Agreements</B>. The Company shall use reasonable best efforts to deliver all notices and take all other
actions that are required to terminate the Contracts set forth in <U>Section</U><U></U><U>&nbsp;5.15</U> of the Company Disclosure Letter, prior to the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.16</B> <B>Communications and Interactions with Governmental Bodies and Regulatory Authorities</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, subject to applicable Legal Requirements including
Healthcare Laws, the Company shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> promptly inform Parent in writing of any material submission, filing or other material
correspondence submitted or transmitted to, or that is received from, the FDA or any other similar Governmental Body with jurisdiction over the development, commercialization, manufacture or marketing of any Company Product Candidate, or otherwise
related to any Company Product Candidate, including any material Healthcare Submission, and to the extent practicable, provide Parent with a reasonable opportunity to consult with the Company with respect to and review any material filing or
submission (including any material Healthcare Submission) proposed to be made by or on behalf of the Company and any material correspondence or other material communication proposed to be submitted or otherwise transmitted to the FDA or any such
Governmental Body by or on behalf of the Company, in each case, relating to any Company Product Candidate, and shall consider in good faith any comments or other input provided by Parent in respect of the foregoing; <I>provided</I> that any such
comments are submitted to the Company within seven (7)&nbsp;days following Parent&#8217;s receipt of notice of such filing or submission; <I>provided</I>, <I>however</I>, nothing in this <U>Section</U><U></U><U>&nbsp;5.16</U> shall oblige the
Company to incorporate any particular comments, input, or other feedback submitted by Parent with respect to any such filings or submissions or otherwise to allow Parent to materially delay any such filings or submissions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> (A) promptly furnish to Parent copies of: (1)&nbsp;all Governmental Authorizations from the FDA or other Regulatory Authority
held by the Company related to any Company Product Candidate, (2)&nbsp;all material Healthcare Submissions and any other written submissions made to and material written regulatory communications with the FDA or other Regulatory Authority related to
any Company Product Candidate in the Company&#8217;s possession or control and (3)&nbsp;all reports, results, data and information in the Company&#8217;s possession or control relating to the safety or efficacy of any Company Product Candidate,
including all final reports prepared under 21 C.F.R. 58.185, all information collected pursuant to 21 C.F.R. Part 58 and all adverse event (as such term is defined or described in 21 C.F.R. 312.32) and other safety information, in the case of each
of the preceding clauses (1)&nbsp;through (3), which arise during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period and (B)&nbsp;take the actions set forth on <U>Section</U><U></U><U>&nbsp;5.16(a)(ii)(B)</U> of the Company Disclosure
Letter; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> (A) provide notice to Parent prior to any scheduled meeting with the FDA or
any other Regulatory Authority (including any <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting referenced in 21 C.F.R. 312.82) relating to any Company Product Candidate, (B)&nbsp;to the extent practicable, consult with Parent regarding any
such meeting and consider in good faith any input with respect thereto timely provided by Parent and (C)&nbsp;to the extent permitted under applicable Healthcare Laws, provide Parent with an opportunity to attend or participate in, any such meeting
that the Company has with the FDA or any Regulatory Authority (provided that, if Parent is unable to attend or participate, the Company shall promptly provide Parent with a copy of its internal meeting minutes taken from any such meeting); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> (A) if the FDA or other Regulatory Authority inspects or audits, or has provided written notice of intent to inspect or audit,
the Company or, to the extent such audits or inspections are related to any Company Product Candidate, or the Company&#8217;s Third Parties, the Company shall promptly notify Parent upon the Company becoming aware thereof; (B)&nbsp;to the extent in
the Company&#8217;s possession or control, promptly provide Parent with a copy of any reports or findings of the FDA or such other Regulatory Authority following any such audit or inspection; and (C)&nbsp;consider Parent&#8217;s comments regarding
any such inspection or audit in good faith; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> consult with Parent prior to (A)&nbsp;commencing any clinical trial of which
Parent has not been informed prior to the date hereof or (B)&nbsp;making any material change to, discontinuing, terminating or suspending any ongoing clinical trial, or any ongoing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical
study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Company shall promptly post all information required to be disclosed or provided to Parent pursuant to this
<U>Section</U><U></U><U>&nbsp;5.16</U> to the in the Company&#8217;s electronic data room maintained by Datasite to which Parent and its Representatives shall have continuous access through the Closing Date, and any failure by the Company to post
and provide continuous access to such information in the in the Company&#8217;s electronic data room maintained by Datasite shall be considered a failure by the Company to disclose such information and a breach of this
<U>Section</U><U></U><U>&nbsp;5.16</U>; <I>provided</I> that any break in the continuity of access not attributable to actions by the Company or its Representatives shall not be deemed a breach of this <U>Section</U><U></U><U>&nbsp;5.16</U>. No
investigation, notice or disclosure pursuant to this <U>Section</U><U></U><U>&nbsp;5.16</U> shall (i)&nbsp;supplement or amend any representation or warranty in this Agreement of the Company (or cure any breach thereof), (ii) supplement or amend the
Company Disclosure Letter or (iii)&nbsp;otherwise limit the rights or remedies available hereunder to Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6. CONDITIONS
PRECEDENT TO THE MERGER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The respective obligations of Parent, Purchaser and the Company to consummate the Merger are subject to the
satisfaction or waiver (where permissible pursuant to applicable Legal Requirements) prior to the Effective Time of each of the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B> <B>No Restraints</B>. No temporary restraining order, preliminary or permanent injunction or other Order preventing the
consummation of the Merger shall have been issued by any Governmental Body of competent jurisdiction after the date hereof and remain in effect, nor shall any Legal Requirement have been entered, enforced, enacted, or issued after the date hereof by
any Governmental Body of competent jurisdiction and remain in effect, in each case, which prohibits, prevents or makes illegal the consummation of the Merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B>Consummation of Offer</B>. Purchaser (or Parent on Purchaser&#8217;s behalf)
shall have accepted for payment and paid for all of the Shares validly tendered pursuant to the Offer and not validly withdrawn. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7. TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B>Termination</B>. This Agreement may be terminated prior to the Effective Time: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> by mutual written consent of Parent and the Company at any time prior to the Offer Acceptance Time; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> by either Parent or the Company, if a Governmental Body shall have entered, enforced, enacted, or issued a final and nonappealable
Legal Restraint after the date hereof having the effect of permanently restraining, enjoining or otherwise prohibiting the acceptance for payment of Shares pursuant to the Offer or the Merger or making consummation of the Offer or the Merger
illegal; <I>provided</I> that the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(b)</U> shall not be available to a Party if (i)&nbsp;in the case of the Company, its, and in the case of Parent, its or
Purchaser&#8217;s, material breach of any provision of this Agreement has resulted in, or was a principal cause of, the issuance of such final and nonappealable Legal Restraint or (ii)&nbsp;it (or in the case of Parent, it or Purchaser) failed to
comply in any material respect with its obligations under this Agreement to prevent the entry of or remove such final and nonappealable Legal Restraint; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> by either Parent or the Company, (i)&nbsp;if the Offer Acceptance Time shall not have occurred on or prior to 11:59 p.m. Eastern
Time on September&nbsp;8, 2026 (such date, the &#8220;<B><I>Outside Date</I></B>&#8221;); <I>provided</I>, <I>however</I>, that in the event that on the original Outside Date, any of the conditions set forth in <U>clause (B)(f)</U> (in connection
with or in respect of any matter involving Antitrust and FDI Laws) or <U>clause (B)(e)</U> of <U>Annex I</U> have not been satisfied but all of the other closing conditions set forth in <U>Annex I</U> have been satisfied or waived (other than the
Minimum Condition and conditions that by their nature are to be satisfied at the Offer Acceptance Time, each of which shall be capable of being satisfied or waived on such date), then the Outside Date shall be automatically extended without further
action by the Parties until 11:59 p.m. Eastern Time on December&nbsp;8, 2026 (and in the case of such extension, any reference to the Outside Date in this Agreement shall be a reference to the Outside Date, as extended); <I>provided, further</I>
that, if on the extended Outside Date, any of the conditions set forth in <U>clause (B)(f)</U> (in connection with or in respect of any matter involving Antitrust and FDI Laws) or <U>clause (B)(e)</U> of <U>Annex I</U> have not been satisfied but
all of the other closing conditions set forth in <U>Annex I</U> have been satisfied or waived (other than the Minimum Condition and conditions that by their nature are to be satisfied at the Offer Acceptance Time, each of which shall be capable of
being satisfied or waived on such date), then the Outside Date shall be automatically extended once more without further action by the Parties until 11:59 p.m. Eastern Time on March&nbsp;8, 2027 (and in the case of such extension, any reference to
the Outside Date in this Agreement shall be a reference to the Outside Date, as extended) or (ii)&nbsp;if the Offer (as it may be required to be extended pursuant to <U>Section</U><U></U><U>&nbsp;1.1(c)</U>, or has otherwise been extended in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordance with this Agreement) shall have expired in accordance with its terms without the acceptance for payment of Shares tendered in the Offer; <I>provided</I>, <I>further </I>that the right
to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(c)</U> shall not be available to any Party if its (or in the case of Parent, Parent or Purchaser&#8217;s) breach of any provision of this Agreement resulted in, or was a
principal cause of the failure of the Offer Acceptance Time to occur by the Outside Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> by the Company, if
(i)&nbsp;Purchaser shall have failed to commence (within the meaning of Rule <FONT STYLE="white-space:nowrap">14d-2</FONT> under the Exchange Act) the Offer within the period specified in <U>Section</U><U></U><U>&nbsp;1.1(a)</U>;
<I>provided</I>,<I>&nbsp;however</I>, that the Company may not terminate this Agreement pursuant to this&nbsp;<U>Section&nbsp;7.1(d)</U> if the Company&#8217;s breach of its obligations under this Agreement resulted in, or was a principal cause of,
such failure to commence the Offer, or (ii)&nbsp;Purchaser shall, when required to do so in accordance with the terms of this Agreement, have failed to accept and pay for all Shares validly tendered (and not validly withdrawn) as of the expiration
of the Offer (as may be extended); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> by Parent at any time prior to the Offer Acceptance Time, if the Company has breached or
failed to perform any of its covenants or other agreements contained in this Agreement, or if any of the representations or warranties of the Company in this Agreement is inaccurate, which breach, failure to perform or inaccuracy would result in a
failure of a condition set forth in <U>clause (B)(b)</U> or <U>clause (B)(c)</U> of <U>Annex I</U>, as applicable, except that if such breach, failure or inaccuracy is capable of being cured by the Outside Date, Parent will not be entitled to
terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(e)</U> prior to the delivery by Parent to the Company of written notice of such breach, delivered at least thirty (30)&nbsp;days prior to such termination (or such shorter
period of time as remains prior to the Outside Date, the shorter of such periods, the &#8220;<B><I>Company Breach Notice Period</I></B>&#8221;), stating Parent&#8217;s intention to terminate this Agreement pursuant to this
<U>Section</U><U></U><U>&nbsp;7.1(e)</U> and the basis for such termination, it being understood that Parent will not be entitled to terminate this Agreement if such breach, failure or inaccuracy has been cured prior to the expiration of the Company
Breach Notice Period (to the extent capable of being cured); <I>provided, however</I>, that Parent shall not have the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(e)</U> if Parent or Purchaser is then in
material breach of any representation, warranty, covenant or agreement of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> by Parent at any time prior to the
Offer Acceptance Time, if (i)&nbsp;a Company Adverse Change Recommendation shall have occurred or (ii)&nbsp;the Company Board or the Company intentionally and materially breaches its obligations under <U>Section</U><U></U><U>&nbsp;5.3</U> or
<U>Section</U><U></U><U>&nbsp;5.4</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> by the Company at any time prior to the Offer Acceptance Time, if Parent or Purchaser
has breached or failed to perform any of its respective covenants or other agreements contained in this Agreement, or if any of the representations or warranties of the Company in this Agreement is inaccurate, which breach, failure to perform or
inaccuracy would or would reasonably be expected to prevent Parent or Purchaser from consummating the Transactions, except that if such breach, failure or inaccuracy is capable of being cured by the Outside Date, the Company will not be entitled to
terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(g)</U> prior to the delivery by the Company to Parent of written notice of such breach, delivered at least thirty (30)&nbsp;days prior to such termination (or such shorter
period of time as remains prior to the Outside Date, the shorter of such periods, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;<B><I>Parent Breach Notice Period</I></B>&#8221;), stating the Company&#8217;s intention to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(g)</U> and the basis
for such termination, it being understood that the Company will not be entitled to terminate this Agreement if such breach, failure or inaccuracy has been cured prior to the expiration of the Parent Breach Notice Period (to the extent capable of
being cured); <I>provided, however</I>, that the Company shall not have the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(g)</U> if the Company is then in material breach of any representation, warranty,
covenant or agreement of this Agreement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> by the Company at any time prior to the Offer Acceptance Time, if (i)&nbsp;the
Company Board (or a duly authorized committee thereof) shall have determined to terminate this Agreement in accordance with the terms set forth in <U>Section</U><U></U><U>&nbsp;5.4</U> in order to enter into a definitive agreement with respect to a
Superior Proposal, (ii)&nbsp;such Superior Proposal shall not have resulted from a material breach of <U>Section</U><U></U><U>&nbsp;5.3</U> or <U>Section</U><U></U><U>&nbsp;5.4</U> with respect to such Superior Proposal and any Acquisition Proposal
that was a precursor thereto, and (iii)&nbsp;the Company has paid or caused to be paid the Company Termination Fee due to Parent as contemplated by <U>Section</U><U></U><U>&nbsp;7.3(b)(i)</U> prior to the termination of this Agreement pursuant to
this <U>Section</U><U></U><U>&nbsp;7.1(h)</U> and substantially concurrently enters into such definitive agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B>Manner
and Notice of Termination; Effect of Termination</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Party terminating this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;7.1</U> (other than pursuant to <U>Section</U><U></U><U>&nbsp;7.1(a)</U>) must deliver prompt written notice thereof to the other Parties setting forth in reasonable detail the provision of
<U>Section</U><U></U><U>&nbsp;7.1</U> pursuant to which this Agreement is being terminated and the facts and circumstances forming the basis for such termination pursuant to such provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Any valid termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> will be effective immediately upon the
delivery of written notice by the terminating Party to the other Parties (provided it complies with <U>Section</U><U></U><U>&nbsp;7.3)</U>. In the event of the valid termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U>,
this Agreement shall immediately be of no further force or effect, without any liability or obligation on of any Party (or any partner, member, manager, stockholder, director, officer, employee, Affiliate, agent or other representative of such
Party) to the other Parties, as applicable, except the provisions of <U>Section</U><U></U><U>&nbsp;1.1(d)</U>, the last sentence of <U>Section</U><U></U><U>&nbsp;1.2(b)</U>, <U>Section</U><U></U><U>&nbsp;3.28</U>,
<U>Section</U><U></U><U>&nbsp;4.11</U>, this <U>Section</U><U></U><U>&nbsp;7.2</U>, <U>Section</U><U></U><U>&nbsp;7.3</U> and <U>Article 8</U> will each survive the termination of this Agreement and shall remain in full force and effect in
accordance with their respective terms. Notwithstanding the foregoing, nothing in this Agreement will relieve any Party from any liability for any Willful Breach of this Agreement arising prior to the valid termination of this Agreement or fraud
(which liability or damages to the extent owed to the Company or the Company Stockholders may include damages on behalf of the Company and the Company Stockholders based on loss of the economic benefit of the Transactions to the Company and the
Company Stockholders to the fullest extent provided by Section&nbsp;261(a)(1) of the DGCL, it being acknowledged and agreed that the Company will have the exclusive right to seek and obtain such damages on behalf of itself and the Company
Stockholders). In addition to the foregoing, no termination of this Agreement will affect the rights or obligations of any Party pursuant to the Confidentiality Agreement or Addendum, which rights, obligations and agreements will survive the
termination of this Agreement in accordance with their respective terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B>Expenses; Termination Fee</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Except as set forth in <U>Section</U><U></U><U>&nbsp;5.5</U> and this <U>Section</U><U></U><U>&nbsp;7.3</U> or as otherwise
provided herein, all fees and expenses incurred in connection with this Agreement and the Merger will be paid by the Party incurring such fees and expenses whether or not the Offer and the Merger are consummated. For the avoidance of doubt, Parent
or the Surviving Corporation will be responsible for all fees and expenses of the Paying Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <I>Company Termination
Fee</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Company terminates this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(h)</U>, then the Company
must, prior to such termination, pay or cause to be paid to Parent an amount equal to $ $47,950,000 in cash (the &#8220;<B><I>Company Termination Fee</I></B>&#8221;) if written wire instructions have been provided by Parent prior to such
termination, and if not, within two (2)&nbsp;Business Days following such receipt of such written instructions from Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>
If Parent terminates this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(f)</U><U>(i)</U> or the Company terminates this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(c)</U> and at such time Parent had the right to terminate
pursuant to <U>Section&nbsp;7.1(f)(i)</U>, then the Company must promptly (and in any event within two&nbsp;(2) Business Days) following such termination pay or cause to be paid to Parent the Company Termination Fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> If (A)(1) this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;7.1(c)(i)</U> (but in the case of such a
termination by the Company, only if at such time Parent would not have been prohibited from terminating this Agreement pursuant to the final proviso of <U>Section</U><U></U><U>&nbsp;7.1(c)</U>), (2)&nbsp;Parent terminates this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;7.1(e)</U>, (3) Parent terminates this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(f)(ii)</U> or (4)&nbsp;the Company terminates this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(c)</U> and at
such time Parent had the right to terminate pursuant to <U>Section</U><U></U><U>&nbsp;7.1(f)(ii)</U>, (B)&nbsp;after the date hereof and prior to the date of such termination, a <I>bona fide</I> Acquisition Proposal is made to the Company or
publicly disclosed (whether by the Company or a third party) or otherwise made known to the Company Board or the Company Stockholders, and in each case, is not publicly withdrawn without qualification at least three Business Days prior to the date
of such termination and (C)&nbsp;within twelve months of such termination, a transaction implementing an Acquisition Proposal is consummated or a definitive agreement in respect of an Acquisition Proposal is entered into (whether or not related to
the Acquisition Proposal commenced prior to the Transactions), then the Company will, prior to the earlier of (as applicable) the consummation of or the entry into the definitive agreement for such Acquisition Proposal, pay or cause to be paid to
Parent the Company Termination Fee. For purposes of this <U>Section</U><U></U><U>&nbsp;7.3(b)(iii)</U>, all references to &#8220;20%&#8221; in the definition of &#8220;Acquisition Proposal&#8221; will be deemed to be references to &#8220;50%.&#8221;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <I>Regulatory Termination Fee.</I> If this Agreement is terminated pursuant to
(i)&nbsp;<U>Section 7.1(c)</U> and as of such termination, the condition set forth in <U>clause (B)(e)</U> of <U>Annex I</U> or the condition set forth in <U>clause (B)(f)</U> of <U>Annex I</U> has not been satisfied (or waived) (in the case of the
condition in <U>clause (B)(f) </U>of <U>Annex I</U>, solely to the extent such failure is the result of any Legal Restraint arising under any Antitrust and FDI Law) or (ii)&nbsp;<U>Section&nbsp;7.1(b)</U> as a result of a final and <FONT
STYLE="white-space:nowrap">non-appealable</FONT> Legal Restraint by a court of competent jurisdiction or other Governmental Body having jurisdiction under any applicable Antitrust and FDI Law (and, in each case, solely to the extent such Legal
Restraint arises under any Antitrust and FDI Law), and in the case of each of clauses (i)&nbsp;and (ii), all of the conditions to the Offer set forth in <U>Annex I</U> (other than (I)&nbsp;the condition set forth in <U>clause (B)(e)</U> of <U>Annex
I</U> or the condition set forth in <U>clause (B)(f)</U> of <U>Annex I</U> (in the case of the condition in <U>clause (B)(f)</U> of <U>Annex I</U>, solely to the extent such failure is the result of any Legal Restraint arising under any Antitrust
and FDI Law) and (II)&nbsp;those conditions that are by their nature to be satisfied at the Offer Acceptance Time) have been satisfied or waived (to the extent waivable), then Parent shall, no later than five (5)&nbsp;Business Days following such
termination, pay, or cause to be paid, in immediately available funds by wire transfer, an amount equal to $68,500,000 (the &#8220;<B><I>Regulatory Termination Fee</I></B>&#8221;) to the Company if written wire instructions have been provided by the
Company prior to such termination, and if not, within two (2)&nbsp;Business Days following such receipt of such written instructions from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <I>Single Payment Only</I>. The Parties acknowledge and agree that in no event will the Company be required to pay the Company
Termination Fee or Parent be required to pay the Regulatory Termination Fee on more than one occasion, whether or not the Company Termination Fee or the Regulatory Termination Fee, as applicable, may be payable pursuant to more than one provision of
this Agreement at the same or at different times and upon the occurrence of different events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <I>Payment; Default</I>. The
Parties acknowledge that the agreements contained in this <U>Section</U><U></U><U>&nbsp;7.3</U> are an integral part of the Transactions, and that, without these agreements, the Parties would not enter into this Agreement. Each Party acknowledges
and agrees, on behalf of itself and its Affiliates, that the payment of the Company Termination Fee or Regulatory Termination Fee is not a penalty but instead is liquidated damages in a reasonable amount that shall compensate Parent, Purchaser and
their respective Affiliates in the circumstances in which the Company Termination Fee is payable, and the Company and its Affiliates in circumstances in which the Regulatory Termination Fee is payable, for the efforts and resources expended and the
opportunities foregone while negotiating this Agreement and in reliance on this Agreement and on the expectation of the consummation of the transactions contemplated by this Agreement, which amount would otherwise be impossible to calculate with
precision. Accordingly, (x)&nbsp;if the Company fails to timely pay the Company Termination Fee pursuant to this <U>Section</U><U></U><U>&nbsp;7.3</U> and, in order to obtain such payment, Parent commences a Legal Proceeding that results in a
judgment against the Company for the amount set forth in this <U>Section</U><U></U><U>&nbsp;7.3</U> or any portion thereof, the Company will pay to Parent its reasonable and documented
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including reasonable and documented attorneys&#8217; fees) in connection with such Legal Proceeding, together with interest on such
amount or portion thereof at the annual rate of the prime rate as published in <I>The Wall Street Journal</I> in effect on the date that such payment or portion thereof was required to be made through the date that such payment or portion thereof
was actually received, or a lesser rate that is the maximum permitted by applicable Legal Requirements (collectively, the &#8220;<B><I>Enforcement Expenses</I></B>&#8221;) and (y)&nbsp;if Parent fails to timely pay the Regulatory Termination Fee
pursuant to this <U>Section</U><U></U><U>&nbsp;7.3</U> and, in order to obtain such payment, the Company commences Legal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Proceeding that results in a judgment against Parent for the amount set forth in this <U>Section</U><U></U><U>&nbsp;7.3</U> or any portion thereof, Parent will pay to the Company the Enforcement
Expenses. The Company Termination Fee, Regulatory Termination Fee and all other payments under this <U>Section</U><U></U><U>&nbsp;7.3</U> shall be made by the Company to Parent or Parent to the Company, as applicable, by wire transfer of immediately
available funds to an account designated in writing by Parent or the Company, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <I>Sole and Exclusive Remedy of
Parent.</I><I> </I>Subject to the provisions of <U>Section</U><U></U><U>&nbsp;7.3(h)</U> and <U>Section</U><U></U><U>&nbsp;8.5(b)</U>, if this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U>, Parent&#8217;s receipt of the
Company Termination Fee to the extent owed pursuant to <U>Section</U><U></U><U>&nbsp;7.3(b)</U> (including, if applicable, Parent&#8217;s right to Enforcement Expenses under <U>Section</U><U></U><U>&nbsp;7.3(e)</U>) will be the sole and exclusive
remedy of Parent, Purchaser and the Parent Related Parties against the Company Related Parties arising out of or in connection with this Agreement, any agreement executed in connection herewith and the Transactions, the termination of this
Agreement, the failure to consummate the Transactions or any claims or actions under applicable Legal Requirements arising out of or in connection with any breach, termination or failure of this Agreement or any other agreement executed in
connection herewith. Parent&#8217;s receipt of the Company Termination Fee to the extent owed pursuant to <U>Section</U><U></U><U>&nbsp;7.3(b)</U> and any Enforcement Expenses payable pursuant to <U>Section</U><U></U><U>&nbsp;7.3(e)</U> will be the
only monetary damages the Parent Related Parties may recover from Company Related Parties in respect of this Agreement, any agreement executed in connection herewith and the Transactions, the termination of this Agreement, the failure to consummate
the Offer or the Merger or any claims or actions under applicable Legal Requirements arising out of or in connection with any such breach, termination or failure, and upon payment of such amounts (i)&nbsp;none of the Company Related Parties will
have any further liability or obligation to any of the Parent Related Parties relating to or arising out of this Agreement, any agreement executed in connection herewith or the transactions contemplated hereby and thereby or any matters forming the
basis of such termination (except that the Parties (or their respective Affiliates) will remain obligated with respect to, and Parent may be entitled to remedies with respect to, the Confidentiality Agreement); and (ii)&nbsp;none of Parent,
Purchaser or any other Person will be entitled to bring or maintain any Legal Proceeding against the Company or any Company Related Party arising out of this Agreement, any agreement executed in connection herewith or the transactions contemplated
hereby and thereby or any matters forming the basis for such termination (except that the Parties (or their respective Affiliates) will remain obligated with respect to, and Parent and the Company, as applicable, may be entitled to remedies with
respect to, the Confidentiality Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <I>Sole and Exclusive Remedy of Company. </I>Subject to the provisions of
<U>Section</U><U></U><U>&nbsp;7.3(h)</U> and <U>Section</U><U></U><U>&nbsp;8.5(b)</U>, if this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U>, the Company&#8217;s receipt of the Regulatory Termination Fee to the extent
owed pursuant to <U>Section</U><U></U><U>&nbsp;7.3(c)</U> (including, if applicable, the Company&#8217;s right to Enforcement Expenses under <U>Section</U><U></U><U>&nbsp;7.3(e)</U>) will be the sole and exclusive remedy of the Company and the
Company Related Parties against the Parent Related Parties arising out of or in connection with this Agreement, any agreement executed in connection herewith and the Transactions, the termination of this Agreement, the failure to consummate the
Transactions or any claims or actions under applicable Legal Requirements arising out of or in connection with any breach, termination or failure of this Agreement or any other agreement executed in connection
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
herewith. The Company&#8217;s receipt of the Regulatory Termination Fee to the extent owed pursuant to <U>Section</U><U></U><U>&nbsp;7.3(c)</U> and any Enforcement Expenses payable pursuant to
<U>Section</U><U></U><U>&nbsp;7.3(e)</U> will be the only monetary damages the Company Related Parties may recover from Parent Related Parties in respect of this Agreement, any agreement executed in connection herewith and the Transactions, the
termination of this Agreement, the failure to consummate the Offer or the Merger or any claims or actions under applicable Legal Requirements arising out of or in connection with any such breach, termination or failure, and upon payment of such
amounts (i)&nbsp;none of the Parent Related Parties will have any further liability or obligation to any of the Company Related Parties relating to or arising out of this Agreement, any agreement executed in connection herewith or the transactions
contemplated hereby and thereby or any matters forming the basis of such termination (except that the Parties (or their respective Affiliates) will remain obligated with respect to, and Company may be entitled to remedies with respect to, the
Confidentiality Agreement); and (ii)&nbsp;none of the Company or any other Person will be entitled to bring or maintain any Legal Proceeding against Parent, Purchaser or any Parent Related Party arising out of this Agreement, any agreement executed
in connection herewith or the transactions contemplated hereby and thereby or any matters forming the basis for such termination (except that the Parties (or their respective Affiliates) will remain obligated with respect to, and Parent and the
Company, as applicable, may be entitled to remedies with respect to, the Confidentiality Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <I>Acknowledgement
Regarding Specific Performance</I>. Notwithstanding anything to the contrary in <U>Section</U><U></U><U>&nbsp;7.3(f)</U> or <U>Section</U><U></U><U>&nbsp;7.3(g)</U>, it is agreed that Parent, Purchaser and Company will be entitled to an injunction,
specific performance or other equitable relief as provided in <U>Section</U><U></U><U>&nbsp;8.5(b)</U>, except that, although the Parties, each in its sole discretion, may determine its choice of remedies hereunder, including by pursuing specific
performance in accordance with, but subject to the limitations of, <U>Section</U><U></U><U>&nbsp;8.5(b)</U>, under no circumstances will a party be permitted or entitled to receive both (i)&nbsp;specific performance of the other party&#8217;s
obligation to effect the Closing and (ii)&nbsp;any payment of the Company Termination Fee (in the case of Parent), the Regulatory Termination Fee (in the case of the Company) or monetary damages in respect of a Willful Breach or fraud of the other
party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8. MISCELLANEOUS PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B> <B>No Survival of Representations, Warranties</B><B>, </B><B>Covenants and </B><B>Agreements</B>. The Parties acknowledge and agree
that (a)&nbsp;none of the representations and warranties contained in this Agreement, the Company Disclosure Letter or in any certificate or schedule or other document delivered pursuant to this Agreement shall survive, and all rights, claims and
causes of action (whether in contract or in tort or otherwise, or whether at law (including at common law or by statute) or in equity) with respect thereto shall terminate at, the Effective Time and (b)&nbsp;except for any covenant or agreement that
by its terms contemplates performance after the Effective Time, none of the covenants or agreements of the Parties in this Agreement shall survive, and all rights, claims and causes of actions (whether in contract or in tort or otherwise, or whether
at law (including at common law or by statute) or in equity) with respect to such covenants and agreements shall terminate at, the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B> <B>Amendment</B>. Prior to the Effective Time and subject to
<U>Section</U><U></U><U>&nbsp;5.7(e)</U>, any provision of this Agreement may be amended by the Parties only if such amendment is in writing and is signed by each Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B> <B>Waiver</B>. At any time prior to the Effective Time, Parent or the Company may, subject to applicable Legal Requirements,
(a)&nbsp;waive any inaccuracies in the representations and warranties of the other Party contained herein or in any document delivered pursuant hereto, (b)&nbsp;extend the time for the performance of any of the obligations or acts of the other Party
or (c)&nbsp;waive compliance by the other Party with any of the agreements contained herein applicable to such Party or, except as otherwise provided herein, waive any of such Party&#8217;s conditions (it being understood that Parent and Purchaser
shall be deemed a single Party for purposes of the foregoing). No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right,
privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of
any other power, right, privilege or remedy. No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or
remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B> <B>Entire </B><B>Agreement</B><B>; Counterparts</B>. This Agreement (including the exhibits, schedules and annexes hereto, the
Company Disclosure Letter and the documents and instruments relating to the Offer and the Merger referred to in this Agreement) and the Confidentiality Agreement and Addendum constitute the entire agreement and supersede all prior agreements and
understandings, both written and oral, among or between any of the Parties, with respect to the subject matter hereof and thereof; <I>provided, however</I>, that, if the Effective Time occurs, the Confidentiality Agreement and Addendum shall
automatically terminate and be of no further force and effect. This Agreement may be executed in several counterparts, including by facsimile, by email with .pdf attachments, or by other electronic signatures (including, DocuSign and AdobeSign),
each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by PDF shall be sufficient to bind the Parties to the terms and
conditions of this Agreement. Until and unless each Party has received a counterpart hereof signed by the other Party, this Agreement shall have no effect, and no party shall have any right or obligation hereunder (whether by virtue of any other
oral or written agreement or other communication). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5</B> <B>Applicable Legal Requirements; Jurisdiction; Specific Performance;
Remedies; Waiver of Jury Trial</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> This Agreement, including any claims or causes of action (whether in contract, tort or
statute) that may be based upon, arise out of or relate to this Agreement, or the negotiation, execution or performance thereof or the Transactions, shall be governed by, and construed in accordance with, the laws of the State of Delaware,
regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. Subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;8.5(c)</U>, in any action or proceeding arising out of or relating to this Agreement or any of the Transactions,&nbsp;each of the Parties irrevocably:
(i)&nbsp;submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware and any state appellate court therefrom or, if such court lacks subject matter jurisdiction or declines to accept jurisdiction over any action or
proceeding, another state court of the State of Delaware or the United States District Court for the District of Delaware (such courts, the &#8220;<B><I>Chosen Courts</I></B>&#8221;) (it being agreed that the consents to jurisdiction and venue set
forth in this <U>Section</U><U></U><U>&nbsp;8.5(a)</U> shall not constitute general consents to service of process in the State of Delaware and shall have no effect for any purpose except as provided in this paragraph and shall not be deemed to
confer rights on any Person other than the Parties); (ii)&nbsp;waives the defense of an inconvenient forum or lack of jurisdiction to the maintenance of any Legal Proceeding in the Chosen Courts; (iii)&nbsp;agrees to not attempt to deny or defeat
such jurisdiction by motion or otherwise request for leave from any Chosen Court and (iv)&nbsp;agrees not to bring or permit any of their Affiliates to bring or support anyone else in bringing any such Legal Proceeding in any court other than the
Chosen Courts (except for an action to enforce a judgment of a Chosen Court). Each of the Parties irrevocably consents to service of process by first class certified mail, return receipt requested, postage prepaid, to the address at which such Party
is to receive notice in accordance with <U>Section</U><U></U><U>&nbsp;8.8</U>. The Parties agree that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any
other manner provided by applicable Legal Requirements; <I>provided, however,</I> that nothing in the foregoing shall restrict any Party&#8217;s rights to seek any post-judgment relief regarding, or any appeal from, such final trial court judgment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy,
would occur and that the Parties would not have any adequate remedy at law in the event that the Parties do not perform their obligations under the provisions of this Agreement in accordance with its (or their) specified terms or otherwise breach
such provisions. The Parties acknowledge and agree that (i)&nbsp;the Parties shall be entitled, in addition to any other remedy to which it is entitled at law or in equity, to an injunction or injunctions, specific performance, or other equitable
relief, to prevent breaches (or threatened breaches) of this Agreement and to enforce specifically the terms and provisions hereof in the courts described in <U>Section</U><U></U><U>&nbsp;8.5(a)</U> without proof of damages or otherwise, this being
in addition to any other remedy to which they are entitled under this Agreement, at law or in equity, (ii)&nbsp;the provisions set forth in <U>Section</U><U></U><U>&nbsp;7.3</U>: (x)&nbsp;are not intended to and do not adequately compensate for the
harm that would result from a breach of this Agreement; and (y)&nbsp;shall not be construed to diminish or otherwise impair in any respect any Party&#8217;s right to specific enforcement and (iii)&nbsp;the right of specific performance is an
integral part of the Transactions and without that right, none of the Company, Parent or Purchaser would have entered into this Agreement. It is explicitly agreed that the Company shall have the right to an injunction, specific performance or other
equitable remedies in connection with enforcing Parent&#8217;s and Purchaser&#8217;s obligations to consummate the Offer, the Merger and the other Transactions. The Parties hereto acknowledge and agree that any Party seeking an injunction or
injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in accordance with this <U>Section</U><U></U><U>&nbsp;8.5(b)</U> shall not be required to provide any bond or other security in
connection with any such Order, and each Party irrevocably waives any right that it may have to require the obtaining, furnishing or posting of any such bond or other security. The Parties agree not to assert that a remedy of specific enforcement is
unenforceable, invalid, contrary to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Legal Requirements or inequitable for any reason, and not to assert that a remedy of monetary damages would provide an adequate remedy or that the parties otherwise have an adequate
remedy at law. The Parties further agree that (x)&nbsp;by seeking the remedies provided for in this <U>Section</U><U></U><U>&nbsp;8.5</U>, a Party shall not in any respect waive its right to seek any other form of relief that may be available to a
Party under this Agreement and (y)&nbsp;nothing set forth in this <U>Section</U><U></U><U>&nbsp;8.5</U> shall require any Party to institute any proceeding for (or limit any Party&#8217;s right to institute any proceeding for) specific performance
under this <U>Section</U><U></U><U>&nbsp;8.5</U> prior to, or as a condition to, exercising any termination right under <U>Article 7</U> (and pursuing damages after such termination to the extent permitted hereunder), nor shall the commencement of
any Legal Proceeding by a Party pursuant to this <U>Section</U><U></U><U>&nbsp;8.5</U> or anything set forth in this <U>Section</U><U></U><U>&nbsp;8.5</U> restrict or limit such Party&#8217;s right to terminate this Agreement in accordance with the
terms of <U>Article 7</U> or pursue any other remedies under this Agreement that may be available then or thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> EACH
PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING BETWEEN OR AMONG THE PARTIES ARISING OUT OF OR RELATING TO THIS AGREEMENT, ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS OR THE ACTIONS OF
PARENT, PURCHASER OR THE COMPANY IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR
OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II)&nbsp;EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (III)&nbsp;EACH PARTY MAKES THIS WAIVER VOLUNTARILY,
AND (IV)&nbsp;EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION</U><U></U><U>&nbsp;8.5(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.6</B> <B>Assignability</B>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the
Parties and their respective successors and permitted assigns. Neither this Agreement nor any of the rights hereunder may be directly or indirectly assigned (including by operation of law) without the prior written consent of the other Parties, and
any attempted assignment of this Agreement or any of such rights without such consent shall be void and of no effect, except that Parent or Purchaser may assign, in its sole discretion and without consent of the other Parties, any of or all of its
rights, interests and obligations under this Agreement to any Affiliate of Parent, <I>provided that</I> no assignment by any Party in accordance herewith will relieve such Party of any of its obligations hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.7</B> <B>No Third Party Beneficiaries</B>. Nothing in this Agreement, express or
implied, is intended to or shall confer upon any Person (other than the Parties) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, except for: (a)&nbsp;if the Offer Acceptance Time and the Effective Time
occurs, (i)&nbsp;the right of the Company&#8217;s stockholders to receive the Offer Price or the Merger Consideration, as applicable and (ii)&nbsp;the right of the holders of Company Options, and RSUs to receive the Option Consideration and the RSU
Consideration, as applicable; (b)&nbsp;the provisions set forth in <U>Section</U><U></U><U>&nbsp;5.7(e)</U>; (c)&nbsp;the limitations on liability of the Company Related Parties set forth in <U>Section</U><U></U><U>&nbsp;7.3(e)</U> and (d)&nbsp;the
limits on liability of the Parent Related Parties set forth in <U>Section</U><U></U><U>&nbsp;7.3(g)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.8</B> <B>Notices</B>. All
notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder: (a)&nbsp;one (1)&nbsp;Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable
international overnight courier service, (b)&nbsp;upon delivery in the case of delivery by hand or (c)&nbsp;if sent by email transmission, upon transmission (<I>provided</I>, that no &#8220;bounce back&#8221; or similar message of <FONT
STYLE="white-space:nowrap">non-delivery</FONT> is received with respect thereto); <I>provided</I>, that, in each case, the notice or other communication is sent to the physical address or email address set forth beneath the name of such Party below
(or to such other physical address or email address as such Party shall have specified in a written notice given to the other Parties): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to Parent or Purchaser (or following the Effective Time, the Company): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Novartis AG </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o Novartis
International AG </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Lichtstrasse 35 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">4056 Basel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Switzerland </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: Legal Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:
[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Hogan Lovells US LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">555 13<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> Street NW </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Washington, DC 20004 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: &#8194;Joseph Gilligan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8194;Mahvesh Qureshi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8194;Gabrielle Witt </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8194;Jessica Bisignano </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:
joseph.gilligan@hoganlovells.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8194;mahvesh.qureshi@hoganlovells.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8194;gabrielle.witt@hoganlovells.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8194;jessica.bisignano@hoganlovells.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to the Company (prior to the Effective Time): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Tourmaline Bio, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">27 West
24th Street, Suite 702 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10010 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: Legal Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:
[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10001 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn:
&#8194;William Sorabella </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8194;Brandon Fenn </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: wsorabella@cooley.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8194;bfenn@cooley.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.9</B> <B>Severability</B>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction
shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of
a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific
words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and
enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that
will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.10</B> <B>Obligation of </B><B>Parent</B><B>&#8217;</B><B>s Subsidiaries</B>. Parent shall cause Purchaser to duly perform, satisfy and
discharge on a timely basis each of the covenants, obligations and liabilities applicable to Purchaser under this Agreement, and Parent shall be jointly and severally liable with Purchaser for the due and timely performance and satisfaction of each
of said covenants, obligations and liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.11</B> <B>T</B><B>ransfer Taxes</B>. Except as expressly provided in
<U>Section</U><U></U><U>&nbsp;2.7(d)</U>, all stock transfer, real estate transfer, documentary, stamp, recording and other similar Taxes imposed on the Transactions shall be borne by Parent and Purchaser when due. Parent and Purchaser shall file,
at their expense, all Tax Returns and other documentation required to be filed with respect to such Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.12</B> <B>Company
Disclosure Letter References</B>. The Parties agree that the disclosure set forth in any particular section or subsection of the Company Disclosure Letter shall be deemed to be an exception to (or, as applicable, a disclosure for purposes of)
(a)&nbsp;the representations and warranties (or covenants, as applicable) of the Company that are set forth in the corresponding Section or subsection of this Agreement; and (b)&nbsp;any other representations and warranties (or covenants, as
applicable) of the Company, as applicable, that are set forth in this Agreement if the relevance of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that disclosure as an exception to (or a disclosure for purposes of) such other representations and warranties (or covenants, as applicable) is reasonably apparent on the face of such disclosure.
The mere inclusion of an item in the Company Disclosure Letter as an exception to a representation or warranty or covenant shall not be deemed an admission that such item represents a material exception or material fact, event or circumstance or
that such item is material or constitutes a Material Adverse Effect, and no reference to, or disclosure of, any item or other matter in the Company Disclosure Letter shall necessarily imply that any other undisclosed matter or item having a greater
value or significance is material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.13</B> <B>Construction</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. For purposes of this Agreement, where a word or
phrase is defined in this Agreement, each of its other grammatical forms has a corresponding meaning unless the context otherwise requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Each Party has participated in the drafting and negotiation of this Agreement. If an ambiguity or question of intent or
interpretation arises, the Parties agree that any rule of construction to the effect that ambiguities or questions of intent or interpretation are to be resolved against the drafting Party shall not be applied in the construction or interpretation
of this Agreement, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of authority of any of the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Parties agree that they have been represented by counsel during the negotiation and execution of this Agreement and, therefore,
waive the application of any Legal Requirement, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the drafting party of such agreement or document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> As used in this Agreement, unless otherwise indicated, the words &#8220;include,&#8221; &#8220;includes&#8221; and
&#8220;including&#8221; shall be deemed in each case to be followed by the words &#8220;without limitation.&#8221; As used in this Agreement, unless otherwise indicated, the words &#8220;hereof,&#8221; &#8220;herein&#8221; and
&#8220;hereunder&#8221; and words of like import shall refer to this Agreement as a whole and not to any particular provision of this Agreement. As used in this Agreement, unless otherwise indicated, the word &#8220;or&#8221; shall not be exclusive
(i.e., &#8220;or&#8221; shall be deemed to mean &#8220;and/or&#8221;). As used in this Agreement, unless otherwise indicated, the word &#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; shall mean the degree to which a subject or other
thing extends and shall not simply mean &#8220;if.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Except as otherwise indicated, all references in this Agreement to
&#8220;Sections,&#8221; &#8220;Exhibits,&#8221; &#8220;Annexes&#8221; and &#8220;Schedules&#8221; are intended to refer to Sections of this Agreement and Exhibits, Annexes or Schedules to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Unless otherwise indicated, all references herein to the Subsidiaries of a Person shall be deemed to include all direct and
indirect Subsidiaries of such Person unless otherwise indicated or the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> References to &#8220;made available&#8221; shall mean that such documents or
information referenced: (i)&nbsp;were physically or electronically delivered or provided to the Company, Parent, Purchaser or their respective Representatives, as applicable; (ii)&nbsp;were contained in the Company&#8217;s electronic data room
maintained by Datasite; or (iii)&nbsp;were publicly available, without redactions, on the EDGAR website, in each case of clause (i)&nbsp;through (iii) at least twenty-four (24)&nbsp;hours prior to the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> References to any specific Legal Requirement or to any provision of any Legal Requirement includes any amendment to, and any
modification, <FONT STYLE="white-space:nowrap">re-enactment</FONT> or successor thereof, any legislative provision substituted therefor and all rules, regulations and statutory instruments issued or promulgated thereunder or pursuant thereto, except
that, for purposes of any representations and warranties in this Agreement that are made as a specific date, references to any specific Legal Requirement will be deemed to refer to such legislation or provision (and all rules, regulations and
statutory instruments issued or promulgated thereunder or pursuant thereto) as of such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> References in this Agreement to
&#8220;ordinary course&#8221; or &#8220;ordinary course of business&#8221; shall mean the ordinary course of operations of the Company, consistent in all material respects with the Company&#8217;s past practice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> References to &#8220;$&#8221; or &#8220;dollars&#8221; refer to United States dollars unless otherwise noted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> The table of contents and bold-faced headings contained in this Agreement are for convenience of reference only, shall not be
deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature pages follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
Parties have caused this Agreement to be executed as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>N<SMALL>OVARTIS</SMALL> AG</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Emery</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan Emery</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tariq El-Rafie</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tariq El-Rafie</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attorney-in-fact</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>T<SMALL>ORINO</SMALL> M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ram Narayan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ram Narayan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attorney-in-fact</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Juliana Mazza-Reis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Juliana Mazza-Reis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attorney-in-fact</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
Parties have caused this Agreement to be executed as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>T<SMALL>OURMALINE</SMALL> B<SMALL>IO</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sandeep Kulkarni</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sandeep Kulkarni</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XHIBIT</SMALL> A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ERTAIN</SMALL> D<SMALL>EFINITIONS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement (including this <B>Exhibit</B><B></B><B>&nbsp;A</B>): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>2025 Bonus Payment</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.6(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>401(k) Termination Date</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.6(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Acceptable Confidentiality Agreement</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.3(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Acquisition Proposal</I></B>&#8221; shall mean any indication of interest, proposal or offer proposal from any Person (other than
Parent and its Affiliates) or &#8220;group&#8221;, within the meaning of Section&nbsp;13(d) of the Exchange Act, relating to, in a single transaction or series of related transactions providing for any (a)&nbsp;purchase, acquisition or license of
assets of the Company equal to 20% or more of the consolidated assets (including equity interests) of the Company or to which 20% or more of the consolidated revenues or earnings of the Company are attributable, (b)&nbsp;purchase, issuance by the
Company or acquisition of 20% or more of the outstanding Shares, or securities convertible into outstanding Shares, (c)&nbsp;tender offer or exchange offer that if consummated would result in any Person or group beneficially owning 20% or more of
the outstanding Shares, (d)&nbsp;merger, consolidation, amalgamation, share exchange, business combination, recapitalization, liquidation, dissolution or similar transaction involving the Company that if consummated would result in any Person or
group beneficially owning 20% or more of the outstanding Shares, or securities convertible into outstanding Shares or (e)&nbsp;sale of the rights of, license (other than any <FONT STYLE="white-space:nowrap">non-exclusive</FONT> and <FONT
STYLE="white-space:nowrap">non-material</FONT> license granted by the Company in the ordinary course of business or expressly permitted to be granted by the Company by Section&nbsp;5.2) of, or joint venture or other similar transaction involving
Pacibekitug, in each case, other than the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Addendum</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;5.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Affiliate</I></B>&#8221; shall mean, as to any Person, any other Person that,
directly or indirectly, controls, or is controlled by, or is under common control with, such Person. For this purpose, &#8220;control&#8221; (including, with its correlative meanings, &#8220;controlled by&#8221; and &#8220;under common control
with&#8221;) shall mean the possession, directly or indirectly, of the power to direct or cause the direction of management or policies of a Person, whether through the ownership of securities or partnership or other ownership interests, by Contract
or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Agreement</I></B>&#8221; shall mean the Agreement and Plan of Merger to which this <U>Exhibit A</U> is
attached, as it may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Anti-Corruption Laws</I></B>&#8221; shall mean the Foreign Corrupt
Practices Act of 1977, the <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Act of 1986, the UK Bribery Act of 2010, and any applicable Legal Requirements relating to the prevention of corruption, bribery or money-laundering or applicable to
record keeping and internal control Legal Requirements, including any such Legal Requirements that prohibit private commercial bribery. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Antitrust and FDI Laws</I></B>&#8221; shall mean the Sherman Act, the Clayton
Act, the HSR Act, the Federal Trade Commission Act, state Legal Requirements and other applicable Legal Requirements (including non-U.S. Legal Requirements) issued by a Governmental Body that are designed or intended to preserve or protect
competition, prohibit and restrict agreements in restraint of trade or monopolization, attempted monopolization, or abuse of a dominant position, or to prevent acquisitions, mergers or other business combinations and similar transactions, the effect
of which may be to lessen or impede competition or to tend to create or strengthen a dominant position or to create a monopoly and all Legal Requirements and Orders issued by a Governmental Body relating to foreign investment or national security.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Applicable Proceeding</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.2(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Balance Sheet</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Bankruptcy and Equity Exceptions</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.15(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Book-Entry Shares</I></B>&#8221; shall mean <FONT STYLE="white-space:nowrap">non-certificated</FONT> Shares represented by
book-entry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Burdensome Condition</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.5(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Business Day</I></B>&#8221; shall mean a day except a Saturday, a Sunday or other day on which banks in New York, New York or
Basel or Zurich, Switzerland are authorized or required by Legal Requirements to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>CC Date</I></B>&#8221; is
defined in <U>Section</U><U></U><U>&nbsp;3.16(e)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Certificate of Incorporation</I></B>&#8221; shall mean the Amended and
Restated Certificate of Incorporation of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Certificates</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;2.7(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Change in Circumstance</I></B>&#8221; shall mean any material event, fact,
occurrence or development or material change in circumstances that occurs or arises after the date of this Agreement that has a material positive effect on the business, assets, Liabilities, financial condition or results of operations of the
Company, and that (a)&nbsp;was not known or reasonably foreseeable to the Company Board as of the date of this Agreement (or if known Company Board as of the date hereof, the consequences of which were not known or reasonably foreseeable to Company
Board as of the date of this Agreement) and (b)&nbsp;does not relate to (i)&nbsp;any Acquisition Proposal or any inquiry, proposal or offer that constitutes or would reasonably be expected to lead to an Acquisition Proposal, (ii)&nbsp;any events,
changes or circumstances relating to Parent, Purchaser or any of their Affiliates, (iii)&nbsp;any change in conditions generally (including any regulatory changes) affecting the industries or sectors in which the Company operates, except to the
extent such change has a disproportionate impact on the Company (taken as a whole) as compared to other similarly situated participants in the industries in which the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operates, (iv)&nbsp;the taking of any action required or expressly contemplated by this Agreement, (v)&nbsp;the fact, in and of itself, that the Company meets or exceeds any internal or
analysts&#8217; expectations or projections for the results of operations for any period ending on or after the date of this Agreement (<I>provided</I>, that the exception in this clause&nbsp;(v) shall not prevent or otherwise affect the development
or change underlying the Company meeting or exceeding such metrics from being taken into account in determining whether a Change in Circumstance has occurred if it is not otherwise excluded by this definition), or (vi)&nbsp;any changes after the
date of this Agreement in the market price or trading volume of the shares of Company Common Stock (<I>provided</I>, that the exception in this clause&nbsp;(vi) shall not prevent or otherwise affect the development or change underlying such change
in market price or trading value from being taken into account in determining whether a Change in Circumstance has occurred if it is not otherwise excluded by this definition). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Chosen Courts</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;8.5(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Closing</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.3(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Closing Date</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.3(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Code</I></B>&#8221; shall mean the Internal Revenue Code of 1986. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Collaboration Partners</I></B>&#8221; shall mean the Company&#8217;s <FONT STYLE="white-space:nowrap">(sub-)licensees</FONT> or <FONT
STYLE="white-space:nowrap">(sub-)</FONT> licensors of Intellectual Property Rights or any third party with which the Company has entered into a Contract that relates to the material research, development, supply, manufacturing, testing,
commercialization, or other exploitation of any Company Product Candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company</I></B>&#8221; is defined in the preamble
to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company 401(k) Plan</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.6(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Acquisition Agreement</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.3(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Adverse Change Recommendation</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Associate</I></B>&#8221;<B><I> </I></B>shall mean each current or former officer or other employee, or individual who is
an individual independent contractor, consultant or director of or to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company
Board</I></B><B><I>&#8221;</I></B> is defined in the recitals of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Board Recommendation</I></B>&#8221;
is defined in the recitals of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Breach Notice Period&#8221;</I></B> is defined in
<U>Section</U><U></U><U>&nbsp;7.1(e)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Common Stock</I></B>&#8221; shall mean Company Voting Common Stock and
Company <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock, collectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Contract</I></B>&#8221;<B> </B>shall mean any Contract to which the
Company is a party or by which any of its assets are bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Disclosure Documents</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;3.7(g)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Disclosure Letter</I></B>&#8221; shall mean the disclosure schedule that
has been prepared by the Company in accordance with the requirements of this Agreement and that has been delivered by the Company to Parent on the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Equity Plans</I></B>&#8221; shall mean the Company&#8217;s 2022 Equity Incentive Plan, as amended and restated, and the
Company&#8217;s 2023 Equity Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company ESPP</I></B>&#8221;<I> </I>is defined in
<U>Section</U><U></U><U>&nbsp;2.10</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Lease</I></B>&#8221;<B><I> </I></B>shall mean any Company Contract pursuant
to which the Company leases, subleases or is otherwise granted a right to use or enjoy Leased Real Property from another Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company </I></B><B><I>Licensed IP</I></B>&#8221; shall mean Intellectual Property Rights that are exclusively licensed to the
Company, including any patent or patent application that claims priority to or shares priority with any patent or patent application identified on <U>Section</U><U></U><U>&nbsp;3.13(a)</U> of the Company Disclosure Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock</I></B>&#8221; shall mean the class designated as <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock, par value $0.0001 per share of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company
Options</I></B>&#8221; shall mean all options to purchase Shares (whether granted by the Company pursuant to the Company Equity Plans, assumed by the Company in connection with any merger, acquisition or similar transaction or otherwise issued or
granted). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Owned IP</I></B>&#8221;<I> </I>shall mean all Intellectual Property Rights that are owned or purported to
be owned (solely or jointly, in whole or in part) by the Company, including any patent or patent application identified on, or that claims priority to or shares priority with any patent or patent application identified on,
<U>Section</U><U></U><U>&nbsp;3.13(a)</U> of the Company Disclosure Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company</I></B><I> </I><B><I>Product
Candidates</I></B>&#8221;<I> </I>means any pharmaceutical product that is being discovered, researched, developed, tested, manufactured, sold or distributed, or otherwise commercialized, by or on behalf of the Company (including by any Collaboration
Partner) and that is owned by, licensed to, or otherwise used in the business of, the Company, on or before the date of this Agreement and during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, including investigational Pacibekitug
and any other investigational products in the Company&#8217;s research and development pipeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Related
Parties</I></B>&#8221; shall mean, collectively, (a)&nbsp;the Company and its Affiliates and (b)&nbsp;the former, current and future holders of any equity, controlling persons, directors, officers, employees, agents, attorneys, members, managers,
general or limited partners, stockholders and assignees of the Company and its Affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Restricted Share</I></B>&#8221; means each share of Company Common
Stock, purchased pursuant to an exercise of a Company Option or otherwise purchased pursuant to an award under a Company Equity Plan or otherwise, which is subject to a repurchase option by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company SEC Documents</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.7(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Securities</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.4(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Stock Award Grant Date</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.4(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Stock Awards</I></B>&#8221; shall mean all Company Options, Company Restricted Shares and RSUs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Stockholder</I></B>&#8221; shall<B><I> </I></B>mean a holder of Company Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Systems</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.14(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Termination Fee</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;7.3(b)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Undesignated Preferred Stock</I></B>&#8221; shall mean the undesignated preferred stock, par value of $0.0001 per share,
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Company Voting Common Stock</I></B>&#8221; shall mean the class designated as common stock, par value
$0.0001 per share of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Confidentiality Agreement</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;5.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Consent</I></B>&#8221; shall mean any approval, consent, ratification, permission,
waiver or authorization (including any Governmental Authorization). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Continuing Employee</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;5.6(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Contract</I></B>&#8221; shall mean any legally binding agreement, contract,
subcontract, lease, instrument, bond, debenture, note, indenture, option, warrant, warranty, purchase order, license, sublicense, insurance policy, benefit plan or other legally binding commitment or undertaking of any nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Data Security Requirements</I></B>&#8221; shall mean, to the extent governing the privacy, data protection or security of any
Personal Information including data breach notification, all applicable (a)&nbsp;Legal Requirements (including, as and to the extent applicable to the relevant Personal Information, the Health Insurance Portability and Accountability Act of 1996 as
amended by Health Information Technology for Economic Clinical Health Act of the American Recovery and Reinvestment Act of 2009, and each of their implementing regulations, and the EU General Data Protection Regulation and the implementing statutes
of EU member states), (b)&nbsp;written external-facing privacy policies of the Company and any governing consents, and (c)&nbsp;legally binding&nbsp;contractual requirements to which the Company is a party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Determination Notice</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;5.4(b)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>DGCL</I></B>&#8221; shall mean the General Corporation Law of the State of
Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Dissenting Shares</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>DOJ</I></B>&#8221; shall mean the U.S. Department of Justice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>DTC</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.7(b)</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Effective Time</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.3(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Employee Plan</I></B>&#8221;<I> </I>shall mean (a)&nbsp;any &#8220;employee benefit plan&#8221; (as defined in Section&nbsp;3(3)
of ERISA, whether or not subject to ERISA), and (b)&nbsp;each other employment, individual consulting, salary, bonus, vacation, deferred compensation, incentive compensation, stock purchase, stock option, equity or equity-based compensation,
severance pay, termination pay, death and disability benefits, hospitalization, medical, life or other insurance, flexible benefits, tax <FONT STYLE="white-space:nowrap">gross-up,</FONT> supplemental unemployment benefits, profit-sharing, pension or
retirement plan, policy, program, agreement or arrangement whether written or unwritten, in each case (i)&nbsp;that is sponsored, maintained, entered into, contributed to or required to be contributed to by the Company or (ii)&nbsp;with respect to
which the Company has or could reasonably be expected to have any liability (including as a result of an ERISA Affiliate). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Encumbrance</I></B>&#8221; shall mean any lien, license, pledge, hypothecation, charge, mortgage, security interest, encumbrance,
claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or other similar restriction (including any restriction on the voting of any security, any restriction on the transfer of any security
or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Enforcement Expenses</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;7.3(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Entity</I></B>&#8221; shall mean any corporation (including any <FONT STYLE="white-space:nowrap">non-profit</FONT> corporation),
general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise,
association, organization or entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Environmental Law</I></B>&#8221; shall mean any federal, state, local or foreign Legal
Requirements relating to pollution or protection of human health, worker health or the environment (including ambient air, surface water, soil, soil vapor, ground water, land surface or subsurface strata), including any Legal Requirement relating to
emissions, discharges, releases or threatened releases of Hazardous Materials or otherwise relating to the labelling, management, recycling, generation, testing, recycling, manufacture, processing, distribution, use, treatment, storage, disposal,
Release, removal, remediation, recovery, reporting, cleanup, transport or handling of Hazardous Materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>ERISA</I></B>&#8221; shall mean the Employee Retirement Income Security Act of 1974. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>ERISA Affiliate</I></B>&#8221; shall mean any trade or business, whether or not
incorporated, that, together with Company, is or has at any relevant time been treated as a single employer with Company under Section&nbsp;4001(b) of ERISA or as part of the same &#8220;controlled group&#8221; as Company for purposes of
Section&nbsp;302(d)(3) of ERISA or Section&nbsp;414 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Exchange Act</I></B>&#8221; shall mean the Securities
Exchange Act of 1934. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Excluded Shares</I></B>&#8221; shall mean (a)&nbsp;any Shares held by (i)&nbsp;the Company (other than
Shares that are held in a fiduciary or agency capacity and are beneficially owned by third parties) or (ii)&nbsp;Parent, Purchaser or any other direct or indirect wholly owned Subsidiary of Parent as of the Effective Time and (b)&nbsp;any Dissenting
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Existing D&amp;O Policies</I></B>&#8221;<B> </B>is defined in <U>Section</U><U></U><U>&nbsp;5.7(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Expiration Date</I></B>&#8221;<B> </B>is defined in <U>Section</U><U></U><U>&nbsp;1.1(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>FAR</I></B>&#8221;<B> </B>is defined in <U>Section</U><U></U><U>&nbsp;3.15(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>FDA</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.16(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>FDA Application Integrity Policy</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.16(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>FTC</I></B>&#8221; shall mean the U.S. Federal Trade Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>GAAP</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.7(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Good Clinical Practices</I></B>&#8221; means the standards for clinical trials for the design, conduct, performance, monitoring,
auditing, recording, analysis, and reporting of pharmaceuticals (including all applicable requirements relating to protection of human subjects), as set forth in the FDCA and applicable regulations promulgated by the FDA (including, for example, 21
C.F.R. Parts 11, 50, 54, 56, and 312), as amended from time to time, and such standards of good clinical practice (including all applicable requirements relating to protection of human subjects)as are required by Regulatory Authority in any other
countries, including applicable regulations or guidelines from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, where the Company currently intends to sell the Company Product
Candidate after receipt of Governmental Authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Good Documentation Practices</I></B>&#8221; mean the standards and
practices of creating and maintaining records that are accurate, attributable, verified as genuine, legible, contemporaneous and complete, and are created and stored using security measures that protect the confidential nature (if applicable) and
integrity of the records, and prevent unauthorized access to, and alteration, corruption or loss of such records in a manner sufficient to satisfy the requirements contained in 21 C.F.R. Parts 58, 312, 210, and211, the FDA&#8217;s relevant guidance
documents including E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) (March 2018), and all comparable standards of any other applicable Governmental Body or Regulatory Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Good Laboratory Practices</I></B>&#8221; mean standards for conducting <FONT
STYLE="white-space:nowrap">non-clinical</FONT> laboratory studies, as set forth in the FDCA and applicable regulations promulgated by the FDA (including, for example, 21 C.F.R. Parts 11 and 58), as amended from time to time, and such standards of
good laboratory practices as are required by Governmental Bodies or Regulatory Authorities in any other countries, including applicable regulations or guidelines from the International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use, where the Company currently intends to sell the Company Product Candidates after receipt of Governmental Authorization, to the extent such standards are not less stringent than in the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Good Manufacturing Practices</I></B>&#8221; mean standards for the manufacture, processing, packaging, testing,
transportation, handling and holding of drug products, as set forth in the FDCA and applicable regulations promulgated by the FDA (including, for example, 21 C.F.R. Parts 11, 210, and 211), as amended from time to time, and such standards of good
manufacturing practices as are required by Governmental Bodies or Regulatory Authorities in any other countries, including applicable regulations or guidelines from the International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use, where the Company currently intends to sell the Company Product Candidates after receipt of Governmental Authorization, to the extent such standards are not less stringent than in the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Government Bid</I></B>&#8221; means any offer, proposal, quotation or bid which, if accepted or awarded, would lead to a
Government Contract for the sale of goods or the provision of services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Government Contract</I></B>&#8221; means any prime
contract, subcontract, joint venture, teaming agreement, basic ordering agreement, blanket purchase agreement, letter agreement, grant, subgrant, cooperative agreement, federal or state funding award, or other commitment or funding vehicle between
the Company and (a)&nbsp;a Governmental Body, (b)&nbsp;any prime contractor, prime recipient, or awardee contracting with a Governmental Body, or (c)&nbsp;any subcontractor, subrecipient, or subawardee with respect to any agreement described in
clause (a)&nbsp;or (b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Government Official</I></B>&#8221; shall mean any officer or employee of a Governmental Body or any
department, agency or instrumentality thereof, including state-owned entities, or of a public organization or any Person acting in an official capacity for or on behalf of any such Governmental Body, department, agency, or instrumentality or on
behalf of any such public organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Governmental Authorization</I></B>&#8221; shall mean any: (a)&nbsp;application,
approval, permit, license, certificate, franchise, permission, variance, clearance, registration, qualification, Consent or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or
pursuant to any Legal Requirement, including any Investigational New Drug Application (&#8220;<B><I>IND</I></B>&#8221;), Clinical Study Authorization, New Drug Application (&#8220;<B><I>NDA</I></B>&#8221;), Biologics License Application
(&#8220;<B><I>BLA</I></B>&#8221;) or other application or permit to test, market, or commercialize a pharmaceutical or biological product, and all supplements, amendments, variations, extensions and renewals thereto, or (b)&nbsp;right under any
Contract with any Governmental Body or Regulatory Authority, including but not limited to Clinical Study Authorization and applications to commercialize a pharmaceutical or biological product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Governmental Body</I></B>&#8221; shall mean: (a)&nbsp;any nation, state,
commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b)&nbsp;any government; (c)&nbsp;any governmental, regulatory or <FONT STYLE="white-space:nowrap">quasi-governmental</FONT> authority of any
nature including any governmental division, department, agency, commission, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity; (d)&nbsp;any court, judicial body, arbitrator, arbitration panel or other
tribunal and (e)&nbsp;any <FONT STYLE="white-space:nowrap">non-governmental</FONT> self-regulatory agency, securities exchange commission or authority, in each of clauses (b)&nbsp;through (e), whether supranational, national, federal, state, local,
municipal, domestic or foreign. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Governmental Program</I></B>&#8221; shall mean any &#8220;Governmental Program&#8221; as
defined in 42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1320a-7b(f),</FONT> including Medicare, Medicaid, CHAMPVA, TRICARE, the United States Department of Veteran Affairs, and all other health care reimbursement programs funded and/or regulated
by any Governmental Body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Hazardous Materials</I></B>&#8221;<B><I> </I></B>shall mean any waste, material, or substance that
is listed, regulated or defined under, or that is the basis for any liability under, any Environmental Law and includes any pollutant, chemical substance, hazardous substance, hazardous waste, special waste, solid waste, asbestos, mold, radioactive
material, polychlorinated biphenyls, petroleum or petroleum-derived substance or waste, <FONT STYLE="white-space:nowrap">per-</FONT> and poly-fluorinated substances (&#8220;<B><I>PFAS</I></B>&#8221;), organofluorines, radon, mold, or silica. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Healthcare Laws</I></B>&#8221; shall mean any and all federal, state, local, or foreign Legal Requirements applicable to the
Company related to the nonclinical and clinical research, investigation, development, design, manufacturing, packaging, labeling, marketing, advertising, promotion, import, export, testing, sale, sampling, distribution, use, and commercialization of
healthcare products (and components thereof), including the United States Federal Food, Drug and Cosmetics Act, 21 U.S.C. &#167;&#167; 301 et seq and the regulations promulgated thereunder and equivalent
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> statutory and regulatory provisions; the Public Health Service Act, 42 U.S.C.&#167;&#167; 201 et seq., and the regulations promulgated thereunder and equivalent
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> statutory and regulatory provisions; the Federal Health Care Program Anti-Kickback Statute, 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b);</FONT> the federal False Claims Act, 31
U.S.C. &#167;&#167; 3729-3733; the Program Fraud Civil Remedies Act, 31 U.S.C. &#167;&#167; 3801-3812; the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1320a-7a</FONT> and
<FONT STYLE="white-space:nowrap">1320a-7b;</FONT> the Exclusions Law, 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7;</FONT> the healthcare fraud and false statement provisions of the Health Insurance Portability and Accountability Act of
1996 (&#8220;<B><I>HIPAA</I></B>&#8221;), as amended by the Health Information Technology for Economic and Clinical Health (&#8220;<B><I>HITECH</I></B>&#8221;) Act; the Animal Welfare Act, 7. U.S.C. &#167;&#167; 2131 et seq.; 42 U.S.C. <FONT
STYLE="white-space:nowrap">&#167;1395w-101</FONT> et seq. and the regulations promulgated thereunder; the <FONT STYLE="white-space:nowrap">so-called</FONT> federal &#8220;Sunshine Law&#8221; or Open Payments 42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7h;</FONT> Legal Requirements governing the protection of human research subjects; 15 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">41-58;</FONT> the Controlled Substances Act, 21 U.S.C. &#167; 801 et seq.,
Legal Requirements governing the manufacture, possession, and distribution of controlled substances; state board of pharmacy Legal Requirements; all applicable healthcare Legal Requirements, rules and regulation, guidance, orders, judgments, decrees
and injunctions administered by the FDA and other applicable Regulatory Authorities, including those governing or relating to Good Clinical Practices, Good Documentation Practices, Good Laboratory Practices, Good Manufacturing Practices,
development, approval, processing, and use of any compounds or products manufactured by or on behalf of the Company, including but not limited to FDA&#8217;s regulations at 21 C.F.R. Parts 11, 50, 54, 56, 58, 210, 211, 312, 600 and 610, each as may
be amended from time to time and equivalent <FONT STYLE="white-space:nowrap">non-U.S.</FONT> statutory and regulatory provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Healthcare Submissions</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;3.16(e)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>HSR Act</I></B>&#8221; shall mean the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I><FONT STYLE="white-space:nowrap">In-bound</FONT> License</I></B><B>&#8221; </B>is defined in
<U>Section</U><U></U><U>&nbsp;3.13(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Indebtedness</I></B>&#8221;<B><I> </I></B>shall mean, with respect to the
Company: (a)&nbsp;any indebtedness for borrowed money (including the issuance of any debt security) to any Person and the capitalized value of any finance leases; (b)&nbsp;any obligations evidenced by notes, bonds, debentures or similar Contracts to
any Person; (c)&nbsp;any obligations in respect of letters of credit (to the extent issued) and bankers&#8217; acceptances or other similar instruments; (d)&nbsp;all liabilities under interest rate, currency, swap, collar, hedging or similar
agreements or arrangements; or (e)&nbsp;any guaranty of any such obligations described in clauses&nbsp;(a) through (d)&nbsp;of any Person (other than, in any case, accounts payable to trade creditors and accrued expenses, in each case arising in the
ordinary course of business and that are not more than ninety (90)&nbsp;days past due). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Indemnification
Agreements</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.7(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Indemnified Persons</I></B>&#8221; is
defined in <U>Section</U><U></U><U>&nbsp;5.7(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Indemnifying Parties</I></B>&#8221;<B> </B>is defined in
<U>Section</U><U></U><U>&nbsp;5.7(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Intellectual Property Rights</I></B>&#8221; shall mean and includes all rights,
title, and interest in intellectual property and similar proprietary rights, which may exist or be created or protected under the laws of any jurisdiction in the world, including: (a)&nbsp;rights associated with works of authorship, including
exclusive exploitation rights, copyrights, moral rights, software, databases, and mask works; (b)&nbsp;trademarks, service marks, business marks, brand names, corporate names, trade dress, logos, trade names and other source or business identifiers,
domain names and URLs, social media identifiers and accounts, and similar rights and any goodwill associated therewith; (c)&nbsp;rights associated with trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> inventions, invention
disclosures, improvements, formulae, formulations, manuals, systems, methods, designs, drawings, procedures, processes, protocols, specifications, techniques and other forms of technology and data, data collections, <I>sui generis</I> database
rights, technical information, techniques, in each case whether or not patentable or copyrightable, and including all biological, chemical, biochemical, toxicological, pharmacological and metabolic material and information and data relating thereto
and formulation, clinical, analytical and stability information and data, and proprietary rights with respect to the foregoing; (d)&nbsp;patents, patent applications, provisional patent applications and similar instruments and industrial property
rights; (e)&nbsp;designs; (f)&nbsp;rights of publicity and privacy and other rights to use the names, likeness, image, photograph, voice, identity and Personal Information of individuals; (g)&nbsp;other proprietary rights in intellectual property of
every kind and nature; and (h)&nbsp;all registrations, renewals, extensions, substitutions, statutory invention registrations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supplemental protection certificates, provisionals, <FONT STYLE="white-space:nowrap">non-provisionals,</FONT> continuations,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisionals, or reissues of, and applications for, any of the rights referred to in clauses&nbsp;(a) through (g) (whether or not in tangible form
and including all tangible embodiments of any of the foregoing, such as samples, studies and summaries), along with all rights to prosecute and perfect the same through administrative prosecution, registration, recordation or other administrative
proceeding, and all causes of action and rights to sue or seek other remedies arising from or relating to the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>IP
Developer</I></B>&#8221;<B> </B>is defined in <U>Section</U><U></U><U>&nbsp;3.13(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>IRS</I></B>&#8221; shall mean the
Internal Revenue Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>knowledge</I></B>&#8221; shall mean, with respect to the Company, the actual knowledge of the
persons holding the positions of Chief Executive Officer or Chief Financial Officer of the Company and the individuals listed on <U>Section</U><U></U><U>&nbsp;1.1(a)</U> of the Company Disclosure Letter, in each case, after making reasonable
inquiry, including of such Company employees who would reasonably be expected to have knowledge of any particular fact or other matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Leased Real Property</I></B>&#8221;<B><I> </I></B>is defined in <U>Section</U><U></U><U>&nbsp;3.12(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Legal Proceeding</I></B>&#8221; shall mean any action, suit, charge, complaint, litigation, arbitration, proceeding (including
any civil, criminal, administrative, or appellate proceeding), inquiry, or hearing commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Legal Requirement</I></B>&#8221; shall mean any federal, state, local, municipal, foreign or other law, statute, constitution,
principle of common law, resolution, ordinance, guidance, treaty, Order, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any
Governmental Body (or under the authority of NYSE or the Nasdaq). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Legal Restraint</I></B>&#8221;<B> </B>is defined in
<U>Annex I</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Liabilities</I></B>&#8221; shall mean any liability, obligation or commitment of any kind (whether accrued,
absolute, contingent, matured, unmatured or otherwise and whether or not required to be recorded or reflected on a balance sheet prepared in accordance with GAAP). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Lookback Date</I></B>&#8221; shall mean January&nbsp;1, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Match Period</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.4(b)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Material Adverse Effect</I></B>&#8221; shall mean any fact, event, occurrence, effect, change, development or circumstance (each,
an &#8220;<B><I>Effect</I></B>&#8221;) that, individually or in the aggregate with all other Effects, (a)&nbsp;has had or would reasonably be expected to have a material adverse effect on the business, financial condition or results of operations of
the Company (taken as a whole) or (b)&nbsp;prevents or materially impairs the ability of the Company to consummate the Offer or the Merger by the Outside Date; <I>provided, however,</I> that for the purposes of the preceding clause (a)&nbsp;only, no
Effect arising </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
out of, relating to or resulting from the following, shall be deemed in and of themselves, either alone or in combination, to be or constitute, or shall be taken into account in determining,
whether there has been, or would reasonably be expected to be, a Material Adverse Effect: (i)&nbsp;general economic, legislative, regulatory or political conditions or conditions in any securities, credit, financial or other capital markets or in
the industry in which the Company operates, in each case in the United States or any other country or region; (ii)&nbsp;any Effect arising directly or indirectly from or otherwise relating to changes in interest rates, inflation rates, tariffs or
fluctuations in the value of any currency; (iii)&nbsp;any Effect in general regulatory, legislative or political conditions in the United States or any other country or region in the world; (iv)&nbsp;any act of terrorism, war, cyber attacks, cyber
terrorism, weather, earthquakes, hurricanes, tornados, natural disasters, climatic conditions, pandemic or epidemic (and any escalation or worsening of any of the foregoing); (v)&nbsp;any change in any Legal Requirements or GAAP, or legally binding
interpretations of any Legal Requirements or GAAP; (vi)&nbsp;any change in the market price, credit rating or trading volume of the Company&#8217;s stock or other securities or any change affecting the ratings or the ratings outlook for the Company
(<I>provided, however</I>, that the underlying factors contributing to any such change shall not be excluded unless such underlying factors would otherwise be excluded from the definition of Material Adverse Effect); (vii)&nbsp;any Effect arising
out of or relating to the announcement, execution, pendency or performance of this Agreement or the Transactions, including (A)&nbsp;any claim or Legal Proceeding after the date hereof against the Company or any of its directors or officers (in
their capacity as such) by any Company Stockholders (on their own behalf or on behalf of the Company) arising out of or related to this Agreement or the Transactions, (B)&nbsp;any negative development in customer, supplier, distributor, employee,
financing source, stockholder, regulatory or business partner of the Company resulting therefrom or (C)&nbsp;any Effect that arises out of or relates to the identity of, or any facts or circumstances relating to, Parent or any of its Affiliates;
<I>provided, however</I>, that this forgoing clause (vii)&nbsp;shall not apply with respect to any representation or warranty that expressly addresses the consequences of the announcement of, or the compliance with, this Agreement, or the pendency
or consummation of the Transactions or with respect to the condition set forth in clause <U>(B)(b)</U> of <U>Annex I</U>, solely to the extent it relates to such representations and warranties; (viii)&nbsp;(A) any action taken (or omitted to be
taken) with the express written consent of Parent or (B)&nbsp;the failure to take any action that is expressly prohibited by the terms of this Agreement to the extent Parent unreasonably fails to give its consent thereto after a written request
therefor; (ix)&nbsp;any failure by the Company to meet any internal or external projection, budget, forecast, estimate or prediction in respect of revenues, earnings or other financial or operating metrics for any period (<I>provided</I>, that the
underlying factors contributing to any such failure shall not be excluded unless such underlying factors would otherwise be excluded from the definition of Material Adverse Effect); (x) any determination by, or delay of a determination by, the FDA
or any other Governmental Body, or any panel, or advisory body empowered or appointed thereby, with respect to any applications, approvals or clearances relating to the Company&#8217;s or its competitors&#8217; or potential competitors&#8217;
product candidates, products, or programs; (xi)&nbsp;any results, outcomes, data, indications, adverse events, side effects or safety observations arising from preclinical trials, clinical trials or testing (including any stability testing),
including any requirement to conduct further clinical studies or tests or any increased incidence or severity of any previously identified side effects, adverse effects, adverse events or safety observations or reports of any new side effects,
adverse events or safety observations, with respect to the Company&#8217;s or its competitors&#8217; product candidates, products or program; (xii)&nbsp;the results of, or any data derived from, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any preclinical or clinical testing being conducted by or on behalf of any actual competitor of the Company or any announcements thereof; (xiii)&nbsp;any regulatory, preclinical or clinical,
competitive, pricing reimbursement or manufacturing effects, changes, events, facts, circumstances or occurrences relating to or affecting any product candidate of the Company or any product or product candidate competitive with or related to any
product candidate of the Company; or (xiv)&nbsp;the availability of or cost of equity, debt or other financing to Parent or Purchaser; <I>provided, however</I>, that any Effect referred to in the foregoing clauses (x), (xi), (xii) and
(xiii)&nbsp;may be taken into account in determining whether there is, or would reasonably be expected to be, a Material Adverse Effect to the extent such Effect involves: (x)&nbsp;any wrongdoing by the Company or any of its Affiliates or
Representatives, (y)&nbsp;any action taken (or the failure to takes any action) by or at the express direction of the Company constituting fraud or violation of applicable Legal Requirement or (z)&nbsp;any willful and material failure on the part of
the Company to comply with the approved clinical protocol of the development of any product or product candidate, unless Parent shall have consented in writing to the taking or failure to take any such action; <I>provided, further</I> that any
Effect referred to in the foregoing clauses (i)&nbsp;through (v) may be taken into account in determining whether there is, or would reasonably be expected to be, a Material Adverse Effect to the extent such Effect has a disproportionate adverse
impact on the Company (taken as a whole) as compared to other similarly situated participants in the industries in which the Company operates (in which case any such incremental disproportionate adverse impact (and only such incremental
disproportionate adverse impact) may be taken into account in determining whether there is, or would reasonably be expected to be a Material Adverse Effect). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Material Contract</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.15(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Maximum Amount</I></B>&#8221;<B> </B>is defined in <U>Section</U><U></U><U>&nbsp;5.7(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Merger</I></B>&#8221; is defined in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Merger Consideration</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.6(a)(iv)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Minimum Condition</I></B>&#8221; is defined in <U>Annex I</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Misconduct Allegation</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.20(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Nasdaq</I></B>&#8221; shall mean The Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>NYSE</I></B>&#8221; shall mean The New York Stock Exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Offer</I></B>&#8221; is defined in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Offer Acceptance Time</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.1(g)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Offer Commencement Date</I></B>&#8221; shall mean the date on which Purchaser commences the Offer, within the meaning of Rule <FONT
STYLE="white-space:nowrap">14d-2</FONT> under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Offer Conditions</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;1.1(b)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Offer Documents</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;1.1(e)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Offer Price</I></B>&#8221; is defined in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Offer to Purchase</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.1(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>OIG</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.16(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Option Consideration</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.9(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Order</I></B>&#8221; shall mean any order, award judgment, injunction, writ, decree (including any consent decree or similar
agreed order or judgment), directive, settlement, stipulation, ruling, determination, decision or verdict, whether civil, criminal or administrative, temporary, preliminary or permanent, in each case, that is entered, issued, made or rendered by any
Governmental Body and that is binding on any Person or its property under applicable Legal Requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I><FONT
STYLE="white-space:nowrap">Out-bound</FONT> License</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.13(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Outside Date</I></B>&#8221;<B><I> </I></B>is defined in <U>Section</U><U></U><U>&nbsp;7.1(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Pacibekitug</I></B>&#8221; shall mean the fully human recombinant immunoglobulin G (IgG2) <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-IL-6</FONT></FONT> monoclonal antibody known by the names pacibekitug and the product codes <FONT STYLE="white-space:nowrap">TOUR-006,</FONT> <FONT STYLE="white-space:nowrap">PF-0436921</FONT> and <FONT
STYLE="white-space:nowrap">PF-4236921.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent</I></B>&#8221; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent 401(k) Plan</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.6(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Breach Notice Period</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;7.1(g)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Material Adverse Effect</I></B>&#8221; shall mean any Effect that, individually or in the aggregate with one or more other
Effects, prevents, materially delays or materially impairs the ability of Parent or Purchaser to consummate the Transactions or perform its obligations under this Agreement or the other documents executed in connection with the Transactions to which
Parent or Purchaser is a party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Plans</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.6(b)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parent Related Parties</I></B>&#8221; shall mean (a)&nbsp;Parent, Purchaser and their Affiliates and (b)&nbsp;the former, current
and future holders of any equity, controlling persons, directors, officers, employees, agents, attorneys, members, managers, general or limited partners, stockholders and assignees of each of Parent, Purchaser and their respective Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Parties</I></B>&#8221; shall mean Parent, Purchaser and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Paying Agent</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.7(a)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Paying Agent Agreement</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;2.7(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Payment Fund</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;2.7(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Permitted Encumbrance</I></B>&#8221; shall mean (a)&nbsp;any Encumbrance that
arises for Taxes either not yet due and payable or the validity of which is being contested in good faith by appropriate proceedings and for which appropriate reserves have been established in accordance with GAAP; (b)&nbsp;any Encumbrance
representing the rights of customers, suppliers and subcontractors in the ordinary course of business under the terms of any Contracts to which the relevant party is a party or under general principles of commercial or government contract law
(including mechanics&#8217;, materialmen&#8217;s, carriers&#8217;, workmen&#8217;s, warehouseman&#8217;s, repairmen&#8217;s, landlords&#8217; and similar liens granted or which arise in the ordinary course of business); (c)&nbsp;in the case of any
Contract, Encumbrances that are restrictions against the transfer or assignment thereof that are included in the terms of such Contract to the extent made available to Parent; (d)&nbsp;any Encumbrances for which appropriate reserves have been
established in the financial statements of the Company; (e)&nbsp;any <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted to use Intellectual Property Rights in the ordinary course of business where such licenses are incidental to
performance under the Contract and granted to a Person solely with limited rights to perform services for the Company; and (f)&nbsp;in the case of real property, Encumbrances that are easements, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">rights-of-way,</FONT></FONT> encroachments, restrictions, conditions and other similar Encumbrances incurred or suffered in the ordinary course of business and which, individually or in the aggregate, do not and would not
materially impair the use (or contemplated use), utility or value of the applicable real property or otherwise materially impair the present or contemplated business operations at such location, or zoning, entitlement, building and other land use
regulations imposed by Governmental Bodies having jurisdiction over such real property or that are otherwise set forth on a title report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Person</I></B>&#8221; shall mean any individual, Entity or Governmental Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Personal Information</I></B>&#8221; shall mean information in the Company&#8217;s possession, custody, or control that
constitutes &#8220;personal data,&#8221; &#8220;personal information,&#8221; or similar term as defined by applicable Legal Requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.1</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#8220;</I><B><I>Process</I></B><I>&#8221;</I><I> </I>or<I> </I><I>&#8220;</I><B><I>Processing</I></B><I>&#8221;</I><I> </I>means the
use, collection, processing, storage, recording, adaption, alteration, transfer, disclosure, or dissemination of Personal Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Purchaser</I></B>&#8221; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Reference Date</I></B>&#8221; shall mean the last Business Day prior to the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Registered Company Owned IP</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.13(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Registered IP</I></B>&#8221; shall<B> </B>mean all Intellectual Property Rights that are pending, registered or issued under the
authority of any Governmental Body or, solely for domain names, private registrar, including all patents, registered copyrights, registered mask works, and registered trademarks, service marks and trade dress, registered domain names, and all
applications for any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Regulatory Authority</I></B>&#8221; shall mean any Governmental Body with
authority over the quality, identity, strength, purity, safety, efficacy, research, development, testing, investigation, manufacture, packaging, labeling, storage, distribution, destruction, disposition, advertising, marketing, import, export, or
sale of any product (including any compound, ingredient, or other material) that the Company or any Subsidiaries or Third Parties manufactures or is developing, or any service the Company or any Subsidiaries or Third Parties provides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Regulatory Permits</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.16(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Regulatory Termination Fee</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;7.3(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Release</I></B>&#8221; shall mean any presence, emission, spill, seepage, leak, escape, leaching, discharge, injection, pumping,
pouring, emptying, dumping, disposal, migration, or release of Hazardous Materials from any source into or upon the environment, including the air, soil, soil vapor, improvements, surface water, groundwater, the sewer, septic system, storm drain,
publicly owned treatment works, or waste treatment, storage, or disposal systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Representatives</I></B>&#8221; shall mean
officers, directors, employees, attorneys, accountants, investment bankers, consultants, agents, financial advisors, other advisors and other representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>RSU</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.9(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>RSU Consideration</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.9(c)</U>.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Sanctioned Country</I></B>&#8221; shall mean any country or territory that is the subject or target of comprehensive sanctions,
which currently includes Cuba, Iran, North Korea, Syria, and the Crimea, Donetsk People&#8217;s Republic, and Luhansk People&#8217;s Republic regions in Ukraine, and, for purposes of this Agreement, Russia and Belarus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Sanctioned Person</I></B>&#8221; shall mean any Person that is: (a)&nbsp;the subject or target of sanctions or restrictions under
Sanctions Laws or any Legal Requirement relating to export, reexport, transfer, and import controls, including the Export Administration Regulations and any other regulation administered by the U.S. Department of Commerce&#8217;s Bureau of Industry
and Security, the customs and import Legal Requirements administered by U.S. Customs and Border Protection, and the EU Dual Use Regulation (collectively, &#8220;<B><I>Export-Import Laws</I></B>&#8221;), including any Person listed on any applicable
U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> sanctions- or export-related restricted party list, including the U.S. Department of Treasury&#8217;s Office of Foreign Asset Control&#8217;s (&#8220;<B><I>OFAC</I></B>&#8221;) Specially
Designated Nationals and Blocked Persons List and the EU Consolidated List; (b)&nbsp;located or a resident in or organized under the Legal Requirements of a Sanctioned Country; or (c) 50% or more owned, directly or indirectly, individually or in the
aggregate, or otherwise controlled by a Person or Persons described in clauses&nbsp;(a) or (b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Sanctions Laws</I></B>&#8221; shall mean all Legal Requirements relating to
economic, financial or trade sanctions, including the Legal Requirements administered or enforced by the United States (including by OFAC or the U.S. Department of State), the United Nations Security Council, His Majesty&#8217;s Treasury of the
United Kingdom, the European Union and EU member states or any other applicable sanctions authority with jurisdiction over the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Sarbanes-Oxley Act</I></B>&#8221; shall mean the Sarbanes-Oxley Act of 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT></I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.2(a)</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Schedule TO</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.1(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>SEC</I></B>&#8221; shall mean the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Securities Act</I></B>&#8221; shall mean the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Security Incident</I></B>&#8221; shall mean a material security incident, ransomware or breach or intrusion into the
Company&#8217;s computer networks or the unauthorized access to, or material disclosure, use or modification of, Personal Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Shares</I></B>&#8221; is defined in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Standard Contracts</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.13(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Subsidiary</I></B>&#8221; shall mean, with respect to any Person, an Entity in which such Person directly or indirectly owns or
purports to own, beneficially or of record, (a)&nbsp;an amount of voting securities or other interests that is sufficient to enable such Person to elect at least a majority of the members of such Entity&#8217;s board of directors or other governing
body or (b)&nbsp;at least 50% of the outstanding equity or financial interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Superior Proposal</I></B>&#8221; shall mean
a <I>bona fide</I> written Acquisition Proposal made after the date hereof that did not result from a breach of <U>Section</U><U></U><U>&nbsp;5.3</U> or <U>Section</U><U></U><U>&nbsp;5.4</U> providing for a transaction or series of related
transactions on terms that the Company Board (or committee thereof) determines in its good faith judgment, after consultation with its financial advisor and outside legal counsel, taking into account all legal, regulatory and financing aspects of
the proposal and the Person making the proposal and other aspects of the Acquisition Proposal (including certainty of closing) that the Company Board deems relevant, (a)&nbsp;is reasonably likely to be consummated in accordance with its terms
without undue delay and (b)&nbsp;if consummated, would result in a transaction more favorable to the Company Stockholders (solely in their capacities as such) from a financial point of view than the Offer and Merger (including any adjustment to the
terms and conditions proposed by Parent in response to such proposal); <I>provided</I> that for purposes of the definition of &#8220;<B><I>Superior Proposal</I></B>&#8221; the references to &#8220;20%&#8221; in the definition of Acquisition Proposal
shall be deemed to be references to &#8220;50%.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Surviving Corporation</I></B>&#8221; is defined in the recitals of
this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Takeover Laws</I></B>&#8221; shall mean any &#8220;moratorium,&#8221;
&#8220;control share acquisition,&#8221; &#8220;fair price,&#8221; &#8220;supermajority,&#8221; &#8220;affiliate transactions,&#8221; &#8220;business combination statute or regulation&#8221; or other similar state anti-takeover Legal Requirements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Tax</I></B>&#8221; and &#8220;<B><I>Taxes</I></B>&#8221; shall mean (a)&nbsp;any and all taxes, fees, levies, duties,
tariffs, imposts, and other similar charges in the nature of a tax imposed by any Governmental Body, including taxes or other similar charges on or with respect to income, capital gains, franchise, business, windfall or other profits, estimated,
gross receipts, property, sales, use, surtax, capital stock, payroll, employment, social security, workers&#8217; compensation, unemployment compensation, or net worth, and taxes or other charges in the nature of excise, withholding, ad valorem,
stamp, transfer, value added, or gains taxes; and (b)&nbsp;any and all interest, penalties, additions to tax and additional amounts imposed in connection with or with respect to any of the foregoing amounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Tax Return</I></B>&#8221; shall mean any return (including any information return), report, statement, declaration, estimate,
schedule, notice, notification, form, election, certificate or other document or information filed with or submitted to, or required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment, collection
or payment of any Tax, including any attachment thereto or amendment thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Third Parties</I></B>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;3.16(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Third-Party Payor Program</I></B>&#8221; shall mean such private, <FONT
STYLE="white-space:nowrap">non-governmental</FONT> healthcare programs, including to any private insurance program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Trade
Control Laws</I></B>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;3.17(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Transactions</I></B>&#8221; shall mean
(a)&nbsp;the execution and delivery of this Agreement and (b)&nbsp;all of the transactions contemplated by this Agreement, including the Offer and the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Transaction Litigation</I></B>&#8221; shall mean any Legal Proceeding commenced or threatened against a Party or any of its
Subsidiaries or Affiliates or otherwise relating to, involving or affecting such Party or any of its Subsidiaries or Affiliates, in each case in connection with, arising from or otherwise relating to the Offer, the Merger or any other Transaction,
other than any Legal Proceedings among the Parties related to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Treasury Regulations</I></B>&#8221; shall mean
the regulations promulgated under the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<B><I>Willful Breach</I></B>&#8221; shall mean a material breach of this Agreement
that is a consequence of an act or failure to act by the breaching party with actual knowledge that such party&#8217;s act or failure to act would or would reasonably be expected to result in or constitute a breach of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>NNEX</SMALL> I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS TO THE OFFER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligation of Purchaser to accept for payment and pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is
subject to the satisfaction of the conditions set forth in <U>clauses</U> &#8220;(a)&#8221; through &#8220;(g)&#8221; below. Accordingly, Purchaser shall not be required to accept for payment or (subject to any applicable rules and regulations of
the SEC, including Rule <FONT STYLE="white-space:nowrap">14e-1(c)</FONT> under the Exchange Act) pay for, and may delay the acceptance for purchase of, or (subject to any such rules and regulations) the purchase and payment for, any validly tendered
(and not validly withdrawn) Shares, and, to the extent permitted by this Agreement, may (i)&nbsp;terminate the Offer: (A)&nbsp;upon termination of this Agreement; and (B)&nbsp;at any scheduled Expiration Date (subject to any extensions of the Offer
pursuant to <U>Section</U><U></U><U>&nbsp;1.1(c)</U> of this Agreement) or (ii)&nbsp;amend the Offer as otherwise permitted by this Agreement, if: (A)&nbsp;the Minimum Condition shall not be satisfied as of one minute following 11:59 p.m. Eastern
Time on the Expiration Date of the Offer; or (B)&nbsp;any of the additional conditions set forth in <U>clauses</U> &#8220;(b)&#8221; through &#8220;(g)&#8221; below shall not be satisfied or waived in writing by Purchaser as of one minute following
11:59 p.m. Eastern Time on the Expiration Date of the Offer: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) there shall have been validly tendered and not validly withdrawn shares
of Company Common Stock that, considered together with all other shares of Company Common Stock (if any) beneficially owned by Parent or any of its wholly owned Subsidiaries, would represent a majority of the total number of shares of Company Common
Stock outstanding at the time of the expiration of the Offer (the &#8220;<B><I>Minimum Condition</I></B>&#8221;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the representations and warranties of the Company set forth in <U>Section</U><U></U><U>&nbsp;3.9(a)(ii)</U> shall be true
and correct in all respects as of the date of the Agreement and at and as of the Offer Acceptance Time as though made at and as of such time (except to the extent expressly made as of an earlier date, in which case as of such earlier date); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the representations and warranties of the Company set forth in <U>Sections 3.4(a)</U>, <U>3.4(c)</U>, <U>3.4(d)</U>,
clauses (ii)&nbsp;and (iii) of the second sentence of <U>Section</U><U></U><U>&nbsp;3.4(e)</U> and the penultimate sentence of <U>Section</U><U></U><U>&nbsp;3.4(e)</U> shall be true and correct in all respects (except for any inaccuracies that
individually or in the aggregate are de minimis) as of the date of the Agreement and at and as of the Offer Acceptance Time as though made at and as of such time (except to the extent expressly made as of an earlier date, in which case as of such
earlier date); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the representations and warranties of the Company set forth in <U>Article 3</U> (other than
<U>Sections 3.1</U>, <U>3.3</U>, <U>3.4</U>, <U>3.5</U>, <U>3.6(a)</U>, <U>3.8</U>, <U>3.9(a)(ii)</U>, clause (i)&nbsp;of the first sentence of <U>3.16(b)</U>, <U>3.16(d)</U>, <U>3.16(e)</U>, <U>3.24</U>, <U>3.25</U> and <U>3.26</U>) shall be true
and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Material Adverse Effect&#8221; set forth therein) as of the date of the Agreement and at and as of the Offer Acceptance Time as if made on and as of such
time (except to the extent any such representation or warranty is expressly made as of an earlier date or time, in which case as of such earlier date or time), except where the failure of any such representation or warranty to be true and correct
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) the representations and warranties of the Company set forth in
<U>Sections 3.1</U>, <U>3.3</U>, <U>3.4</U> (other than <U>Sections 3.4(a)</U>, <U>3.4(c)</U>, <U>3.4(d)</U>, clauses (ii)&nbsp;and (iii) of the second sentence of <U>Section</U><U></U><U>&nbsp;3.4(e)</U> and the penultimate sentence of
<U>Section</U><U></U><U>&nbsp;3.4(e)</U>), <U>3.5</U>, <U>3.6(a)</U>, <U>3.8</U>, clause (i)&nbsp;of the first sentence of <U>3.16(b)</U>, <U>3.16(d)</U>, <U>3.16(e)</U>, <U>3.24</U>, <U>3.25</U> and <U>3.26</U> shall be true and correct in all
material respects (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Material Adverse Effect&#8221; set forth therein) as of the date of the Agreement and at and as of the Offer Acceptance Time as if made on and as of
such time (except to the extent any such representation or warranty is expressly made as of an earlier date or time, in which case as of such earlier date or time); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the Company shall have complied with or performed in all material respects all of the Company&#8217;s covenants and agreements it is
required to comply with or perform at or prior to the Offer Acceptance Time; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Parent and Purchaser shall have received a certificate of
the Company, validly executed for and on behalf of the Company and in its name by the chief executive officer or chief financial officer thereof, certifying that the conditions set forth in <U>clauses</U> &#8220;(b)&#8221; and &#8220;(c)&#8221;
above and <U>clause</U> &#8220;(g)&#8221; below have been duly satisfied; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) (i) any waiting period (and any extension thereof)
applicable to the Offer under the HSR Act shall have expired or terminated, and any agreement between a Party with any Governmental Body, if agreed to by the other Party in writing, not to consummate the Offer shall have expired or been earlier
terminated and (ii)&nbsp;any required consents, approvals, or expiration or termination of waiting periods from Governmental Bodies in the jurisdictions set forth on <U>Section</U><U></U><U>&nbsp;5.5(b)</U> of the Company Disclosure Letter, if any,
shall have been obtained (or deemed to have been obtained by virtue of the expiration or termination of any applicable waiting periods); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) (i) no Order shall have been issued by any court of competent jurisdiction after the date hereof and remain in effect, nor (ii)&nbsp;shall
any Legal Requirement have been entered, enforced, enacted, or issued after the date hereof by any Governmental Body and remain in effect, in the case of each of clause (i)&nbsp;and (ii), which prohibits or makes illegal the acquisition of or
payment for Shares pursuant to the Offer, or the consummation of the Merger (such Orders and Legal Requirements, each a &#8220;<B><I>Legal Restraint</I></B>&#8221;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) since the date of this Agreement, there shall not have occurred any Material Adverse Effect; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) this Agreement shall not have been terminated in accordance with its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annex I-2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d80074dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80074dsp004.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8211; Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4&nbsp;billion &#8211;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8211; Transaction reflects the potential of Tourmaline&#8217;s pacibekitug, a long-acting, fully-human,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-6</FONT></FONT> monoclonal antibody with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> potential, for the treatment of
cardiovascular diseases &#8211; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8211; Transaction is expected to be completed in the fourth quarter of 2025, subject to customary
closing conditions &#8211; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NEW YORK &#8211; September&nbsp;9, 2025 &#8211; Tourmaline Bio, Inc. (&#8220;Tourmaline&#8221;) (NASDAQ: TRML), a late-stage
clinical biotechnology company developing transformative medicines that establish new standards of care for patients with life-altering inflammatory and immune diseases, today announced that it has entered into a merger agreement with Novartis AG
(&#8220;Novartis&#8221;), pursuant to which Novartis will acquire Tourmaline for $48.00 per share in cash at closing, or a total equity value of approximately $1.4&nbsp;billion. This represents a premium of 59% to Tourmaline&#8217;s closing stock
price on September&nbsp;8, 2025, the last trading day before the announcement of the transaction, and 127% to Tourmaline&#8217;s <FONT STYLE="white-space:nowrap">60-day</FONT> volume-weighted average stock price as of that same date. The transaction
has been unanimously approved by the Boards of Directors of both companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Our mission at Tourmaline has been to establish new standards of care
in areas of high unmet medical need, and today&#8217;s transaction announcement both underscores our commitment to that focus and also delivers compelling shareholder value,&#8221; said Sandeep Kulkarni, MD,
<FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer of Tourmaline. &#8220;We are thrilled that Novartis, a company with deep roots and a commitment to innovation in the cardiovascular, renal, and metabolic disease space,
will continue to advance this mission. Novartis shares our conviction in the critical, but largely unaddressed, role of inflammation in driving cardiovascular diseases and will be an ideal partner to accelerate the development of pacibekitug. I want
to extend my heartfelt thanks to our Tourmaline colleagues and advisors for their dedication and hard work, as well as to our investigators and clinical trial participants who have helped expand our understanding of cardiovascular
inflammation.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;With no widely adopted anti-inflammatory therapies currently available for cardiovascular risk reduction, pacibekitug
represents a potential breakthrough in addressing&nbsp;residual inflammatory risk in ASCVD with a differentiated mechanism of action targeting <FONT STYLE="white-space:nowrap">IL-6,&#8221;</FONT> said Shreeram Aradhye, President, Development and
Chief Medical Officer, Novartis. &#8220;Inflammation is a major driver of cardiovascular disease, and the team at Tourmaline has made significant progress with this asset. We are excited to bring pacibekitug into the Novartis portfolio and
collaborate with the Tourmaline team to advance its development as we diversify our efforts in cardiovascular care.&#8221; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80074dsp004.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction Details: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the merger agreement, a subsidiary of Novartis will commence a tender offer to acquire all of Tourmaline&#8217;s outstanding shares for a
price of $48.00 per share in cash at closing. The closing of the tender offer will be subject to certain conditions, including the tender of shares representing at least a majority of the total number of Tourmaline&#8217;s outstanding shares and
receipt of regulatory approvals, and other customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Completion of the transaction is expected in the fourth quarter of 2025, subject
to the satisfaction or waiver of customary closing conditions. Until that time, Tourmaline will continue to operate as a separate and independent company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners is serving as exclusive financial advisor to Tourmaline, and Cooley LLP is serving as legal counsel to Tourmaline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Pacibekitug: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacibekitug is a long-acting,
fully-human, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-6</FONT></FONT> monoclonal antibody with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> potential and
differentiated properties, including a naturally long half-life, low immunogenicity, and high binding affinity to <FONT STYLE="white-space:nowrap">IL-6.</FONT> Pacibekitug has been previously studied in approximately 450 participants, including
patients with autoimmune disorders, across six completed clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Tourmaline: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that establish new standards of care for
patients with life-altering inflammatory and immune diseases. Tourmaline&#8217;s lead asset is pacibekitug. For more information about Tourmaline and pacibekitug, please visit <U>https://www.tourmalinebio.com</U> or follow us on <U>LinkedIn</U>,
<U>X</U> or <U>Bluesky</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Tourmaline
and Novartis, including statements relating to the ability to complete and the timing of completion of the transactions contemplated by the Agreement and Plan of Merger dated as of September&nbsp;8, 2025 by and among Tourmaline, Novartis, and the
other parties thereto (the &#8220;Merger Agreement&#8221;), including the anticipated occurrence, manner and timing of the proposed tender offer, the parties&#8217; ability to satisfy the conditions to the consummation of the tender offer and the
other conditions to the consummation of the subsequent merger set forth in the Merger Agreement, the possibility of any termination of the Merger Agreement, and the prospective benefits of the proposed transaction, and other statements that are not
historical facts. The forward-looking statements contained in this communication are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the
forward-looking statements. These statements may contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
&#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;opportunity,&#8221; &#8220;potential&#8221; or other similar words and expressions
indicating future results. Risks that may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the timing of the tender offer; uncertainties as to how many of Tourmaline&#8217;s stockholders will
tender their stock in the offer; the possibility that competing offers or acquisition proposals will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity
may prohibit, delay, or refuse to grant approval for the consummation of the transaction (or only grant approval subject to adverse conditions or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80074dsp004.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations); the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; the occurrence of any event, change or other circumstance that could give rise to the
termination of the Merger Agreement; the possibility that the transaction does not close; risks related to the parties&#8217; ability to realize the anticipated benefits of the proposed transaction, including the possibility that the expected
benefits from the proposed acquisition will not be realized or will not be realized within the expected time period and that Tourmaline and Novartis will not be integrated successfully or that such integration may be more difficult, time-consuming
or costly than expected; the effects of the transaction on relationships with employees, suppliers, manufacturers, other business partners or governmental entities; negative effects of this announcement or the consummation of the proposed
transaction on the market price of Tourmaline&#8217;s common stock and/or Tourmaline&#8217;s operating results; significant transaction costs; unknown or inestimable liabilities; the risk of litigation and/or regulatory actions related to the
proposed transaction; Novartis&#8217;s ability to fund the proposed transaction; the time-consuming and uncertain regulatory approval process; the uncertainties inherent in the costly and time-consuming therapeutic product development process and
the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and
potential future negative impacts to the parties&#8217; business operations and financial results; the sufficiency of the parties&#8217; cash flows and capital resources; the parties&#8217; ability to achieve targeted or expected future financial
performance and results and the uncertainty of future tax, accounting and other provisions and estimates; and other risks and uncertainties affecting Tourmaline, including those described from time to time under the caption &#8220;Risk
Factors&#8221; and elsewhere in Tourmaline&#8217;s filings and reports with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), including Tourmaline&#8217;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
fiscal year ended December&nbsp;31, 2024 and Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended June&nbsp;30, 2025, as well as the Tender Offer Statement on Schedule TO and related tender offer
documents to be filed by Novartis and its acquisition subsidiary, and the Solicitation/Recommendation Statement on Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> to be filed by Tourmaline. Any forward-looking statements are made based on the
current beliefs and judgments of Tourmaline&#8217;s and Novartis&#8217;s management, and the reader is cautioned not to rely on any forward-looking statements made by Tourmaline or Novartis. Except as required by law, Tourmaline and Novartis do not
undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Information about the Tender Offer and Where to Find It: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tender offer (the &#8220;Offer&#8221;) for Tourmaline outstanding common stock referred to in this communication has not yet commenced. The description
contained in this communication is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell any shares of common stock of Tourmaline or any other securities, nor is it a substitute for the tender offer materials that
Novartis and its acquisition subsidiary will file with the SEC. The solicitation and offer to purchase Tourmaline&#8217;s common stock will only be made pursuant to an offer to purchase and related tender offer materials. At the time the Offer is
commenced, Novartis and its acquisition subsidiary will file a tender offer statement on Schedule TO and thereafter Tourmaline will file a solicitation/recommendation statement on Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> with the SEC
with respect to the Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER OFFER DOCUMENTS)
AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE <FONT STYLE="white-space:nowrap">14D-9,</FONT> AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER
OFFER. ANY HOLDERS OF TOURMALINE SHARES ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80074dsp004.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offer to purchase, the letter of transmittal, the solicitation/recommendation statement and related offer
documents will be made available for free at the SEC&#8217;s website at <U>www.sec.gov</U>. Copies of those offer documents and all other documents filed by Novartis and its acquisition subsidiary and Tourmaline will be made available at no charge
by directing a request to the information agent for the Offer, which will be named in the Schedule TO to be filed with the SEC. Copies of the solicitation/recommendation statement on Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> to be filed
with the SEC by Tourmaline will be available free of charge on Tourmaline&#8217;s investor relations website at <U>https://ir.tourmalinebio.com/</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In addition, Tourmaline files annual, quarterly and current reports and other information with the SEC, which are also made available free of charge on
the Company&#8217;s investor relations website at <U>https://ir.tourmalinebio.com/</U> and at the SEC&#8217;s website at <U>www.sec.gov</U>. </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adam Silverstein </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scient PR </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>adam@scientpr.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ryan Robinson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>rrobinson@tourmalinebio.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>trml-20250908.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 9/9/2025 1:49:50 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:trml="http://www.tourmalinebio.com/20250908"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.tourmalinebio.com/20250908"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="trml-20250908_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="trml-20250908_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>trml-20250908_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 9/9/2025 1:49:50 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>trml-20250908_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 9/9/2025 1:49:50 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="trml-20250908.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g80074dsp004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80074dsp004.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M$UO-/I<[2QPL$<LA7!QGN*)PE!V80FI*Z+6L:M9Z%I<VHW\ACM8<;V"EL9(
MX'N14QBY.R*;LKF/H7CWP[XBOS8Z;?%[C:7"/&R$@=<9'-7*E*.Y*J)Z(Z:L
MRPH XR]^*7A33]3GTZXOY%NH)3"ZB!SA@<$9QZU:IR:N%SLZ@#D]<^(WAKPY
MJKZ;J=Y)%=( Q40NPP1D<@8JU3E+5!<SO^%Q^"_^@C+_ . TG^%/V4Q70?\
M"X_!?_01E_\  :3_  H]E,+HGLOBOX1U"^M[*VOY6GN)%BC4V[C+$X'./>AT
MI)7871VU9C"@"M>0&ZLI[<-M\V-DSC.,C%4GRM&=2//%Q[W1P'_"KY/^@N/^
M_'_V5=?UI?RGSO\ 8+_G_#_@C9/AEY4;/)K**JC)8PX _P#'J%BKNRB)Y&HJ
M\JEEZ?\ !*FE^ DU:S^U6VK_ +G>RJ3!][!QG[WM52Q'*[.)E0RA5H\\9Z>G
M_!-K2/A^^E:O;7QU(2^0V[;Y.,_CFLYXA2BXV.[#90Z%6,^?;R_X)TNOZU%H
M6E27CX9Q\L:$XW,>E84X<\K(]/%XE8:DYO<XVTT.T\:9OI-:G:YQ\\+*,Q>P
M'I73*;H^[8\:EA:>8+VCJ._5=O(M?\*QM1UU*;_O@4OK4NQI_85+^=F+K7P_
MN]-MGN;.;[7&G)0)AP/7'>M*>)4W9G'B<HJ48N4)715\*>+)]$G2WG)DL6/*
MY_U>>X_PJJM&,U>)C@,PGAI<C^'MV/7T<.BLI!4C(([UYUK,^P4DTFNIY1\1
M_P#D9D_Z]U_F:]+"?P_F?)9W_O*]%^IWOA#_ )%/3O\ KE_4UPXC^+(^AR[_
M '6'H;HZ5D=R.'^)W_($M/\ KX_]E-=V!_B/T/"SO^#'U_1E'X6_>U7_ +9?
M^SU>.VA\SGR'_EY\OU-[QTL3>&I%F=DC,J!F5=Q W#G'%<V%;51-*YZ6:)/#
MVD[:HYJW^'$5W D]OK:21.,JRP9!_P#'J['C>71P/*CDRJ+FC4NO3_@DO_"K
MS_T%O_('_P!E1_:%MHEK(FO^7GX?\$P/$'@V^T&+[1O6YM<\R(,;?J*Z:.*C
M6=K:G!B\MJX5<Z=T=-\/?$%S>/)I5W)Y@CCWPL>H4'!'OU%<N.H1C:<3U,HQ
MDZEZ,W>QVU_8PZA8S6D^?*E4J<'!KSHS<)<R/;JTHUH.$MF>*:OI=UX>U@PL
M6#1N&BE P&'4$5])1J1Q%/4^)Q-">#J\O;9GJWA37O[=TA9I"HN8SLE ]?7'
MO7A8FA["I;H?68'%K%4^9[HVIYX[:WDGE<+'&I9F/0 5SJ+D[([)RY(N3Z'A
MWB/79M>U1KJ0;(P-L:#^%?\ &OJ,-0CAZ?+U/B<9BI8JKS/;H=9\*C^\U7Z1
M?^SUYN9_9/6R7[9Z4*\@^C T <1\3]5GL/#:VT*D"[?RW<= N,X_'_&N[!04
MJEWT/-S&K*%*T>NA@_"C6V%W<Z1+)E77S8LGN, C\L?E6V.HI)31S9;7DVX2
M?H>K5Y9[84 >%?%LX\9+_P!>R?S:O6P7\(\3'+]Y\CU/P-_R).D?]<!7G5_X
MK/5H?PD=$*R-@H \]^*]M8WFG:3;ZA?&RMY+O!G\O>$.QL9&1Q73AY.+;1SU
MXII)FIX \*1>%=,N$AU%;Z.Z=95D5-HQC'')S45JCF]2J,%!.QNZ[H]MKVBW
M.EW@;R+A=I*G!!Z@CW! -9*3B[HU:NK'S+XAT?4_ ?BGREF=)8&$MM<(-H<=
MB/Y$?6O14XU8W.5QY'H?07@7Q?;^+M BN0R)>1_+<P@\HWKCT/45PS@X,Z8N
MZ.IK,H^2_%W_ "4?6/\ L(R?^C*[H?"B'N?68KA+/(OB9X TZ]U*Z\2ZEXB7
M3X3&J^68 Q)5<8'S#)..F*WISMH)HQM&^"$.KZ+8ZDNO21K=0I,$-J"5##./
MO>]4ZUG85B[_ ,,_Q?\ 0QO_ . G_P!E2]OY#Y2YI/P.CTK6;'4!KS2&UG2;
M9]FQNVL#C.[CI2=:ZL'*>O5@,* "@ H \Y^)=_/'+:622%8'4NZCC<<X&?:N
MW"Q3O)GS>=5IQM3CLS=^'_\ R*5O_OO_ .A&LL1_$9Z&4Z85?/\ -G3FN<],
M\J^(]ZTVNQ6@)V01#C/&X\Y_+%>CA8VC<^3SJJY5E3Z)'4_#[2$L=#%X>9KO
MYB<=%'0?U_&N;$3YI6/6RG#^RHJ;6K.NZ5SGKB'I0!X_X]TQ-.\0F6)0L=R@
MDP. #T/^/XUZF&GS0MV/C<UPZI5_=V9WW@F[-YX4M2Y.^+,1/T/'Z8KAKKEG
M8^@RRI[7"Q;Z:'.?$70[AWCU>+YXD01R =5P3@_3G%=.$JI/E9YV<X6<FJ\=
M4E9_YG4^$/\ D4]._P"N7]37+7_B2/4R[_=:?H;HZ5D=Z.'^)W_($M/^OC_V
M4UW8'^(_0\+._P"#'U_1E'X6_>U7_ME_[/6F/VA\SGR'_EY\OU-SX@?\BC<?
M]=$_]"%88+^,CT,V=L,_5'-?#.YG.HW5KYC>1Y6_83P&R!FNG'P246CSLDG*
M\HWTT_4].[5Y9]-L<WXUU"VM/#=U%,X\R==D:=V.?Z=:ZL+"4ZL7$\S,JL*>
M'E&3U:.(^',+OXF+@';%"Q)^I %>GF#2IV?<\/)HMXCF6R1Z#XJED@\,W\L,
MCQR+'E71L$<CH:\G#14JT4SZ+'3E##RE'>QYEHEM>>*+BZLKF]GF=;=I(?.D
M+!7#+Z^O2O:K.&%49P5E?4^8PT:F.DZ<Y7:3:]=!GA_5I_"VO-Y\3A,^7/$>
MN/7ZBKQ%&.)I7C\B,)B)X&M[Z]3=\?>)TGC72K*0-$5625U/WLC('TZ'\JY,
M!A7&]6IOT1Z.:8Y2M1IO3JSGI/#[VG@]]7N5*O-*BQ*1R%YR?Q_I78L0I8CV
M4=K:G"L(X85UI;MV1T7PH_UFK?2+_P!GK@S/3E/3R56YT>F"O)/H2.XFCMX'
MFE;;'&I9F/8#K32;=D*4E%79P7B?Q)X=\2Z#/IEM?>9=R8-NHA?)D!X X[]/
MQKNHT:U&:G):=3S,1B*%>FX)ZGE.D:I+HVL6M_""7@<-MSC<.X_$9%>K5IJ<
M>3N>-0G[*?/V/H[3[R+4-/M[R YBGC$BGV(S7SLH\K:/JH2YHJ1:J2SP?XN'
M'C-?^O9/YM7JX/\ A'C8Q?O#U;P)_P B/H__ %P%>?6_B,]+#_PD=$*R-PH
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M/H#A/B?KQT[1$L(& FO<JQ[B,8S^><?G7=@J7//F?0\S,:W)!074XWX8Z/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
&% !0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001827506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  08,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TOURMALINE BIO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-2377352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">27 West 24th Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-9832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TRML<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d80074d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d80074d8k.htm">d80074d8k.htm</File>
    <File>trml-20250908.xsd</File>
    <File>trml-20250908_lab.xml</File>
    <File>trml-20250908_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d80074d8k.htm": {
   "nsprefix": "trml",
   "nsuri": "http://www.tourmalinebio.com/20250908",
   "dts": {
    "inline": {
     "local": [
      "d80074d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "trml-20250908.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "trml-20250908_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "trml-20250908_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-09-08_to_2025-09-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d80074d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-09-08_to_2025-09-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d80074d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.tourmalinebio.com//20250908/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-198747-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-198747-xbrl.zip
M4$L#!!0    ( #PQ*5O<'\-HFRL   SG   -    9#@P,#<T9#AK+FAT;>T]
M:W?:2);?\ROJ>+9W[#T8 W82/]+>0S!)V';L+)#MZ?TR1Z "U!$2(PG;S*_?
M^Z@JE80$V,9VLI,Y9SI&*M7CUGW7O;?>_>?=U!<W,HJ],/CUK_5J[:]"!L/0
M]8+QKW]M]EJ=SE__\_S5NTD"S:!I$)^ZTOMU9Y(DL].#@[M!Y%=C.:R.PYL#
M>''0J#5>[ZB&\W@_6<QD;%J/G'A0#:/Q@7Z3:1Z$03"?FL:WM[=5ZAX_<)/H
M +\X@$;[T$I&WE!_=^=[P;?,9[>']%']Y.3D@-[JIDLMS0"-6NWP %\/G%CJ
MYDDT]3/-DW >31UH)@=>6!V&4UI [:1V;"83>T53@>[K!W_[?-D;3N34V?>"
M.'&"H1EHGD2ETSHY@+>ZH1>'1XWZVQ5K4"W,!W=E;>O0-L"E_.U]]S)MGA2W
M3YL>))$3Q*,0 )$ SF!/K_=KC?W&&ZN3?<")3$<:1];U<[Q_6#>PA,&]54O-
M01'?NCG<5(W?'/!+U;0<6Q#/=Q#?I>/"/XF7^/+\>/^W=P?\YZMW4YDX C_?
ME_^8>S>_[K3"()%!LM\'_-P10_[UZTXB[Y(#ZNX OCK@#H40[P:ANSA_YWHW
M(DX6OOQUQ_7BF>\LD #DSKEXY]V=8FL9J;\]UY4!_PU-KAC[1>!,\5OIG3:G
M,G#A_\D'WQFK&=PE73F"U_.(H/MWQ-/]V@D ^.]):/W:$9[[ZXYW=[-_5&OL
MG(\</Y;O#C(C+8V,7WRB2?T=AO][.P#0+%HP?N3XG<"5=[_)Q8XUOY(&]YOG
M>0U(Z+CQ]G7MS?+\#G)@BN1(1L#&9 R_D:I/8R(\&.LIF0:-A&SJUYW8F\Y\
M\VP2X2*1G>QKAE&]BUW]VHF&48B8L'Z0 [7:S KI=PR\B7\2W9PJ\-)N;0!>
M_9FDS3(_/1<?C#P9"0*A+*3J5N>W[ ;E/\99%_8_@QT,7?,3"#I*+IQ$GJ=S
MTU^F[]*YNB5M]1LSK!GG( ,= \T4>@<V^1T F<(_%K'B5_L@ L;!Z1#6(J.=
M[/M;STTFI\?5UUYP9K7UY2@YFSK1V OV\>]3X<R34#^)O/%$/<IUA]QR?R+I
M/0CGF>DD"6>GUL]!F"3AE)X,P@@FKY_49W<B#GW/%7^IT?]VSO_]+_4WM;."
MM=F#':X?K''_P69Z**OC(^A&+"]#C&"+]F/OG_*T?FQ^CYRIYR].^]Y4QN)*
MWHIN.'6",WIWRS,?A+Y[5K!-7Z\Z_?:%Z/6;_7;OW<&L9#JU9YI.K]WZVNWT
M.^V>:%Y=B/;?6I^:5Q_;HG7]^7.GU^M<7SUJCHUMS/'W9N]3Y^IC__JJ(BZJ
MK:IHU%X?G>3FE1MT'7ZF*#&['V79V/GF0=A9K4&S+(*>,;TVZK\LKW]#>K4Q
M?!6>\Y8\ V9]N.Y^+M<6+L+A')4%2UUY@+)0/]QAM2@KBG^BQI.AQE8(&EA.
MMWW5%]WVE^MN_^49S)=Y%,^=(!%)*'IRB-C',*L?BC 2]=>[[M[+SS(<B60B
M<8+SR$L\^+Y]-YPXP5B*YC 1\+I^<GA4/L]GVU[4>7 Z73D+HT3LZM_2 9U'
MQHF0-]!21/1:NGNGZ]G$%U*<VJQ/W9M?L'F'/",Y=:&#*7P^<9W% F8D YN?
M'(%$E#-H,0!5\[@BL)>?W.6YN$OC:!OH5XY-; )VY=B+T>Q/KN#-(X3/ZYWS
M_O77[N?F9>>J+=YWKBNB<]6J%AB&CV =M6V 9+=]YP"+0$@P86H(""<6O9D<
MHGGD"B\0G206K0F8.#+*L[R?B+X"T1\#G%?O$F?@2S&4OA_/G"$Z/7=J._1[
MYKBN_JV&4HL=AK[OS&)YJO]8C2863J%ZQ^"HUVJ_:."ID4]K:K:G-6T)POPB
M^J^;-2\/CWY!3X#]XD9&B3=T? 5?7G"^D?JZL=G7>JI+K>UNWAVH*4;Z[<P9
MR_U!))UOZ.?T7'GJW(2 #QM#J4[;M&I^L+M%Q/8.(!ED\,*B3GB]FCMU@F$8
M@6 D-M1+0%JUPGF01(M6Z#Y*\J$S%+T7B9Q%X0T.FQ5];T!P2]^Y!9&X+/%P
M20AD=Y/M-KB]IOF3P.^#YTMX!_+[$9S]+?J1ZOM'M</CHQ\9&'WGKJ.\7T-:
M_:,A<PP&U^%^X_#MV\/7C56@>0**/'X@03Y4]F[%#-XE&D8SXAJT]TC\%RCO
ML>N1D7$OQ:#^!),#72##;TCD/Q-FO^RNM,+IU(OC[V$3D&,))LQ_'?AWJMUJ
MKRK:TYD?+F3TXIN099/B*JRF>T&L#/Z#2MJ/JO.1';$-I>]U;2MJV]'QBZEM
M:GY;)(GM&&EK9'G3=2,9Q^J?2S"2Z@^6XV_K.^>-M^)W=,8TCM[%\P*<?OOZ
MES.QS$IVSI,)R/DYX' OB:1,\DI 99W]O;R0QB,4DI.=\][< PG[ME:@CSR<
MJSSGGK;@S^NH']X&#P=$H[9SCG/[(XR^/71+2%6YCKZ ?>!11,.#)P/X=?5'
MT79L6[B5$_/C-&<%D2\A6$S^_WJS!UE?*3P:.^? =NNU'T1C7@.[704=]"5]
MB0!5O)GCB_:=',X3[T:*ZQ$(4AGO?5>FTB[LHL!MW%L">H%LOZ???"O,(G7+
M_?M?CAOUMV>QZ$M?SB9AH!7$"NKK_AS5 ]$$Q* %K?"?(V?!=H]$WT, WYNC
M-WOK8G+2@2]#V*\O.//'FIR-HYWSH^/Z_LGQX3T8_+-MVE68B.9LY@-^ @H]
MQM6['<7Z0Q@!;,05N7HCH7XJ@JT(;X3NW6 L7=%#'B\N'= !^*3FI\/WZ<Y-
MU^':SGEK(H??Z(3/F<VB<!9YZ#<8A'=B(/WP%G<.7^*&BN/]W\3(\Y$+>+'P
M,-;/A1U-0A%[T[F?.($,Y[&_$#&063Q:T)?J@W  D& K1YTH1NEQP!SZB803
M+/2[$1@:X2U^AUY##PWF^+043]X\U S:JIFS9-ND=L^R@94SP#82P#N%%LTO
M9ZOE%&+;"KWC]\A+8!_1,3$/E!T:/]KA.PA#?^# 'B: 2397?8W[</+VZ.AL
MF:G>3_[RNBQ\$%D4$(_FPTN#*5@!<&Q@B9EUCM^= UK!,A5*YT[.\<!\M_Y6
MM#YT1>.P5H6&]['W?^+YP_&\!UQZ"+L0C#\#@P,NYS\=DK_YD9$\!11TS9!:
MQO#ZD;-?;UA(GHD),2A^5*MRRY]8_CQ8_B62R,DQ-IK"W%! 1V 7/4 3WAC;
MW_[(V X VQ]:$%O+V^M'[GYC=["W&>YSVY_8_R+8WXGCN8R>A0:._[5HX%#N
M'^T.-Z,!U78]#6S=M+$4+[8U9 36RJPTZI+(6AD@L(QR>^/[/W?Y&6OS,#_E
M!@9^R0HF7B()P!*H_S9R'G?X^11GC7W,X>. V.%$#'TGCK?B&G\PS+X[ $4.
M$N*[071PWEM,H=ENO)VC\1<!T5/X^:Y4*">AD%0\_\5/T<-  /W!C%(VGY4V
MWTN(7JEQRI)J46\,B$H?X;8^V3E''2C$(XEP^*TB9DXD;AQ_+L6_U:J8IBAF
MF,\X*0RX>YX3DS(P* )DVGLX# Y!!^UW/U]^;\O3NZQUI0?%@>=54B3"I:C*
MPSI  +28*R=VG7^(CWX(6BMH.S[H.^*S$WU;/C]_7M6L$[BH7DHQ6(@A>:"A
MQV] Q9*BU7+N82\63B! -\5!QV(<A;?)!+74&;J,G5BX<N0%'$G.#KC::[&<
MMY*FJQR*7=SCMV?LA=.M81S8F1D&H>,A!NNZC<%^HZ"SHB28M%=4?-,/K7ZK
M3WMVM'/>+H'2FH-G_=E'^JK%'SV9O7384/;2FP)[Z6GATQFMP*4*8% A8GI+
M1Q830#NB)T"[("1K8AY+:@4 4P<C6.3!HS,/3L%& -%8_@('O_5@:-R< .8'
M;R)YX\7P'2"S$PS1\>8,AQB&C8VQW(/K1&[,1R+N2E/F<-<QIHR-J=6U>'#7
M-Y/F[*>G0X+#%49SF>6U21)XZ8G@_ZM\\LP!X:M7Q20CITL4@X\L%6@@8;]
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M3E18V> OLH1#6@;]5.UW/=1'%GLP8  6*WKT#"*A.&*M-321SQZ(UF)L\R0
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M9-6Q# J$*[EB28ZGBNR(Z)HS+7+-2%8Q402X*=.8WA&]U>HR[599?96.!2Z
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M(M(Y*CJTS=",G5^C$0!#$L<>JS3&@-A EI4@04'> &TR)7.>*;:>2S L5P!
M.?=!%5S2-384F5EEI7"NIGZ>Z=)("].I31%$!R8:G6;'2%OTW')"I'7Z,,](
MQ=6;*.<2]2_3*W+[,<>0@"#"4N@<6ZAS<4@ZZ48Z&!$I%NO[&0RLT 3V&?L5
MW@W#&)-2*2E&SY.WE_-ZXD+Z(/.2#=YXXLU434C4(,.%Q.0#,ET]NED,6-F<
MPE,C^LG8:,J1X?X'BOLLT[B'^<Z!''-^7&9&&)B5J4563MJ%&*(#^?'B=)FD
M=Q86<-S,M8NP1P<P5D&SM&JKDC=G(*C& 06'H^,@DP<9X^MYP.G,%$+, IGN
MLDB#CG@K*# :YH;/QN;:T0-B=2FO4.O*$UC1XL\,FIG96Y0WFJ>::M&WBG/9
MF)11UHHX&/:%>,M?9\6>%V!<67K!B<))?7NB-0SBCC.3<RQ(HQ,+7&!X?CC3
MZ95T3X!6M=-QB/L.8;](159$9'.))>Z$Y?90>:"B:CY6S>/@IY3Z* 6;=YPH
MB4TLE'YZG 2U4*/THH)"H>9X[2[N_]@/!XCJL,!PZ@TK:8505ODGP$R2R9#4
MXT6,7B?7BZ/Y+%6E"5Q*SZ8R6UIGTJJ/(1YO.J,$DF*^:^C1JGV,_:4E2PU.
M<\ ULA2/+O3)%A77'=+5K",_O%7I,,X,0[RQ%R"<H4;L<N[O#">HM8K$ =&C
MZE$9/JK6ED[.MJAQ.&T2E."!^CYQ[BI4U&9.UQY85A:E:<4&"EI7CL^L-F56
MBL/5G#+'L5EQA D%:1 JRQR4#+@U^&]:J07 1M2N-&)47\4'ARH;6%<C"NG'
M\I;KIP1%G(FC]6(%&@[S-X&&7ZN]ZGVC_'OM5M'58 5#-X, ;;3[VI3U6FI4
M:JUMY,5(4POI8#D$=/1?R*%U$'18IY.@(UK!?\\!M>C*I@<,_=_YH?]A>E/2
MF\?_KSFNE,:NZ0-YT.%O)2:I<W9LGW5S]DT89QG.QA0Y[5^KC5&LQ[[/6)]9
M:".$DS,&BU1-T"B>N1B+'_6L@C0'N3SVXJG<K]YJ;DKI[O,-+RLL*N1H'-RJ
MG04V(R.+=<1+^W/NCOF;8MELJTSF(3 "9YSSNH!BAF %B('5AR"0KKZQ3N?U
M.:LGK:-Q+84-T$,/7D6B48&UN32-2JF.IQ1D(GA3&M6Z,A,FQRD@8M>4)[$S
M*?=6S]FFS653E;]->2@;_BK3?#SWJ-)76B"$+GE1E;@IF>_6#GZN9%V>E5S"
MYXH@^.,G\5-W3.9<IS"Q-D.7N">_$_\$@'_PX%<G>7YWMO9@CC+J9:ZJG:6)
M4E2V*LJP11^>3K%?R"2MU\'N1#N!_$G\AY@QK<HX.+EZ6%BDARIF+-^;3B^$
M77Z+;>&T:4P<&2OQE-ZEGJ7J-"X_-I*19X"YYER5=:#J<1@ID>'<V@>IW$WE
M_)H-/>2BF>!_AGAF4:1[+*U^G<%"W9,S0[EP\K<+%%Q$7R:.S** PUMWMZ;>
M=\^J?%W9;-%.=HAXE8S$'9&<K6?ME]V7#;"#+ :5='W/&N-V?D:^K*^!0_4'
M+I;T^N<1ZV./6!\G"#ZU1;]]=='NBNL/'^"_GYO]=K?3O.R)W<Y5Z_+K1>?J
MHVA>J;= &5^^=EN?FKUV131%MWT)S2_$9;O?IQY$O]N\ZGWN]/O-2_CJ0K3:
MW7ZS Y_#0'J(B^O6U\_MJWYOCYK@%'K7EYU6I]_L=ZZO#KKMUO5G:'!!/T4/
M'K>QO< ?K4_MBZ^7[0T)J:(IJ=G#<?Z Y?TAWK=%$[N'B5]W1>_KER^7U#_\
M_M"]_BSZG<]M7"G^6Q&_=RXO1>OZBI;1^?SE&A8$<^E<?;CN?J895D0**89G
M]W./5W]]=='!)CV"#;PC"  _N_I#?+J^!+#SF^NOT-=EYPH@\:G9;</7W;;X
MVOT(4X*)=-M- E.OG<).M*#)AZ^7EW^(WS^UKWAU[Q%RL+K_:78NF^\!2O"@
M^14^H[?K5P+MFGTSL=ZGZZ^7M(A>!Q'D?1L:M@&$OS%._"$NVJU.#[_KMC\V
MNPP 0B8%BDY7K>>%KH//RQH^4O6E2=Q&3Q.&MJ /),E)P'*&;DNLO.5D'U\(
MY\;QJ#0U2>U1)*6NZ*-L6KX*00YB+Z%7M[>W5= !JN/PI@KF\,QD G(M@^Q0
MV4)$Z?,ELZV2$X<<EYV5:,M3ANG@?983](E@;UPCB<N7Z5L;E!C*E),92ZM\
MOSI]Y\-4/5#@3-,$=5OJVC9>5CVQ8;'I-FW'ULS(X*Q!IM=C;7/$)<D4U,)"
M!XDNU)!ZM6T4F"3)+#X]./"B:F*^'7AA%59Y\"#;YA%T5&#KK"NJT$F+\69,
M480F>='G2&RICX,<=DJ9U^ZBU.]E8Y:]$QJE3"63/+TM;825UKJ-G6#JVYR8
M33[ECZJIO?FIJ;UD,%S1EO0Z'Z^:_:^H+SRW>/V2N[; O@M]XVQX_G#L81"'
M*H\&S%I%2KAVL0!=& ]6SQX\/#\=R(GCCW0$&;FU5 .RW.:8\D[]P69-P@@/
M2E?ED'_WN;;K4EQ6)[4<W3.KI5Z2U7*T83?%7Q]N:1*OT]2:9\^M*5[?RMR#
M35,5GJ+/-)WD<&T1@*),&+L2P(.R79"R2M)=Z%4VWV6[S5XD>T;O$Z:+G)9D
M$-TS>>5%$(A28=XO3I]HKH_+/5]*>KF? #N(#T1W ;30#0> !_G,Z)\\Y=G[
M/,]MQ\^M>+FM:$T\.1)I(95KC,# >@O+J6P_I#'SML28>7> MY7![TDR]<__
M#U!+ P04    "  \,2E;?5!!MWN3 0#COP@ #P   &0X,# W-&1E>#(Q+FAT
M;>R]>W/;R'(^_#^K^!U0FTM15;#6DJ^[<EPE2_*N?O'*CJ0]F[S_020HX1@$
M& "4K//IW^G;3 \N)"71EGC"5)*U2! 8S/3T].7II]_]?O['I_?O?C_:/WS?
M[[T[/S[_=/3^Z+^?[6[OO/N9_C(?_\S?!^\^?#[\G^##;P>?/WT^_8^?_OK]
M^/SHI^#L_'\^'?W'3VF2Q<^NXN3RJOKU)"\F4?K3^Z#?,[\_B+,J+MZ_.SS^
MFUQ\DXRJJU_?;K]*LI^"*$TN,W.#>%S]A(_Y(I=-HN(RR9Y5^?37Y]-J+^"_
M+_*JRB?TT3C/JF=E\H_XUQWW]SB:).GMK^?))"Z#D_@F.,TGD7G2_J?CWT[^
MXZ<"!OG3^W<?WA]]NTHNDBHP+QR\^_G#^W<_?X$W;AO Z]4/X.B_CP[^/#_^
M?!+\[>CT#/Y;?[ZZ^:ZY>6T^&J/YZ?V_9Q?E= ]NHZ=;K\W.]O,E[K1WD1>C
MN)!/=J;?@C)/DU'P+\_Q?^1)(![F09U/>['X:;O+/XV>U2X@.$&K6J ABBR*
MR/YOIT='?QR=G ?[)X?!ET_[)\'GC_W>'T>GOQV=6J'Y@6.ZN VB;!1$DSR[
M_+4A,3]@1D[>G?VQ_^G3^\]_VS\]/SY[]S/]&>S_%B[:1-]E2%$PS"?3*+L-
MTF225/$H,%-47D6%^=7@W?'[_:]5$F>7<1FG:3F\BL;5NY^/WV\%23;,BVE>
M1/"3668$,*BNXB"-;LH@'P=G-TGUC[A(S63O/<8TG\LTGQZ??+:3_ =_BN)G
M/SWC3__\8#\ZYH].#N2C[<=:GL/8S*E9CD#F.\DSFM(?N&U@SSSF*OYY:OY[
M?')D%^@#?W-L%S=\ZHNVTO-IV#0+],GQ^EXGQ_9S<YE_>.R1L;&[\V_^,?+N
M9Q[!CYS70U0V$2F8>%K%DPNC=MZ&P>[SW5?__-.[L6=:[!G[S)\/9,8"_-]W
MTZ"L;M/8%\MXTI!*^&@:7<;/+HHX^OKL(A[G1?QKE-Y$MZ6QPM_]/(6'_'X:
MG!W_?^:%7OPD]T5+_M=_^07_YZ?@K^/#\]__XZ>=Y\__S4KN@3%]CD[O:\N#
M5['_X=-1<'#TZ=/9E_V#XY/?_N.GYS_AWU_V#P_E;^_1'SZ?'AZ=XN?\$/KD
MF1GOI_TO9T>_RC_F[K[Z5FWL1G@E'.*IC/70#@3DV3A!A^Z;O_&O:=;=D.5"
M_P9O7]WS!O/_;?[?J1JWS(]:_20KDY%9_>O<"-S=YN=]^T#U,1WXLA^T:DC^
M"*0 =0;(9Q5_J\S81F;J?WTF']Y%E:(Q;@S.@T]'M'MVMN5DU--?'[OLM.85
MYA6>T*N=_WYD'(N/8-0M^U+=K[;XY44&?8_TM;[TY/-?I_M?YMT3A=$71/7:
M2J!^/SK^[?=SLRG\K>(^#LR&-NK!/&9W\24O?WK?]?COLP\>+"DO5BDI.Q"=
M>8C@R]K3 J/P&;_G\W@<%W3CNPO>8EF9>^%&#-=1#'=7+88'[,?O#\';*)^&
M,/ZR$<;ULPUV_ZEL PXVGI_NGYSM'T#$^#&-A)WGFQWQ]-7S[NJMA#_BXO*I
MF @;(5P/(5RYC7!DS-1A!?$S"-9O1'(CDG<5R1<K-UO3O$RRR[V 9#.YC@-X
M\D8J-U*YO%2^7+E4QD65C)-A5,6@+8\SG<B!;-B'6TAU/A$IW=E(Z3I(Z:M5
M2^EA4AB5F1<EBN3GL1'8N-@(Y48H[R"4KU<?A\JNC12"HH0\+4))-B*Y$<GE
M1?+-JD7R;%84,6*4C$2JH[W<"\ZJ?/@U."^BK!R;[S_D^=>G(JV[&VE=!VE]
MN_I3O2PQQU[^^[^\W=UYLQ><@D0\%;%\M1'+=1#+7U:>YC0S5DW,J%")<K*)
MU.?^352,GHI\;O*?:R&?$%KY/@G0H[,O7YZ(++[9R.):R.+*LSTG>7"87)OY
MRD9ED!?FC[(JDHO9$TK-;X1S381SY5F@C[.BNC+.#B%%GH@TOMU(XUI(X\H3
M0)2%#/Y*JJM\5@51\+><@NYH6U[EZ>CIQ#0W0KJ&<*87_U1PIM.C+Z='9T<G
MY_L 93K#PLJ_]D]/]T_.CX_.@L\? P!#'WS^PXC"_SPJTFFS6=9 H[]8/=+I
M<!8'GXO+*$O^X?*EO^7YR&AT\\\DN]QH\XV +B^@JT=*KU5R?P.A7@LI7;E=
MO#\S!G&15+=[P8<$U69P$E6S F5V_[*(8PC&[@7[694\.X^^QOFU,:,_;01W
M([AW$MS58Z>B:5)%*9_^87!4#;<W(KD1R>5%<N5 *8XQ[$^G17X=I4]#&G<W
M<)2UD,:5(Z3>??Q\<FX9 *Z2*GY63J-A_&N6WQ21>?F3/'MV8,951-=F[$#X
M\NYG^,W[P'P*V( G<L1O)'@])'CU@*JC@^!CDAJ;M-PS_\BB;)A$*?CW%5JE
M3T4^-Q"JM9#/E4.H3F=I'"Q4LSLO1\\ AH"J]8E([ 9=M182NW)TU?Z%.=>'
MZ-L?7$5 N+<1R(U WB&*OW(XU:<DNC!'?)5L1'$CBG<2Q=4S["25.<^K/-@O
MR_C)&)<;<5P/<5QY_N@T-K[.ER*?QD5UNQ'&C3#>01A7GB8ZSJHX3>-A-7MZ
M0GD?*+ZY^&=DO83?!>^F'73VC64+]'*\]>E/OS\KOI!B[A S,])];GA)-[RD
M<H/Y_W[W(WE)GYQ*7'D"\C"J(E"%5?R$ ,Z[F]SC>HCCRI./E,D9/A6_Y<6&
MTV8]!/$[,#-,IFD209CQ)JFN@D_QI;$93^/_G24%I6WVS%^7LS2J\N(V^".J
MJB<#O7_Q8B.U:R&U*\\UGA?1* Y0B>8IXML8\W:0%\5LBJ#-IX-Z>[$I/UX/
M.5UYSO$WP%]FH$:-4F7P)D'@C, N5KU/1'PW1:'K(;ZKIW>(OCVQ$W]3GK$6
MHKB[\LSCD=&5^6T<BSSN!1_B+!XG5? EC9Y*^?S+C1NU'N*Y\FSD47:=%+F<
M]$]*9[[< -[60RA7GI,\SLI9 ?;E$Q'$C;N^'H*X\GPD>39?BGP8QR,""'\N
MG@Z%PT8PUT0P5YX5^E#D7V.F2OX( WPR(OER(Y)K(9(KSPQ]C)(BB\LR^#Q-
MLB>3J=S(XYK(X\H31"<8KH1"GG@X@]+SC4!N!/(. KGRW,]IG&+/[R]14=T2
M2W?TE-H;OMS +M=#,E>>[3G)@\](HG@:3XL8:G(IU0-DGW]%A9%4*)S8"_:'
M7[/\)HU'ETB=?'&+G;>8JG8CQ$]9B.75GPSUF\=J]_+_&*O=E_U3\S5^\>7/
MTX/?]\\>M]OW9M>L@^I_^?WI[39*?"..RXOCR@/_7V;%\"HJGTH?SY<;_--:
MR.$CT=5MA'0CI,L+Z<IS /\TS$L;"5X/"?X.+3_+89J71J\^$4'< $;70A!7
MGBM0A#6?DBJY?$J^T$8FUT(FOT.?3VB!G!BYO 6Y_#C+GDI7NHU(KH=(KCQ/
M\/DFBXOR*IGJKHGFOY,\HP8W&_G<R.?R\KGRLH^GBXK:2.1:2.3JB>=4WR\4
MRS^BS,PDID_W(;%Z^90*YEYNJI360TR_1XO/.R( 8H$ ?(D*^!<(]U,+W]]'
MG-^M,6'3[H:P:4/8=#_"ID?6XC^&+>II@V!>_5.!8 X^_^WH9/_D_.Q1<2T;
MGJHU,&A>K1[7LC\<0BD"&"7'V75</K&8[D8LUT(L5XYO^3R-N3-C/GYZV-E7
M&Q: M1#+E<-=C/=WEJ?),*F>D))\M0$!KH4TKK[E(B<6/N11,0I.XV$^F<39
MZ"F)YB9.MA:BN?H:5VH3%EH %5J8THGQB41Q7V^.\;60SI6C6"S5%#-,/15Y
MW+!4K(4\KAS!<FR&-,FH.3W[/)\!TR(IVL.DB(=5_E22M*\W!N=:R.G*82U"
M$,!IVJ>& 'R] 0^LA5RN',[R979AG/)@/\OR639\0B4G&XE<#XE</9SE//H:
M S6T4)>/KI,GV.?S]<8_7P_Y7'G>YXRZY-!/=EX_+4+3C5BNB5BNOLGBW5MX
M;T1W([KW$-V5YX80P!H<?1OB 1\<QFE25DEVN6?^6<27YH_B*?E*&SE=#SE=
M>=;(8D\##;GF./T3$<X-[&,]A'/E>:/SN)@DF8V"'L1%%2698Y)X*J?\1D#7
M0T"_1S>]R2SC0+W@YHSYR025U.?):PKU(1\E,5VIVNP)<4KR9$(!&Y%>*RAT
M\/J?# 5]<GA,+(!?3H\.C@Z!]N_\<W#^^U'PQ]'I;X]+^_=F@Q18 WW_>O7P
MZ)/<*&WPW)(G8WML9'$]9''EL3%PT6:3B88(/)4"PC<[&YE<*^/AS3^5\7!^
M=/K'\0F2"#^JE;#9!6N@F=^LWDI048N-/MY(XO*2N'(;X8\HRYA XR2O&'*@
MQ',O.#)6P["J??Q$I':#?UT+J5UYZNSHVS3.2J#-T/'?C_$38;M\L^E$M%[6
M[=M_*NOVC^,S8.S8/SGZ_"=$QS[_[?@, F6/:NIN@(UKH*K??I> V-FLN$ZN
MHQ1LB!H+4A@X#B2H_;J.L\@6?SVQ'-Y&A-=#A%=N(^]#D>S3P8B_V2!QUD(.
M5V[U_A4EUT\F@+L1PK40PI6CP8[,65W$[G#>,Z?V#  -TZAX,B?U1CC70CA7
MC@;;GT[39!A=I''P*;XT%N=I_+\S(ZYH1>X%_V]6).4H&5)@ZVP:#Z&$-O@2
M%^.\,,,:QGOF%Y-XA(R<I&[!:#6_@[:R291NY'LCW\O+]^J[:91E<IE%%TGZ
M9+INO[T/NN#=&E/!OMA0P6ZH8.]'!?MCN%B?FA9<.?O%21Z<7R6%]'LG3I9A
M$A5/!AO[=I-.70O1_ []WB&'NI'"C13>00I73F]Q%AO'Y6E9B;L;45P'45P]
MK\7GBY0Y?\"3II86__XO;W=WWNR5P=GLPDSEDSJY-X*Z'H*Z>DQ>$67E."Z"
M\^C;1AHWTG@G:?P.V'VBZG6-?(-/,=!6!*>Q$5+HJ;J1T8V,WD5&5YZ/A/J2
MJI@-GPX@].U] *$0Q^-PI%LM-;^[+A;9&9KT0I'_AX-G;_]-;S/WJ!^PU=[]
M^?[HVU5R@>R\?SX$R/?=U=2/U4$\*\'^ Z;D,!XG68*0K4=\@P\/>(./>3$1
MA@@BSD6H^W$VS(MI[GJ'$%@MR2Z# _?%([[SP0K>^<-M&MV4=WZ[-95WHPCV
MLRQ&(WZC!]SKX*0$QP^8$'/@CT@)!%6.77:XI+3E*%W#S-[+_PN9O1\VFY"N
M_NWTZ.@/(&;8/SD,OGS:/PD^?V1VAD"L4?,.;4-ZW3$D;0V__+=[E'Z^._MC
M_].G][\?G[W[F?YI3D;ZAPS7?L&?F]&[CV#8']Y_X:_,.]6O_OQ1/NGW_N#/
MF)""_L!;R#_YMTEI7G84(_ 9)S >!4EF=EE$>CN>5O'DPKA_;\-@]_GNJQ :
MQ,+%T20WVAQ2#_+XOT%5@WJYW^!Y81 %0_8ITV225.;^Y@[E5528*1J\.WZ_
M_[5*8F":C=.T'%Y%X^K=S\?OM\PHY(0T/YE!ZV_<^?9$N4FJ?\1%:L;2[PT@
MLK?[?,\,Q]R1@GUP%Q@!?K6SM[47J%7X?'I\\MD.M76V@C/^],\/]J-C_NCD
M0#[:EI<\C,W(S(,#?:[C1&7F549(C!_<7.5I>AOD-YEY)QN$O'41RJ#V)J[]
M;OUE\+WU&_UY:OY[?')D!_N!OSFV+QK>^04&,.7>D&Q_,W] VY8":QA-D\KL
M_G^85S3R-"F#68E"99;/2)L%\ 7PK!'8=_2MLZ/!8OSS_78P9Y>B<_0=-,>I
M2,+!\?G^IS-_]]UC. _5&ONX/,'G#&6?IA.$JIQ=_!T$BH_#H3L@L0V=GN=0
M1,L(4A#!IR/XV3 RR^+Z.^-'V)9I&,.6C<HK\SC<=3F<M6:/F9^;M9E$M\&%
MN02PZ>9.XR*?!)49.0X%_FLNFT)Q7*7WK3^@AE#Q<>Z+%-PQ&B*.SIPFJ338
MRV=569DY &.2U0B8UZQC@/;*R"UQ7#:E]PQ_T'A2CIVRJRNS5X^^#=,9O!E=
MVN^9$Q3VL-%W,S.)*.!F;N+_G44IC/!?7[[=?OX<7IE^$2*SEADDJ%&C3DOS
MOK45@W'"1<!H"&\!):X0^PT*0@VBAHSF00IA&-'0;-01@ >)R\OL'^9*1O,3
M+%#\#UDTN]MO!I?PR=:@G VOY'7PW6Z#J^02)H _G,)RX\L86\+8@--94<ZB
MK/*,KZY5#+X4R3!NJH=ND^J[;9X/M'D^&IV;W\!$\U;QR$G<"_5[;C?<)$;@
MC)A/XN+2K =.,*PB'HVJS6.+B/T!/VD(,XF%]U,SDBK)9C PLV?@F])Z25H'
M)[3YZ;YM,MWN6]6?GW?KD'ZOID3*N#*S6Y@!-]2V>1$C*O'%;1C$WX;&/(#!
MQ]^@NJHT1QOTS4I&5J//E<C7\'<8#)(M^B2.C& F93F+1SA O=-)' =JH\(4
MUC;K%ELM\#94/IY<QP&(!F@*6E'SEM?FI&(SA]X<HW@@W>:0CN$G5BA(FFD'
M#Q(9J%Y%N;%1GO$=SWK0Q^:1Y2RM9-2TR/<[^AZZ70YHNYR;85Q@HSXSII$T
M]*FU-^TV#*C)7T/#PN$SRZ(L,2H&Y"0:Y5-8!//Z>3I#J3-'C$SP**ZPOIHV
M;50U3 >S'%V;&?-IPG((0A.-KI,2%&D8C*.D( T\DFUU832T5=7F'J'WFGBA
MT;>E8Z M0R4)+0.U.]6*W"6R++)0QRB7*'[]7EV'>V3WNZ]V!E=;\EJ'OQU\
MPB?+HR,B9OP'Z@^P,[%GG:BY^%L\Q&D-C8V5 J"<7F;J,.=PRNAW;5@.=YAF
MW![7/#)<4QH);BGJ]FCGI]_CB40SGDYP,Q&@2MR^PT?'8O4GA5QH[NBT=.O!
M1*)9>$TFZ]*+,MIR@LUO5-EVI/WH37JXC;9H]R9%):ITC)E'-V%+[,)@V4UH
MI/=>N["F2U<BQG-?^OYR_3A+?$1Z^,A[IU"]D S?*JGAURR_2>/1)=.WHI5?
M.H7DBS4(@:QM/.I46_V>555ZGRU04619P"U";?*69H[+,4VK7+ZLO7&A%@J4
MJ+D\!]_:^!G(9DM&\KC;RAO@"UM'<\$;;/5[VBS<EN#<VH457VW"BBO>F1_O
MNC-'<9GPJ36)OAJQY!A)46,CZ/=N%!W!T*,CB"P=05!2Y9@18S#!$W0-C*1G
M)-#B8>C=<R^_ZZ'1U\ZHYF,$4>"D!+Q^$G/RP%<N8/F1AV&^-)HF!5_;G(P7
MQA,V%@)./J@:4B_EKX\1E!*VF)UM9!G^_/'CXC#V=SN==HBJ X.I+A'SX9[A
M.CV:7^XQFD&T):,YX.@5GO!:@]/HOHACVN9/T)F7Y1 DNP:?(,Z"BAF>Z-!H
MB;;L&Z$:FI/G#;BQSAKR'4.\'\3%M&\,1FR;I0(_2#(T;'!#VW@0R:;]O;%X
MDLH[E>>[VF;-!O$6>=MX;)HA5F#^^4=H-*XXR#[B+'5MFBXPJF7F*8BOX>_4
M7%: "VW\WG%B?FVF;;#SBBV[#[/2'+EE&1R:4Z)V/K<_0*M2FKX!3A#-%7W2
MC%MNN<#E -:&';M)'&4<75N^6=.N]&IR"0?;*&=_6&TINP!.U0>%M.XE[Q=6
MWL]M(.>@%OWUY/[,CQ3[AA@X2SD;VE5,H3^.W,()@Y.P%=S8@F3TWKKL-LE_
MMTG@,?P5#(9&""@JD]YV!A#=ZS2#6!W&GY/<HV_3A.-FAT;&[B]18G"Z^>SW
M6O0 ! =<2,WM+/)G(78\C6ZMTV&_AS!63*,VW^-U,!1V<J^-E3."J] !YL !
M:"?S>[-"*86/1T5TD[7[P-N!U<TN#(%Y/J,Z8&.@I$09Q?;AIU-^??2>^[V6
M95&>=S-2#SH5XIG&N"E5F'&N79]D$+P3C5!?^VVU(BZ\"%93<1W3,VS8SKJL
MYI9F6LN6 )YS.%&:X>D8H8MA$YA_ XM$"$K\MCX2\5?E]VC(8;P$8Y&D'"PP
MP<E"/2<C X)UA-QF5B8E[CD;&*;?-K3B7F#60'1_&%SE-U!F$\(BT,3/LA34
M+([G)BG]@Z(1O>7L!#QP6B2Y$>N; K8\FI*E.CSY(&MN(7B#Q=L(KC);:;!O
MPPF=:_.!+V%%"Q>,&4*$\V0V 6UILU=PO[.*YT3$X*#M$9/H6S*938)LAOEK
M%VLJ\QG)3;\'ARH/>%2_Z:'(U&2:EWZ*K9"3F<QR+_H$.F+$DN-]X43;W/Q(
MHA\8&3,WG.2C9'P;V#A<\U>2J^$0.,E*,3?UAX,Q$X%4JR@J26ED?&3$IXQE
M=,U@7,X7W^2S=!1B1-N(TPSM8MHM\+OHTCSF$G4L3'J>F97!U*#9K10V +52
MD*4 ;PC&0H(W&<5I=#L_&P._X!^'S9_ZMS,KA'%=&!05GZE8$ AX+<O95.VA
M#H#D="N:9QT.,NOVT9=4<RFJ$_IYDJ' V24SU_\F&0,Q)OTWA&,B!>&.0SJ!
M41;<1E8;HG:P>4NKLR(JBPBO[@[TAB[ X_]W'B"K#)0P5O[E[*(TMR*-8 8,
MFMK<+LE'K/># 8LD#KU,*,-4Q/EX*WBH(09U-F2)P9DY2R]K,!!ME6TK:UHO
M-H>A,.H^+T!(^LN\ 50[H.2[=',">QW\;DPEP1%7@ TS"O;'8R-J9E2E/(?#
MU3 AO)&NXI3G/9Z8(P1.W-LMET-<\_C2ZTU\:=76_=!:]VJ[@[ >V1W6M/#K
MIAX"IBF(82RY<G@5CV8IJ>,8[FHVN=G1F=F823:K=.1T9^?75[\$T^W)=A@<
M1<8Z*3+,GKKD\4T,,2ICKPQVG[\[^[.E;.'-*_/BD&$UIGGZ#*?S5P1Q5E?O
M?C:_>+\5:,=0/7U 63EM%(Y UX^WO/-0>?EDX:M8=J1,3C37[Z!P!I=;@Q=;
MHG6P"]J2/X[-CZ.M^9YCV+32'!8';%%HL6;>VF@+I:.\C"OB-LAQ-DL-?R@-
MC9^;6YD1#J\HJQT[$?).UJ3DLZ8]LC''$O5M=O/-XK##D,,.#5^O=IXULVLU
MQY5C>%S"JY5RY:BX^SWT"4I>A'J0YM>'HE!V7MQG5R>TJX_'(>,38#G-.V7/
MW.9L^*TMGDBH#WIE<?1[ZA*S*F!YDY^?H!40!KZ3#R:+F-'=JT\G>8CI(K@C
M!L70VL$S3>77BI9(^"2Z11\+_.-14AJ[G%,QV<AS0=I]#M_6_6+,TSS;HI.<
MDU5@Y,1E97,U7<Z*M:N4W96A]D.CVRC#?#B,2K2?!>G%YGN4LKD#@YM-<1(Q
MP/6\-<"%)L84O576U3CO9(#1?JU[EA36LTNU]^ 0ZCWEDP6T81'59ZX)]ANS
ML3QAVY<GS .RF75L(-A(OA%V8:S\BC<OV/QYF6B5=79T0,JCK*+Q6.Q+6+R3
MJ!Q%_ZMQ<MJL0H#L(VUWF<_$;GC<55T;OM_C'>\PC@W?SX6E5[>Q:2];&)?+
M ]?]&%\%V $\?+N#XNK>[RW;?5%H8B6[W679F@"9Q6J@4P.T*^P6'>""/7 H
MAO !QWSH;W+D51B>=JN;BHO8RQPTIL0/&9H#8YAB[$8%N<8R7WS60!;,6$<<
MM'!3AFK-OFZY9Y17;?COX%P_AA.??GRW5QE\XV<N>J>+^#;G#^*H2!,0%G.=
M6>Z91*XIK*K-A?:("90K&,^N,]5C+;//LPIB4WA@H_(:W+K1.L=[P7#U79K1
MN6!^<&X[^,@:&,NU<-" ",IG%T;'FCU[!;8:.^+@5%WF""_%!4>LCPZ-PBLX
M&>#),4NZI)7G0LTCF$TR;3$V$U+MAQ_< ,!=D0PI2F6VEXU326277U5G;U48
MQ5LV+=(,[IMKU];7])&RER,OFZ.D4KEWQ[1XM#_:DI=)J7.5]7Q IREO-YGQ
M$>^0&;$I#+@\E+7C0!U'?4#A>DZ>>3QJ"K7WC. E11%?YT.,&\*S9YD-9J+[
MVA8TL_ B/)!L>8"+N73D0XY]#\AX2&[*8)?9?(HV;9NA;_OVYH";%5FHQD.3
M1:@/M&*@>S9$#B'T9>X;FZO&&(/2T4BY3XO SJT ('/!)H@<.I).RTO(+< 7
M$MUEPTFREFL8;GJS"3>M6OW$5OW0OCC,AS/;^&1;JHXZ R]MP52K3*PED:1*
M 1MS/HB\PB(P["N.1V?!&=O'T%$;?\1^?AWAFU_&:"K21C'/BZ171@FX0[-S
M.#>#P5^F9Z!-4.4MT0CUW/;D)A:$<(:3DB"V.M&HC'ZO$'8<-4R5,<5Q2$Z+
MMFB*NB<E<AWX%#(-8#*8G>Y#9$FS=-]7[C62Y6.CTACB92Q*SGS4R/1L=\!0
M$/0D_L"MI]]P$=UD$>SEK@L0##!,%=AE!..F2JH9J_J6[+,2S=KR@("AJ1XG
MY#U(WD>]D2=_5.DVA<11AD.75)((6^FNUR$\:_<5YMU+>G.C:6=IQ*7I%C)!
MU2LXFKE*?/LN(%_&].;N##(2B)4FY$H[V% -)P2V/"R=SF^Z^0PP+3&J>9*X
M^'ADZQNC(/1[[(QBQ<LX2DORKI(RC:,1FYMDS_G3&F)F+?>&;:_)S>]+-XT0
M::##E9=S/"MH/NTT5)B'-\MG3KJI\4_CH;$VH,#&%C>VO2T"2&0(%EE%,N1K
MJ8R_[/<6[B,\OC'^8YS+&)W^YI0N7]PW\(/@'@")POT^QLP*A)FD+"FO?#.;
M\ K749)*D*0=)5_42!+[/<1"FKF:&<\C;8#3S)X=QD4FH]05,^IO2[FH*VA(
MO+B25*4K=2*9/7Z*4==!KH1ZEV&8XV-*&E!RG,O"X;:#/RDJKT;<[SF8O$7
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M.VH)9GH\GX)UY]R6T'@@QVA!WYO#!9A DX;"6E D)>9.7OC6BA>$ENKN^@Y
MJ&%S\*&#W2.+@O1GNM-DUK@A6J>U?O"J0H?6.;5IG0Y83[VZ0JSMW,-4**?2
MM[<#-+<?*U"^\]QV@I91G7WYPGV>%QHS/JD]VB9B$3=S'=2G X/2M&OT1%H<
M<;TIX^[SW1?!D:AY6ABQLG'JVE@LO5=I<S8:.]PANJ/J5X<RF_."1FP80$H
M3PP<12X;YW2Q'HZ ;G*H-D"\'9]UPC)FC&TXO5ND17YM06NEW^L>HG6SB6#@
M?1A0XT:\) @K@+>:'_1O#>\_DL#NB,">Y,$A-_C!37H(-4K)!:EX 3?:'D!J
M'X_TA:WEK$(9W=ZU"0XCIPXY?JNSF,S>W*5P,+%K\0YYW8S*FHRJ-6[7A16G
M:QPF>K,)$ZU^S^S*GOG(!]T^'Z6P2:#UE[;'NROT5'"DW^/H2.(=#@JI9/GW
MV*OIXL[+S6XKX%/)/T@4MAEU)5UTS87>'>8)[D<(X--Y'3*=+1K-.?9I2Z2O
M&'7G23UPK]<NHUX79\U0[G@F#;F1BVBYMN@-EJ,+23=$L^HJ+Y K?L G!_)R
MZ(%8QF/Y1BMVRUT (3LL77,V+JW6HRGM%R* '.;Y2\)MP=]R:C2G6XFXIO-\
MN6C,2RSID7*WD:+I;<&6O=H97'E D.U^[YP#>0G2"4 1=MTX\7FU=#V1M!?+
M53"%QX<2C@: ERP2ZZG;9&H[L[$04?$;(,*]!4B#,F;QV#7/O]];-!GW\?,>
MHMG-XN^?GA\??#H*7FP'IT=?3H_.C!+=/S_^?'(6[)\<!G_MGY[NGYP?'YT%
MGS\&Y[\?!0>?__BR?_(_U!/M1TON$;DCUA;$'C(EUTXG4NX,H"QL.&A$Q"6T
MV-#@*L0R&"/XM 9VLX"?LR,D2#6J-2,2HMJ%MH[[Z*#>C[R>.3N2<II]" (K
M.^3_1=G,2#5W.PC!KGY)(EX%J5'@U3R6?,\.[&@-6>\=RW.%3'C@'T=X*B 0
M'AM #@5\95[(6;O&\D*SK-]CB_X4V,D_1JA9=8Z!OSX#LG-CJ9W 'CG%R#/L
MK8]Y <[;LT_&,D(TDET>?0_=H7KIP?HK4(N($39.W0RLMRE0J*!2"$%U8)24
MCL$Q#S/E80)!=@;=.8SZ'B2 R\14R/!KEM\8 ;KDF""S"C);EUD%XKMWHNJ0
MG1 RO'7@7S8C%=[//!_\55"(=^C<^V)[ASK)'<Z,PBHNHTP:8\(]?\OS$76(
M,</?6I0%?;&-15/]WD!7OQD!.\Z&M8/SPVT:W91+W/$%C6Z?CM3J=B_XD) ;
M?H+3"[>WHKL7[)L)>'9NC@ X7X)/RSWC)3WCP&L,&@9'U7![B5^_XG?F$V0?
M#IKK*%WBEY0S7HA+')SDV3,JWH)^&.9V>P)2/"!$X3(O^7;)A^V\'#V#6 (]
MX(\(FAF46Y1;6[C\/),?BORK6%,?06N;.U#7B0Z/UV;GYS_A+=H?&!XJFW M
M4;*'=M<&G[ 7@^\U,TS4;B%O]R".U]&'*[8A>"0=^>6OCU$5B!N5JP(7;M7'
MQT*>JQE/2BR/<!H 67QS>@-(3TCK9JQ.$C"=6=5+>*>6N!OH#FLX5:QD#N,4
MDN0Q%^$!&YIG!4[S&[;_(U$FOZK4:HZ\C9!Q!;:@"SDU_2@\\NP!5,6_II0,
M$J+\8*Q\KWBT)Y%,]YS\QBB7U)8[8#\%I((P$CWW@7P%]F*VSX-2B!'?CS&@
MT/]PN[X"D%LV*ID.P]1X.QGSK8UR^R84=DW*QMR[H](K:;E!HAGR8D09>S/#
M^;"2CE,>PM!&GVD8>'^!3ML[0IG/K)#R\3)W+Q"ZX6,!  ZUW[-R,LJ)K!FC
MYYRMPI)]^$RYN% !]6U*;@=7B(0*L"1DPX&7CX3\Z1],*!WLCZ@9-;G7C]OW
M6R^WG0$C')1>J87!0I^O):;XM2*^LA<TO\*/>;W!B+*WZ?>.H.3EUA>]*TD4
MDJG# H:#(XX0U:9*?7F10X*,R5 .\/ ;2N&5[ @=KVW<3((</$[;WHT8?V1"
M\%CE"*(%T^"<R+NL;?SM[2;^MO(CV(;?YAFX4ISO[%P7!M&[PM8K(0U'DVF2
MS1";I;.9E%-E_5_'V#UQ9BL#A!S?_&.JTH%#?\!)PR*_N-6GJJ,V=IVM(.%C
MMM!(BI\PZL+,&12G,V(QC%4\)Y1PFSZ(8'>#>W2=Y*D-E\"IL>00'X63 1T1
M6OJYK@BOO>I(30W?^[VF9^*,M!^=I&^QT:Z8_U_F/&ZSE[""'#8H(=T4<;O$
M8*$D%XB+$J ;T>U/VQEXH,*MY@JT<33_D63)9#:!<X"8M9$ZTH;<R& X5WE\
M?[,1TF  H?%@$L=H85(CB<B"^ "9LX6S,,N,63HAHD=$'9@K-.3 FHP2(K?]
MV>#MS$+KU^N,#>K1HD6'?>Q@ZX=4-<OSR_;'!34I5>=S/5Z,[8^]+L[.Z&P9
MJ8UXNFRWA&2]>&P+%*D]'DF!+2HUUDT=.!8N5CW&86T-(/7NP 6U;=DP=D]B
MA,^LA=":\:KEIQDM\6O;9M&LZ37SHT#2#Q*VBCF]I=(1N]2ZT"Y9VU4L?DE2
MJ!YESG&L1_8X+,P[1MH-5@V!/94Q>0W&[UC/*([\#=0K4?#2BU92PL,X%I0^
MKM?.VC/'%RVTP*"@TVX+;Q_/]^)?4< E=,0A6)=M?E\"23UZ-5[!_B0?D><"
MPBB>4<2VMSTH8<][<@&;&>^,>]VUB7%:JZ6A!\IH:>2(E$1LDSD4%,(".Q)9
M?:-;E23#O)#F*/8&!4)J#,L9E@R#*POP/_: Z9#C,Z76C+JQW:' ',]; J,R
M'95WUC:W+B@)C+4TU.Z'*/M:S*;5D&[/B!:*G*-&-=8]N6A2)0%4DL01A@_U
M#V^;[A%1BZ$E>T1=%ZW+WNJ_(R!#-<=5)Y*J9<X=SJL%UFUGJHX.L:DY7_TT
MUE+=Q)QC=97#+&1SE11:-$:E9I%-):@5=4 NGLU%RNMQG<M]V1'H"Z.Y.;15
M!ZL+1K^D*&785(;]'AHHQGS*/.11F3N%+843- B/"=$&)%0;;IT?,"/S3[7G
M+[S"<S_'X%EQNJ.K]]!??=S^,D==Z]D&'/?Z1G,RC>I8ET.11]R0I!]N/[^T
MKE,SS/XTPI4J;=\*&Q*!Q&+*$@FXU!KOO'P>/G^._T?EGZ7&=OXMKP@_,)F8
M5<,4.3;AXH-T]U7XYM7K\/GNCOQ6<=J^>1F^??&ZLU:RW%+D)E %$MO&),TR
M'!2@E @9W*Y@#7HJ*;+@T*C;/0*T[LQ[K84V"*0NZ-U=RD)-0;^7,;V_-(_X
M+B]2 Y/.?:4_,V**1V/H"V8-P4[@)?.'"T-S [W;( 'RKT>Y'>RGJ?Q(WTIZ
M)LC4L(V2IAX%C":HY"'-+_$AG85F(5T?DIVD=@$\1T+S<DW$?*U4T:!1+]0^
M"$&1683P'.J&L[8!M%\V ;3O9$Y8I2G-/3ID7C=GQF(BUQ\%:7W,(3D%F3:>
M""'$++455"XQM)BR\^,XP1C-H-9QJENKJKLY8AX\L>SGT%FC @N/N(@0(<UM
M.7A [NC.%KYJ[?7L4\9)44+B8CP#SI8:/Z8"LBD-A\$YY@[SG@;LN"58(!=F
M8F=(QF0<,,U,?FR6]\), ZDJ_^0CNF3 R$I](R&:*,DPH5QQD&?->FX/%<9E
M#;6[^-XYO0&&"^T]) T CB>$#AVUZ34=KWFCPT%(G[%AB#$(V] #">=93(@K
M,4Y3_,<4(!I\0U<Z:]SD*1:R8$TFB!7< (L$Y,ZY+0/RY* .3=[2A*N-3!UX
MQ.0;X"VMUX"G)78L3[KR(\V:^HXLB;36XDT2 D6XV4W^"^L"DZ;(^N/6QWK#
MR45R07V'81J1='76K:A&99KA\\Q=OT_,?W6L%)^CZF'=SW#F!J+X;7H*CT^D
M1@465]S>S.,JO61]0E=R29SQKY[8UKO&;U=0>R6T^!D3=0'$>>776X$Z=76F
M^-'QXZ&MD;V;):;,Y1?AV^=OPU<OGZOF=,#4;%4@UC/##[5,URLYI4('W>NE
M2W2T6C:VX(NW;W2'/#4&?_N3UR8UUG7:7/UX+"ZE,;0^'UTZ.X+P]?/=\)>=
M%WZ;OC(NKIG*7I*8,B.-MZO5V-"CCC.P9,#B@X>&2K>^?FV>M_O\_L_C$I:2
MH[E-G"/J\NNMFNO2)/4HZ];]G"Q9\+ DF4N'P69M6Q8,U]@*ULZBX78SOP-+
M:>'FV"M"GEZC0BD#U9#4*RO5Y6NA5!RU?&GU$B+WKZG%"QY/>#M\^./6TQ^U
M=.*I(;@6%@>^D,#QG5W $+,3UB12>L@[**PSZ/G_H3..ZF@('WFVI_2*=]_9
M!13O3CE0GLL_(/T$P72&GH66V-O23SH)&0@OAOD2# 0' %*,;UNULE#LG=3^
M2JTL(PA_-G\\NT PD0Y-X=<^:D38N:6VR=A.7RF!H((7<#F?9E-S1ANYDL.,
M!S+G2WX"#PJ5#6"$4>=Z7_%X]1CK'1)ER<"N9ZO!\M*RI43H>X!S@\&$=^0>
M-&9KH6Z$#>7]DFLBVZ98=>KKLC_VM,G>;K&$BN#4_#''?/?3K7914&E:^X^I
M2A(ZP^B$D[X-7-10U%ZJNFI4T2U\L6!@]A<71-O8BY'W/$V%DCEL+_1TQE"]
MW',/#S!^LGY5Z/"@G^W 1+:(N73+B8'[@LEC[3I6K@(#4*IR4*JDETC[%$^*
M@;+PX1,L]T0KUP:,8"<"[E'D.T^PB6"2IK: -2^LY5YZT*8:8L)?0XUT,AL\
M3E/?3D'SM;:(F(RH+Z+;R6XAN;];4X,Z>+RD3-JS(H7NAY,Y,ZYL29%X]>-*
MY&,_T63M$,5V4\^I6JH]%<E3#;T06.!(<<Q%<X[RVHNWI-$HUXN)M/6-;QD#
M<!/?^C[L%RNR8<%>OAO2ZUZFK6N!UV*>/\3J#>YE]/9[2UN]CDQP.?MWD76)
MZ_?G^_IIUB@H"!"'C:;K?8S1(,K:5[+?2Q/"V!+EMIIS?\VZETQ6C+!5?DV3
MBU# V;R%7V'YZ2!WC$<!+$KE8-K$-&8K#ODTK(0\ <]XO-&RO+$>4PA:!N0A
MU5E<A;V5/-=F,)%EX#>PG7E>!RIZ:"F(A(F!..+YNJ3EPI*1-1[H$8P(908/
M!8%F; "1<EN\@IZOQRU,L[1E-X30+2G&2T>(H]_*;"?'ZFP9\#H/*7PE_4Y
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MX<_+;LL=#P[Y+1X;07EKM-8$JQ_@F,^$[35/S=M?XSD@\T(1!5CUFAV[6.6
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M&:'G'@$+IL!D%CQ,U#A!SCGC!KX&XV"<O\JER4Y[.]N)WHA]))U]X][$^;D
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M0O$E=5T[/NI_=+2TS\*E]?"UQ$L\B:#&[$3!T>I.&/W=UI,J@#+O&,*3LW.
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MG"./2PN>/-<.45NM28$U&5YH4>4*AAW"+_$ELB&!/0(N5"9*,^B1SB(=,+%
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M.&0?%Y41YS+:C,F8#(<AT@#B,0[0;E$B 5]@(CQ@OX@A2%G9+,5Z(+JNH\
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MQQQ32J;?0R72$S\P:=5DV(&KD8"B%ZO-#?3J< [G9[^)(&IR21+BPE_7+'P
M5U7.V7P0IWEOO,+O/61;,:OA,Y BHR3K"%^%U_A\I @ASD1'?V3>OF#G9&2L
M8W</[F4ZL<\<!Q-NJ*:FOC02PLQ'.VFJ,=W(H(?03^</S[V&GY:*I8$DN3OW
M?*0Y;LZBJ940SLZ<Z2AGA"&NHWN<$Q45TS[Y 'VP'+$7KFK!+27$GT]>\1)
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MRV:+C[@WP7Y/XC&Y$1KKLNLO,C1>>0A086R<]8M&6H)S[Z/6.U:!2X)"8OR
M_03Z[54SVP\B I-)563@$MH-7JEK[<65U+TW.P2TGHFQ<I%/!2@!!XK)3*<"
M9]HW5U/*V=YR)\/L0I5H0W9\U%?BF&>[,M*&='OJG#.\#U/-AP;Y:EJV>*UC
M\?<%[]'(1E>POKK[/" 92SPP^[C!DNLF5(JI:D_DWJ'&>B3L _1IS!%:(WV$
M>_&\OO%M): V/00_TMHZZQ0Y;J<;Y'G@5BV[VWFZX77[TB6N(4"(MSVM"(9E
M4@AMJ:$(]ZMF2T_@31[P# F#>@(U,L4#O6TX5>YG 8R8SC8J3C!P'OAQI]2M
MLZN"N<?ZC[*W& RV-!:#\"&^/I"1=^;KI$ST_'4_9_"/3F$OV>D[\E*2,5.X
M,,%30M1<*LX,3RF;990'U(XL&A?N5";;X# &A7&2)BYLXKB2>%;1&,:N >B\
ME'N%[R2-=U,09L38<O8) 6K^^"BUYJ;]A>B=76']O0[EGB/#Z8RO<5@"7D.-
M9%,\J#6%%#/$#3KQ[-8H[6L&.&XY8+.J 65'X]\'LR=!UW8D'7_'NO0K,+UH
MT!*T')RDZEX .>6L5C$O!W1/YC!P [ R:K#948)TK>.FH;N'?GK/IM!)R_6F
M\FV5;8LV$VZ=TH?&WS/:\.F/>-_]XGT^&^\.![.XAD 1P6,' ?4]:"#!@;2F
M+*EEK"O^H==Q0=Y6ND61+*EF(2,5M"'Z;'P&%J L+.$WR1=<L?1'MA;OH[DG
MW\G#"0(=77%P-Y,X:?Q:C.4NXW&'28AV9VP2)L78 #OQ0,B4Z<@#^M;<T&EH
MP."/E.BGN-2>4&$&H4*(0D6Q0@_9"L'L'&R*HP*I@;9Q* Z5LH ;)"S7?J&X
MG&7.BWDL;+"C:_A\J?!*?4ED=7HB28[X?J0#+2%=HSQ<N:G69W">6KN?XCI:
ME$K'O(6R2,&#H1;=$[F1OTMA:4L4"E4;C3*9O1^T#TDSKG#/7B"RF)?,T]'W
MQ"?VAAHP!K5GQ &XY5-9KF35S'DD9X!:Z159IPP'.J=5W0ZD07'NU-V_>;UB
M9W00'J8WQ<*-@78B*(Z/[GFK? )D]SZL?;=Y2_#)]'\$BZ B&@H"S\(&#QX5
MHZ_QF79A0&$.$45P: ==DWI1.U>B45IAF7>W,C*!D7D]&?(*CM.^L_\EA-EI
M]J]4V>)EN70+-C<"Q13'!A4*8/[F7@7@4N&E)'H#Z8,M^Y;' -(33?&$X/U1
MI[8,LF&-T_C>"YMG4'6-Q^)$,I'*FL5%5^CZ8$.I2LAV.CQ)YBRUDZMRNIFS
MC"@_LP6F)R,$-_1OGW27GBH)4T(ZA6*I ZGB0P>LGNY94W]#OHR;&PE%_SY<
M'GCC@:R34JV3]VI8O])"CS9EE+SC4K&AA>826<_*>5L2Y9Q\]<+7HJAY0^9V
MM(-=@P_C_B=+N+J< 3;79SXG+&E A:A *.8/>$EB[$-)QWC*X3(?UY<HP%1*
M7Q(XQ(\>V=1BIHK/  3[H769E*@.Z.P#[=?HS>>/RP=0GZQM*_;:+_:[TP?/
MY'MN==ZZ8?!?SL[AH;!*^Y]77F[FA4=F_>/!Q?">;]9BH3M"4;BP@*AW%25*
M-KC9;Z#F%SYVPSBTUMV@/)O7]2?<RSDZ& )#"^H^;]?3(EKSD]DHL43'1_UK
M)"J/]):,6@3.C/,[VEUY)CECJ16):CR&7D6"^"&1P%;1T@28T/WIEC+LKLEG
M^PBLFUT(#QN],QLU\& 8U1'VP/!079^;43.&,'U$IP>8OC[6AU'6"3>3I+E"
MKF!VBZ?$P/NIC*G P3O&!'CD'N_("QFG>*%.L5F+KY K\2HY=8VJ-8<S\$GN
MWM33+*P% FO*EC/S4"&QTNT[R0'&38M!O0C!V6?X=^D6/0A4C@S D]=$4EA,
M)AML84P)D.\7"/C3C\#@_0*#_FA2I2U'ZMMDUD:MYMGNN'N/J[_/\LM3SM5.
M%P0;E:PM*TWB,NRM[*?R/>G3PRAF"1)JNL(#%PC* Q<L+OHS8BBZU9R#PU*8
M'HD9FE1:2X(!511G4H&W64*%8PY@$I.,(5I]7BV^UWX\^5!3#@4W1DVEC13J
MO*K0[,M I$>0!K<IYE0V9<OLHR8PQY/M#-LY=LEQPTI$W6W$+F9C<M^XG9EW
M(MVC?(-OD^]36S^P>(8LQX'\E)GZ*9$KE?)0+OS"P4+BBF+I&O[ Z,@]#B%O
M-V%")9CAS)HAU"F*-:T;@T+%(W1=U7-$6\+59D6CRQY[3/'?,]X#6S$[ABQ?
M"0&L@A_.LH-"[-X8D&>$U_G^VWFW*O?'LIV[),=?HN3]73U,W*0.XOWRI,='
M$H->EA7#=V.!L]1ZD@7>Z%*#=G0\G+#7]#3(O&E3( 7C?SGSJ9IMN?8%$:&>
MRC_;Q;1GR-?V27[#/.^K.Z0&I)&/4N@*0&LE]!YVW@U56O>%2)][[FFIR9&*
M\;VJB%7C1XX\[=^5\\>OO#M] S@C($PM"6^-SD#*57GNR9LYLY)4^E!*+ 2K
M<($A@K"FIAL4=82@B3B-]!NIZ#-=9[*/5T4C^.U6>>A#V3ZLMSLXL@]EMFG'
M-4"2C[<!!:-'D_L([4@+IW3#W2X3X37"7%9K5,B1E1$X?B+-=J]-KADPMTLG
MYV<I_+723UNR_OCQ\8.?>XIK/Q?JEK+_Q/DQ'1_U#8I2J]8FU41-)^)MHEM4
MV8GFD=1,:6.%_KOSQH>W A,#L!:?2TAY["RGE?)9RRHX$OT7*%W2LRC$>AXE
MX>CP60H%_L,]!GA/L]^*&P^P^266*!2L+SL%8H8/\,0,KLN4288Q/=7)2_:!
MF])M/8-0\&:FJRH#E0!)R% G1"1S,(%N.5Q*%&9&$BI*M&1VQ"%?PSV!HQ+C
M_:BTAJCP8^+63JFH\3["KK?9((865"<3P,(-M[K1^CD0J'^<"(</W>IDI#P@
M/G5/H= Y.SK(X4E-6TPD;XAU/R"DG@>U!H&#]3L*T LO?&$M_G8@2F7F$&;-
M3!X3FLH!6.;^!0X[4^,@<RA(S=**8@B)4@/;&F382:9G!3 >L<267P>.<PN$
M>LX9Y?[(1-6FL.$IXR\ 5Q/E]4!/W0WO/VK;95#YD&.LLI:Z=9OY17)F7R''
M3Z?G)U=TD0C)73;?;_3PYQ_1P_M%#TD'[M& R990B:NQ+P#G^Q A-)O05X!
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M<;__\$3P+<09VAJ"1;WTJ!U^BA""PEKJ%1H;>K+^YJL3ZO&:!0;Z!DIP*"-
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M(IKIW3I-1.D>HN<*:BU\B;5VBR7:UVS^CS4ZBA^$Q*Y(AIS)9PPK"H=+D$]
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MF<U=[:K83ZR?460S<FH'^5(I^Q[7.1G=E0AP4_%R/LW[GUD/++4ZD+@A.!$
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M+*7M1.R": 0O<VX_ [*N%E_O)ESI BN]^Q&6?-]0RQBO;X$F8.:< UJ5)JG
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MI^.#[AD\>GC./_L(5U$$?QP=_KU[](_HXB0Z//[]Y.CW+K3R\?3H<'_OHGM
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ME09\BT.!"2W?PMF5&4HQ+0,T6:R;,;X>J<1U@A'T1OXI,62Y4DGX2K X2=,
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M##F4C=P%+LRDM56@+RX\=YMP193/<.%)2XXW&E70,DVU-(5UFK_-DZ(&M&Q
M*:#J/93&Y_Y664<T^ 9"DLD)G%I/[#1+=M51^R_7STY(,N_*Q'"LDZB[,T-
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MFG2L##2<)PV;^UD@X4=L7KX+ZM=35+F7[-,6(6R2DK)2Z(HI5-Z[T[(V'"!
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ME')3"R2.%<P:/9H/ )4V5 -KIQY4M$K92>!(UCB-AQ&/%"RY3:ZY]EQ2Q*
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M&#$]V<(Q# Y8NZB@5VZ54[?Q8^VGY.A4?N5TNB K<FDC$6?14Q]CIV80#P7
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M#78$OGW^F_WRE_-?7__K_P!02P,$%     @ /#$I6P>8X\)C%0  VT@  !
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M;!.O$0Y8QM4J@XJY][6P8+ZDGT*3A1ZM.TV+#+>4< 9R%5Y[ D'(%B^PYK)
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M59A"$L#&8>]FJ-51+&8%U#0<H@H-');0CI*(GJ\YGM0<WI8FMMRJ68%R7RV
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M2'[UPE;S/C]I"=7=1#H-P[33BO"^6E%4&$0K9[-A"U!&6XYB)!3H\X+$<!2
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M1K!7YE3D1VO+FHI</&S9XK&>@X=GYLG1;;5/0G::][YL4JH(2$Z+6I[_8J-
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M ]*VWJU^@PO;,$F=44R5] '38:ZOS:F8DE2J^DG5K+F#2#YNGYBMJ-JTJF5
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MT521[IZ[1_Z=PLA6WK[?+&*X)T)2SDYZP_Y1#P@+>439[*2WDEX@0TI[().
M14',&3GI;8GLO7_W\L7;'SP/SBXN/X$'\R19RM%@L%ZO^]$=99+'JT1)RG[(
M%P/PO")^//D"?V3E1O"9Q"20!/PW0Q]^6]$X&OE'_INC7WV_/RPG"1)H-8B"
MA(S@>' \T'$P'/UR/'IS!#<?X3R0"1$,)G1!RIE\N15T-D_@I_!G2)/..&,D
MCLD6+B@+6$B#&&Z+=E_!)0O[<!K'\%FG2=6C).*>1/U<-:;LOY'^,M6=P\L7
M .H4,IGN.^GI$Y&?A\U4Q'TN9JK7H]>#(J7WD+'92UF_3A.&Q\?'@_1H.5I2
M4ZP2'P[^^GAU&\[)(O#4J5<O59B7D70DT_U7/$S/H$6#4!FAO_.*,$_O\H:^
M]WK8W\BH]TX7S,].,"7QE=J"U,-(\)C4%-:'T^J]/#[9+E4\V22$1217_J;-
MPSQJ+LA=IJK!2R4E"?LS?C^("$T!T1N>WM =_JB^^3KFBO73J4Q$$":[]6)]
MBK@H=J8F3GJ&I,%N0SKN5(0[6H$("QVU><!_'C$(N7K=EHF7*A;I=X(OC%WD
MY;CAX-=X&AO;U"2I+3W:A'E?;@]YS83*Q@21?"447DU>VM3/NU09_BFT_WT[
M>*C]7%I5EQ!)KIKVZX;DZ4)AKOXE%W$PLT7R45)'2)I;YX:#+D@:A)"0_*8,
M6MH9R!8:+0-IVZT;CN<LH<EVK,J((+Y4%^#-[V1KBV5%<D=XUEOA-4$NN-8(
M(F&;58"\!*0U0!5Q!KC%ULL@-^_?#>DS'J[TW$Q4][8D[^9T!+"Q<;Y_S 77
M?1TD2@MAT,K.:.*W62;2LE<<#&^(H#PZ9]&9^FVF*8^/DCL&TVR%UP1AH&H0
MQ&8V*P&J!N@B:/BVT+J18^O^,18+G\F,ZD4R2SX%"VNBS;F=+A4JC/#J&/>%
M@DD/=YWP4 %T":150AM]&Q8)ULUC@'S)0BZ67*2W2FX3-3ACOE*+E.V81PVY
M/B#5*>9V-KEUBOL06,CCSL1.04@K0EX2=$VD(?D.O@PS\W1S&$-T06/R:;68
M$M%L8LIYG8Z'P0 W'W<'_[$6+N5:'3)Y)*"Q^S70:]4T!JB38',9J<42O:/9
MS?&G4%LITBG"AZQQBV!WN&N%<4E7I6"W%B[WK5HQ#,$3_&",Q&D4*0,R_^^*
M,C)L-@Y&@4Y'H<X2/Q#H/@*5HKCXY_JOB@W0E>":8:UC6K-A0/\)7MI!WW=%
MWW]VZ/NVZ/MMH.]_/_0G:]X:^D@VK-&O]8*(_EAM7HL)7[,G@5].?P[8&^R8
MH'\(0T/^L61+P.LRP 7H0KBP8QNH0]W.!2+FZ>_#U^)&\'O*PH:W=:HTG@/P
M5<9,U#^*14/?J-L2_]F-#85.40UW"%JQ4C<)#?P@CL,-ETD0_TV7S>]QFA6>
MPRB839D&82<2;0P,JBT-058)5"G,^Y;MV:@; &LOCI\!U 8%"9H OYO3U2<
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M=)"7>RRPCS!OCM@W^T NEOP-4$L! A0#%     @ /#$I6]P?PVB;*P  #.<
M  T              ( !     &0X,# W-&0X:RYH=&U02P$"% ,4    "  \
M,2E;?5!!MWN3 0#COP@ #P              @ '&*P  9#@P,#<T9&5X,C$N
M:'1M4$L! A0#%     @ /#$I6P>8X\)C%0  VT@  !               ( !
M;K\! &0X,# W-&1E>#DY,2YH=&U02P$"% ,4    "  \,2E;[D-_JS\#  !8
M"P  $0              @ '_U $ =')M;"TR,#(U,#DP."YX<V102P$"% ,4
M    "  \,2E;.599V:D&  "A20  %0              @ %MV $ =')M;"TR
M,#(U,#DP.%]L86(N>&UL4$L! A0#%     @ /#$I6UIL%I7=!   !BX  !4
M             ( !2=\! '1R;6PM,C R-3 Y,#A?<')E+GAM;%!+!08
.!@ & 'L!  !9Y $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d80074d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="trml-20250908.xsd" xlink:type="simple"/>
    <context id="duration_2025-09-08_to_2025-09-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001827506</identifier>
        </entity>
        <period>
            <startDate>2025-09-08</startDate>
            <endDate>2025-09-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-402">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-09-08_to_2025-09-08"
      id="Hidden_dei_EntityCentralIndexKey">0001827506</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-413">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-414">2025-09-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-415">TOURMALINE BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-416">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-417">001-40384</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-418">83-2377352</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-71">27 West 24th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-419">Suite 702</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-420">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-421">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-422">10010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-423">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-424">481-9832</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-425">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-426">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-427">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-428">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-429">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-430">TRML</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-431">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-432">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2025-09-08_to_2025-09-08" id="ixv-433">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
